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Summary 
 
Epilepsy is a common neurological disorder, characterized by recurrent unprovoked seizures. 
Globally it affects over 69 million people of whom 90% live in Resource Poor Countries (RPCs).  
The prevalence is high in RPCs due to parasitic and infectious diseases, head injury and perinatal 
insults. Despite the high prevalence, many People with Epilepsy (PWE) do not receive 
appropriate treatment for their condition leading to a high Epilepsy Treatment Gap (ETG).  The 
ETG is defined as the difference between the number of people with active epilepsy (who may 
benefit from treatment) and the number whose seizures are being appropriately treated. 
 
The attention given to epilepsy by international health agencies such as the International League 
Against Epilepsy (ILAE), the International Bureau for Epilepsy (IBE) and World Health 
Organization (WHO) highlights its significance as the most common neurological disorder.  In 
1997, the Global Campaign Against Epilepsy, a partnership between ILAE/ IBE /WHO was 
launched to reduce the ETG in RPCs by providing information about the treatment and 
prevention of epilepsy among other measures. 
 
Epidemiological studies conducted in the Kilifi Health Demographic Surveillance System 
(KHDSS) have shown that epilepsy is prevalent in the community but no studies have been 
conducted on health care utilization by PWE.  Therefore, the overall goal of this study was to 
estimate the ETG and investigate the factors associated with treatment seeking and non-
adherence to Antiepileptic Drugs (AEDs) in order to develop appropriate interventions to reduce 
the gap.  
 
The studies in this thesis were conducted in the KHDSS, a rural area in the coast of Kenya, 
which is served by one district hospital and other public and private health facilities.  Besides the 
biomedical resources, traditional medicine is well represented with different types of Traditional 
Healers (THs) offering their services to the community. 
 
The various research methodologies used to achieve the study goals included: synthesis of 
existing literature, qualitative and quantitative techniques.  The first literature synthesis involved 
reviewing previous studies that looked at magnitude, causes and intervention strategies for the 
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ETG in RPCs and the second one reviewed the evidence from RPCs on the efficacy of treatments 
and the delivery of interventions. In the qualitative studies, information was elicited on 
perceptions of epilepsy and its treatment from PWE and their caregivers, THs, community health 
workers, nurses and clinicians using in-depth interviews, focus group discussions, key informant 
interviews and observations. The literature review and qualitative study informed development 
of the Kilifi Stigma Scale for Epilepsy (KSSE) and the Kilifi Epilepsy Beliefs and Attitude Scale 
(KEBAS) that were used in the quantitative aspect of the study.  The quantitative aspect involved 
administering a structured questionnaire to 673 PWE to investigate risk factors for treatment 
seeking and non-adherence to AEDs.   Blood samples from PWE were also collected and assayed 
for AEDs to determine adherence.  The studies were conducted by trained field staff following 
written informed consent.   
 
Findings from the systematic review in Chapter 2 indicated a wide variability in ETG estimates 
with a prevalence of 46.8/100 in urban settings and 73.3/100 for rural regions.  The ETG was 
mainly attributed to inadequate skilled manpower, cost of treatment, cultural beliefs and 
unavailability of AEDs.  These factors were addressed using intervention strategies such as 
education and supply of AEDs.   
 
The literature review in Chapter 7 highlighted some of the treatments available for epilepsy in 
RPCs: AEDs therapy, surgery and psychosocial therapy.  Among the interventions feasible in 
these countries are: ensuring an adequate drug supply, educating PWE and caregivers about 
epilepsy, community-based interventions to improve awareness, training health care providers, 
involving THs and integrating epilepsy care into existing health services, particularly mental 
health.   
 
Chapters 3 and 4 provide details of how to construct culturally varied tools.  The KSSE was 
unidimensional, indicating that it measured only one construct (perceived stigma).  In addition, it 
had high internal consistency (Cronbach‘s α=0.91) and excellent test-retest reliability (r=0.92).  
The KEBAS had five subscales (causes of epilepsy, biomedical treatment of epilepsy, cultural 
treatment of epilepsy, risk and safety concerns and negative stereotypes about epilepsy).  The 
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subscales demonstrated adequate internal consistency ranging from α=0.56 to α=0.76 and 
acceptable test-retest reliability ranging from r=0.64 to r=0.81. 
 
The quantitative part of the study (Chapters 5 and 6) identified the obstacles to treatment seeking 
and adherence as: duration of epilepsy; religion; distance to health facilities; paying for AEDs; 
injury during a seizure; beliefs about causes of epilepsy; beliefs about biomedical treatment of 
epilepsy; duration of medication; seizure frequency; number of AEDs prescribed and having a 
good relationship with the healthcare provider.   
 
Multivariate logistic regression analysis indicated the most important factor influencing 
treatment seeking was long duration of epilepsy in children (Adjusted Odds Ratio (aOR)=8.01, 
95% Confidence Interval (CI); 3.02–21.2) and in adults (aOR=9.00, 95% CI 2.87–18.9).  The 
most important factor affecting adherence among children was long duration of medication 
(aOR=4.25, 95% CI 1.86–8.75) and in adults (aOR=6.50, 95% CI 1.58–9.63).  The ETG based 
on detectable and optimal AEDs blood levels was 74.9% (95% CI; 71.4-78.1).   
 
The qualitative part of the study demonstrated that PWE utilize both biomedical and traditional 
medicine.  The study in Chapter 8 identified six key differences between biomedical and 
traditional treatments that made PWE prefer seeking treatment from THs: explanations of 
causation, communication styles, social roles, referral practices, location and systems of 
payment.  The study in Chapter 9 established the following as factors that hindered treatment 
seeking from health facilities: lack of knowledge on causes, treatment and prognosis of epilepsy, 
financial constraints, distance to health facilities, unavailability of the AEDs, superstitions and 
beliefs about epilepsy and poor doctor-patient relationship.  These findings indicated several 
possible avenues for intervention such as education of PWE and their caregivers, communication 
skills training for health providers, improving drug supplies in health facilities, increasing 
cooperation and dialogue with THs and supporting PWE and their families. 
 
The studies in this thesis enabled us to examine the ETG using multi-disciplinary approaches. 
The results contribute to our understanding of the factors that guide PWE in their labyrinthic 
treatment seeking paths, including biomedical and traditional health services for the same 
condition.  The qualitative part enabled us to understand cultural reasons for treatment seeking 
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behaviour for epilepsy while the quantitative part allowed us to estimate the ETG using a robust 
pharmacological measure.  The findings further underscore the important roles that can be played 
by different stakeholders in order to reduce the ETG.  At the community level efforts should be 
put to improve knowledge about epilepsy.  Healthcare providers should continually improve 
their relationship and communication with patients in addition to educating and counseling them.  
Traditional healers need to be integrated in health workers‘ trainings and encouraged to offer 
interventions that are consistent with their ability and style of knowledge.  Policy makers need to 
incorporate epilepsy in the National Health Agenda in addition to ensuring adequate supply of 
AEDs to health facilities.  Researchers should strive to disseminate research findings to policy 
makers as well as the community.  The study concludes by making suggestions for future 
research among them the need for prevalence studies to estimate ETG so that it can be used as an 
outcome measure in health care. 
 
Zusammenfassung 
   
xi 
 
Zusammenfassung 
 
Epilepsie ist eine häufige neurologische Störung, die durch unprovozierte wiederkehrende 
Anfälle charakterisiert ist. Weltweit sind 69 Millionen Menschen von dieser Krankheit betroffen, 
wobei 90% in Ländern mit extremer Mittelknappheit (RPC) wohnen. In diesen Ländern ist die 
Prävalenz aufgrund der parasitären und anderen Infektionskrankheiten, Kopfverletzungen und 
Geburtsschäden hoch. Trotz der hohen Prävalenz erhalten nicht alle Epilepsiepatienten (PWE) 
eine adäquate Behandlung für ihre Pathologie was zu einer grossen Diskrepanz zwischen Anzahl 
Fälle und Patienten mit adäquater Behandlung führt (Epilepsy Treatment Gap, ETG).  Der ETG 
ist die Differenz zwischen der Anzahl Patienten mit einer aktiven Epilepsie (die von einer 
Behandlung profitieren würden) und der Anzahl solcher Patienten, deren Anfälle adäquate 
behandelt sind. 
 
Die Aufmerksamkeit, die Epilepsie von internationalen Organisationen wie die International 
League Against Epilepsy (ILAE), dem International Bureau for Epilepsy (IBE) und der 
Weltgesundheitsorganisation (WHO) gegeben wird, unterstreicht die Bedeutung als häufigste 
neurologische Erkrankung. 1997 wurde in Partnerschaft zwischen ILAE/IBE/WHO die 
weltweite Kampagne gegen Epilepsie (Global Campaign Against Epilepsy) lanciert, mit dem 
Ziel, die ETG in RPC zu reduzieren. Informationen zur Behandlung und Prävention der 
Epilepsie sind die Hauptbestandteile dieses Programms. 
 
Epidemiologische Studien die durch das Kilifi gesundheitsdemographische Überwachungs-
system (KHDSS) gemacht wurden, haben gezeigt, dass Epilepsie in den Dörfern häufig auftritt. 
Bis heute aber wurden keine Studien zum Zugang von Epilepsie-Patienten zum lokalen 
Gesundheitssystem gemacht. Das Ziel dieser Doktorarbeit war den ETG zu bestimmen und die 
Faktoren, die mit der Behandlungsaufnahme und Behandlungseinhaltung mit anti-epileptischen 
Medikamenten im Zusammenhang stehen zu identifizieren um eine Gesundheitsintervention 
gegen den ETG zu entwickeln. 
 
Die Studien in dieser Doktorarbeit wurden im KHDSS durchgeführt, eine ländliche Gegend an 
der Küste von Kenia, die durch ein Spital und anderen öffentlichen und privaten 
Gesundheitsdiensten versorgt wird. Die traditionelle Medizin bietet neben den biomedizinischen 
Behandlungen mit verschiedenen möglichen Behandlungen von traditionellen Heilern (TH) ihre 
Heilungsdienste an. 
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Um das Studienziel zu erreichen, wurden verschiedene Methodologien eingesetzt: systematische 
Literaturstudien, qualitative und quantitative Forschungstechniken. Die erste systematische 
Literaturstudie untersuchte frühere Studien, die das Ausmass und die Ursachen für den ETG und 
Interventionen gegen den ETG in RPC untersucht haben. In einer zweiten systematischen 
Literaturuntersuchung wurden die Beweise für die Effizient von Behandlung gegen Epilepsie 
zusammengetragen und analysiert. In den qualitativen Studien wurden Informationen zur 
Wahrnehmung der Epilepsie und deren Behandlung durch PWE und deren Pflegern, der 
traditionellen Heilern, der Gesundheitsdienste im Dorf, und Krankenpflegern und Ärzte 
untersucht; dafür wurden Interviews, Fokus Gruppen Diskussionen und direkte Beobachtungen 
angewendet. Die systematischen Literaturstudien und qualitativen Untersuchungen führten zur 
Kilifi Stigma Skala für Epilepsie (KSSE) und zur Kilifi Epilepsie Glaubens- und 
Einstellungsskala (KEBAS), die dann in den quantitativen Studien gebraucht wurden. Die 
quantitativen Aspekte der Studien beinhalteten die Anwendung von strukturierten Fragebogen an 
673 Epilepsiepatienten um die Risikofaktoren für die Behandlungssuche und die 
Behandlungseinhaltung (Adhärenz) zu untersuchen. Blutproben wurden von den 
Epilepsiepatienten gesammelt um das Vorhandensein von anti-epileptischen Medikamenten 
nachzuweisen. Die Studien wurden durch ausgebildete Feldassistenten durchgeführt nach dem 
Erhalt von schriftlichen Zustimmungserklärungen der Patienten. 
 
Die Resultate der systematischen Literaturstudien des Kapitels 2 brachten eine grosse 
Variabilität des Ausmasses des ETG zu Tage. In urbanen Zentren war die Prävalenz im 
Durchschnitt 46.8 nicht behandelte Patienten auf 100 PWE und in ländlichen Gebieten 73.3 nicht 
behandelte Patienten auf 100 PWE. Der ETG konnte hauptsächlich auf das nicht adäquat 
ausgebildetes Gesundheitspersonal die Kosten der Behandlung, der kulturellen Sichtweisen und 
der Abwesenheit der anti-epileptischen Medikamente zurückgeführt werden. Diese Faktoren 
wurden in Interventionen durch eine Verbesserung der Gesundheitsinformation und 
Medikamentenversorgung angegangen.  
 
Die systematische Literaturstudie des Kapitels 7 brachte eine Zusammenstellung der 
Epilepsiebehandlungen in RPC zu Tage: die anti-epileptischen Medikamente, und die 
chirurgischen und psychosozialen Therapien. Zu den durchführbaren Interventionen in RPC 
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gehören die Absicherung des Vorhandenseins der Medikamente, die Gesundheitserziehung der 
Epilepsiepatienten und deren Pflegern in Bezug auf die Epilepsie, die Bewusstseinsförderung der 
Bevölkerung, die Ausbildung der Gesundheitsdienste, die auch die traditionellen Heiler 
einbeziehen und die Integration der Epilepsiebehandlung in die existierenden 
Gesundheitsdienste. 
 
Die Kapitel 3 und 4 dokumentieren detailliert das Entwickeln der kulturellen sensitiven 
Datenerhebungswerkzeuge. Die KSSE ist ein eindimensionales Werkzeug, das die empfundene 
Stigmatisierung misst. Es hatte eine hohe interne Konsistenz (Cronbach‘s α=0.91) und eine 
ausgezeichnete retest Zuverlässigkeit (r=0.92). Die KEBAS bestand aus 5 Unterskalas (Ursachen 
der Epilepsie, biomedizinische Behandlung, der Epilepsie, traditionelle Behandlung der 
Epilepsie, Risiken und Sicherheitswahrnehmungen und negative Stereotypen der Epilepsie). Die 
Unterskala demonstrierten adäquate interne Konsistenzen von α=0.56 bis α=0.76 und eine 
akzeptable retest Zuverlässigkeit zwischen r=0.64 und r=0.81. 
 
Der quantitative Teil der Studien identifiziert die Hürden für Behandlungssuche und 
Behandlungseinhaltung: die Dauer der Epilepsie, die Religion des Patienten, die Distanz zu den 
Gesundheitsdiensten, die Bezahlung der anti-epileptischen Medikamente, eine Verletzung 
während eines epileptischen Anfalls, die Überzeugung zu den Ursachen der Epilepsie, die 
Überzeugung von biomedizinischen Behandlungen, die Dauer der Behandlung, die 
Anfallhäufigkeit, die Anzahl verschriebener anti-epileptischen Medikamente und das Verhältnis 
zwischen Patient und Gesundheitsdienst. 
 
Multivariate logistische Regressionsanalysen identifizierten den wichtigsten Faktor für eine 
Behandlungsaufnahme als die lange Krankheitsdauer in Kindern (adjusted odds ratio (aOR)= 
8.01, 95% Vertrauensintervall CI: 3.2-21.2) und in Erwachsenen (aOR=9.00, 95% CI 2.87–18.9). 
Die wichtigsten Faktoren, die mit der Behandlungseinhaltung assoziiert sind, waren die lange 
Dauer der Medikation in Kindern (aOR=4.25, 95% CI 1.86–8.75) und in Erwachsenen (aOR = 
6.50, 95% CI 1.58–9.63). Der ETG basierend auf dem Blutnachweis von anti-epileptischen 
Medikamenten war 74.9% (95% CI; 71.4-78.1). 
 
Der qualitative Teil der Studie zeigte, dass Epilepsiepatienten biomedizinische und traditionelle 
Medizin benützen. Die Studie in Kapitel 8 identifiziert sechs Schlüsselunterschiede zwischen der 
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biomedizinischer und traditioneller Behandlung, die Epilepsiepatienten die traditionellen Heiler 
vorziehen: Erklärungen der Bedeutung und Ursache der Erkrankung, Kommunikationsstil, 
soziale Rollen, Überweisungen an andere Dienste, der Ort der Behandlung und die Art und 
Weise der Bezahlung. In der Studie in Kapitel 9 wurden folgende Faktoren identifiziert, die 
Epilepsiepatienten von der Behandlungssuche abhalten: der Mangel an Wissen der Ursachen der 
Epilepsie, Behandlung und Prognosen der Epilepsie, die finanziellen Folgen, die Distanz zu den 
Gesundheitsdiensten, die Abwesenheit der anti-epileptischen Medikamente, Aberglaube und 
Überzeugungen über Epilepsie und ein schlechte Patienten-Ärzte Verhältnisse. Diese Resultate 
deuten auf mehrere mögliche Intervention hin, wie bessere Information für Epilepsiepatienten 
und deren Pfleger, Kommunikationsschulung von Gesundheitsdiensten, verbesserte 
Medikamentenversorgung in Gesundheitsdiensten, vermehrte Zusammenarbeit und Dialog mit 
traditionellen Heilern, Epilepsiepatienten und deren Familien. 
 
Die Studien in dieser Doktorarbeit erlaubten uns den ETG mit einem multi-disciplinären Ansatz 
zu untersuchen. Die Resultate tragen dazu bei, die Logik, welche die Epilepsiepatienten im 
Labyrinth der Suche ihrer biomedizinischen und traditionellen Behandlungen verfolgen. Die 
qualitativen Studien erlaubten uns die Gründe der Behandlungssuche der Epilepsiepatienten zu 
verstehen während der quantitative Teil uns erlaubte den ETG mittels eines robusten 
pharmakologischen Masses zu messen. Die Befunde unterstreichen die wichtige Rolle, die die 
verschiednen Akteure bei der Verminderung des ETG spielen. In der Bevölkerung die sollte das 
Bewusstsein und das Wissen in Bezug auf die Epilepsie verbessert werden. Die 
Gesundheitsdienste sollten kontinuierlich ihr Verhältnis und die Kommunikation mit den 
Epilepsiepatienten verbessern ohne dabei die Gesundheitserziehung und das Beraten der 
Epilepsiepatienten zu unterlassen. Die traditionellen Heiler sollten in die Ausbildung des 
Gesundheitspersonals integriert werden. Zusätzlich sollten sie motiviert werden die 
Epilepsiepatienten nach ihren Möglichkeiten und Wissen zu behandeln. Politische 
Entscheidungsträger müssen Epilepsie in die Nationalen Gesundheitsagenda integrieren und die 
adäquate Versorgung mit anti-epileptischen Medikamenten garantieren. Die Forschung sollte 
sich vermehrt für eine Verbreitung der Resultate an die politischen Entscheidungsträger und der 
betroffenen Bevölkerung einsetzen. Diese Arbeit wird durch Vorschläge für zukünftige 
Forschungsfragen beendet, unter anderem die Entwicklung von Prävalenzstudien von ETG, die 
als Mass der Effizienz von Gesundheitsdiensten verwendet werden können. 
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Muhtasari 
 
Kifafa ni ugonjwa uliosambaa sana na ambao hutokana na kuathirika kwa mishipa ya ubongo na 
husababisha kuanguka na kupoteza fahamu kwa mwathiriwa. Takriban watu milioni 69 huugua 
maradhi haya duniani kote ambao ni asilimia 90 ya watu wanaoishi katika mataifa yenye 
rasilimali duni. Kuenea kwa maradhi haya ni kwa kiwango cha juu katika mataifa yenye 
upungufu wa rasilimali kutokana na magonjwa yanaoambukizwa na wadudu na yale 
yanaoambukiza, majeraha ya kichwa au athari za ajali wakati wa uja-uzito. Licha ya kuenea kwa 
ugonjwa wa kifafa, wagonjwa wengi hawapati matibabu yafaayo, jambo linalopelekea kuwapo 
kwa pengo kubwa katika huduma za matibabu. Pengo hili linaweza kuelezwa kama tofauti 
iliyoko baina ya idadi ya watu wanaougua maradhi haya na ambao wanaweza kunufaika na 
matibabu na wale ambao wanaendelea kupata tiba kwa njia mwafaka. 
 
Umuhimu unaopewa kwa ugonjwa wa kifafa na mashirika ya kimataifa ya afya kama vile 
Muungano wa Kimataifa Dhidi ya Kifafa (International League Against Epilepsy (ILAE), 
Shirika la Kimataifa Kuhusu Kifaa (IBE) na Shirika la Afya Duniani (WHO) unaonyesha 
kwamba ugonjwa huu umepewa kapaumbele kama moja ya maradhi ya akili yaliyosambaa sana. 
Mnamo mwaka wa 1997, Kampeni ya Kimataifa Dhidi ya Kifafa kwa ushirikiano na Muungano 
wa Kimataifa Dhidi ya Kifafa (ILAE), Shirika la Kimataifa Kuhusu Kifafa (IBE) na Shirika la 
Afya Duniani (WHO) ilizinduliwa ili kukabiliana na pengo la kimatibabu lililopo kuhusu kifafa 
hasa katika mataifa yenye rasilimali duni. Hii ilikuwa ni kwa kutoa maelezo kuhusu tiba na jinsi 
ya kuzuia kuenea kwa ugonjwa huu miongoni mwa hatua nyingine. 
 
Utafiti wa kimatibabu uliofanywa wilayani Kilifi na Kundi la utafiti la Uchunguzi wa Afya ya 
Umma Wilayani Kilifi (KHDSS) unaonyesha kwamba ugonjwa wa Kifafa umeenea sana katika 
jamii zinazoishi wilayani humu lakini hakuna utafiti maalum uliofanywa kuhusu jinsi  huduma 
za kimatibabu zinavyotumiwa na kuwanufaisha wanaougua maradhi ya kifafa (PWE). Hivyo, 
lengo kuu la utafiti huu ni kukadiria pengo la kimatibabu kwa wanaougua kifafa na pia 
kuchunguza mambo yanayohusiana na usakaji tiba pamoja na kutozingatia matumizi ya dawa za 
kutibu kifafa ili kuunda mikakati ifaayo ya kupunguza pengo hili. 
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Utafiti katika tasnifu hii ulifanyika katika eneo la Uchunguzi wa Afya ya Umma Wilayani Kilifi 
(KHDSS), ambayo ni sehemu ya mashambani katika Pwani ya Kenya, na ambayo huudumiwa na 
hospitali moja tu ya wilaya pamoja na zahanati nyingine chache za umma na za kibinafsi. 
Pamoja na rasilimali za tiba za kiasili, madawa ya kienyeji yamewakilishwa vyema na wauguzi 
wa kienyeji kwa kutoa huduma zao za kiafya kwa jamii. 
 
Mbinu mbalimbali za kiutafiti zilizotumiwa kuafikia malengo ya utafiti huu ni pamoja na: 
uchanganuzi wa matini za kifasihi zilizomo; tathmini za matini maalum na tathmini za matini 
jumla. Uchanganuzi awali wa matini za kifasihi zilizomo, uchanganuzi wa kiuamilifu na 
uchanganuzi wa kijumla vilichunguza viwango, asili na mikakati ya kuingilia kati na kupunguza 
pengo lililopo la kupatikana kwa matibabu kwa wagonjwa wa kifafa kwa mataifa yenye 
rasilimali duni; pili, uchanganuzi huu ulichunguza idhibati kutoka kwa mataifa yenye rasilimali 
duni kwa kuzingatia kuwepo kwa tiba na kupatikana kwa njia za kuukinga ugonjwa wa kifafa. 
Katika utafiti wa tathmini maalum, taarifa zilitokana na mielekeo kuhusu ugonjwa wa kifafa na 
tiba zipatikanazo kwa wanaougua kifafa na watoa tiba, wauguzi wa kiasili, maafisa wa afya ya 
umma, manesi na wauguzi kwa jumla kwa kuzingatia mahojiano ya kina, mijadala ya makundi, 
kuwahoji watoa taarifa mahususi pamoja na uchunguzi. Uchanganuzi wa matini za kifasihi na 
tathmini na uchunguzi wa matini maalum vilipelekea kuundwa kwa Viwango wa Unyanyapaa 
kwa Wanaougua Kifafa wilayani Kilifi (KSSE) na Viwango vya Imani na Mielekeo Kuhusu 
Kifafa Wilayani Kilifi (KEBAS) vilitumika kukadiria tathmini ya jumla katika utafiti huu. 
Kitengo cha tathmini ya jumla kilihusu maswali yenye mpangilio maalum yaliyoulizwa watu 673 
wanaougua ugonjwa wa kifafa ili kuchunguza uwezekano wa shida zinazoweza kutokana na 
matibabu ya kifafa na kutozingatia matumizi ya dawa za kutibu kifafa. Sampuli za damu za 
wagonjwa wa kifafa zilikusanywa na kuchunguzwa kwa nia ya kudhihirisha viwango vya 
kuzingatia matibabu kwa matumizi ya dawa za kutibu kifafa. Uchunguzi huu ulifanywa na 
wachunguzi wa nyanyani waliohitimu kupitia makubaliano yaliyotiwa sahihi. 
 
Matokeo ya tathmini ya kiuzingativu yalidhihirisha kuwepo kwa utengano wa kimakadirio ya 
pengo la kimatibabu ya kifafa na kudhihirisha kuwepo kwa ugonjwa huu kwa asilimia 46.8 
katika maeneo ya miji na asilimia 73.3 katika maeneo ya mashambani. Pengo la kimatibabu kwa 
wagonjwa wa kifafa linaweza kuelezwa kuwa linatokana na ukosefu wa matabibu waliohitimu, 
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gharama ya matibabu, imani za kitamaduni kuhusu ugonjwa huu na ukosefu wa madawa ya 
kutibu kifafa (AEDs). Matatizo haya yalisuluhishwa kwa kutumia mbinu za kuelimisha 
wanaohusika pamoja na utoaji wa dawa za AEDs. 
 
Tathmini ya kimatini katika sura ya 7 ilitaja yafuatayo kama baadhi ya aina za matibabu 
zinazopatikana katika mataifa yenye rasilimali duni; tiba kwa kutumia madawa ya kifafa, 
upasuaji na ushauri.  Baadhi ya njia kuu za kupambana na ugonjwa wa kifafa katika mataifa haya 
ni pamoja na: kuhakikisha kuna dawa za kutosha, kuelimisha wanaougua kifafa pamoja na 
wauguzi kuhusu ugonjwa huu, kuingilia kati kwa njia mbalimbali kwa kuuhusisha umma ili 
kuihamasisha, kuwaelimisha maafisa wa afya, kuwahusisha matabibu wa kiasili na kuijumuisha 
huduma kwa wagonjwa wa kifafa katika huduma nyingine za kiafya zilizomo, hasa afya ya akili. 
 
Sura ya tatu (3) na ya nne (4) zinatoa maelezo kuhusu jinsi ya kujenga nguzo mbalimbali za 
kitamaduni kuhusu tiba ya kifafa. Tathmini ya Viwango vya Unyanyapaa kwa Wagonjwa wa 
Kifafa Wilayani Kilifi (KSSE) iliegemea upande mmoja tu, jambo linalodhihirisha kwamba 
ilipima kitengo kimoja cha athari ya ugonjwa wa kifafa-yaani unyanyapaa. Zaidi ya hili, tathmini 
hii ilikuwa na uzingatiaji mkubwa wa vipimo vya (Cronbach‘s α=0.19) na ubora wa utegemeo 
wa majaribio rudufu (r =0.92). Viwango vya Imani na Mielekeo Kuhusu Kifafa Wilayani Kilifi 
(KEBAS) vilikuwa na vipimo vitano vidogo ambavyo ni: chanzo cha kifafa, tiba kwa matumizi 
ya madawa ya kisasa, tiba za kiasili, hatari, usalama na mielekeo potovu kuhusu kifafa. Vipimo 
hivi vilidhihirisha mfuatano thabiti wa matokeo yaliyosambaa katika viwango vya 0.56 hadi 0.76 
na ubora wa utegemeo wa majaribio rudufu yenye matokeo yaliyosambaa kutoka 0.64 hadi 0.81. 
 
Tathmini ya jumla ya utafiti (Sura ya 5 na ya 6) ilitambua vikwazo kwa wanaotafuta matibabu na 
uzingativu wa tiba kama vifuatavyo: muda ambao mgonjwa ameishi na ugonjwa wa kifafa, 
mielekeo ya kidini , umbali na iliko zahanati, gharama ya dawa za kutibu kifafa, kutokea kwa 
ugonjwa wenyewe, idadi na aina za dawa za kutibu kifafa zilizopendekezwa na uhusiano uliopo 
baina ya mgonjwa na tabibu. 
 
Uchanganuzi anuwai wa upotevu na matukio awali kuhusu tiba ulionyesha kwamba jambo kuu 
linalochangia utafutaji wa tiba na wagonjwa wa kifafa ni kuishi na ugonjwa huu kwa muda 
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mrefu hasa miongoni mwa watoto; yaani kwa viwango amilifu vya kiulinganifu (Adjusted Odds 
Ratio (aOR)) ambayo ni 8.01, asilimia 95 ya kiwango cha kiuhakikifu (CI); 3.02–21.2) na watu 
wazima katika viwango amilifu vya  (aOR)=9.00, asilimia 95 na kiwango cha kiuhakikifu (CI) 
2.87–18.9). Jambo la kimsingi au muhimu linaloathiri watoto katika matumizi ya dawa za kutibu 
kifafa ni muda mrefu wanaotumia katika kupata matibabu (aOR=4.25, 95 asilimia CI 1.86 – 
8.75) na watu wazima (aOR=6.50, 95 asilimia na CI 1.58–9.63. Pengo la kimatibabu la 
wagonjwa wanaougua kifafa (ETG) kwa kuegemea viwango vinavyoweza kugundulika na tiba 
kwa matumizi ya dawa za kutibu kifafa (AEDs) katika mishipa ya damu vilikuwa asilimia 74.9 
ambayo ni asilimia (95 katika viwango vya CI; na 71.4–78.1). 
 
Tathmini ya viwango mahususi katika utafiti huu vilidhihirisha kwamba wagonjwa wanaougua 
kifafa (PWE) hutumia madawa ya kisasa na tiba za kiasili. Matokeo ya utafiti katika sura ya nane 
(8) yalitambua tofauti sita kuu baina ya tiba kwa matumizi ya madawa ya kisasa na tiba za 
kiasili, tofauti zilizopelekea wagonjwa wanaougua kifafa (PWE) kupendelea kutafuta tiba kutoka 
kwa matabibu wa kienyeji; maelezo ya vianzo vya ugonjwa huu, mbinu za kimawasiliano, 
majukumu ya kijamii, mitindo ya kiuelekezi na urejeshi kwa wagonjwa kwa watoa matibu 
wengine, viliko vituo vya kutolea malipo na njia za kutoa malipo yenyewe. Uchunguzi katika 
sura ya 9 ulitambua sababu zifuatazo kama vizingiti vya usakaji huduma katika zahanati za 
umma: ukosefu wa maarifa kuhusu vianzo vya ugonjwa wa kifafa, tiba na utambuzi wa kuwepo 
kifafa, ukosefu wa pesa za kugharamia matibabu, umbali wa viliko vituo vya afya, ukosefu wa 
dawa za kutibu kifafa (AED‘s), itikadi na imani kuhusu kifafa na uhusiano mbaya baina ya 
madaktari na wagonjwa. Matokeo haya yalibainisha njia mbalimbali za kupambana na kifafa 
zikiwemo kuwaelimisha wagonjwa na wahudumu wao, kuwafunzia  wahudumu na watunza 
wagonjwa mbinu mwafaka za mawasiliano, kuimarisha utoaji wa dawa katika vituo vya afya, 
kuimarisha utagusiano na mijadala kuhusu kifafa baina ya matabibu wa kiasili na kuwasaidia 
wagonjwa wa kifafa (PWE) pamoja na familia zao. 
 
Uchunguzi katika tasnifu hii ulituwezesha kutathmini pengo lililopo katika kutibu kifafa (ETG) 
kwa kutumia mbinu anuwai. Matokeo yake yatachangia kuelewa maantiki inayowaongoza 
wanaougua kifafa (PWE) katika harakati zao ngumu za kuisaka tiba zikiwemo huduma za dawa 
za kisasa na zile za kiasili zinazolenga kuitatua hali hii. Tathmini maalum ilitusaidia kuzielewa 
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sababu za kiasili na tabia za kuyasaka matibabu ilhali tathmini ya jumla ilituwezesha kukadiria 
pengo lililopo katika kutibu kifafa kwa kutumia hatua chanya za kimaabara. Zaidi, matokeo haya 
yanadhihirisha umuhimu na majukumu yanayoweza kutekelezwa na washika dau mbalimbali 
katika kupunguza pengo la kimatibabu kwa wanaougua kifafa. Katika ngazi ya vijijini juhudi 
zinafaa kufanywa ili kuimarisha ufahamu kuhusu ugonjwa wa kifafa. Wanaotoa huduma za afya 
wanafaa kuendelea kuimarisha uhusiano wao na mawasiliano na wagonjwa pamoja na 
kuwaelimisha na kuwapa ushauri nasaha. Matabibu wa kiasili wanahitaji kuhusishwa katika 
kutoa mafunzo kwa wahudumu wa afya na pia wahimizwe kutoa huduma zinazoambatana na 
uwezo na mbinu zao za kimaarifa. Waunda sera wanafaa kuhusisha sera ya kushughulikia 
ugonjwa wa kifafa katika ajenda ya afya ya taifa pamoja na kuhakikisha kwamba kuna madawa 
ya kutosha ya kutibu kifafa katika vituo vya afya. Watafiti pia wanapaswa kutoa matokeo ya 
tafiti zao kwa waunda sera na kwa jamii yote kwa jumla. Utafiti huu unatamatika kwa kutoa 
mapendekezo kuhusu tafiti za baadaye ukiwemo uchunguzi wa kuenea kwa ugonjwa wa kifafa 
ili kukadiria pengo lililoko katika utoaji tiba kwa wagonjwa wa kifafa ili utumike kama kigezo 
cha kutathmini utoaji wa matibabu. 
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1. 1 Epilepsy 
 
Epilepsy is a common neurological disorder, characterized by recurrent unprovoked seizures 
(ILAE, 1993; Shorvon, 2009).  It affects over 69 million people worldwide of whom 90% live in 
Resource Poor Countries (RPCs) (Ngugi et al., 2010).  An estimated 500 million people are also 
affected indirectly, as family members and friends of those who are living with epilepsy (WHO, 
2006; Kale, 2002). The prevalence of epilepsy is reported to vary substantially between 
developed and RPCs: estimated as 4–7 per 1,000 persons in the developed countries (Sander & 
Sharvon, 1996), and 5–74 per 1,000 persons in RPCs (Preux & Druet-Cabanac, 2005).  The 
result of a recent systematic review suggest that the annual incidence in developed countries is 
approximately 44.9  per 100 000 of the general population whereas in RPCs it is 80.3 per 
100 000 (Ngugi et al., In press).  The high incidence rates in RPCs are attributable to parasitic 
and infectious diseases such as neurocysticercosis, toxocara, onchocerciasis and malaria, head 
injury, perinatal insults, possibly genetic causes, which may be the result of consanguinity in 
some areas (Placencia et al., 1994; Pal et al., 2000a; Asindi et al., 1995; WHO, 2004; WHO, 
2005). 
 
Epileptic seizures are divided into three major categories: partial (focal), generalized and  
unclassified seizures (Shorvon, 2009). Partial seizures arise from one part of the brain and 
generalized seizures probably arise from the central parts of the brain or spread so rapidly that 
their origin cannot be determined by standard techniques.  Partial seizures are further divided 
into simple partial seizures where consciousness is maintained and complex partial seizures 
where there is impairment of consciousness (Shorvon, 2009; Dekker, 1994). The types of 
generalized seizures are: absence seizures, tonic seizures, clonic seizures, myoclonic seizures, 
atonic seizures and tonic-clonic seizures (Shorvon, 2009; Dekker, 1994; Engel, 2006; ILAE, 
2009; WHO, 2007). Unclassified epileptic seizures include all seizures which cannot be 
classified because of inadequate or incomplete data, or seizures that defy classification in the 
partial or generalized categories (Dekker, 1994).  More details on classification of epileptic 
seizures can be found in Chapter 7 (Textbox 7.1).  
 
Epilepsy has many possible causes because anything that injures the brain can lead to seizures. 
The type of injury that can lead to a seizure is age‐dependent.  Seizures in children may be 
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caused by birth traumas, infections such as meningitis, congenital abnormalities or high fever 
(febrile seizures) (Shorvon, 2009; Carter et al., 2004; Annegers et al., 1988; Baulac et al., 2004).  
Seizures in adulthood are commonly caused by head injuries, infections, alcohol withdrawal, 
stimulant drugs or medication side effects (Shorvon, 2009; Annegers et al., 1998; Carpio et al., 
1998; Pal et al., 2000a; Teasell et al., 2007; Gordon & Devinsky, 2001; Hillbom et al., 2003).  In 
the elderly, brain tumors and strokes cause a higher proportion of seizures (Shorvon, 2009; Burn 
et al., 1997; Camilo & Goldstein, 2004).  However, not all seizures result from a structural 
problem in the brain.  Epilepsy can also develop as a result of genetic abnormalities (Baulac et 
al., 2004; Inoue et al., 1997; Singh et al., 2002) but in most epilepsies the cause is not found 
(Shorvon, 2009). 
 
Epilepsy in RPCs can be prevented through various public health strategies.  Prevention of 
trauma is the most effective way of preventing post-traumatic epilepsy, with use of head 
protection when riding motorcycles or bicycles (Dreifuss, 1997).  Good prenatal care, including 
avoiding alcohol and treatment of high blood pressure and infections during pregnancy can 
prevent brain damage of the foetus that may lead to epilepsy (WHO, 2006; WHO, 2004).  
Reduction of childhood infections by improved public hygiene and immunization can lessen the 
risk of cerebral damage and the subsequent risk of epilepsy (Dreifuss, 1997; Sander).  
Elimination of parasites in the environment that cause diseases such as malaria and cysticercosis, 
use of bed nets to prevent mosquito bites as well as education on how to avoid infections may 
also be effective in reducing the burden of epilepsy (Pal et al., 2000a; Carter et al., 2004).  
 
1.2 Epilepsy treatment gap 
 
The Epilepsy Treatment Gap (ETG) has been defined by the International League Against 
Epilepsy (ILAE) as ―the difference between the number of people with active epilepsy and the 
number whose seizures are being appropriately treated in a given population at a given point in 
time, expressed as a percentage (Meinardi et al., 2001).  The definition of active epilepsy is 
usually a seizure within the last five years, although in many RPCs, this is reduced to one year 
because of difficulties in recall and in supplying the Antiepileptic Drugs (AEDs). 
 
Introduction 
4 
 
The primary focus of care for People with Epilepsy (PWE) is the prevention of further seizures 
(Kwan & Brodie, 2002).  Studies in both developed and RPCs have shown that up to 70% of 
PWE can have their seizures completely controlled with AEDs (WHO, 2006; Shorvon & Farmer, 
1988; Coleman et al., 2002).  Despite this, an estimated 90% of PWE do not receive treatment 
for their condition in RPCs (Shorvon & Farmer, 1988; Scott et al., 2001; Diop et al., 2003; Diop 
et al., 2005; Mbuba et al., 2008).  The factors contributing to the high ETG in RPCs have not 
been systematically studied, but include: cost of seeking care, distance to health-care facilities, 
inadequate planning at government level, poor infrastructure, non-availability of AEDs, scarcity 
of trained medical personnel, poor community knowledge and awareness, cultural beliefs and 
stigma (WHO, 2004; WHO, 2005; Das et al., 2007; Stock, 1983; El Sharkawy et al., 2006; 
Baskind & Birbeck, 2005b).   
 
The Global Campaign Against Epilepsy was established by the ILAE, the International Bureau 
for Epilepsy (IBE) and the World Health Organization (WHO) in order to tackle some of the 
problems outlined above.  The aim is to bridge the ETG and bring epilepsy out of the ‗shadows‘ 
so that the physical and socioeconomic burdens of epilepsy on individuals and society as a whole 
can be reduced (WHO, 2000; Reynolds, 2001; Reynolds, 2002a; Reynolds, 2002b).  The WHO‘s 
report for 2004, which focuses on bridging the ETG in the Africa region, and the WHO Atlas on 
epilepsy care in the world also emphasize the need for integrating epilepsy related interventions 
in the existing  primary health care system and the need for enhancing policy and programs for 
epilepsy (WHO, 2004; WHO, 2005). 
 
1.3 Focus of the thesis 
 
The common theme linking the various studies in this thesis is the estimation of the ETG with 
particular attention to risk factors and possible intervention strategies.  The study was informed 
by a comprehensive systematic review on the subject and previous studies conducted in the Kilifi 
Health Demographic Surveillance System (KHDSS) (El Sharkawy et al., 2006; Edwards et al., 
2008; Carter et al., 2004).  Designing a community-based study enabled us to interview all the 
people in the KHDSS who were identified to have active convulsive epilepsy.  Relevant tools to 
collect data were developed based on literature review and themes from a qualitative study that 
was conducted among PWE and their caregivers as well as health care providers in Kilifi.   
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This appreciation of local cultural beliefs and terms facilitated the translation of professional 
concepts into terms that were locally understood and acceptable.  It also provided an opportunity 
to develop public health interventions that are informed by the views of PWE and those working 
with PWE.  
 
This research has been designed to be especially attentive to the rural context of social, economic 
and cultural factors in Kilifi that affect utilization of health services by PWE.  These factors were 
classified using Andersen‘s Behavioral Model that considers health service utilization as a 
function of predisposing, enabling and need factors (Andersen, 1995).  Predisposing 
characteristics are preexisting factors such as age, religion, education, occupation and beliefs that 
influence treatment seeking.  Enabling factors describe the means individuals have available to 
them for the use of health services such as income, health insurance, travel and waiting time.  
Need refers to severity of illness and whether people judge their problem to be of sufficient 
magnitude to consult health services.  Even when patients are predisposed to seek treatment and 
they have access to enabling resources, they must perceive a need to do so because need is the 
most immediate cause of health service use. 
 
The studies in this thesis are presented in eight chapters, which provide the background, 
methods, results, and discussion of complimentary research activities.  Each chapter is self-
explanatory but also complementary and indicative of how different research methodologies can 
be applied to address a public health problem.  The first of these research reports is chapter Two 
which provides an overview of the ETG in RPCs.  The third and fourth chapters focus on the 
development and validation of tools that were used to collect data on perceived stigma and 
epilepsy beliefs and attitudes among PWE.  Chapters Five and Six outline risk factors for ETG 
and non-adherence to AEDs in Kilifi. The seventh chapter highlights a combination of treatments 
and interventions aimed at improving the recognition and management of epilepsy in RPCs.  It 
acts a precursor to the final two chapters, which look at how interventions have been developed 
in Kilifi to address the ETG.   
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1.4 Study site 
 
Figure 1.1: Map showing the Kilifi Health Demographic Surveillance System  
 
 
All the studies in this thesis were conducted in the KHDSS (Figure 1.1). The KHDSS provides 
population size and other demographic characteristics of the community as well as a platform 
upon which various studies recruit and locate the study subjects.  It is located in Kilifi District of 
Coast Province.  Most of it is the coastal plain (below 30 metres above sea level) with several 
creeks and swamps stretching for about 137 kilometres along the shore-line of the Indian Ocean.  
Soils are generally poor for agriculture and include coral limestone, marble, clay stones and 
limited alluvial deposits along river valleys.  The only tarmac road from Mombasa to Malindi 
traverses the KHDSS.  Farming activities include the cultivation of food crops (maize, cowpeas, 
green grams, bananas) tree crops (mango, citrus, cashewnuts, coconuts) and vegetables (chilli, 
aubergines, okra), and keeping of goats and cows. 
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The KHDSS comprises 15 locations with 40 sub-locations sub-divided into 187 enumeration 
zones which can easily be located using digital maps of homesteads.  It covers an estimated area 
of 891 km2 with 233,881 residents in 28,000 homesteads.  This area is about 18% of the total 
area of Kilifi District (4779 sq. kms).  Re-enumeration of the population in KHDSS is carried out 
every 4-6 months to collect vital statistics such as births, deaths and migration.  The residents are 
mainly Mijikenda, a Bantu grouping of nine tribes with Giriama (45%), Chonyi (33%) and 
Kauma (11%) dominating.  The average per capita income is about Ksh.700 (10 US dollars) per 
month and about 55% of the population is considered poor.  The majority (80%) depend on 
subsistence farming which is limited by the low productivity of the land, since only 19% of the 
land is arable.  Literacy levels are low: only 45% of  people can read and write (GOK, 2000). 
 
The KHDSS is served by one District hospital, one health centre, 12 dispensaries and 23 private 
clinics. The staff members at these dispensaries and private clinics have little training in the 
diagnosis of epilepsy or its‘ management.  The dispensaries stock only one AED (phenobarbital) 
which is often out of stock.  Consequently, most PWE opt to seek treatment at Kilifi District 
Hospital (KDH) which serves as a primary care centre and first level referral facility for the 
District. Kilifi District Hospital stocks phenytoin, carbamazepine and sodium valproate in 
addition to phenobarbital. The Kenya Medical Research Institute (KEMRI) neuro-clinic, which 
offers specialized care to PWE is also located within the District hospital.  It is run by a pediatric 
neurologist and three clinicians with experience in the management of epilepsy and provides free 
assessment and AEDs at subsidized prices.  In addition to epilepsy patients, the neuro-clinic 
reviews patients from the KDH who have other neuro-cognitive disorders such as cerebral palsy.  
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1.5 Study goal  
 
To estimate the ETG and investigate the factors associated with treatment seeking and non-
adherence to AEDs in order to develop appropriate interventions to reduce the gap.  
 
1.6 Study objectives 
 
The studies in this thesis had six main objectives 
 
1. To review existing literature on magnitude, causes and intervention strategies for the 
ETG in RPCs (Chapter 2) 
2. To review literature on the efficacy of treatments and delivery of interventions  in RPCs 
(Chapter 7) 
3. To develop culturally appropriate tools for investigating risk factors for the ETG 
(Chapters 3 and 4) 
4. To estimate ETG and investigate the factors associated with treatment seeking and 
adherence among PWE (Chapters 5 and 6)  
5. To understand barriers to biomedical and traditional treatment of epilepsy (Chapter 8)  
6. To explore stakeholders‘ perceptions of epilepsy and its treatment and examine possible 
intervention strategies to reduce the ETG (Chapter 9) 
 
1.7 Identification of study participants 
 
PWE were identified in a 3-stage cross-sectional survey that was conducted to determine the 
prevalence and incidence of epilepsy (Ngugi et al., In preparation).  In the first stage, all 
household heads were asked two questions regarding the history of convulsions for each member 
of their household. Those who were positive were followed- up with a more detailed 
questionnaire in the second stage to identify those with possible Active Convulsive Epilepsy 
(ACE).  Active convulsive epilepsy was defined as two or more unprovoked seizures in a life-
time, of which at least one was within the 12 months preceding the study.  Those positive in the 
second stage were referred to the KEMRI neuro-clinic where clinical history and neurological 
examination were performed by experienced clinicians to confirm ACE.  All cases of confirmed 
ACE were eligible for the ETG study.  
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Figure 1.2: Flow diagram showing how people with epilepsy were identified 
 
 
 
STAGE I Eligible population: n=233,881 
 
Screened: n=32,176 (99.3%) 
Screened: n=4,886 (94.8%) 
Positive: n=1,125 (23.0%) 
STAGE III 
Assessed: n=948 (84.3%) 
Positive (ACE): n=699 (73.7%) 
 
Not found: n=266 (5.2%)   
 
STAGE II 
Not found: n=177 (15.7%) 
 
Crude prevalence of ACE=3.0/1,000 
 
Positive: n=5,152 (2.2%) 
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1.8 Overview of methods 
 
This thesis employed various research methodologies ranging from synthesis of existing 
literature to qualitative and quantitative techniques.  Literature synthesis involved reviewing 
previous studies in the area of research interest.  Qualitative and participatory methods involved 
in-depth interviews, key informants and Focus Group Discussions (FGD) with PWE and their 
caregivers, Traditional Healers (THs), Community Health Workers (CHWs), nurses and 
clinicians.  Participatory workshops with the above stakeholders were undertaken to identify 
service needs and to formulate culturally appropriate interventions for PWE, with the ultimate 
goal of reducing the ETG in the KHDSS.  Findings from the qualitative study were also 
incorporated into the development of stigma and epilepsy beliefs tools that were used in the 
quantitative aspect of the study.  The quantitative aspect involved individual interviews with 673 
PWE to investigate risk factors for treatment seeking and non-adherence to AEDs. It 
strengthened the qualitative study findings and enhanced our understanding of factors that hinder 
PWE from utilizing health services. The ethnographic phase of the research was undertaken to 
examine differences between traditional healing and biomedical care for epilepsy in Kilifi. It 
involved a period of participant observation and extended interactions with THs and biomedical 
personnel.  Further details concerning research methods are presented in each chapter. 
 
Chapter 2: Epilepsy treatment gap in developing countries: A systematic review of 
magnitude, causes and intervention strategies 
 
With the aim of providing a broad understanding of the research topic, research reported in this 
Chapter examined previous studies concerning magnitude, causes and intervention strategies for 
the ETG in RPCs.  A proforma was prepared that highlighted the procedures to be followed 
when conducting the systematic review. A literature search was carried out using three 
databases.  Additional articles were identified by searching references cited in the key papers.  
Findings provided a pooled estimate of the ETG, identified its causes and examined interventions 
that have been instituted to address it. This provided useful background information that 
informed the design of the studies in Kilifi. 
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Chapter 3: Development and validation of the Kilifi Stigma Scale for Epilepsy 
 
Epilepsy has long been recognized as a health-related condition that often carries with it a heavy 
burden of stigma (Scambler & Hopkins, 1986).  This stigma has a severe impact on PWE and 
their families (Baker, 2002; Morrel, 2002).  Cultural perceptions and values play an important 
role in understanding the concept and content of stigma by an individual.  Therefore the purpose 
of this study was to develop and validate a culturally-appropriate measure of perceived stigma 
using findings from a qualitative study conducted among PWE and their caregivers in Kilifi.  
Our approach followed the set criteria for evaluating psychometric properties of the scale 
(Jacoby et al., 1993; Cicchetti, 1994). The scale was later used to find out whether perceived 
stigma has any influence on treatment seeking and adherence to AEDs among PWE. 
 
Chapter 4: Development and validation of the Kilifi Epilepsy Beliefs and Attitude Scale 
 
Negative beliefs and attitudes towards epilepsy are still common among PWE and the general 
public (Rwiza et al., 1993; Gambhir et al., 1995; Radhakrishnan et al., 2000). Traditional belief 
systems that attribute epilepsy to demons, possession, witchcraft and curses are still prevalent in 
Kilifi (El Sharkawy et al., 2006).  These beliefs and attitudes are important because they 
constitute predisposing factors that influence treatment seeking behaviour among PWE. 
Therefore the purpose of this study was to develop and validate a tool to measure epilepsy beliefs 
and attitudes among PWE in Kilifi.  Literature review and formative research led to the 
development of a tool that had five subscales. The psychometric properties of the subscales were 
evaluated using criteria set out by Cicchetti (Cicchetti, 1994). We investigated whether the 
various subscales predicted treatment seeking and adherence to AEDs among PWE. 
 
Chapter 5: Treatment seeking among people with epilepsy in Kilifi, Kenya 
 
Research reported in this Chapter uses quantitative techniques to estimate the magnitude of the 
ETG in Kilifi.  We were interested in delineating factors that influence the 673 people identified 
to have active convulsive epilepsy in the KHDSS to seek treatment. Some of the factors 
examined included: socio-demographic characteristics, socioeconomic status, distance to health 
facilities, cost of AEDs, seizure frequency, stigma and epilepsy beliefs and attitudes.  The 
findings provide background data that can be used in developing culturally appropriate 
interventions that can reduce the ETG in Kilifi. 
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Chapter 6: Factors associated with adherence to antiepileptic drugs in Kilifi, Kenya 
 
After quantifying the ETG we investigated whether the 385 PWE who reported taking AEDs 
were adherent to treatment.  Adherence was determined using detectable and therapeutic blood 
levels of phenobarbital, phenytoin and carbamazepine.  This was compared with self-reported 
adherence that was assessed concurrently using the Morisky Medication Adherence Scale.  
Factors influencing adherence were also explored among those who reported taking AEDs.  
Among the factors investigated were: socio-demographic characteristics, socio economic status, 
relationship with health care providers, seizure frequency, injury during a seizure, number of 
prescribed AEDs, AEDs side effects, stigma and epilepsy beliefs and attitudes.  The findings of 
this study may help in developing  interventions to improve patient adherence and reduce the risk 
of preventable seizures.  
 
Chapter 7: Packages of care for epilepsy in low and middle-income countries 
 
This is a review of the literature focusing on the management of epilepsy in Low- and Middle 
Income Countries (LMICs).  Charles Newton and I reviewed the evidence from LMICs on the 
efficacy of treatments and the delivery of interventions.  On the basis of this review, we proposed 
a combination of interventions aimed at improving the recognition and management of epilepsy 
to achieve optimal outcomes.  Findings from this review provided additional information about 
effective interventions that can be developed in Kilifi to reduce the ETG. 
 
Chapter 8: Comparing characteristics of epilepsy treatment providers on the Kenyan 
coast: implications for treatment-seeking and intervention 
 
This study employed ethnographic techniques to examine ways in which treatment-seeking may 
be facilitated or deterred by the characteristics of available treatment providers.  It focused 
explicitly on treatment providers as a source of data and the ways in which treatment-seeking 
may be facilitated or deterred by the availability of treatment options and the characteristics of 
service providers, rather than by the characteristics of the patients.  The methods used included 
open-ended interviews using semi-structured questionnaires, FGDs, participant observations and 
the usually long-term participation of the researcher in the community under study. 
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The researcher observed a total of 52 healing sessions with eight THs in addition to taking field 
notes and tape recording interviews.  To understand the types and delivery of treatment provided 
in health facilities, interviews and observation data were gathered from 12 biomedical health 
providers: doctors, neurological technicians, research staff, nurses and general health aids.  
Comparing data on treatment providers provided an account of the important role played by THs 
in the treatment of epilepsy in Kilifi and revealed barriers to obtaining biomedical care.  
Therefore there is need for biomedical providers to involve THs in designing interventions aimed 
at reducing the ETG in Kilifi. 
 
Chapter 9: The reasons for the epilepsy treatment gap in Kilifi, Kenya: using formative 
research to develop interventions to improve adherence to antiepileptic drugs 
 
In this Chapter I report findings from an analysis of a qualitative study that was conducted 
among PWE and their caregivers, THs, CHWs, nurses and clinicians. The study included a 
combination of strategies for data collection: individual interviews, FGDs and participatory 
workshops.  Experiences and beliefs about epilepsy in the household and in the community were 
explored as well as the range of treatments available for PWE and the pros and cons of different 
types and sources of treatment.  Drawing on the qualitative findings, a series of workshops were 
organized with key stakeholders to negotiate realistic and sustainable interventions to reduce the 
ETG in Kilifi District.   
 
Chapter 10: Discussion and Conclusion 
 
This Chapter gives a general overview of the study, including background about epilepsy, 
methodological issues, results, recommendations, implication for future research and conclusion. 
 
Overall, the research reported in this thesis provides a comprehensive approach to investigating 
the ETG and designing interventions in a rural setting of a RPC.  Individually and collectively, 
these studies address practical and relevant issues that policy makers and health providers must 
take into consideration, both at community and health facility level, if the ETG is to be reduced 
in Kilifi District.  In addition to contributing to epilepsy care in Kilifi, it is hoped that these 
studies demonstrate an integrated approach to addressing the ETG that will be useful in other 
settings.  
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Abstract 
 
Introduction 
 
In many Developing Countries (DCs), people with epilepsy do not receive appropriate treatment 
for their condition, a phenomenon called the Epilepsy Treatment Gap (ETG).   
 
Methods 
 
We carried out a systematic review to investigate the magnitude, causes and intervention 
strategies to improve outcomes in DCs.  We systematically searched MEDLINE, EMBASE and 
PsycINFO databases, supplemented by a hand search of references in the key papers.  The 
degree of heterogeneity and a pooled ETG estimate were determined using meta-analysis 
techniques.  The estimates were further stratified by continent and location of study (urban and 
rural). Twenty-seven studies met the inclusion criteria: twelve from Africa, nine from Asia and 
six from Latin America.   
 
Results 
 
We observed a high degree of heterogeneity and inconsistency between studies.  The overall 
estimate of the ETG was 56.0/100 (95% CI: 31.1-100.0).  The variation in estimates could 
possibly be explained by non-uniform ETG estimation methods and the diverse study 
populations, among other factors. The ETG was mainly attributed to inadequate skilled 
manpower, cost of treatment, cultural beliefs and unavailability of Anti-epileptic Drugs (AEDs).  
These factors have been addressed using different intervention strategies for instance education 
and supply of AEDs. 
 
Conclusion 
 
Future research should estimate the ETG coherently and develop sustainable interventions that 
will address the causes.   
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2.1 Introduction 
 
Epilepsy is the most common chronic  neurological disorder, affecting approximately 50 million 
people worldwide, of whom 40 million are estimated to live in Developing Countries (DCs)* 
(WHO, 2004).  Several studies have reported that over 90% of People with Epilepsy (PWE) in 
DCs do not receive appropriate treatment for their condition, a phenomenon known as the 
Epilepsy Treatment Gap (ETG) (Scott et al., 2001; Diop et al., 2003; Diop et al., 2005; Shorvon 
& Farmer, 1988).  However, none of the studies provide a confidence interval, suggesting that 
the estimate is not data driven.  The ETG is defined as the number of people with active epilepsy 
not on treatment (diagnostic and therapeutic) or on inadequate treatment, expressed as a 
percentage of the total number with active epilepsy (Kale, 2002; Meinardi et al., 2001). The ETG 
also includes the influence of epilepsy on mental and social well being (Meinardi et al., 2001).  
For the purpose of this review, active epilepsy is defined as having at least one unprovoked 
seizure in the last 5 years.  The ETG  has been estimated by the direct method during prevalence 
studies, and indirectly from the amount of Anti-epileptic Drugs (AEDs) consumed in the country 
and the number of people with active epilepsy (Kale, 2002).  The gap is reported to be influenced 
by various factors, including lack of access to or knowledge of AEDs, poverty, cultural beliefs, 
stigma, poor health delivery infrastructure and shortage of trained professionals (Scott et al., 
2001; Meinardi et al., 2001). 
 
The Global Campaign Against Epilepsy, a partnership between the International League Against 
Epilepsy (ILAE), the International Bureau for Epilepsy (IBE) and World Health Organization 
(WHO) was launched in 1997 to bring epilepsy ―out of the shadows‖ by addressing some of the 
factors outlined above (Diop et al., 2003; Sander, 2002).  In 2002, the Global Campaign entered 
its second phase and several demonstration projects were set up in various countries, to reduce 
the ETG and the physical, economic and social burden of epilepsy through community-level 
interventions (Sander, 2002; Li et al., 2007).  
                                                          
* Developing countries were defined according to the World Bank classification for low and upper middle 
income as a Gross National Income per capita of less than $11, 115 (http://www.worldbank.org).  
Estimate of the number of PWE in the world is quoted as 50 million and not 69 million as in chapter 1 
because the latter estimate was not available when this paper was published. 
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Despite this concerted effort by different stakeholders, there are no systematic reviews on the 
magnitude, causes or intervention strategies to improve the outcomes in DCs.  Therefore, we 
conducted a systematic review of the literature on the ETG to answer the following questions: 
1. What is the magnitude of the ETG in DCs? 
2. What are the factors responsible for the ETG in DCs? 
3. What interventions have been implemented to address causes of the ETG? 
 
2.2 Methods 
2.2.1 Data sources and search strategy 
 
A literature search was carried out using three databases: MEDLINE (1966 – 6/2007), EMBASE 
(1980 – 6/2007) and PsycINFO (1887 –6/2007) using a combined text word and Medical Subject 
Headings (MeSH) to identify relevant papers (Appendix 2.1).  Additional articles were identified 
by searching references cited in the key papers. The strategy was developed by breaking the 
review question into its elemental facets: exposure, outcome, population, publication language 
and keywords according to the recommendations of the National Health Service Centre for 
Reviews and Dissemination (Khan et al., 2001) (Appendix 2.1).  Publication language was left 
open to ascertain how many studies were available in languages other than English.   
 
2.2.2 Study Selection 
 
The online abstracts of studies identified from the database search were reviewed and reprints of 
potential eligible studies obtained.  Studies meeting one of the following criteria were chosen for 
more detailed review: 
1. Cross-sectional studies that provide the prevalence of the ETG, or studies using the indirect 
method to estimate the gap; 
2. Qualitative or observational studies that identify potential causes of the ETG;  
3. Interventions to address some of the attributed causes of the ETG: prospective cohort or those 
that have used randomized control or pre-post designs and focused on either education or 
supply of drugs. 
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2.2.3 Studies excluded  
 
1. Epilepsy prevalence studies that did not estimate the ETG;    
2. Studies reported in languages other than English; 
3. Reviews; 
4. Editorials, letters or reports; 
5. Studies conducted in developed countries; 
6. Studies that reported same results in different papers. 
 
2.2.4 Data extraction  
 
Data were extracted using a proforma designed for the review.  The first reviewer extracted all 
the data and the fourth reviewer re-extracted data from a sample of half of the studies.  The 
studies were organized into three broad categories: those on magnitude, attributed causes and 
interventions.  Information from each study was then obtained on author, year of publication, 
country, study design, sample size, ascertainment method, length of study, age of participants 
and outcome. We extracted data on magnitude of the ETG and calculated a 95% Confidence 
Interval (CI) around the estimates. We further stratified the ETG estimates by continent and 
location of study (urban and rural). All data were entered in an Excel spreadsheet and transferred 
to STATA version 11 (StataCorp, College Station, TX, USA) for analysis.  
 
2.2.5 Analysis 
 
The 95% CI for the ETG estimates were calculated and heterogeneity investigated.  The ETG 
prevalence estimates were transformed to logits (log (p/1-p)) to improve their statistical 
properties and later back-transformed to prevalences and expressed as percentages.  For further 
analysis, the data was stratified by continent and location of the study.   Attributed causes of the 
ETG were listed and compared across continents using descriptive statistics but such comparison 
was not performed for the interventions because they measured different outcomes and few 
provided numerical estimates.  
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2.2.6 Description of heterogeneity and summary estimates 
 
We used a forest plot (Lewis & Clarke, 2001) to visualize the extent of heterogeneity among the 
studies that investigated the magnitude of the ETG.  The standard test for heterogeneity, the 
Cochrane χ 2 test, was used to examine the null hypothesis of homogeneity.  We used a method 
that quantifies inconsistency across studies, thus assessing its impact on the meta-analysis. This 
statistic is I2 = ((Q – df)/Q) x 100%, where Q is the chi-squared statistic and df  is its degrees of 
freedom (Higgins & Thompson, 2002; Higgins, 2003). I2 describes the percentage of the 
variability in estimates that is due to true heterogeneity (true differences in ETG prevalence) and 
a value greater than 50% was considered substantial heterogeneity. 
 
The mean ETG prevalence and its confidence intervals were derived from random effects meta-
analysis, an analytical approach used when heterogeneity cannot be readily explained.  This 
assumes that the outcomes being estimated in the different studies are not identical, but follow a 
normal distribution, allowing for variation between studies.  However, the usual CI of mean in 
the random effects model does not take into account the between study variance and so can be 
narrow where there is substantial heterogeneity.  We therefore calculated the 95% CI for the true 
ETG prevalence as the mean of logits ± 1.96ℓ, where ℓ is the among study standard deviation 
(Goodman, 1989).  
 
2.2.7 Assessment of methodological quality 
 
The studies were appraised by two independent reviewers based on the criteria outlined in a 
critical appraisal guide (Crombie, 1996) and guidelines on how to appraise a paper (Greenhalgh, 
2001). The relevant methodological aspects were identified and assessed individually for each 
study.  The studies were then rated as good, average or poor as outlined in (Appendix 2.2).  We 
did not use a composite numerical score to reflect overall methodological quality because there is 
no gold standard for the ―true‖ methodological quality and such scores are probably neither valid 
nor reliable in practice (Greenhalgh, 2001).  Empirical evidence and theoretical considerations 
suggest that although summary quality scores may in some circumstances provide a useful 
overall assessment, they should not generally be used to assess the quality of studies in 
systematic reviews because different scales give divergent scores and rankings on one study 
(Juni et al., 1999; Greenland, 1994).  
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2.3 Results 
 
The electronic search produced 130 references.  A hand search of references cited in the key 
papers identified fifteen additional papers (Appendix 2.3).  These papers were obtained and 
reviewed and the majority were subsequently excluded  because they did not meet the review 
criteria: they were review articles (n=20), editorials or letters (n=12), reports (n=20), not in 
English (n=2), prevalence studies that did not estimate the ETG (n=19), trials of AEDs (n=10), 
economic evaluation studies (n=5), studies in developed countries (n=28) or studies reporting the 
same results in different papers (n=2).  
 
Twenty seven studies fulfilled the inclusion criteria. Twelve (44%) were prevalence studies that 
measured the ETG, eight (30%) identified attributed causes of the ETG and the remaining seven 
(26%) reported the effect of interventions designed to address the attributed causes of the ETG.  
Twelve (45%) of the studies were conducted in Africa, nine (33%) in Asia, and six (22%) in 
Latin America.  
 
2.3.1 Magnitude of the epilepsy treatment gap 
 
Out of the twelve studies identified, six (50%) were conducted in Latin America (Mendizabal & 
Salguero, 1996; Nicoletti et al., 1999; Noronha et al., 2004; Medina et al., 2005; Somoza et al., 
2005; Noronha et al., 2007), three (25%) in Africa (Coleman et al., 2002; Ndoye et al., 2005; 
Dent et al., 2005) and three (25%) in Asia (Aziz et al., 1997b; Radhakrishnan et al., 2000; Wang 
et al., 2003).  The majority, eleven (92%) were population-based cross-sectional surveys, while 
one (8%) used indirect method to estimate the gap.  There was wide variability in the ETG 
estimates among the studies that provided its magnitude (Fig 2.1). The Cochrane χ 2 statistic and 
measure of inconsistency were large (Q = 1331.5, df = 13, p < 0.0001; I2 = 99%), suggesting 
substantial variation among the studies that was beyond sampling variation.  The random effects 
mean of the ETG prevalence for all of the studies was 56.0/100 (95% CI for true prevalence: 
31.1- 100.0).  When stratified by continent, the random effects mean of the ETG prevalence for 
Latin America was 55.4/100 (95% CI: 39.0 -78.6), Asia 64.0/100 (95% CI: 24.3-100.0) while 
that of Africa was 49.0/100 (95% CI: 14.3-100.0). The mean of the ETG prevalence for urban 
settings was estimated at 46.8/100 (95% CI: 34.1-64.2) and 73.3/100 (95% CI: 49.5-100.0) for 
rural regions (Table 2.1). 
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The ETG estimate from Turkey was not included in this stratification because distinct figures 
were not provided for rural and urban regions (Aziz et al., 1997b).  The ETG summary is 
outlined in (Table 2.1) and details of individual studies in (Appendix 2.4). 
 
Figure 2.1: Forest plot for the epilepsy treatment gap prevalence 
 
Table 2.1: Magnitude of the epilepsy treatment gap by region and location 
 
 
 
 
 
 
 
 
 
 
 
Continent/Location No. of 
studies 
TG% Lower  
95% CI 
Upper 
95% CI 
Latin America 
 
7 55.4 39.0 78.6 
Asia 
 
4 64.0 24.3 100.0 
Africa 
 
3 49.0 14.3 100.0 
     
Urban 
 
7 46.8 34.1 64.2 
Rural 
 
7 73.3 49.5 100.0 
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2.3.2 Causes of the epilepsy treatment gap 
 
Eight studies investigated causes of the ETG.  Half were conducted in Africa (Elechi, 1991; 
Preux et al., 2000; Bassili et al., 2002; El Sharkawy et al., 2006) and the other half in Asia (Pal 
et al., 2000b; Asawavichienjinda et al., 2003; Mac et al., 2006; Das et al., 2007).  No studies 
were indentified from Latin America.  Two were qualitative, six quantitative and one study 
combined both methodologies.  Most of the studies were small (less than 100 participants), 
except two that interviewed 229 and 1450 PWE, respectively (Bassili et al., 2002; Das et al., 
2007).  All the eight studies reported that the cost associated with seeking epilepsy care 
contributed to the ETG (Bassili et al., 2002; Das et al., 2007; Pal et al., 2000b; Mac et al., 2006; 
Preux et al., 2000; Elechi, 1991; Asawavichienjinda et al., 2003; El Sharkawy et al., 2006).  
Attributed causes of the ETG were multiple and overlapping in the two continents, as 
summarized in (Table 2.2).  These causes were also similar for rural and urban regions.  The 
highest median (70%) was associated with inadequate skilled manpower and the lowest (18.5%) 
with long distances to health facilities (Table 2.2).  Non-adherence to AEDs, a factor that also 
contributes to ETG was investigated in two studies (Elechi, 1991; Asawavichienjinda et al., 
2003).  Details of individual studies are shown in (Appendix 2.5).   
 
Table 2.2: Cause of the epilepsy treatment gap expressed as median and range 
 
 
 
Causes of ETG No. of 
studies 
Median 
(%) 
Minimum 
(%) 
Maximum 
(%) 
Cost of treatment 
 
8 62 11 90 
Superstitions and cultural beliefs 
 
5 40 7 65 
Unavailability of drugs 
 
5 53 18 44 
Long distance to health facilities 
 
3 18.5 18 19 
Traditional treatment 
 
3 44 6 82 
Inadequate skilled manpower 
 
3 70 64 76 
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2.3.3 Intervention strategies to address causes of the epilepsy treatment gap 
 
Seven studies were identified that addressed attributed causes of the ETG.  Five (71%) were 
conducted in Africa (Adamolekun et al., 1999; Adamolekun et al., 2000; Olley et al., 2001; 
Berhanu et al., 2002; Feksi et al., 1991b) and two (29 %) in Asia (Gourie-Devi et al., 2003; Liu 
et al., 2003).  No studies were indentified from Latin America.  Five interventions were solely 
educational (Adamolekun et al., 1999; Olley et al., 2001; Adamolekun et al., 2000; Gourie-Devi 
et al., 2003; Liu et al., 2003), one provided AEDs (Feksi et al., 1991b) and one combined 
education with provision of AEDs (Berhanu et al., 2002).  The education interventions were 
modular in nature and were delivered verbally through workshops to PWE and health 
professionals.  They covered different topics such as causes of epilepsy, epidemiology of 
epilepsy, diagnosis and management of epilepsy, psychosocial aspects and community based 
care.  These interventions led to an increase in knowledge among PWE and health professionals, 
as measured by the difference between assessment before and after the intervention (Olley et al., 
2001; Gourie-Devi et al., 2003; Adamolekun et al., 1999; Liu et al., 2003).   In addition, 
education led to an increase in patient recruitment (Adamolekun et al., 1999; Adamolekun et al., 
2000; Berhanu et al., 2002).  Though information pamphlets led to improvements in knowledge 
and a reduced default rate, they did not have any effect on adherence, as measured by self reports 
and serum AED levels (Adamolekun et al., 1999; Liu et al., 2003).  However, verbal education 
and drug supply led to an increase in adherence (Feksi et al., 1991b; Adamolekun et al., 1999; 
Adamolekun et al., 2000; Liu et al., 2003).  Only one study assessed psychosocial factors, which 
are known to affect quality of life among PWE.  This study reported decreased levels of 
depression and neurotic disorders in the group receiving education (Olley et al., 2001).  Details 
of individual studies are summarized in (Appendix 2.6).  
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2.4 Discussion 
 
2.4.1 Magnitude of the epilepsy treatment gap 
 
A comprehensive search of the literature identified only twelve studies that estimated the 
magnitude of the ETG: this paucity of studies substantiates Kale‘s findings that the ETG as an 
outcome measure is not well studied in the developing world (Kale, 2002). The results of this 
review show that the pooled ETG estimate of 56% is lower than the 90% that is widely quoted in 
many studies (Scott et al., 2001; Diop et al., 2003; Diop et al., 2005; Shorvon & Farmer, 1988; 
Dua et al., 2006) although the CI are wide.  The higher estimate is not based upon systematic 
review of the data and does not provide confidence intervals.  To the best of our knowledge, this 
is the first study that comprehensively reviews the literature to assess the variability of the ETG 
using a robust and reproducible method.  The few narrative reviews that have been conducted in 
DCs have addressed the epidemiology of epilepsy with a mention of the ETG (Bharucha, 2003; 
Mac et al., 2007; Sridharan, 2002; Rajbhandari, 2004; Ray et al., 2002; Shorvon & Farmer, 
1988). A substantial amount of variation in the ETG among studies was demonstrated by 
graphical display of the estimates, a statistical test of heterogeneity and a measure of 
inconsistency.  The pooled estimate, using a method that corrects for among study variation, 
provides a meaningful indication of the magnitude of the ETG.  When stratified by continent, 
studies conducted in Africa had the highest variability whereas Latin America had the lowest.  
Variability was also higher in rural compared to urban areas (Table 2.1), although none of the 
studies in this review attempted to identify specific reasons for such rural/urban differences.  
  
Though we did not investigate sources of heterogeneity, some variation in estimates may be 
explained by a failure to calculate the ETG uniformly. Seven studies calculated it using active 
epilepsy as the denominator (Medina et al., 2005; Noronha et al., 2007; Coleman et al., 2002; 
Dent et al., 2005; Aziz et al., 1997b; Radhakrishnan et al., 2000; Wang et al., 2003) and four 
used both active and passive epilepsy (Mendizabal & Salguero, 1996; Nicoletti et al., 1999; 
Ndoye et al., 2005; Somoza et al., 2005).  In addition, studies defined active epilepsy differently: 
Eight confined it to five years, according to the ILAE definition (Somoza et al., 2005; Coleman 
et al., 2002; Aziz et al., 1997b; Nicoletti et al., 1999; Radhakrishnan et al., 2000; Medina et al., 
2005; Dent et al., 2005), two limited it to one year (Ndoye et al., 2005; Wang et al., 2003), 
whereas one study used two years (Noronha et al., 2007).   
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Other factors that might have contributed to heterogeneity include different study populations, 
unskilled manpower in rural settings, variable socioeconomic conditions and diverse levels of 
health care development in the study regions (Nicoletti et al., 1999; Jallon, 1997).  The study by 
Somoza et al., which had the widest CI (Figure 2.1) consisted of school children and only a small 
number failed to seek treatment.  This could have been influenced by the high level of literacy 
and the study setting, which was described as a district where social, economic and health 
indicators ranked among the country‘s highest and reached levels comparable to developed 
countries.  
 
2.4.2 Causes of the epilepsy treatment gap 
 
We found that attributed causes of the large ETG in DCs were multiple and overlapped between 
continents (Appendix 2.5).  All the eight studies included in the review reported that the cost of 
seeking epilepsy treatment was associated with the ETG in DCs (Bassili et al., 2002; Das et al., 
2007; Pal et al., 2000b; Mac et al., 2006; Preux et al., 2000; Elechi, 1991; Asawavichienjinda et 
al., 2003; El Sharkawy et al., 2006).  The attributed causes with the highest medians were related 
to the health systems mainly: inadequate skilled manpower, cost of treatment and unavailability 
of drugs.  This indicates that health system issues are a major obstacle for ETG.  Though 
individual perceptions such as cultural beliefs, traditional treatment and distance to health 
facilities had lower medians, they greatly influence treatment seeking among PWE.  The findings 
of this review show that superstations and cultural beliefs influence PWE to seek treatment from 
Traditional Healers (THs) instead of allopathic practitioners (Pal et al., 2000b; Preux et al., 2000; 
Asawavichienjinda et al., 2003; El Sharkawy et al., 2006; Das et al., 2007).  Shorvon et al., also 
observed that many patients spent considerable amounts of money to obtain traditional cures and 
it was common for patients to travel hundreds of miles or donate treasured items to a healer in 
return for antiepileptic treatment (Shorvon & Farmer, 1988).  This negates the usefulness of the 
advances made in the diagnosis and treatment of epilepsy (Das et al., 2007; Leppik, 1988) hence 
the need for comprehensive programs to address these attributed causes.  
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2.4.3 Intervention strategies to address causes of the epilepsy treatment gap 
 
The results of this review suggest that some attributed causes of the ETG in DCs can be 
addressed through educational interventions and supply of AEDs.  Such interventions should 
target health providers (including THs), PWE and the wider community (Scott et al., 2001; 
Berhanu et al., 2002).  The interventions should be tailored to the needs of each target group: 
those for health providers should be geared towards improving skills in diagnosis and 
management of epilepsy whereas for PWE emphasis should be on adherence, when and how to 
take AEDs as well as how to live with epilepsy.  They should also include psychosocial aspects 
of epilepsy that may lead to the development of a positive attitude towards PWE which is 
essential in improving quality of life and treatment (Jallon, 1997).  Educational interventions in 
developed and DCs have been shown to improve epilepsy knowledge, AED adherence, seizure 
outcome and self-esteem among PWE (Olley et al., 2001; Gourie-Devi et al., 2003; Adamolekun 
et al., 1999; Liu et al., 2003; Berhanu et al., 2002; Snead et al., 2004; Helde et al., 2003; Helde 
et al., 2005; Clark et al., 2001; May & Pfafflin, 2002; Wohlrab et al., 2007; Helgeson et al., 
1990).  Other studies have suggested that adequate drug supplies have to be provided for the 
success of any epilepsy management program (Gourie-Devi et al., 2003; Feksi et al., 1991b; 
Mani et al., 2001; Watts, 1989).  However, experience in DCs with other major public health 
problems, particularly communicable diseases, has demonstrated that simply delivering drugs to 
these countries will not necessarily reduce the ETG (Reynolds, 2000).  This indicates that health 
system interventions are not sufficient on their own. There is need to accompany such 
interventions with non-pharmacological, community-based interventions in order to reduce the 
stigma of epilepsy and reduce barriers to effective care (Krishnamoorthy et al., 2003).   
 
2.5 Limitations of the review 
 
Studies may not have been identified at the search stage if they were not indexed in the three 
databases used or not published in mainstream journals.  Studies on causes and interventions 
varied in the population studied, selection procedures, methods of ascertainment, study length 
and outcomes measured. Due to these variations, data from separate studies could not be 
statistically combined.  Numeric estimates were not available for some quantitative outcomes in 
intervention studies hence descriptive statistics were not calculated for this section of the review.  
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Studies that investigated the ETG were independent of those that instituted interventions; hence 
it was not possible to compare differences in the ETG before and after an intervention.  We did 
not investigate the potential sources of heterogeneity due to the small number of studies and 
inadequate variables in studies that estimated the ETG.  Though we included all languages 
during the search, we were not able to translate two Chinese papers reporting magnitude of the 
ETG, although the abstracts indicated an estimate similar to the included studies.   
 
2.6 Conclusion 
 
This review provides a more accurate pooled estimate of the ETG in DCs with confidence 
intervals.  Furthermore, it provides attributed causes of the gap and lists interventions that have 
been implemented to improve outcome in DCs.  Given the economic, social, political and 
cultural context of the ETG, there is need for future research to focus on well-planned and 
coordinated interventions.  The findings of this review suggest that such interventions should 
consider the medical, developmental and psychosocial needs of PWE as well as being 
financially, geographically and culturally accessible. These interventions should also involve 
health system personnel as well as other personnel such as THs who incorporate cultural beliefs 
and provide more comprehensive care. 
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Appendix 2.1: Description of the search strategy 
 
Search element MEDLINE EMBASE PSYCINFO 
Exposure Thesaurus terms exploded 
AED intervention 
Education Intervention 
Thesaurus terms exploded 
AED intervention 
Education Intervention 
Thesaurus terms exploded 
AED intervention 
Education Intervention 
Outcome Thesaurus terms exploded 
Increased knowledge 
AED adherence 
Drug level 
Seizure frequency 
Clinic attendance 
Thesaurus terms exploded 
Increased knowledge 
AED adherence 
Drug level 
Seizure frequency 
Clinic attendance 
Thesaurus terms exploded 
Increased knowledge 
AED adherence 
Drug level 
Seizure frequency 
Clinic attendance 
Epilepsy Thesaurus terms exploded 
Epilepsy:  
Reflex 
Absence 
Roland 
Generalized 
Tonic-clonic 
Frontal Lobe 
Partial motor 
Partial sensory 
Post-traumatic 
Temporal lobe 
Benign neonatal 
Complex partial 
Epilepsies:  
Myoclonic 
Partial 
Myoclonic epilepsy:  
Juvenile 
Progressive  
Seizures: 
Alcohol withdrawal 
seizures 
Febrile seizures           
  
Thesaurus terms exploded 
Epilepsy: 
Absence 
Temporal lobe 
Generalized 
Grand mal 
Frontal lobe 
Myoclonus 
Focal 
Petit mal 
Rolandic 
Reflex 
Startle 
Intractable 
Seizures: 
Atonic 
Audiogenic 
Clonic 
Gelastic 
Nocturnal 
Thesaurus terms exploded 
Epilepsy: 
Absence 
Generalized 
Tonic clonic 
Complex partial 
Seizures 
Developing 
Countries 
Resource poor countries 
Third world countries 
Majority world countries 
South America 
Africa  
Asia 
Resource poor countries 
Third world countries 
Majority world countries 
South America 
Africa 
Asia 
Resource poor countries 
Third world countries 
Majority world countries 
South America 
Africa  
Asia 
Treatment gap Treatment gap 
Treatment status  
Treatment gap 
Treatment status 
Treatment gap 
Treatment status 
Anti-epileptic   
drugs 
Anticonvulsants Anticonvulsants Anticonvulsants 
Adherence Compliance 
Patient compliance 
Treatment refusal 
Compliance 
Patient compliance 
Treatment refusal 
Compliance 
Patient compliance 
Treatment refusal 
Interventions Projects 
Programmes 
Projects 
Programmes 
Projects 
Programmes 
Population Adults or Children Adults or Children Adults or children 
Language Any Any Any  
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Appendix 2.2: Domain of methodological quality of studies included in the review                           
Cross sectional surveys 
 
Author Year Description of the 
study population 
Description of 
sampling procedure 
Response rate 
Mendizabal 1996 Poor   Poor  
 
Good (97.3%) 
Aziz 1997 Good  Good  Good (100%) 
 
Nicoletti 1999 Good  Good  Good (98.3%) 
 
Radhakrishnan 2000 Good  Good  Good (98%) 
 
Coleman 2002 Good  
 
Good  Good (99.8%) 
Wang 2003 Poor  
 
Average  Good (94.6%) 
Ndoye 2005 Good Good 
 
Good (100%)   
Medina 2005 Good  Good 3 
 
Good (86%) 
Somoza 2005 Good Good 
 
Good (83.1%) 
Dent 2005 Good Good 
 
Good (99%) 
Naronha 2007 Good Good 
 
Good (100% ) 
Preux 2000 Good Average  Average (72% ) 
 
Bassili 2002 Good Good 
 
Good (100%) 
Thanin 2003 Good Good 
 
Good (89.2) 
Mac 2006 Good Good Good (100%) 
 
Qualitative studies 
 
  Description of 
setting and selection 
of subjects 
Description of data 
collection methods 
Description of data 
analysis and 
quality control 
measures 
Gehane 2006 Good 
 
Good Average 
Pal 2000 Average Poor 
 
Poor 
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Appendix 2.2: Continued from previous page 
 
Case control studies 
 
Author Year Clear explanation 
on how cases were 
obtained 
Selection of 
appropriate controls 
Identical data 
collection for 
cases and 
controls 
Pal 2000 Good  Good 
 
Average  
Prospective cohort studies 
 
  Clear explanation 
of the study 
participants 
Appropriateness of the 
control group if any 
Adequate follow 
up  
Elechi 
 
1991 Good N/A Good (2.5 years) 
Das  2007 Good N/A 
 
Good (1 year) 
Adamolekun 2000 Good N/A 
 
Good( 2 years) 
Berhanu 2002 Good N/A 
 
Good (1.5 years) 
Feksi 1991 Good N/A Good (1 year) 
 
Pre-post interventions studies 
 
  Description  of 
study participants 
Description  of the 
intervention 
Evaluation 
interval 
Adamolekun 
 
1999 Good Average Good (6 months) 
Olley 
 
2001 Good Good Poor (2months) 
Gourie-Devi 
 
2003 Good Average Average (3 
months) 
Liu 
 
2003 Good Average Poor (1 month) 
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Treatment gap Causes of 
treatment 
Treatment gap 
interventions (n=7) 
Appendix 2.3: Flow Diagram of Study Selection Process 
 
 
 
 
Excluded editorial, letters and reports (n=32) 
 
 
 
 
Excluded review papers (n=20) 
Excluded studies not in English (n=2) 
 
 
 
 
 
Studies excluded (after evaluation of full text) 
Rejected because they did not estimate the TG (n=34) 
Reported similar results in different papers (n=2) 
 
 
 
 
Studies omitted from systematic review (n=28) 
(Conducted in developed nations) 
 
 
 
 
 
 
 
 
    
 
                                           
 
 
magnitude (n=12)        gap (n=8)                        
Number of papers identified through electronic and hand search 
(n = 145) 
Relevant papers on epilepsy treatment gap 
(n=91) 
Studies retrieved for more detailed evaluation 
 (n=55) 
Studies included in review 
(n=27) 
Limit to papers in English 
(n=113) 
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Appendix 2.4: Magnitude of the epilepsy treatment gap in developing countries  
Prev: Prevalence, TG: Treatment gap, CS: Cross sectional survey, Q: Questionnaire, R: Rural, U: Urban, SU: Semi urban, C: Campinas city,   S: Sao Jose do Rio Preto city
Author Year Country Study  
design 
 
Ascertain* Age 
Years 
Length of 
study 
Sample size Active 
epilepsy 
Prev/1000 TG % L 95% 
CI 
U 95%   
CI 
Mendizabal 1996 Guatemala CS  
 
Q All N/A 1882 (R) 11 5.8 68.8 41.3 89 
Aziz 1997 Pakistan 
 
Turkey 
CS Q All N/A 
 
8513 (R) 
15 617 (U) 
6680 (R) 
4817 (U) 
126 (R) 
115 (U) 
59(R) 
22 (U) 
14.8 (R) 
7.4 (U) 
8.8 (R) 
4.5(U) 
98 (R) 
73 (U) 
70 
93.2 
64 
99.5 
80.9 
Nicoletti 1999 Bolivia CS Q All 2 years 
 
9955 (R) 112 11.1 89.5 82.7 94.3 
Radhakrishnan 2000 India CS 
 
Q All 5 months 238 102 (SU) 1175 4.9 38 35.3 40.9 
Coleman 2002 Gambia CS 
 
Q All 9 months 16 200 (R) 69 4.3 48 35.6 60.2 
Wang 2003 China CS 
 
Q All N/A 55 000 (R) 257 4.6 63 56.8 69.0 
Ndoye 2005 Senegal CS 
 
Q All N/A 4500 (SU) 64 14.2 23.4 13.8 35.7 
Noronha 2004 Brazil Indirect 
method 
Formula 
n1–
n2/n1x100 
N/A N/A 6324 (S) (U) 
18600 (C) U) 
2591 (S) 
8182 (C) 
18.6 (S) 
18.6 (C) 
59 (S) 
56 (C) 
57.1 
55 
61.0 
57.1 
Medina 2005 Honduras CS 
 
Q All 11 days 6473 (R) 100  15.4 53.3 42.8 63.1 
Somoza 2005 Argentina CS 
 
Q Children 7 months 31 615 (U) 68 2.6 7.1 2.9 16.0 
Dent 2005 Tanzania CS 
 
Q All 5 months 4905 (R) 42 8.6 95.8 83.8 99.4 
Naronha 2007 Brazil CS 
 
Q All 4 months 96 300 (U) 290 5.4 38 32.3 43.8 
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Appendix 2.5: Causes of the epilepsy treatment gap in developing countries 
 
Author Year Country Study design Sample size Ascertain* Age 
Years 
Length of 
study 
Causes of treatment gap 
 
Elechi 
 
1991 Nigeria 
 
Prospective 
cohort 
45 PWE (R) 
 
Questionnaire 
 
Adults 2 .5 yrs Non-availability of drugs  
Excessive cost of drugs  
Continuity of seizures  
Side effects of drugs  
Long distance to health facility  
Pal 2000 India 
 
 
Case control 
 
 
 
 
Qualitative 
94 children   
- 32 (cases) 
- 62 (controls) 
 
 
32 parents   
 
(R) 
 
Questionnaire 
 
 
 
 
Semi structured 
topic schedule  
 
  
 
2-18 
 
1 year 
 
Seasonal income  
Inter-current illness in family members 
Domestic commitment among women  
Religious festivals  
Local cultural customs and beliefs  
Impassable roads during rainy season  
Long distance to health facilities  
Denial of diagnosis  
Drug side effects  
Alternative treatment  
Continuing seizures  
Lack of benefit from the treatment  
Symptoms resolution  
Preux 2000 Cameroon Cross sectional 
survey 
33 PWE   
26 physicians 
21 pharmacists 
3 distributors 
8 THs 
 
( U) 
Questionnaire ≥ 18 4mths Poor health delivery infrastructure  
Ignorance about causes of epilepsy  
Uneven supply of drugs  
Superstitions and cultural beliefs 
Alternative treatment  
Unavailability of drugs  
Long term treatment  
Expensive to consult physician  
Bassili 2002 Egypt Cross sectional 
survey 
229 children (U) Questionnaire 1-15 4 mths Lack of access to  neurologists  
Lack of diagnostic services (EEG)   
Defective health education of 
caregivers 
Non-compliance to AEDs 
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 Thanin 2003 Thailand 
 
Cross sectional 
survey 
72 PWE (R) Questionnaire 
 
≥ 15 5 mths Misunderstanding need for long-term 
treatment  
Forgetting to take drugs   
Economic problems  
Continuity of seizures despite 
treatment  
Misbeliefs  
No caregiver to take PWE to hospital  
Mac 2006 Vietnam Cross sectional 
survey 
33 pharmacies  
(U) 
Questionnaire Adults 2 mth Non-availability of AEDs 
Cost of AEDs 
Lack of skilled manpower  
Drugs dispensed for short periods  
Pharmacies concentrated around 
hospitals and main market  
Gehane 2006 Kenya Qualitative 9 grandparents  
16 parents 
19 HCP 
19 CWE 
 
(R) 
Checklist of 
questions 
All N/A Inadequate knowledge on causes 
epilepsy 
Inadequate skilled manpower 
Superstitions and cultural beliefs 
Severity of seizures 
Distance and time to health facilities 
Lack of finances 
Continuity of seizures despite 
treatment 
Inconsistent drug supply 
Alternative treatment 
Discrimination and stigma 
Das  2007 India 
  
Prospective 
cohort  
1450 PWE 
 (SU) 
 
Questionnaire Adults 1 year Low annual income  
Unemployment  
Loss of jobs  
Marital disharmony  
Superstitions and beliefs and   
Non-availability of drugs  
Frustration and despair  
PWE: People with Epilepsy, CWE: Children with epilepsy, THs: Traditional Healers, HCP: Health care personnel, AEDs: Antiepileptic Drugs     
R: Rural, U: Urban, SU: Semi-urban 
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Appendix 2.6: Intervention strategies to mitigate causes of the epilepsy treatment gap 
 
Author Year Country Study 
Design 
Sample size Intervention/ 
ascertainment 
Age 
Years 
Study 
length 
Findings 
Adamolekun 1999 Zimbabwe Pre-post 31 PHCNs 
24 EHTs 
296 PWE 
 
(R) 
Education 
 
Questionnaire 
 
AEDs blood 
level 
 
Adults 6 months Improved knowledge in diagnosis and management of 
epilepsy among PHCNs by11%  and EHTs by 9% as 
measured by pre and post test 
 
PHCNs and EHTs education led to a 35% increase in 
patient recruitment and drug compliance as measured by 
serum levels of AEDs 
 
Information pamphlets led to a reduction in patient 
default rate (56.3% in the control group) and 22.3% in 
the experimental group but did not influence drug 
compliance or seizure frequency 
Adamolekun 2000 Zimbabwe Prospective 
cohort  
114 PWE 
(U) 
Education 
 
AEDs blood 
level 
 
8-56 2 years No cases of non-compliance as defined by undetectable 
serum AED levels. 26% out of 38 clinically indicated 
cases had normal levels, 58% were below therapeutic 
ranges and 16 % were above the range 
 
47% increase in PWE registered in epilepsy support 
group   
Olley 2001 Nigeria Pre-post 30 PWE 
(R) 
Education 
 
Questionnaire 
21-65 2 months Significant increase in knowledge about epilepsy in the 
education group as measured by the knowledge about 
illness schedule P<0.001 
 
Significant decrease in level of depression in education 
group as measured by Becks Depression Inventory 
(BDI) P<0.001 
 
Significant decrease in neurotic disorders in the 
education group  as measured by the Crown-Crisp 
Experiential Index (CCEI) P<0.001        
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Berhanu 2002 Ethiopia Prospective 
cohort 
813 PWE 
5-10 Nurses  
(R) 
AEDs supply 
 
Education 
 
Self reports 
 
1-75 1.5 years Rapid increase in number of new patients attending the 
clinics due to awareness created by community leaders, 
community health workers and the trained nurses 
 
Regular and adequate supply of phenobarbitone to each 
health centre 
Feksi 1991 Kenya Prospective 
cohort 
302 PWE 
(R, SU) 
AEDs supply 
 
AEDs blood 
level 
 
6-65 1 year 76% of  249 patients had detectable serum drug 
concentrations and the AEDs were effective in reducing 
seizure frequency in 79% of the patients 
 
There was low drop-out 17%, low rate of non-
compliance 6%, and good response to therapy 53%. 
Gourie-Devi 2003 India Pre-post 148 DMOs 
21 SHA 
28 neulog 
 
Education 
 
Questionnaire 
Adults 3 years Increase of knowledge and skills in identification, 
diagnosis, investigation and management of epilepsy 
among DMOs as measured by pre and post test 
 
Improved understanding of issues related to compliance, 
medication, counselling, psychosocial and legal aspects 
among DMOs 
 
Endorsement of the epilepsy control program by SHAs 
and neurologists which lead to initiation and 
strengthening of epilepsy services at the periphery 
Liu 2003 Taiwan Prospective 
cohort 
 
Pre-post 
51 PWE Education 
 
Questionnaire 
 
AEDs blood 
level 
18-59 7 months Provision of drug leaflets improved medication 
knowledge by 30% among PWE hence an increase in 
Epilepsy Medication Score (EMA) P<0.001   
 
Significant reduction in drug side effects after the 
awareness campaign P<0.05 
 
Non-significant improvement in AED compliance after 
provision of leaflets as measured by self reports and 
serum AEDs levels 
PHCNs: Primary Health Care Nurses, EHTs: Environmental Health Technicians, DMOs: District Medical Officers, Neulog: Neurologists,      
SHA: State Health Administrators, DCs: Developing Countries, R: Rural, U: Urban, SU: Semi-urban 
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Development and validation of the Kilifi Stigma Scale for Epilepsy 
 
 
 
Caroline K. Mbuba1*, Amina Abubakar1,2,3 ,  Peter Odermatt4,5,  Charles R. Newton1,,6,7,8, Julie A. 
Carter9 
 
 
 
1 KEMRI/Wellcome Trust Research Programme, Centre for Geographic Medicine Research 
(Coast), Kilifi, Kenya  
2 Tilburg University, the Netherlands  
3 Utrecht University, the Netherlands 
4 Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, 
Basel, Switzerland  
5 University of Basel, Basel, Switzerland  
6 London School of Hygiene and Tropical Medicine, London, United Kingdom (UK) 
7 Neurosciences Unit, Institute of Child Health, University College London, London, UK 
8 Department of Psychiatry, University of Oxford, Oxford, UK  
9 Centre for International Health and Development, Institute of Child Health, London, UK  
 
*Corresponding author 
 
Email: ckathomi@kilifi.kemri-wellcome.org   
 
 
 
 
This article has been prepared for submission to Epilepsia 
 
 
Stigma Scale 
38 
 
Abstract 
 
Introduction 
 
Stigma is considered to be one of the most important factors exerting a negative influence on the 
lives of People with Epilepsy (PWE) and their families.  Despite its importance, there are few 
culturally appropriate measures to investigate it, especially in sub-Saharan Africa where the 
prevalence of epilepsy is high and the stigma is thought to be more severe. We developed and 
validated a tool to measure perceived stigma among PWE in Kilifi, Kenya.  
 
Methods 
 
We reviewed the existing scales that measured stigma, particularly of epilepsy.  We conducted a 
qualitative study to determine salient concerns related to stigma in Kilifi.  Themes were 
generated and those related to stigma were used to construct an 18-item stigma scale.  A 
descriptive cross-sectional survey was then conducted among 673 PWE to assess the reliability 
and validity of the scale.  Internal consistency was calculated using Cronbach‘s alpha and an 
interclass correlation coefficient was used to evaluate the test-retest reliability.  Factor analysis 
was performed to examine the structure of the scale and correlation analysis was used to evaluate 
the relationship between the scale scores and demographic characteristics. 
 
Results 
 
The final scale had 15 items, which had high internal consistency (Cronbach‘s α= 0.91) and 
excellent test-retest reliability (r=0.92). Factor analysis indicated that the scale was 
unidimensional with one factor solution explaining 45.8% of the variance.  No association was 
found between perceived stigma and sex but there was an association with age, physical and 
sexual abuse. 
 
Conclusion 
 
The Kilifi Stigma Scale for Epilepsy is a culturally appropriate measure of stigma with strong 
psychometric properties that could be used in other resource poor settings after some adaptation 
and validation. 
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3.1 Introduction 
 
Stigma associated with epilepsy is common in many cultures (Jacoby et al., 2005) and is 
considered to be one of the most important factors that has a negative influence on the lives of 
People with Epilepsy (PWE) and their families (Baker, 2002; Morrel, 2002; Mclin & de Boer, 
1995; Jacoby, 1992).  It erodes individuals‘ social status, social networks and self-esteem, all 
which contribute to poor outcomes such as isolation, unemployment, impaired prospects for 
marriage and not seeking treatment (Collings, 1990; Jacoby et al., 1993).  PWE report that 
dealing with stigma and the associated prejudicial responses from others is one of their biggest 
challenges (Austin et al., 2002).  Consequently, the Global Campaign Against Epilepsy ―Out of 
the Shadows‖ project  has focused attention on the problems caused by the stigma associated 
with epilepsy (Reynolds, 2001).   
 
Epilepsy fits well into ‗Weiss and Ramakrishna‘  definition of stigma as ―a social process or 
related personal experience characterized by exclusion, rejection, blame, or devaluation that 
results from experience or reasonable anticipation of an adverse social judgment about a person 
or group identified with a particular health problem‖ (Weiss & Ramakrishna, 2006).  Thus, 
epilepsy-associated stigma can best be understood by drawing a distinction between ‗enacted‘ 
and ‗perceived‘ stigma.  Enacted stigma refers to episodes of discrimination against PWE on the 
grounds of their social unacceptability; whereas perceived stigma refers to the shame associated 
with having epilepsy and the fear of anticipated discrimination (Reis & Meinardi, 2002; Jacoby, 
1994; Scambler & Hopkins, 1986).  There is no distinct evidence about which type of stigma is 
more likely to affect treatment seeking, but we presume perceived stigma has a profound 
influence because it emanates from the patient. 
 
Stigma is a complex concept to investigate in PWE because it involves personal attitudes and 
beliefs, elements of secrecy and disclosure management, as well as influences from the social 
environment (Austin et al., 2004).  Tools to measure perceived stigma among PWE have been 
developed mostly in Western countries (Jacoby et al., 1993; Jacoby, 1994; Austin et al., 2004; 
Austin & Huberty, 1993; Westbrook et al., 1992; Ryan et al., 1980; Austin et al., 2002; Cramer 
et al., 1999) and middle income countries (Fernandes et al., 2004; Fernandes et al., 2007; 
Fernandes et al., 2008; Aziz et al., 1997a).  The most commonly used scale in epilepsy is a three-
Stigma Scale 
40 
 
item scale developed by Jacoby (Jacoby, 1994), though it has been shown to produce disparate 
results in Western and Resource Poor Countries (RPCs) (Baker et al., 1999; Baker et al., 2005; 
Rafael et al., 2010; Lee et al., 2005; Birbeck et al., 2007).  This highlights the fact that cultural 
perceptions and values play an important role in understanding the concept and content of stigma 
by an individual.  Therefore, in designing a reliable and valid tool, it is essential to accommodate 
the cultural beliefs and understanding of each target group.  Taking this into consideration, we 
developed and validated a tool to measure perceived stigma among PWE in Kilifi, Kenya.  
Recently it was reported from Zambia that PWE experienced higher rate of physical abuse and 
women with epilepsy are more likely to have experienced sexual abuse (Birbeck et al., 2007; 
Birbeck et al., 2008).  We hypothesized that PWE who experience abuse, whether physical or 
sexual, would report a much higher level of perceived stigma compared to those who had not 
experienced abuse.   
 
3.2 Methods 
3.2.1 Study site and previous work  
 
The development of the scale took place in the Kilifi Health Demographic Surveillance System 
(KHDSS), where 86% of PWE were not receiving treatment from health facilities (Edwards et 
al., 2008), which may be due to cultural beliefs and attitudes held by PWE (El Sharkawy et al., 
2006).  A previous study suggested that PWE were more likely to consult Traditional Healers 
(THs) due to misconceptions and  superstitions associated with epilepsy (Kendall-Taylor et al., 
2009).  However, these studies did not assess the level of stigma experienced by PWE and how 
this might affect where and how they seek health care.  Therefore, we developed the Kilifi 
Stigma Scale for Epilepsy (KSSE) and used it to measure perceived stigma among PWE. 
 
3.2.2 Development of the Kilifi Stigma Scale for Epilepsy 
 
The items for the scale were developed in three phases: (1) formative research and concept 
development; (2) item development and validity assessment and (3) evaluating the scale. 
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Phase 1: Formative research and concept development 
 
First, we reviewed the literature to examine the existing scales that measured perceived stigma 
(Jacoby et al., 1993; Austin et al., 2002; Jacoby, 1994; Austin et al., 2004; Austin & Huberty, 
1993; Westbrook et al., 1992; Ryan et al., 1980; Cramer et al., 1999; Fernandes et al., 2004; 
Fernandes et al., 2007; Fernandes et al., 2008; Aziz et al., 1997a).  Second, we conducted a 
qualitative study with PWE and their caregivers to identify the issues related to stigma in Kilifi. 
Focus Group Discussions (FGDs) and in-depth interviews were conducted by three trained 
interviewers fluent in the local language.  The interviews were recorded, translated and 
transcribed.  The data were entered onto an NVivo qualitative analysis software (QSR; 
Melbourne, Vic, Australia; http://www.qsrinternational.com/) to enable storage, organisation and 
retrieval.  Data were analysed using framework analysis, as described by Ritchie and Spencer 
(Ritchie & Spencer, 1994).  Themes were independently generated from the data by two 
researchers (CK and JA) and once thematic consensus was reached, all the data was coded.  This 
process served to maximise the rigour and validity of the analysis.  The themes related to stigma 
were then used to construct the KSSE.  For more information on the qualitative study refer to 
Chapter 9.  
 
Phase 2: Item development and validity assessment 
Item generation 
 
The project team held discussions about the concepts to include, an appropriate response scale 
and the overall structure of the questionnaire.  A first version was developed that contained 18-
items that were considered to cover the most important aspects of perceived stigma.  Eight of the 
18 items in the KSSE were taken directly or revised from questions used in previous studies 
investigating perceived stigma in epilepsy (Jacoby et al., 1993; Jacoby, 1994; Fernandes et al., 
2004; Fernandes et al., 2007). The remaining ten items were developed from thematic analysis of 
FGDs and in-depth interviews.  The scale was developed in English and translated into the local 
dialect, Kigiriama. 
 
Scoring the scale 
 
A simple three-point Likert scoring system was employed to make it as easy as possible to 
respond to the items (Atadzhanov et al., 2010).  PWE were asked to respond to each item by 
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stating how much they thought a particular aspect of their life was affected by epilepsy.  
Responses were as follows: ―not at all‘ (score of 0), ―sometimes‖ (score of 1) and ―always‖ 
(score of 2).  A total impact score was calculated by addition of all item scores.  The higher the 
score, the greater the sense of perceived stigma.  
 
Face validation of the scale 
 
This was assessed to determine if the questionnaire contained relevant items for assessing 
perceived stigma in our context.  Two clinicians and five research assistants with experience in 
epilepsy were asked to evaluate the relevance, clarity and conciseness of the items included in 
the questionnaire. The seven respondents were of the opinion that the questions measured 
stigma.  Based on this initial assessment, all 18 items were retained.  
 
The questionnaire was then pilot tested with six PWE and seven caregivers of PWE.  It was 
administered by two interviewers fluent in the local language.  The respondents were asked to: 
(a) comment on whether the items measured perceived stigma; (b) rate the items on a three-point 
rating scale (0= not at all, 1=sometimes, 2=always); (c) provide explanation supporting their 
decision to assign a rating to an item; and (d) comment on the clarity and flow of the questions. 
All 18 items were found to assess perceived stigma and were clear to all respondents.   
 
Phase 3: Evaluating the scale 
 
A descriptive cross-sectional survey was conducted in the KHDSS to assess the reliability and 
validity of the scale.  Six hundred and seventy three PWE completed the scale, of whom 203 
were PWE and 470 caregivers of children with epilepsy.  Data on a subset of 70 PWE were then 
used to evaluate test-retest reliability of the scale. The interviewer administered the scale twice to 
the same respondents at an interval of three weeks.   
 
3.2.3 Ethical considerations 
 
Written informed consent was obtained from all study participants. Where PWE was a child or 
an adult who could not respond, a caregiver was interviewed.  Approval for the study was 
obtained from the Kenya Medical Research Institute/ National Ethical Review Committee. 
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3.2.4 Data analysis 
 
Data were double entered in MySQL and verified before being transferred to SPSS (version 15, 
SPSS Inc., Chicago) for analysis.  Descriptive statistics were generated to evaluate the score 
distribution per response category. The internal consistency of the scale was calculated using 
Cronbach‘s alpha (α) (Cronbach, 1951). An interclass correlation coefficient was used to 
evaluate the test-retest reliability.  Factor analysis was performed to examine the structure of the 
scale using varimax rotation. Items were retained if they had an item-total correlation ≥ 0.2 and a 
factor loading ≥ 0.40 (Dilorio et al., 2004; Nunnally & Bernstein, 1994).  Correlation analysis 
was used to evaluate the relationship between the scale scores, sex, age and history of physical 
and sexual abuse. 
 
3.3 Results 
3.3.1 Psychometric properties 
3.3.1.1 Descriptives 
 
The descriptive statistics show that majority of participants responded ‗not at all‘ to most of the 
items on the stigma scale meaning they did not feel stigmatized (Table 3.1).  However, higher 
rate of perceived stigma was reported on three items (not relating well with family members, not 
being accepted by peers and not being taken seriously by other people (Table 3.1). 
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Table 3.1: Proportion of responses by study participants (n=673)  
 
 Item Not at all 
(%) 
Sometimes 
(%) 
Always 
(%) 
1 Do you feel different from other people? 
 
36.1 37.4 26.5 
2 Do you feel lonely? 
 
59.8 27.9 12.3 
3 Do you feel embarrassed? 
 
65.3 23.3 11.4 
4 Do you feel disappointed in yourself? 
 
42.0 39.7 18.3 
5 Do you feel you cannot have a rewarding life? 
 
62.0 22.7 15.3 
6 Do you feel you cannot contribute anything in society? 
 
60.9 21.6 17.5 
7 Do you feel you cannot join others in public places? 
 
56.9 19.8 23.3 
8 Do you feel other people are uncomfortable with you? 
 
59.7 29.1 11.2 
9 Do you feel other people don‘t want to go to occasions 
with you? 
57.4 27.6 15.0 
10 Do you feel other people treat you like an inferior person? 
 
54.7 26.7 18.6 
11 Do you feel other people would prefer to avoid you? 
 
62.2 25.6 12.2 
12 Do you feel other people avoid exchanging greetings with 
you? 
75.6 18.1 6.3 
13 Do you feel you do not relate well with your family? 
 
21.4 11.9 66.7 
14 Do you feel you are not accepted by your peers? 
 
6.7 18.0 75.3 
15 Do you feel you are mistreated by other people? 
 
67.8 24.8 7.4 
16 Do you feel other people discriminate against you? 
 
67.3 23.3 9.4 
17 Do you feel other people do not take you seriously? 
 
8.8 18.9 72.3 
18 Do you feel other people treat you like an outcast? 
 
69.4 19.9 10.7 
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3.3.1.2 Internal consistency  
 
The alpha score for the whole scale (18 items) was 0.85.  This initial analysis demonstrated that 
three items had a negative total correlation: not relating well with family members (-0.02), not 
being accepted by peers (-0.46) and not being taken seriously by other people (-0.27).  After 
exclusion of these items, the remaining 15 items had excellent internal consistency (α =0.91).  
The internal consistency of the scale is outlined in (Table 3.2). 
 
Table 3.2: Internal consistency of the Kilifi Stigma Scale for Epilepsy (n=673) 
 
 Item Scale mean 
if item 
deleted 
Scale variance 
if item deleted 
Corrected 
item-total 
correlation 
Alpha if 
item 
deleted 
1 Different  
 
7.27 44.6 0.53 0.91 
2 Lonely 
 
7.65 44.8 0.59 0.90 
3 Embarrassed 
 
7.72 45.7 0.49 0.91 
4 Disappointed  
 
7.41 45.8 0.44 0.91 
5 Rewarding life 
 
7.64 45.9 0.42 0.91 
6 Society 
 
7.61 44.7 0.53 0.91 
7 Public places 
 
7.51 44.2 0.53 0.90 
8 Uncomfortable  
 
7.66 43.5 0.75 0.89 
9 Occasions  
 
7.60 42.9 0.74 0.89 
10 Inferior  
 
7.54 42.5 0.75 0.89 
11 Avoid  
 
7.68 43.3 0.75 0.89 
12 Greetings  
 
7.87 45.2 0.67 0.90 
13 Mistreated  
 
7.78 45.4 0.59 0.90 
14 Discriminate  
 
7.76 44.2 0.70 0.90 
15 Outcast 
 
7.76 44.5 0.64 0.90 
Items were preceded with the following phrase:  Do you feel…… as indicated on (Table 3.1) 
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3.3.1.3 Test retest reliability 
 
Test retest reliability was estimated by computing the inter-correlation coefficient and found to 
be excellent (r=0.93).   
 
3.3.1.4 Factor analysis  
 
The dimensionality of the scale was studied using factor analysis. All the items loaded on one 
factor, which accounted for 45.8% of the variance (Eigenvalue=6.87).  The consistently high 
factor loadings (0.46-0.82) strongly supported one unitary construct of the scale as depicted in 
(Table 3.3). These results support the use of a summated score to compute an overall index 
called ‗perceived stigma‘. 
 
Table 3.3: Factor loading of the fifteen items of the Kilifi Stigma Scale for Epilepsy (n=673) 
 
 Item Factor  loading 
 
1 Do you feel different from other people? 
 
0.58 
2 Do you feel lonely? 
 
0.63 
3 Do you feel embarrassed? 
 
0.54 
4 Do you feel disappointed in yourself? 
 
0.48 
5 Do you feel you cannot have a rewarding life? 
 
0.46 
6 Do you feel you cannot contribute anything in society? 
 
0.57 
7 Do you feel you cannot join others in public places? 
 
0.58 
8 Do you feel other people are uncomfortable with you? 
 
0.81 
9 Do you feel other people don‘t want to go to occasions 
with you? 
0.81 
10 Do you feel other people treat you like an inferior 
person? 
0.82 
11 Do you feel other people would prefer to avoid you? 
 
0.82 
12 Do you feel other people avoid exchanging greetings 
with you? 
0.74 
13 Do you feel you are mistreated by other people? 
 
0.67 
14 Do you feel other people discriminate against you? 
 
0.77 
15 Do you feel other people treat you like an outcast? 
 
0.72 
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3.3.1.5 Construct validity 
 
Given that we had two different samples, we split the data based on who responded to the 
questionnaire (203 PWE and 470 caregivers). There was no difference in internal consistency 
based on who responded (0.90) for PWE or (0.91) for caregivers.  
 
Correlations were calculated to explore the relationship between socio-demographic 
characteristics and stigma scores.  We hypothesised that there would be no differences in stigma 
scores by sex but we anticipated significant differences by age.  Results indicated that there was 
no relationship between sex and perceived stigma score (r= 0.04, p=0.30). High correlations 
were found between age and perceived stigma score, with younger age associated with greater 
perception of stigma (r=0.68, p<0. 03).  Our analysis confirmed there was a correlation between 
perceived stigma scores and physical abuse (r=0.33, p<0. 001) as well as perceived stigma score 
and sexual abuse (r=0.76, p<0. 01).  
 
3.3.1.6 Perceived stigma scores 
 
The index of stigma was calculated for each individual by adding the responses to each question. 
The lowest score was 0 and the highest was 30 (Figure 3.1). The lower quartile, median and 
upper quartile values were 2, 7, and 13 respectively.  The 66th percentile was used to categorize 
the scores (Holding et al., 2004), so that scores above 10 were considered to show the PWE who 
felt stigmatized.  Out of the 673 respondents, 33% reported being stigmatized as measured by the 
KSSE. 
 
Figure 3.1: Scores for the Kilifi Stigma Scale for Epilepsy  
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3.4 Discussion 
 
The purpose of this study was to develop and evaluate a culturally-appropriate measure of 
perceived stigma among PWE in a rural Kenyan setting.  Using a systematic approach to tool 
development, as previously used in Kilifi (Abubakar et al., 2008; Abubakar et al., 2007; Holding 
et al., 2004), we developed a 15-item scale that provides a measure of stigma in epilepsy with 
proven reliability and validity. 
 
3.4.1 Reliability 
 
Criteria set out by Cicchetti (Cicchetti, 1994) were employed in evaluating the level of 
acceptability of the observed values of reliability coefficients.  Correlations of 0.70 or higher are 
usually considered acceptable levels of internal consistency of items (Jacoby et al., 1993; 
Cicchetti, 1994). 
 
The excellent internal consistency and retest reliability observed in this study supported the 
suitability of items selected and the reliability of the tool in our setting.  Furthermore the 
selection of culturally-appropriate items through qualitative research ensured the items were 
understood.  The reliability of KSSE compares well to other scales developed to measure stigma 
in epilepsy (Jacoby et al., 1993; Austin et al., 2004; Fernandes et al., 2007; Fernandes et al., 
2004). 
 
3.4.2 Validity 
 
Factor-analytic evidence suggests that the scale is uni-dimensional, indicating that it measured 
only one construct (i.e. perceived stigma).  Internal consistency did not differ whether it was a 
PWE who responded or a caregiver.  This suggests that perceived stigma of children or PWE 
with neuro-cognitive impairment can be assessed through a caregiver (mother, father or 
guardian) using the same scale. 
 
Further analysis was conducted to examine the correlation between the demographic variables 
and stigma scores.  Results indicated sex was not correlated with the stigma scores.  However, 
we observed an association between perceived stigma and age, which provides support for the 
age-sensitivity of the scale.   
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Younger age was associated with greater perceptions of stigma, a finding also reported in other 
studies (Jacoby, 1994; Austin et al., 2004; Westbrook et al., 1992).  Possibly, older people were 
less likely to report feeling stigmatized because discriminatory attitudes towards epilepsy may 
have less significance to them than younger people who want to fit in with peers.  Given its 
potential negative impact there is a need to address stigma as part of a comprehensive care 
system especially for young PWE.   
 
An additional approach to validation was to correlate perceived stigma and reported abuse. 
Consistent with our hypothesis, PWE who experience physical and sexual abuse were more 
likely to report more perceived stigma.  This provides further evidence of the discriminant 
validity of the tool.  Moreover, it highlights other aspects of the psychosocial needs of PWE.  
Future studies should examine the prevalence and impact of abuse of PWE in this context.  
However, such studies should also investigate physical and sexual abuse in a detailed manner in 
order to accurately assess the level of abuse.  Our study may have underestimated the problem 
since we asked a single (yes/no) question regarding physical and sexual abuse. 
 
3.4.3 Perceived stigma scores 
 
Contrary to the observations that stigmatization and psychosocial problems for PWE are more 
common in RPCs (Van, 1972; Walker, 1972; Senanayake & Abeykoon, 1984), the results of our 
study do not indicate a high degree of perceived stigma in Kilifi.  Thirty three percent of PWE 
felt stigmatized by their condition, which contrasts with the findings of a study in Benin that 
demonstrated 69% of PWE felt stigmatized (Rafael et al., 2010).  However, this study assessed 
perceived stigma using the Jacoby scale (Jacoby, 1994), that has been shown to produce 
disparate results in different geographical areas (Rafael et al., 2010; Baker et al., 1999; Baker et 
al., 2005; Lee et al., 2005; Birbeck et al., 2007).  The low prevalence of stigma in Kilifi could be 
explained by the information that PWE in the KHDSS continue to receive as a result of previous 
and ongoing epilepsy studies or that PWE may have deliberately unde-reported the level of 
stigma. 
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3.5 Limitations 
 
It would have been preferable to explore concurrent validity with another stigma scale developed 
in an African setting but no such scale was available for this analysis.  
 
3.6 Conclusion 
 
Our results suggest that the KSSE is a culturally-appropriate measure with strong psychometric 
properties that could be adapted and validated for use in other research settings.  We think that 
the scale allows objective quantification that can be used to assess public health interventions 
aimed at reducing stigma.  Future work could also use the tool to understand how stigma changes 
over time as well as to explore reasons for the comparatively low level of stigmatization 
observed in this part of rural Kenya.   
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Abstract 
 
Introduction 
 
Epilepsy remains misunderstood, particularly in Resource Poor Countries (RPCs). Studies 
conducted in RPCs have reported that there are considerable differences in people‘s beliefs and 
attitudes about epilepsy.  We developed and validated a tool to assess beliefs and attitudes about 
epilepsy among People with Epilepsy (PWE) in Kilifi, Kenya. 
 
Methods 
 
A 50-item scale was developed through literature review and qualitative study findings. A 
descriptive cross-sectional survey was then conducted among 673 PWE to assess the reliability 
and validity of the scale.  Internal consistency was calculated using Cronbach‘s alpha and an 
interclass correlation coefficient was used to evaluate the test-retest reliability. Confirmatory 
factor analysis was used to verify the structure of the scale and correlation analysis was used to 
evaluate the relationship between the scale scores and demographic characteristics. 
 
Results 
 
The final scale had 34 items. Alpha scores for the five subscales were as follows: causes of 
epilepsy: α=0.71; biomedical treatment of epilepsy: α=0.70; cultural treatment of epilepsy: 
α=0.75; risk and safety concerns about epilepsy: α=0.56; negative stereotype about epilepsy: 
α=0.76 and entire scale α=0.70. Test-retest reliability was acceptable for all the subscales. 
Participants did not differ on subscale scores by sex and age. 
 
Conclusion 
 
The Kilifi Epilepsy Beliefs and Attitudes Scale is a reliable and valid tool that can be used to 
measure beliefs and attitudes about epilepsy in RPCs.  It can also be used as an evaluation tool to 
assess the effectiveness of interventions designed to increase knowledge, influence beliefs and 
improve attitudes about epilepsy. 
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4.1 Introduction 
 
Epilepsy remains misunderstood, particularly in Resource Poor Countries (RPCs) (WHO, 1997; 
Nyamae & Biritwum, 1997). Studies indicate that negative beliefs and attitudes towards epilepsy 
are still prevalent among People with Epilepsy (PWE) and the general public (Rwiza et al., 1993; 
Gambhir et al., 1995; Radhakrishnan et al., 2000).  Beliefs are derived culturally from previous 
experiences, education and what people have heard and learned from families, friends and/or 
storytelling (Gajjar et al., 2000).  Attitudes are considered to develop from the evaluation of 
recurrent experiences within a socio-cultural context (Gajjar et al., 2000; Gerow, 1993).  Lack of 
knowledge and negative attitudes about epilepsy affects the utilization of biomedical services, 
particularly the use of Antiepileptic Drugs (AEDs) (El Sharkawy et al., 2006; Martiniuk et al., 
2007).  In addition, several studies have indicated that beliefs and attitudes may affect the quality 
of life of PWE more than seizures themselves (WHO, 1997; Gajjar et al., 2000; Choi-Kwon et 
al., 2004; Atadzhanov et al., 2006).  
 
There are a range of diverse beliefs and practices relating to the causes and treatment of epilepsy 
which correspond to the heterogeneity of cultures and places throughout the world (Andermann, 
1995). Different models have been used to describe epilepsy in Africa, Asia, South America, 
North America and Middle East (Andermann, 1995; Reis, 1994; Banerjee & Banerjee, 1995; 
Placencia et al., 1995; Khan et al., 2004; Gajjar et al., 2000).  Despite the great differences 
between these cultures and settings, some generalizations can be made and traditional beliefs 
about epilepsy can be grouped into four main themes: epilepsy as a punishment for sin, epilepsy 
as bewitchment or possession, epilepsy as a contagious disease and epilepsy as a disease of the 
brain (Andermann, 2000).  One or more of these beliefs can often be held simultaneously, for 
example, when people rely on both traditional and biomedical forms of healing. The problem 
may be complicated by different terms for epilepsy, often on perceived differences in aetiology.  
Thus on the coast of Kenya, El Sharkawy et al. found that the local community used different 
terms such as ‗Nyuni‘, ‗Nyago‘, ‗Nyama ya dzula‘ ‗vitsala‘ and ‗Kifafa‘ (El Sharkawy et al., 
2006). When medical explanations fail to help PWE to understand  their condition, and the 
prescribed medication proves ineffective in preventing seizures, they are likely to hold onto a 
culture-specific meaning of the illness and beliefs about its aetiology (Gajjar et al., 2000).  
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Understanding cultural beliefs helps to provide an insight into the way people cope with and 
respond to their experiences with epilepsy (Albert, 1983; Andermann, 2000; Desai et al., 1998). 
Without knowledge of these beliefs, misunderstandings and miscommunication can occur 
between patients and health professionals (Albert, 1983). Treatment and other interventions may 
also fail. Therefore, it is important for health professionals to be familiar with patients‘ 
understanding about the causes and treatment of epilepsy so that effective communication and 
treatment can be maintained (Dekker, 1994; Sue, 1998; Kim et al., 1996).  One method to 
effectively assess a patient‘s beliefs about an illness is to administer a culturally reliable and 
valid tool. We developed and validated a tool to assess beliefs and attitudes about epilepsy 
among PWE in Kilifi, Kenya. 
 
4.2 Methods 
4.2.1 Development of the Kilifi Epilepsy Beliefs and Attitude Scale 
The items for the scale were developed in four phases: (1) formative research and concept 
development; (2) item development and validity assessment; (3) revising the scale for the main 
survey and (4) evaluating the scale. 
 
Phase 1: Formative research and concept development 
 
This phase included literature review to locate instruments designed to measure beliefs and 
attitudes towards epilepsy.  A number of assessments were identified and reviewed (Gajjar et al., 
2000; Martiniuk et al., 2007; Ndoye et al., 2005; George et al., 2006; Dilorio et al., 2004; Lowe-
Pearce & Camfield, 2005; Antonak, 1990).  In addition, we conducted a qualitative study to 
explore attitudes and beliefs relating to PWE, particularly current community perceptions and 
practices relating to epilepsy in Kilifi.  An interview guide was developed that built on the work 
conducted in Kilifi by El Sharkawy and colleagues (El Sharkawy et al., 2006). 
 
Purposive sampling was used to select the participants, who included PWE and their caregivers, 
community health workers, traditional healers, nurses, clinicians and doctors.  Efforts were made 
to ensure that all groups included males and females and that groups of children/parents of 
children with epilepsy covered the spectrum of disease severity.  Focus group discussions and  
in-depth interviews were conducted by three trained interviewers fluent in Kigiriama, Kiswahili 
and English.  The interviews were recorded, translated and transcribed.  The data were entered 
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onto an NVivo qualitative analysis software (QSR; Melbourne, Vic, Australia; 
http://www.qsrinternational.com/) to enable storage, organisation and retrieval.  Data were 
analysed using framework analysis, as described by Ritchie and Spencer (Ritchie & Spencer, 
1994).  Themes were independently generated from the data by two researchers (CK and JA) and 
once thematic consensus was reached, all the data were coded.  This process served to maximise 
the rigour and validity of the analysis. For further information on the qualitative study, refer to 
Chapter 9.  
 
Phase 2: Item development and content validity assessment 
Item generation 
 
Based on the literature review and qualitative study findings, a pool of 56 items was generated.  
Twenty-eight of the 56 items in the Kilifi Epilepsy Beliefs and Attitudes Scale (KEBAS) were 
taken directly or adapted from questions used in previous studies investigating beliefs and 
attitudes towards epilepsy (Gajjar et al., 2000; Martiniuk et al., 2007; Ndoye et al., 2005; George 
et al., 2006; Dilorio et al., 2004; Lowe-Pearce & Camfield, 2005; Antonak, 1990).  The 
remaining items were newly-developed from qualitative study findings.  The items were grouped 
into five subscales: causes of epilepsy (n=14); biomedical treatment of epilepsy (n=13); cultural 
treatment of epilepsy (n=12); risk and safety concerns about epilepsy (n=5) and negative 
stereotypes about epilepsy (n=12).  This grouping was informed by previous studies (Gajjar et 
al., 2000; Dilorio et al., 2004; Kobau et al., 2006; Martiniuk et al., 2007), as well as themes from 
the qualitative study.  
 
Items were worded both positively and negatively within the same subscale to avoid 
acquiescence, affirmation or agreement bias (DeVellis, 1991). The scale was developed in 
English and translated into Kigiriama, which is the local language spoken in Kilifi District, and 
underwent a process of back translation.  
  
Scoring the questionnaire 
 
The 56-item questionnaire used a 4-point Likert scale scored from 1 to 4 (Aday, 1996). The 
scores were assigned as follows: 0=not at all, 1=believe a little, 2= believe a lot and 3=totally 
believe.   
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Positive questions were those in which ‗totally believe‘ was the most positive belief or attitude 
with a score of ‗3‘ (26 items).  Reverse scoring was used for negative questions where ‗not at all‘ 
was the most positive belief or attitude with a score of ‗3‘ (30 items).  This ensured the positively 
and negatively worded items were scored in the same direction.  The total score ranges for the 
five subscales were as follows: causes of epilepsy: 0-42; biomedical treatment: 0-39; cultural 
treatment: 0-36; risk and safety concerns: 0-15; and negative stereotypes: 0-36.  Higher scores 
reflected positive believes and attitudes about epilepsy.   
 
Face validation of the scale 
   
This was assessed to determine if the scale contained items that could be used to measure beliefs 
and attitudes about epilepsy. Two clinicians and five research assistants with experience in 
epilepsy were asked to evaluate the relevance, clarity and conciseness of the items included in 
the questionnaire.  They were asked to determine whether the set of items accurately represented 
the concept under study by answering the following questions.   
1. Do you think the questions measure beliefs and attitudes about epilepsy found in this 
community? 
2. Are all these questions relevant? If not, specify which ones are irrelevant? 
 
The seven respondents were of the opinion that the questions measured beliefs and attitudes 
found in the community. They also agreed on the item subscales but recommended minor 
revisions in the wording and structuring of some items.  Based on this initial assessment, all the 
56 items were retained.  
 
The questionnaire was then pilot tested with six PWE and seven caregivers of Childern with 
Epilepsy (CWE).  It was administered by two interviewers fluent in the local language.  The 
respondents were asked to (a) comment on whether the items measured beliefs and attitudes 
about epilepsy; (b) rate the items on the 4-point rating scale; (c) provide explanation supporting 
their decision to give a certain rating (high or low) to an item; (d) comment on the time required 
to complete the scale; (e) comment on the clarity and flow of the questions; and (f) comment on 
the cultural adaptation and sensitivity of the items. The outcome of the pilot indicated that six of 
the 56 items were not relevant for the purpose of the study.  The six questions and reasons why 
they were not relevant are outlined on (Table 4.1). 
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Table 4.1: Items that were not considered relevant after piloting the Kilifi Epilepsy Beliefs 
and Attitude Scale  
 
 Item Reason for irrelevance 
 
1 I believe epilepsy can be a result of having 
water in the brain 
Respondent said they have never heard of 
water in the brain. It was difficult to 
describe hydrocephalus in local language  
2 I believe that having fever can cause epilepsy Respondents interpreted fever as malaria 
and  there was already an item on 
malaria/fever   
3 I believe that when a child is born and the 
immediate sibling enters and cries before the 
newborn does, then the newborn can have 
epilepsy 
The concept was not familiar to all 
respondents 
4 I believe prayers can treat epilepsy Question was answered on religious 
grounds and was not relevant to all 
respondents 
5 I believe that drugs can cure epilepsy 
completely 
Not clear whether the type of drugs 
referred to were ―traditional or 
biomedical‖ 
6 I believe there is no cure for epilepsy The word ―cure ―was ambiguous to some 
respondents as it  meant being seizure-free 
for life 
 
The remaining 50 items were found to assess beliefs and attitudes about epilepsy and were 
reported to be clear to all respondents.  This high level of acceptability may be explained by the 
use of qualitative findings to develop the scale.  However, respondents said that the time required 
to complete the questionnaire (30-45 minutes) was too long.  All of the respondents repeatedly 
referred to their unique epilepsy experience during the interview.  They also offered divergent 
explanations even when they assigned the same rating to an item.  This made it difficult to make 
generalizations about a particular group‘s ratings to the items.  Maintaining focus in the 
interview was also a challenge: to control for this, we decided to add a vignette describing a child 
with epilepsy to the introduction of the scale.  We adopted the vignette used in the Gajjar study 
(Gajjar et al., 2000), but modified it to reflect secondary generalized tonic-clonic seizures which 
are the most common form of epilepsy in our population (Munyoki et al., 2010).  
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Phase 3: Revising the questionnaire for the main survey  
 
Some changes were made based on the pilot information. The revised version of the scale had 50 
items and five subscales: causes of epilepsy (n=11); biomedical treatment (n=13); cultural 
treatment (n=9); risk and safety concerns (n=5) and negative stereotype (n=12).  We maintained 
the 4-point Likert scale but changed the response categories as follows: the response ‗believe a 
lot‘ was deleted because participants did not differentiate it from the ‗totally believe‘ response. 
We added the response ‗don‘t know‘ because several respondents had indicated they did not 
know how to answer an item.  This helped to minimize the perceived threat of the questions and 
to decrease the tendency of the respondents to guess.  The new scores were assigned as follows: 
0=not at all, 1=believe a little, 2=totally believe and missing (.)= don‘t know.  Positive questions 
were those in which ‗totally believe‘ was the most positive belief or attitude with a score of ‗2‘ 
(23 items).  Reverse scoring was used for negative questions where ‗not at all‘ was the most 
positive belief or attitude with a score of ‗2‘ (27 items).  The total score ranges for the five 
subscales were as follows: causes of epilepsy: 0-22; biomedical treatment: 0-26; cultural 
treatment: 0-18, risk and safety concerns: 0-10 and negative stereotype: 0-24. Higher scores 
reflected positive beliefs and attitudes about epilepsy.   
 
Phase 4: Evaluating the scale 
 
A descriptive cross-sectional survey was conducted in the Kilifi Health Demographic 
Surveillance System (KHDSS) to assess reliability and validity of the scale.  Six hundred and 
seventy-three PWE completed the scale, of whom 203 were PWE and 470 caregivers of CWE.  
Data on a subset of 65 PWE were then used to evaluate test-retest reliability of the scale.  The 
interviewer administered the scale twice to the same respondents at an interval of three weeks.   
 
4.2.2 Ethical considerations 
 
Written informed consent was obtained from all study participants. Where the PWE was a child 
or an adult who could not respond, a caregiver was interviewed.  Approval for the study was 
obtained from the Kenya Medical Research Institute/ National Ethical Review Committee. 
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4.2.3 Data analysis 
 
Data were double entered in MySQL and verified before being transferred to SPSS (version 15, 
SPSS Inc., Chicago) for analysis.  Descriptive statistics were generated to evaluate the score 
distribution per response category.  The internal consistency of the entire scale and subscales was 
calculated using Cronbach‘s alpha (α) (Cronbach, 1951).  An interclass correlation coefficient 
was used to evaluate the test-retest reliability. Confirmatory factor analysis was performed for 
each subscale using varimax rotation.  Items were retained if they had an item-total correlation ≥ 
0.2 and a factor loading ≥ 0.40 (Nunnally & Bernstein, 1994; Dilorio et al., 2004).  Correlation 
analysis was used to evaluate the relationship between subscale total scores, sex and age. 
 
The ―don‘t know‖ responses were recorded as missing values.  To ensure missing data did not 
have an undue effect on the scale, we excluded twelve items that had considerable missing 
information (more than 10% of the respondents had not answered) (Jarvie et al., 1993). This 
reduced the number of items on the scale from 50 to 38.  We estimated the probable values of the 
items that did not have substantial missing data using multiple imputation (Rubin, 1976; Allison, 
2000).   
 
4.3 Results 
4.3.1 Psychometric properties of the final scale 
4.3.1.1 Descriptives 
 
The descriptive statistics show that majority of participants responded ‗totally believe‘ to three 
subscales (causes of epilepsy, biomedical treatment, risks and safety concerns) meaning they had 
positive beliefs about epilepsy (Table 4.2). In the other two subscales (cultural treatment and 
negative stereotypes) majority of participants responded ―not at all‖ which also showed they had 
positive beliefs since most items in the two scales were reverse coded (Table 4.2).   
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Table 4.2: Proportion of responses by study participants (n=673) 
 
 Item 
 
Not at 
all (%) 
Believe 
a little 
(%) 
Totally 
believe 
(%) 
 Causes of epilepsy subscale 
1 …Epilepsy is inherited 
 
22.0 11.6 66.4 
2 …Head injury causes epilepsy 
 
21.7 10.4 67.9 
3 …Injury at birth causes epilepsy 
 
42.6 5.4 50.0 
4 …Malaria/fever causes epilepsy 
 
10.2 7.0 82.8 
5 …Brain damage causes epilepsy 
 
20.0 9.6 70.4 
 Biomedical treatment subscale 
6 …It is possible to treat epilepsy 
 
9.0 8.5 82.5 
7 …AEDs should be taken continuously for them to work 
 
3.4 2.8 93.8 
8 …AEDs are available in health facilities 
 
4.9 4.9 90.2 
9 …Nyuni* is better treated by a doctor 
 
3.9 5.5 90.6 
10 …PWE should be put in a safe place during a fit 
 
0.2 1.0 98.8 
11 …AEDs control seizures 
 
2.5 5.2 92.3 
12 …Missing AEDs can make PWE fit 
 
9.4 4.0 86.6 
13 …Vitsala* is better treated by a doctor 
 
3.6 3.6 92.8 
14 …AEDs can cause side effects 
 
26.3 6.1 67.6 
 Cultural treatment subscale 
15 …PWE who are burnt never get healed 
 
41.6 5.2 53.2 
16 …Nyuni* is treatable but not Vitsala* 
 
57.9 5.8 36.3 
17 …Vitsala* is better treated by a Mganga* 
 
62.1 11.0 26.9 
18 …Pouring water on PWE during a fit treats epilepsy 
 
59.9 8.2 31.9 
19 …Smearing paraffin on PWE during a fit treats epilepsy 
 
61.4 5.9 32.7 
20 …Fumigation treats epilepsy 
 
64.0 7.0 29.0 
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Table 4.2: Continued from previous page  
 Item 
 
Not at 
all (%) 
Believe 
a little 
(%) 
Totally 
believe 
(%) 
21 …It good to put a stick in the mouth of PWE during a fit 
 
53.3 3.2 43.5 
22 …Joints of PWE should be straightened during a fit 
 
51.7 4.3 44 
23 …Nyuni* is better treated by a Mganga* 
 
70.1 9.4 20.5 
 Risks and safety concerns subscale 
24 …PWE cannot climb trees 
 
8.9 3.4 87.7 
25 …PWE cannot drive 
 
12.6 3.4 84.0 
26 …PWE should avoid being near fires 
 
1.2 1.9 96.9 
27 …PWE should avoid being near waters 
 
1.6 1.5 96.9 
 Negative stereotypes subscale 
28 …PWE cannot marry 
 
48.6 13.1 38.3 
29 …PWE cannot go to school 
 
58.7 7.0 34.3 
30 …PWE cannot have a job 
 
47.1 9.8 43.1 
31 …PWE cannot lead a normal life 
 
29.7 6.1 64.2 
32 …PWE should be isolated 
 
78.6 1.5 19.9 
33 …PWE should be rejected 
 
72.2 2.7 25.1 
34 …PWE should be resented 
 
89.9 1.6 8.5 
35 …PWE are a burden 
 
26.0 3.3 70.7 
36 …PWE perform poorly in school 
 
17.7 12.8 69.5 
37 …PWE are dull 
 
21.4 16.5 62.1 
38 …PWE are mad 
 
42.0 10.6 47.4 
Items were preceded with the following phrase: I believe….  
PWE: People with Epilepsy; AEDs: Antiepileptic Drugs; SD: Standard Deviation  
*Nyuni: Fever provoked seizures or febrile convulsions  
*Vitsala: A local term for epilepsy or non-fever-provoked seizures 
*Mganga: Traditional Healer 
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4.3.1.2 Internal consistency 
 
The initial analysis demonstrated that four items had an item-total correlation < 0.2: one from the 
biomedical treatment subscale and three from the negative stereotype subscale: AEDs can cause 
side effects (-0.05); PWE cannot lead a normal life (0.13); PWE should be resented (0.10) and 
PWE are a burden (0.17).  After exclusion of these items, the final scale had 34 items and alpha 
scores for the five subscales were as follows: causes of epilepsy: α=0.71; biomedical treatment: 
α=0.70; cultural treatment: α=0.75; risk and safety concerns: α=0.56; negative stereotype: α=0.76 
and entire scale α =0.70.  The internal consistency of the subscales is outlined on (Table 4.3). 
 
Table 4.3: Internal consistency of the five subscales of the Kilifi Epilepsy Beliefs and 
Attitude Scale (n=673) 
 
 Item Scale 
mean if 
Item 
deleted 
Scale 
variance 
if Item 
deleted 
Corrected 
item-total 
correlation 
Alpha if 
Item 
deleted 
 Causes of epilepsy subscale 
1 …Epilepsy is inherited 
 
6.50 3.85 0.34 0.68 
2 …Head injury causes epilepsy 6.44 
 
3.49 0.55 0.58 
3 …Injury at birth causes epilepsy 6.66 
 
3.22 0.47 0.63 
4 …Malaria causes epilepsy 
 
6.27 4.11 0.44 0.64 
5 …Brain damage causes epilepsy 6.35 
 
3.99 0.43 0.64 
 Biomedical treatment subscale 
6 …It is possible to treat epilepsy 13.32 
 
2.26 0.45 0.67 
7 …AEDs should be taken continuously for    
    them to work 
13.17 2.83 0.36 0.68 
8 …AEDs are available in health facilities 13.21 
 
2.41 0.59 0.62 
9 …Nyuni*  is better treated by a doctor 13.20 
 
2.74 0.36 0.68 
10 …PWE should be put in a safe place  
    during a fit 
13.10 3.25 0.27 0.71 
11 …AEDs control seizures 13.18 
 
2.63 0.55 0.64 
12 …Missing AEDs can make PWE fit 13.27 
 
2.67 0.24 0.72 
13 …Vitsala* is better treated by a doctor 13.17 
 
2.68 0.52 0.65 
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Table 4.3: Continued from previous page 
 
 Item Scale 
mean 
Scale 
variance 
Correlation Alpha 
 Cultural treatment subscale 
14 …PWE who are burnt never get healed 9.86 
 
19.1 0.31 0.74 
15 …Nyuni* is treatable but not vitsala* 9.53 
 
18.6 0.38 0.73 
16 …Vitsala* is better treated by a mganga* 9.39 
 
18.7 0.42 0.72 
17 …Pouring water on PWE during a fit  
    treats epilepsy 
9.47 18.3 0.43 0.72 
18 …Smearing paraffin on PWE during a fit  
     treats epilepsy 
9.50 18.2 0.44 0.72 
19 …Fumigation treats epilepsy 9.41 
 
17.7 0.54 0.70 
20 …It is good to put a stick in the mouth of  
    PWE during a fit 
9.70 18.3 0.41 0.72 
21 …Joints of PWE should be straightened  
    during a fit 
9.69 18.2 0.41 0.72 
22 …Nyuni* is better treated by a mganga* 9.25 
 
18.6 0.47 0.72 
 Risks and safety concerns subscale 
23 …PWE cannot climb trees 5.66 
 
0.79 0.39 0.46 
24 …PWE cannot drive 5.70 
 
0.69 0.41 0.46 
25 …PWE should avoid being near fires 5.48 
 
1.25 0.43 0.50 
26 …PWE should avoid being near waters 5.49 
 
1.25 0.36 0.52 
 Negative stereotype subscale 
27 …PWE cannot marry 7.30 
 
14.6 0.43 0.74 
28 …PWE cannot go to school 7.16 
 
13.6 0.59 0.71 
29 …PWE cannot have a job 7.37 
 
13.7 0.56 0.72 
30 …PWE should be isolated 6.81 
 
15.2 0.43 0.74 
31 …PWE should be rejected 6.93 
 
15.0 0.41 0.75 
32 …PWE perform poorly in school 7.93 
 
15.2 0.46 0.74 
33 …PWE are dull 7.82 
 
14.4 0.57 0.72 
34 …PWE are mad 7.45 
 
15.6 0.27 0.77 
  Items were preceded with the following phrase: I believe…..  
PWE: People with Epilepsy; AEDs: Antiepileptic Drugs 
 *Nyuni: Fever provoked seizures or febrile convulsions 
*Vitsala: A local term for epilepsy or non-fever-provoked seizures 
 *Mganga: Traditional Healer 
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4.3.1.3 Test retest reliability  
 
Test retest reliability coefficients estimated by calculating the inter correlation coefficient were 
as follows: causes of epilepsy: r=0.64; biomedical treatment: r= 0.70; cultural treatment: r=0.70; 
risk and safety concerns: r=0.80; negative stereotype: r=0.81 and entire scale r=0.70. 
 
4.3.1.4 Factor analysis  
 
The dimensionality of the scale was studied using factor analysis. Items in each subscale had a 
high factor loading (≥0.40) as outlined on (Table 4.4).  The variance explained by each subscale 
was: causes of epilepsy: 45.3% (eigenvalue=2.27); biomedical treatment: 36.1% (eigenvalue= 
2.89); cultural treatment: 33.4% (eigenvalue=3.01); risk and safety concerns: 50.2% 
(eigenvalue=2.01) and negative stereotypes 38.7% (eigenvalue=3.10).  
 
Table 4.4: Confirmatory factors analysis and factor loadings of the five subscales Kilifi 
Epilepsy Beliefs and Attitude Scale (n=673)  
 
 Item Causes 
of 
epilepsy 
Biomedical 
treatment 
Cultural 
treatment 
Risk 
concerns 
Negative 
stereotypes 
1 …Epilepsy is inherited 
 
0.54     
2 …Head injury causes epilepsy 0.77  
 
   
3 …Injury at birth causes epilepsy 0.69  
 
   
4 …Malaria causes epilepsy 
 
0.68     
5 …Brain damage causes epilepsy 0.67  
 
   
6 …It is possible to treat epilepsy  0.62 
 
   
7 …AEDs should be taken     
    continuously for them to work 
 0.46    
8 …AEDs are available in health  
    facilities 
 0.78    
9 …Nyuni* is better treated by a  
    doctor 
 0.57    
10 …PWE should be put in a safe  
    place during a fit 
 0.40    
11 …AEDs control seizures  0.75 
 
   
12 …Missing AEDs can make PWE  
    fit 
 0.34    
13 …Vitsala* is better treated by a  
     doctor 
 0.73    
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Table 4.4: Continued from previous page 
 
 Item Causes 
epilepsy  
Biomedical 
treatment 
Cultural 
treatment 
Risk 
concerns 
Negative 
stereotypes 
14 …PWE who are burnt never get  
    healed 
  0.43   
15 …Nyuni* is treatable but not  
    Vitsala* 
  0.51   
16 …Vitsala* is better treated by  
     Mganga* 
  0.58   
17 …Pouring water on PWE during a  
    fit treats epilepsy 
  0.59   
18 …Smearing paraffin on PWE  
    during a fit treats epilepsy 
  0.60   
19 …Fumigation treats epilepsy   0.70 
 
  
20 …It is good to put a stick in the     
    mouth of PWE during a fit 
  0.56   
21 …Joints of PWE should be  
    straightened during a fit 
  0.56   
22 …Nyuni* is better treated by  
     Mganga* 
  0.63   
23 …PWE cannot climb trees    
 
0.55  
24 …PWE cannot drive    
 
0.58  
25 …PWE should avoid being near  
    fires 
   0.84  
26 …PWE should avoid being near  
     waters 
   0.81  
27 …PWE cannot marry    
 
 0.59 
28 …PWE cannot go to school    
 
 0.74 
29 …PWE cannot have a job    
 
 0.72 
30 …PWE should be isolated    
 
 0.57 
31 …PWE should be rejected    
 
 0.56 
32 …PWE perform poorly in school 
 
    0.62 
33 …PWE are dull    
 
 0.72 
34 …PWE are mad    
 
 0.40 
Items were preceded with the following phrase: I believe…. 
PWE: People with epilepsy; AEDs: Antiepileptic drugs 
*Nyuni: Fever provoked seizures or febrile convulsions  
*Vitsala:  A local term for epilepsy or non-fever-provoked seizures 
*Mganga: Traditional Healer 
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4.3.1.5 Construct validity 
 
Given that we had two different samples, we split the data based on who responded to the 
questionnaire (203 PWE and 470 caregivers).  There was no difference in internal consistency 
based on who responded (α=0.79) for PWE and (α=0.76) for caregivers.  
 
Correlations were calculated to explore the relation between sex and each subscale total score. 
We hypothesised that there would be no differences in subscale scores by sex but we anticipated 
a significant difference by age.  There was no relationship between sex and any subscale scores 
(causes of epilepsy: r=0.01, p=0.76; biomedical treatment: r=0.01, p=0.71; cultural treatment: 
r=0.02, p=0.97; risk and safety concerns: r=0.06, p=0.08; negative stereotype r=0.01, p=0.80).   
 
The age sensitivity of the subscales was investigated by examining their correlations with age:  
There was no relationship between age and any subscale scores: (causes of epilepsy: r=0.02, 
p=0.64; biomedical treatment: r=0.02, p<0.68; cultural treatment: r=0.04, p<0.31; risk and safety 
concerns: r=0.02, p<0.66; negative stereotypes: r=0.14, p< 0.54).   
 
4.3.1.6 Beliefs and attitude scores 
 
The final scale had 34 items and the number of items in each subscale was as follows: causes of 
epilepsy (n=5); biomedical treatment of epilepsy (n=8); cultural treatment of epilepsy (n=9); 
risks and safety concerns about epilepsy (n=4) and negative stereotypes about epilepsy (n=8). 
The total score ranges for the five subscales were as follows: causes of epilepsy: 0-10, 
biomedical treatment: 0-16, cultural treatment: 0-18; risk and safety concerns: 0-8 and negative 
stereotypes: 0-16 (Figure 4.1). The 66th percentile was used to categorize the scores in each 
subscale (Holding et al., 2004).  Those below the percentile were categorized as having negative 
beliefs and attitudes about epilepsy and those above were considered to have positive beliefs and 
attitudes about epilepsy. The categories for the negative beliefs were as follows: causes of 
epilepsy: 0-6; biomedical treatment: 0-11; cultural treatment: 0-14; risks and safety concerns: 0-5 
and negative stereotypes: 0-10.  The categories for the positive beliefs were as follows: causes of 
epilepsy: 7-10; biomedical treatment: 12-16; cultural treatment: 15-18; risks and safety concerns: 
6-8 and negative stereotypes: 11-16. 
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Out of the 673 respondents, the majority had positives beliefs and attitudes about epilepsy as 
depicted in (Figure 4.1): causes of epilepsy (63%); biomedical treatment (91%); cultural 
treatment (73%); risks and safety concerns (93%) and negative stereotypes (69%).  This may be 
explained by the level of exposure to health information that PWE in KHDSS have received and 
continue to receive. 
 
Figure 4.1: Scores for the five subscales of the Kilifi Epilepsy Beliefs and Attitude Scale 
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4.4 Discussion 
 
The purpose of this study was to develop and evaluate a tool to measure epilepsy beliefs and 
attitudes among PWE in Kilifi.  Literature review and formative research were undertaken to 
identify beliefs and attitudes about epilepsy.  This led to the development of a tool that had five 
subscales, which represented medical and nonmedical beliefs about epilepsy.  
 
4.4.1 Reliability  
 
Criteria set out by Cicchetti (Cicchetti, 1994) were employed in evaluating the level of 
acceptability of the observed values of the reliability coefficient.  Correlations of α= 0.70 or 
higher are considered acceptable levels of internal consistency. Reliability analysis demonstrated 
an acceptable alpha for the overall scale (α=0.70). Alpha values for the four subscales were also 
acceptable, ranging from α=0.70 to α=0.76 which demonstrated adequate internal consistency 
meeting the standard criteria for scale development (De Vellis, 1991; Cicchetti, 1994).  
However, the risks and safety concerns subscale demonstrated poor internal consistency (α=0.56) 
which could be attributed to the few items in this subscale.  
 
The items in each subscale had acceptable item-to-total correlation (r=0.24-0.59) (Aday, 1996; 
Martiniuk et al., 2007), suggesting that all the items correlated well with the overall subscale 
scores.  According to the criteria set out by Cicchetti (Cicchetti, 1994), the test retest reliability 
for three subscales was good (r=0.64 to r=0.70) and for two subscales was excellent (r=0.80 to 
r=0.81).  This suggests the subscales are highly repeatable and thus adequately reliable.  
 
4.4.2 Validity 
 
The confirmatory factor analysis suggests that the scale is not uni-dimensional, since it did not 
measure one construct.  It had five subscales assessing different types of beliefs and attitudes 
among PWE.  The first factor assessing causes of epilepsy captured what is perceived to cause 
recurrent seizures. The one on biomedical treatment looked at beliefs surrounding modern 
medicine, whereas the cultural treatment looked at beliefs that have a cultural orientation. The 
risk and safety concerns addressed activities that are perceived to be dangerous for PWE due to 
the unpredictability of seizures.   
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The final subscale assessing negative stereotypes captured beliefs that could lead to the 
segregation of PWE.  The items in all the subscales had strong factor loading (≥0.40) (Dilorio et 
al., 2004), similar to that reported in other studies (Dilorio et al., 2004; Kobau et al., 2006; 
Martiniuk et al., 2007).  Internal consistency did not differ whether it was a PWE who responded 
or a caregiver.  This suggests that beliefs and attitudes of children or PWE with neuro-cognitive 
impairment can be assessed through a caregiver using the same scale. 
 
Further analysis was conducted to examine the correlation between the demographic variables 
and participants‘ subscale scores.  Results indicated that sex and age were not correlated with 
any of the subscale scores. The absence of sex differences supports the validity of the scale 
hence failure to reject our hypothesis. The correlations did not provide support for the age-
sensitivity of the subscales scores hence rejection of our hypothesis. These findings lend support 
to the utility of the KEBAS as a tool that could capture differences in beliefs and attitudes among 
participants regardless of sex and age.  These findings are supported by other studies that showed 
beliefs and attitudes did not vary by these two demographic variables (Gajjar et al., 2000; Kobau 
et al., 2006), although this is contradicted by other studies (Dilorio et al., 2004; Lowe-Pearce & 
Camfield, 2005).  
 
4.4.3 Strengths 
 
The use of a Likert scale provided a systematic method of gathering information about 
participants‘ beliefs and attitudes about epilepsy.  Therefore, it served as an efficient and 
practical way to make an evaluation within a shorter period and with less effort than would be 
required using interviews.  Moreover, the scale provided numerical scores, which were used to 
compare participants with high and low scores. 
 
The KEBAS also had two methodological strengths that are important in interpreting the 
findings of acceptable psychometric properties.  The first is the large sample size on which the 
measurement was performed.  Insufficient sample sizes are a common methodological flaw in 
principal component and factor analysis.  According to a review of more than 1000 articles using 
principal component or factor analysis to evaluate questionnaires, about half failed to obtain 
appropriate sample size (Costelllo & Osborne, 2003).   
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Antonak and Levneh recommended that when testing the properties of a scale, the sample size 
should be five times the number of items on the scale (i.e. 5 x 34 = 170)  (Antonak & Livneh, 
1988).  We had 673 respondents, lending confidence to the estimates we reported.  
 
The second methodological strength is the excellent response rate.  All the participants 
completed the questionnaire, which minimized the likelihood that non-responders may be 
systematically different than responders.  This strengthens the generalizability of the findings 
and potentially increases the stability of the findings.   
 
4.5 Limitations 
 
Despite extensive efforts spent on developing and pretesting the scale, the possibility still exists 
that it does not represent accurately all possible beliefs and attitudes about epilepsy.  Even 
though the test-retest reliability was conducted within an acceptable period of three weeks, 
responses may have been biased because the respondents were sensitized by the first testing. 
Lack of uni-dimensionality also suggests that the KEBAS cannot be used to measure a single 
construct of beliefs and attitudes. 
 
4.6 Conclusion 
 
The findings revealed that the 34-item KEBAS is a reliable and valid tool that captures beliefs 
and attitudes about epilepsy in a resource poor setting.  One of its possible applications would be 
as an evaluation tool to assess the effectiveness of interventions designed to increase knowledge, 
influence beliefs and improve attitudes about epilepsy. To enhance its utility, the tool should 
undergo further validation in different population groups preferably in the language spoken by 
the participants.   
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Abstract 
 
Introduction 
 
Several studies have reported that People with Epilepsy (PWE) in resource poor countries do not 
receive appropriate treatment for their condition, a phenomenon known as the Epilepsy 
Treatment Gap (ETG). We estimated the ETG and examined the factors that were responsible for 
treatment-seeking behaviour among PWE in rural Kenya.  
 
Methods 
 
A cross-sectional survey was conducted among PWE in Kilifi District, Kenya. Three trained 
field staff interviewed PWE between June and December 2008.  The ETG was determined by 
checking for detectable levels of Anti-epileptic Drugs (AEDs) in blood samples from PWE.  An 
assets-based wealth index was developed using principal component analysis; distance to health 
facilities was calculated using global positioning system coordinates and stigma and health 
beliefs were measured using Likert scales.  Factors influencing treatment seeking were explored 
using univariate and multivariate logistic regression models. Only variables with a p-value ≤ 
0.20 in the univariate analysis were included in a multivariate logistic regression model. 
 
Results 
 
A total of 673 PWE were interviewed.  Only 499 (74.1%) PWE reported seeking treatment from 
a health facility.  The ETG based on blood levels of AEDs was 74.9% (95% confidence interval 
(CI); 71.4-78.1). Out of 673 PWE, 334 (49.6%) were aware of traditional healers (THs) who 
treated seizures and 277 (41.2%) reported seeking treatment from a TH. 
 
The most important factor influencing treatment seeking was long duration of epilepsy in 
children (adjusted odds ratio (aOR) = 8.01, 95% CI 3.02–21.2) and adults (aOR= 9.00, 95% CI 
2.87–18.9).  Other significant predictors in the multivariate analysis were religion, distance to 
health facilities, paying for AEDs, injury during a seizure, beliefs about causes and biomedical 
treatment of epilepsy.  Sex, education level, marital status, occupation, social economic status 
and perceived stigma did not influence treatment seeking. 
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Conclusion 
 
The results of the study show that PWE were more likely to seek treatment when they lived close 
to health facilities that provided specialized epilepsy care and had epilepsy for a long time.  
Positive beliefs about the causes and biomedical treatment of epilepsy also influenced treatment 
seeking.  These data can be used to inform the development of appropriate interventions in order 
to reduce the TG in Kilifi District. 
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5.1 Introduction 
 
Over 62 million People with Epilepsy (PWE) live in Resource Poor Countries (RPCs) (Ngugi et 
al., 2010).  Several studies have reported that PWE in RPCs do not receive appropriate treatment 
for their condition, a phenomenon known as the Epilepsy Treatment Gap (ETG) (Scott et al., 
2001; Diop et al., 2003; Diop et al., 2005; Shorvon & Farmer, 1988).  The ETG is defined as the 
number of people with active epilepsy not on treatment (diagnostic and therapeutic) or on 
inadequate treatment, expressed as a percentage of the total number with active epilepsy (Kale, 
2002; Meinardi et al., 2001).  In a systematic review of studies conducted in RPCs, the overall 
estimate of the ETG was 56% (95% CI 31-100), with a higher proportion in rural areas than in 
urban areas (Mbuba et al., 2008).  In a separate review, Meyer et al. reported that the ETG was 
over 75% in low-income countries and over 50%  in most lower middle and upper middle 
income countries, while many high-income countries had gaps of less than 10% (Meyer et al., 
2010). The ETG could be caused by lack of access to diagnosis and treatment or lack of 
adherence to treatment (Meinardi et al., 2001; Kale, 2002).   
 
There are few studies devoted to studying health seeking behaviour associated with epilepsy.  
Studies on other chronic ailments have shown healthcare seeking behaviour is influenced by 
household size, age, sex, education, geographic proximity of services, stigma, health beliefs, 
perceived need, income, cost of care, the level of service provision and the distribution of 
services (Sreeramareddy et al., 2006; Pillai et al., 2003; Habib & Vaughan, 1986; Abbas & 
Walker, 1986; Placencia et al., 1995).  Information on the health seeking behavior of PWE can 
help policy makers develop strategies to reduce the ETG in RPCs.  We examined the effect of 
socio-demographic, socioeconomic, accessibility, perceived severity, stigma and health beliefs 
variables on treatment seeking among PWE in Kilifi.  
 
5.1.1 Conceptual model 
 
We used the Andersen Behavioural Model as a basis for understanding the determinants of 
health service utilization (Andersen, 1995).  The model considers that health service utilization is 
a function of three categories: (a) predisposing factors such as age, sex, education status, marital 
status, race, religion, occupation and health beliefs; (b) enabling factors that describe the means 
individuals have available to them for the use of services such as income, health insurance, 
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regular sources of care, travel and waiting time, transportation, social support and supervision 
and relationship with providers; and (c) need, which refers to severity of illness and whether  
people judge their problem to be of sufficient magnitude to consult health services (Andersen, 
1995).  We choose the Andersen Behavioural Model because it is one of the most frequently 
used frameworks for analyzing patient utilization of healthcare (Phillips et al., 1998).  Since its 
first development in 1968 (Andersen, 1968), it has been revised to integrate a range of 
individual, environmental, and provider-related variables associated with decisions to seek care 
(Andersen, 1995), unlike other models which have remained narrow in scope (Weinstein & 
Sandman, 2002; Bandura, 1988; Miller & Dollard, 1941; Rosenstock, 1966; Rosenstock, 1974; 
Young, 1981). 
 
5.2 Methods 
5.2.1 Study Area 
 
The study was conducted in the Kilifi Health Demographic Surveillance System (KHDSS), 
which is described in Chapter 1. 
 
5.2.2.1 Health Services 
 
The KHDSS is served by one district hospital, one health centre and 12 dispensaries. Kilifi 
District Hospital (KDH) serves as a primary care centre and first level referral facility for the 
District. Kilifi District Hospital has four major drugs used to treat epilepsy – phenobarbital, 
phenytoin, carbamazepine and sodium valproate - although the health centres and dispensaries 
only stock phenobarbital.   
 
5.2.2 Identification of study participants 
 
People with epilepsy were identified in a 3-stage cross-sectional survey that was conducted to 
determine the prevalence and incidence of epilepsy in KHDSS (Ngugi et al., In preparation).  
This methodology is described in details in chapter 1.   
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5.2.3 Data collection 
 
The questionnaires for the study were developed in English and translated into the local 
language, Kigiriama. They were grouped into six categories: socio-demographic characteristics 
(age, sex, religion, education, occupation and marital status); socioeconomic aspects of the 
households based on asset indicators; accessibility factors (distance from home to health facility, 
time to health facilities and payment of AEDs); severity of epilepsy (duration of epilepsy, seizure 
frequency, duration of seizures, injury during a seizure); stigma and questions on epilepsy beliefs 
and attitudes.  Three field staff were trained for four days on how the tools were developed, how 
to approach homesteads, how to administer the questionnaires and check data.  The field staff 
piloted the questionnaires among 12 PWE who were outside the study area to check for clarity, 
flow and ease of administration of the questions.  Respondents were also requested to comment 
on the relevance of the questions and the time required to complete the questionnaires.  The 
questionnaires were then revised based on the comments received from the pilot study.  The 
questionnaires were administered to all people with a confirmed diagnosis of ACE following 
written informed consent.  Where the person with epilepsy was a child, a caregiver (mother, 
father or guardian) was interviewed.  The participants were interviewed between June-December 
2008.  
 
Data were checked at the end of each day by the investigator for accuracy, completeness and 
consistency. The study was reviewed and approved by KEMRI/National Ethical Review 
Committee and the Swiss Tropical and Public Health Research Committee. 
 
5.2.3.1 Measuring treatment seeking 
 
We established treatment-seeking behaviour by asking PWE if they had ever sought treatment 
for epilepsy from a health facility prior to the epidemiological survey in which they were 
identified (yes/no).  Those answering ‗yes‘ were asked to identify the health facility they sought 
treatment from.  A list of health facilities in the KHDSS was provided, as well as the option to 
specify health facilities outside the KHDSS.  Other types of care such as visiting Traditional 
Healers (THs) or churches and the administration of home remedies were not considered as 
appropriate care for the purposes of this study. 
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5.2.3.2 Measuring the epilepsy treatment gap 
 
We estimated the ETG by finding out whether PWE sought and adhered to treatment.  
Adherence was determined by checking if PWE had AEDs in their blood.  More details on how 
the ETG was measured are provided in Chapter 6.  
 
5.2.3.3 Measuring socio-economic status 
 
Data were collected from households on 15 assets including livestock (goats, cows, chickens), 
radio, telephone, video machine, land, television, cooking stoves (electrical/gas), refrigerators, 
bicycle, cars, tractors and motorbikes.  Other indicators of household characteristics included 
roofing material, source of energy for cooking and lighting, toilet facilities, type of main wall for 
the dwelling and source of drinking water.  Principal Component Analysis (PCA) was performed 
to construct a homestead wealth assets index from the range of assets and household 
characteristics. Households were classified into Socio Economic Status (SES) quintiles on the 
basis of the asset index.  The assets indicator tool has been validated and used in other settings 
including Kilifi (Chuma & Molyneux, 2009; Seema & Lilani, 2006; Filmer & Pritchett, 2001; 
Montgomery et al., 2000; McKenzie, 2003; Cortinovis et al., 1993; Schellenberg et al., 2003). 
 
5.2.3.4 Measuring stigma, epilepsy beliefs and attitudes  
 
Perceived stigma and epilepsy beliefs and attitudes were measured using Likert scales.  The 
Kilifi Stigma Scale for Epilepsy had 15 questions and measured only one construct (perceived 
stigma). The Kilifi Epilepsy Beliefs and Attitude Scale had 34 questions, divided into five 
subscales (causes of epilepsy, biomedical treatment of epilepsy, cultural treatment of epilepsy, 
risk and safety concerns and negative stereotypes about epilepsy).  The development, validation 
and scoring of these tools is described in Chapters 3 and 4.   
 
5.2.3.5 Calculating distance to health facilities 
 
Homesteads and health facilities were mapped using Global Positioning System (GPS) (Noor et 
al., 2003; Paul et al.).  The Euclidean (straight line) distance was calculated using GPS 
coordinates for the two points.  The health facility used was defined as the one where PWE 
reported seeking treatment most frequently.   
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We also estimated the distance PWE would travel if they were to seek treatment from the nearest 
health facility and compared this with the distance to the actual health facility where they 
reported seeking treatment. 
 
5.2.4 Statistical analysis  
 
Data were double entered and verified in MySQL.  Statistical analyses were undertaken using 
STATA version 11 (StataCorp, College Station, TX, USA). The data were screened for 
consistency, missing values and unexplained outliers.  The distribution pattern was examined for 
shape and skewing before selecting the appropriate test statistic. 
 
People with epilepsy were categorized by age into children (<18 years) and adults (≥18 years). 
People with epilepsy who reported seeking treatment from health facilities were compared to 
PWE who reported never seeking such treatment.  First, a chi-square test was used to measure 
associations between socio-demographic characteristics and treatment seeking.  Second, a 
univariate regression analysis was performed to identify which of the predictor variables were 
significant to the outcome measure, i.e. seeking treatment from health facilities.  In the univariate 
analysis, any factor with a p-value > 0.20 was not considered an important covariate of treatment 
seeking.  
 
All variables with a p-value ≤ 0.20 in the univariate analysis were included in a multivariate 
logistic regression model, using a forward stepwise strategy to identify their combined effect on 
treatment seeking among PWE. At each step, non significant explanatory variables were 
removed and only variables with a p ≤ 0.1 were retained in the model.  Regression models were 
compared with the Likelihood Ratio Test (LRT).  Parameter estimates, Odds Ratio (OR), 95% 
Confidence Interval (CI) and p-values were recorded for each predictor.   
Treatment seeking 
79 
 
5.3 Results 
5.3.1 Study participants 
 
The epidemiological survey identified 699 PWE, of whom 673 (96.3%) were interviewed.  The 
remaining 26 (3.7%) were not interviewed because seven refused to participate, nine moved 
from the study area, two died and eight denied having epilepsy.  PWE were relatively young, 
with 58.3% of individuals aged 18 years and below.  Majority of the adults 133 (47.5%) had no 
formal education and only eight (2.9%) had attained tertiary level of education.  The largest faith 
group was Christian (45.7%).  The main assets owned by households were land (95.7%) and 
livestock (74.6%). Christians and single adults were significantly more likely to access treatment 
(Table 5.1).   
 
Of the 673 PWE who were interviewed, 499 (74.1%) reported seeking treatment for epilepsy 
from a health facility and 174 (25.9%) reported never seeking treatment. Of the 499 who 
reported seeking treatment, 79.2% went to KDH, 12.9% to peripheral government health clinics 
and 7.9% to private clinics. Of the 673 PWE, 334 (49.6%) were aware of THs who treated 
epilepsy and 277 (41.0%) reported seeking treatment from a TH. Two hundred and twenty 
(32.7%) sought treatment from both the health facility and THs. The ETG based on AEDs blood 
level tests was 74.9% (95% CI; 71.4-78.1).    
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Table 5.1: Demographic characteristics of study participants (n=673) 
 
Variable Children (n=393) Adults (n=280) 
 Sought 
treatment 
n=299 
Never 
sought 
treatment 
n=94 
X
2
 P value Sought 
treatment 
n=200 
Never 
sought 
treatment 
n=80 
X
2
 P value 
Age years: 
Median  
[IQR] 
 
11 
15-6 
 
8 
13-3 
   
29 
37-23 
 
37 
57- 24.5 
  
Sex: n (%) 
Female  
Male 
 
135 (73.4) 
164 (78.5) 
 
49 (26.6) 
45 (21.5) 
1.40 0.237  
104 (70.3) 
96 (72.7) 
 
44 (29.7) 
36 (27.3) 
0.206 0.650 
Religion: n 
(%) 
Traditional 
Christian 
Islam 
 
 
124 (71.3) 
134 (80.2) 
41(78.8) 
 
 
50 (28.7) 
33 (19.8) 
11(21.2) 
4.02 0.134  
 
80 (65.0) 
103 (80.5) 
17 (58.6) 
 
 
43 (35.0) 
25 (19.5) 
12 (41.4) 
9.916 0.007 
Educational 
level n: (%) 
None 
Primary 
Secondary 
Tertiary 
 
 
136 (78.6) 
139 (71.6) 
24 (92.3) 
n/a 
 
 
37 (21.4) 
55 (28.4) 
2 (7.7) 
n/a 
6.58 0.087  
 
95 (71.4) 
88 (72.1) 
10 (58.8) 
7 (87.5) 
 
 
38 (28.6) 
34 (27.9) 
7 (41.2) 
1 (12.5) 
2.366 0.500 
SES: n (%) 
Least poor 
Less poor 
Poor 
Very poor 
Most poor 
 
61 (83.6) 
55 (73.3) 
62 (71.3) 
55 (74.3) 
66 (78.6) 
 
12 (16.4) 
20 (26.7) 
25 (28.7) 
19 (25.7) 
18 (21.4) 
4.08 0.396  
49 (80.3) 
40 (67.8) 
32 (68.1) 
42 (72.4) 
37 (67.3) 
 
12 (19.7) 
19 (32.2) 
15 (31.9) 
16 (27.6) 
18 (32.7) 
3.499 0.478 
Occupation: 
n (%) 
Farmer 
Trader 
Casual 
Other 
 
n/a.. 
n/a 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a n/a  
 
110 (73.3) 
30 (65.2) 
22 (64.7) 
38 (76.0) 
 
 
40 (26.7) 
16 (34.8) 
12 (35.3) 
12 (24.0) 
2.401 0.493 
Marital 
status: n (%) 
Single 
Married 
Separated 
Divorced 
Widowed 
 
 
n/a 
n/a 
n/a 
n/a 
n/a 
 
 
n/a 
n/a 
n/a 
n/a 
n/a 
 
 
  
 
65 (84.4) 
94 (66.2) 
5 (71.4) 
10 (58.8) 
26 (70.3) 
 
 
12 (15.6) 
48 (33.8) 
2 (28.6) 
7 (41.2) 
11(29.7) 
9.616 0.047 
* Socio Economic Status was estimated using principal component analysis 
   n/a: Not applicable 
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5.3.2 Predictors of treatment seeking 
 
We studied 17 variables as potential predictors of treatment seeking. Of these, seven had 
univariate p-values > 0.20 and were dropped from the multivariate analysis (Table 5.2).  The 
remaining ten variables were retained in the multivariate logistic regression model building 
process to predict treatment seeking (Table 5.2).   
 
There is a high density of health facilities within the KHDSS, with the majority of PWE being 
within 6 kilometres of the nearest health facility (Figure 5.1).  However, many PWE opted to 
seek treatment elsewhere, especially at KDH. Consequently there was a relationship between 
distance and treatment seeking among PWE (Figure 5.2) because the majority live far from 
KDH.  From the multivariate analysis, caregivers of Children with Epilepsy (CWE) and adults 
with epilepsy who lived more than 30 kilometres from where they sought health care were 81% 
and 76% respectively less likely to seek treatment compared to those who lived closer. The most 
important factor affecting treatment seeking among children and adults was long duration of 
epilepsy: Children who had epilepsy for more than ten years were eight times more likely to seek 
treatment than those who had epilepsy for  less than one year and adults with a similar duration 
of epilepsy were nine times more likely to seek treatment (Table 5.3). 
 
Adults who had biomedical beliefs about the causes and treatment of epilepsy (high scores) were 
more likely to seek treatment from a health facility than those with low scores. Religion 
influenced treatment seeking among adults with epilepsy with those belonging to Christian being 
more likely to seek treatment compared to those in traditional faith.  Other significant predictors 
of treatment seeking were having to pay for AEDs and injury during a seizure (Table 5.3).   
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Table 5.2: Factors included in univariate analysis to predict treatment seeking among 
people with epilepsy (n=673)  
 
 Children Adults 
Variable OR (95%CI) P value OR (95%CI) P value 
Predisposing factors 
Sex 
Female 
Male 
 
1.0 
1.32 (0.83-2.10) 
 
 
0.238 
 
1.0 
1.13 (0.67-1.90) 
 
 
0.650 
Religion 
Traditional 
Islam 
Christian 
 
1.0 
1.50 (0.72-3.16) 
1.64 (0.99-2.71) 
 
 
0.282 
0.055 
 
1.0 
1.76 (1.33-4.74) 
2.21 (1.23-3.93) 
 
 
0.015 
0.007 
Educational  
level 
None 
Primary 
Secondary 
Tertiary 
 
 
1.0 
0.69 (0.43-1.1) 
2.86 (0.64-12.7) 
n/a 
 
 
 
0.125 
0.169 
n/a 
 
 
1.0 
1.04 (0.60-1.79) 
0.57 (0.20-1.61) 
2.80 (0.33-23.5) 
 
 
 
0.901 
0.180 
0.343 
Marital status 
Single 
Married 
Separated 
Divorced 
Windowed 
 
n/a 
n/a 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
n/a 
n/a 
 
1.0 
0.61 (0.27-1.34) 
0.99 (0.14-7.12) 
0.42 (0.12-1.60) 
0.65 (0.22-1.94) 
 
 
0.217 
0.998 
0.208 
0.442 
Occupation 
Farmer 
Trader 
Casual 
Other 
 
n/a 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
n/a 
 
1.0 
0.68 (0.34-1.38) 
0.67 (0.30-1.47) 
1.15 (0.55-2.42) 
 
 
0.288 
0.315 
0.710 
Stigma scores 
0-10 points 
11-30 points 
 
1.0 
1.29 (0.76-2.19) 
 
 
0.352 
 
1.0 
1.13 (0.67-1.93) 
 
 
0.643 
Beliefs about 
causes of 
epilepsy 
0-6 points 
7-10 points 
 
 
 
1.0 
3.07 (1.30-7.12) 
 
 
 
 
0.010 
 
 
 
1.0 
3.61 (1.78-7.32) 
 
 
 
 
0.001 
Beliefs about 
biomedical 
treatment  
0-11 points 
12-16 points 
 
 
 
1.0 
2.96 (1.43-6.15) 
 
 
 
 
0.003 
 
 
 
1.0 
3.97 (1.73-9.07) 
 
 
 
 
0.001 
Beliefs about 
cultural 
treatment  
0-14 points 
15-18 points 
 
 
 
1.0 
1.78 (0.47-1.29) 
 
 
 
 
0.332 
 
 
 
1.0 
1.37 (0.75-2.52) 
 
 
 
 
0.307 
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Table 5.2: Continued from previous page 
 
 OR (95%CI) P value OR (95%CI) P value 
Risk and safety 
concerns beliefs  
0-5 points 
6-8 points 
 
 
1.0 
1.67 (0.78-3.58) 
 
 
 
0.289 
 
 
1.0 
2.04 (0.73-5.67) 
 
 
 
0.274 
Negative 
stereotype 
beliefs  
0-10 points 
11-16 points 
 
 
 
1.0 
0.91 (0.56-1.48) 
 
 
 
 
0.715 
 
 
 
1.0 
1.37 (0.75-2.52) 
 
 
 
 
0.307 
Enabling factors 
Distance to 
health facility 
(Kms) 
<10 
10-20 
20-30 
>30 
 
 
 
1.0 
0.43 (0.22-0.84) 
0.35 (0.19-0.67) 
0.19 (0.08-0.49) 
 
 
 
 
0.014 
0.001 
0.001 
 
 
 
1.0 
0.53(0.33-0.84) 
0.51(0.31-0.82) 
0.24(0.12-0.47) 
 
 
 
 
0.006 
0.006 
0.001 
Paying for 
AEDs 
No 
Yes 
 
 
1.0 
2.57 (1.41-4.69) 
 
 
 
0.002 
 
 
1.0 
3.49 (1.90-6.38) 
 
 
 
<0.0001 
SES n (%) 
Least poor 
Less poor 
Poor 
Very poor 
Most poor 
 
1.0 
0.72 (0.32-1.62 
0.57 (0.25-1.27) 
0.49 (0.23-1.06) 
0.54 (0.24-1.20) 
 
 
0.429 
0.173 
0.069 
0.134 
 
1.0 
0.50 (0.22-1.17) 
0.64 (0.27-1.51) 
0.52 (0.22-1.26) 
0.52 (0.22-1.19) 
 
 
0.112 
0.311 
0.148 
0.120 
Need and disease specific factors 
Duration of 
epilepsy (yrs) 
<1  
1-5  
6-10 
>10 
 
 
1.0 
3.05 (1.46-6.39) 
 6.63 (2.68-9.40) 
 8.41 (3.42-13.7) 
 
 
 
0.003 
<0.0001 
<0.0001 
 
 
1.0 
6.63 (1.25-13.1) 
7.88 (1.47-14.12) 
9.61 (2.31-18.2) 
 
 
 
0.026 
0.016 
0.003 
Seizure 
frequency in 
three months 
None 
1-3 
4-6 
>6 
 
 
 
1.0 
1.57 (0.87-2.82) 
1.12 (0.54-2.30) 
1.39 (0.71-2.60) 
 
 
 
 
0.137 
0.761 
0.305 
 
 
 
1.0 
1.17 (0.62-2.19) 
2.00 (0.81-4.93) 
1.47 (0.70-3.09) 
 
 
 
 
0.631 
0.132 
0.314 
Injury  
during seizure 
No 
Yes 
 
 
1.0 
2.25(1.41-3.58) 
 
 
 
0.001 
 
 
1.0 
2.82(1.62-4.89) 
 
 
 
<0.0001 
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 Figure 5.1: People with epilepsy in relation to nearest health facility (n=673) 
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Figure 5.2: Distance to health facility where people with epilepsy sought treatment (n=499) 
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Table 5.3: Multivariate analysis of factors associated with treatment seeking (n=673)  
 
 Children Adults 
Variable OR (95%CI) P value OR (95%CI) P value 
Predisposing factors 
Religion: n (%) 
Traditional 
Islam 
Christian 
 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
 
1.0 
1.45 (1.15-4.81) 
1.94 (1.25-5.80) 
 
 
0.006 
0.001 
Beliefs about 
causes of 
epilepsy 
*0-6 points 
±7-10 points 
 
 
 
1.0 
3.15 (1.51-6.59) 
 
 
 
 
0.002 
 
 
 
1.0 
3.36 (1.41-8.01) 
 
 
 
 
0.006 
Beliefs about 
biomedical 
treatment  
*0-11 points 
±12-16 points 
 
 
 
1.0 
2.81 (1.26-6.28) 
 
 
 
 
0.011 
 
 
 
1.0 
4.88 (1.98-8.01) 
 
 
 
 
0.001 
Enabling factors 
Distance to 
health 
facility(Kms) 
<10 
10-20 
20-30 
>30 
 
 
 
1.0 
0.37 (0.18-0.77) 
0.35 (0.18-0.68) 
0.19 (0.07-0.51) 
 
 
 
 
0.007 
0.002 
0.001 
 
 
 
1.0 
0.45 (0.23-0.91) 
0.42 (0.20-0.90) 
0.24 (0.09-0.68) 
 
 
 
 
0.025 
0.026 
0.007 
Paying for 
AEDs 
No 
Yes 
 
 
1.0 
2.60 (1.35-4.99) 
 
 
 
0.004 
 
 
1.0 
3.56 (1.84-6.88) 
 
 
 
<0.0001 
Need and disease specific factors 
Duration of 
epilepsy (yrs) 
<1  
1-5  
6-10 
>10 
 
 
1.0 
3.08 (1.39-6.83) 
6.28 (2.36-16.8) 
8.01 (3.02-21.2) 
 
 
 
0.006 
<0.0001 
<0.0001 
 
 
1.0 
6.14 (2.02-13.7) 
7.15 (2.22-15.0) 
9.00 (2.87-18.9) 
 
 
 
0.001 
0.001 
<0.001 
Injury  
during seizure 
No 
Yes 
 
 
1.0 
1.66 (1.17-2.35) 
 
 
 
0.005 
 
 
1.0 
2.56 (1.37-4.78) 
 
 
 
0.003 
*Scores below 66
th
 percentile that were categorized as negative beliefs 
±Scores above 66
th
 percentile that were categorized as positive beliefs 
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5.4 Discussion 
 
People with epilepsy reported seeking treatment from health facilities, particularly KDH 
although a minority sought treatment from both the health facility and THs. 
                                               
5.4.1 Predisposing factors  
 
Our results indicate that factors that influenced treatment seeking were religion, biomedical 
beliefs about causes of epilepsy and treatment of epilepsy.  Adults with Christian or Islamic 
beliefs were more likely to seek treatment than those who held traditional religious beliefs.  A 
study from the Philippines by Thind et al. reported that religion was not a significant predictor of 
health service utilization (Thind & Cruz, 2003), but these contrasting findings could be explained 
by different religious beliefs held by people in the Philippines and Kilifi.  In addition, the study 
in Philippines only looked at two categories of religion (Catholics and Non-Catholic) and this 
may have failed to capture those with traditional religious beliefs (Thind & Cruz, 2003).  People 
with epilepsy with traditional beliefs may be more likely to seek alternative medicine as opposed 
to going to health facilities due to misconceptions and superstitions associated with epilepsy in 
Kilifi (El Sharkawy et al., 2006; Kendall-Taylor et al., 2009).   
 
Only two subscales of the Kilifi Epilepsy Beliefs and Attitude Scale influenced treatment 
seeking.  PWE and their caregivers, i.e. those who had high scores on biomedical causes and 
treatment of epilepsy subscales were more likely to seek treatment from a health facility.  A few 
studies have investigated PWE‘s beliefs and attitudes towards their condition, but have not 
linked this to utilization of health services (El Sharkawy et al., 2006; Desai et al., 1998).  Our 
study correlated beliefs and attitudes held by PWE and their caregivers with their decision to 
seek biomedical treatment. Our findings concur with other studies, that familiarity with patients‘ 
beliefs and attitudes is an important step in improving patient care (Albert, 1983; Ngubane, 
1981). 
 
The following factors were not found to be significant predictors of treatment seeking: sex, 
education level, marital status, occupation, stigma, beliefs about how epilepsy is treated 
culturally, risk and safety concerns about epilepsy and negative stereotypes about epilepsy.   
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Our findings that sex is not associated with the decision to seek care contrasts with other studies 
that provide conflicting data on the influence of sex on treatment seeking (Thind & Andersen, 
2003; Ganatra & Hirve, 1994; Das, 1987).  A study in Dominican Republic by Thind showed 
that female children were more likely to use health services but the other two studies conducted 
in India noted a male predominance in utilization of health services by children.  Some studies 
have documented education level as an important predictor of health care utilization in RPCs 
(Thind & Cruz, 2003; Sreeramareddy et al., 2006; Abbas & Walker, 1986; Cleland & Van 
Ginneken, 1988; Streatfield et al., 1990) but other studies have not found this to be an important 
factor (Pillai et al., 2003; Thind & Cruz, 2003; Perez-Cuevas et al., 1996).  In Kilifi, literacy 
levels are low and more than half of the population cannot read or write (GOK, 2000).  This is 
supported by our finding of low educational level among study participants (children with 
epilepsy and their caregivers) which may explain the insignificance of education in predicting 
treatment seeking.  
 
Stigma associated with epilepsy has been shown to delay appropriate health-seeking behaviour in 
various studies (Rafael et al., 2010; Weiss & Ramakrishna, 2006; Placencia et al., 1995).  
However in Kilifi, the majority of PWE reported low scores on the stigma scale, suggesting they 
did not feel stigmatized by their condition (Chapter 3).  Consequently, perceived stigma did not 
have an impact on treatment seeking.  Our study concurs with others that failed to demonstrate 
high levels of perceived stigma among PWE (Ryan et al., 1980; Westbrook et al., 1992; Cramer 
et al., 1999).  It is possible that PWE in our setting did not experience a high level of stigma 
because they have been exposed to continuous information about epilepsy during census 
enumeration and previous epilepsy studies which started in 2003 (Edwards et al., 2008; El 
Sharkawy et al., 2006; Kendall-Taylor et al., 2009).   
 
5.4.2 Enabling factors 
 
The enabling factors that had an effect on treatment seeking were distance to health facilities and 
paying for AEDs. The geographic proximity of health services to people‘s homes is an important 
factor that affects utilization of health services, particularly in resource poor settings where 
density of biomedical health facilities is often low (Habib & Vaughan, 1986; Stock, 1983).  As 
distance increases, the level of utilization decreases and vice versa (Abbas & Walker, 1986; 
Stock, 1983; Muller et al., 1998; Annis, 1981; Shannon et al., 1969).  Our study supported these 
findings as it demonstrated PWE who travelled the longest distance to KDH were less likely to 
seek treatment.  
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The 1997 Kenyan health policy strategic framework states that all households should have access 
to health  services within a five kilometre range (1997), in accordance with the notion that 
improved physical access could lessen delays in seeking care and time travelled to obtain 
treatment.  In KHDSS, there is a high density of biomedical health services within reach by both 
PWE who sought and those who never sought treatment (Figure 5.1).  However, it is only KDH 
that offers specialized care for epilepsy, as well as AEDs other than phenobarbital.  This explains 
why PWE opted to travel long distances to KDH as opposed to going to the nearest health 
facility, where the supply of AEDs was likely to be erratic.  If PWE were to seek treatment from 
the nearest health facility the furthest one would travel is 15 kilometres.   
  
Caregivers of CWE, as well as adults with epilepsy who reported paying for AEDs, were more 
likely to seek treatment than those who did not pay.  The cost of AEDs in peripheral facilities 
was 10 Kenyan shillings (Kes) (0.13 U$), whereas at KDH it was 40 Kes (0.51 U$).  This may 
mean the cost of AEDs per se is not a hindrance compared to the indirect costs involved in 
seeking care (time, days of work lost, transport costs etc).  People with epilepsy travelled long 
distances to access specialized care and the effect of distance has been shown to be greater when 
it interacts with economic factors, thus combining the effects of distance with time, transport, 
income and cost of care (Habib & Vaughan, 1986).  
 
Socio-economic status was not a significant predictor of health service utilization.  This contrasts 
with findings from other studies that have shown that families with a higher SES were more 
likely to seek care from health facilities because they have the resources needed to do so (Thind 
& Andersen, 2003; Carr-Hill et al., 1996; Neumark et al., 1992).  Multi-country studies have 
also shown differences in the types of care sought by wealthy people compared to poor people, 
with poor people more frequently opting for care outside the biomedical sector and wealthy 
people more frequently opting for care involving the biomedical sector (Hausmann-Muela et al., 
2003).  In Kilifi, there was similarity in assets owned by PWE since they all come from a rural 
setting.  This lack of variation in assets could explain why SES did not influence treatment 
seeking. When the same SES tool was used in rural and urban settings of Kilifi District to 
estimate inequalities in insecticide treated bed nets,  there was a significant difference between 
the assets owned by rural and urban households (Chuma & Molyneux, 2009).  
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5.4.3 Perceived need factors 
 
Duration of epilepsy and experiencing an injury during a seizure were the two disease-specific 
variables that predicted treatment seeking.  PWE who had epilepsy for a long period were more 
likely to seek medical services, as were those who reported injuries directly associated with 
epilepsy such as burns, broken bones, cuts and bruises.  Severity (seizure frequency) was not a 
significant predictor of treatment seeking despite several studies reporting that the most 
immediate cause of health services utilization is disease severity (perceived need) (Habib & 
Vaughan, 1986; Sreeramareddy et al., 2006; Wolinsky, 1978; Pillai et al., 2003; Kloos, 1990).  
This could point to inequality of access because predisposing and enabling factors were the main 
factors that influenced utilization of health services as opposed to perceived need (seizure 
frequency (Andersen et al., 2001). 
 
5.5 Limitations of the study 
 
We relied on self-reported answers, and these may be subject to recall and reporting bias. 
Attempts were made to minimize this potential source of bias by piloting the questionnaires and 
training field staff how to administer the questionnaires.  Our model does not control for quality 
of care, which may play a role in determining health service utilization.  Unidentified predictors 
or confounders are still possible regarding perceptions of PWE about epilepsy and health seeking 
behaviour.   
 
5.6 Conclusion 
 
The results of the study show that PWE were more likely to seek treatment when they were close 
to health facilities that provided specialized epilepsy care, had epilepsy for a long time, and when 
they had high scores on biomedical causes and treatment of epilepsy subscales.  This highlights 
the need for researchers to understand factors that influence treatment seeking in order to 
develop and implement culturally appropriate interventions that can reduce the ETG in RPCs.  In 
our setting, we developed an educational intervention to increase awareness of epilepsy as a 
treatable disorder with the aim of reducing the ETG in Kilifi.  Health education programs are 
effective in altering health beliefs and perceptions about illnesses and we are likely to increase 
the number of PWE who seek treatment from health facilities.  
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People‘s perceived need for care may also be increased through health education programs.  At 
policy level, the government can improve the delivery of epilepsy services at the peripheral 
health facilities by increasing skilled manpower and supply of AEDs.  This would reduce the 
indirect cost of seeking care especially in KHDSS where there is a high density of health 
facilities within reach by PWE. 
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Abstract 
 
Introduction 
 
Patient adherence to medication regimens is important in the management of epilepsy.  Research 
has shown that between 25% and 75% of People with Epilepsy (PWE) fail to follow prescribed 
drug regimes. This reduces the benefit that could be gained from the medication leading to 
uncontrolled epilepsy. We measured adherence to Anti-epileptic Drugs (AEDs) using blood 
levels of AEDs and investigated the factors associated with adherence.  
 
Methods 
 
A cross-sectional survey was conducted among PWE in Kilifi District, from June to December 
2008.  Adherence was determined using detectable and optimal blood levels of phenobarbital, 
phenytoin and carbamazepine.  This was compared with self reported adherence, which was 
assessed concurrently using the Morisky Medication Adherence Scale. The sensitivity and 
specificity of self-reporting were determined using AED blood levels as the gold standard.  
Factors influencing adherence were explored using univariate and multivariate logistic regression 
models. Only variables with a p-value ≤ 0.20 in the univariate analysis were included in a 
multivariate logistic regression model. 
 
Results 
 
A total of 673 PWE were interviewed.  Of these, 499 (74.1%) reported seeking treatment but 
only 385 (77.2%) were currently taking AEDs to control seizures.  Of the 385, 341(88.6%) gave 
blood but only 169 (49.6%) were found to have AEDs in their blood. The sensitivity and 
specificity of self-reported adherence, compared to the assumed gold standard of blood testing 
was 44.4% (95% CI 36.8-52.2) and 52.9% (95% CI 45.2-60.5%), respectively.  The concordance 
and discordance between self reporting and AEDs blood levels was 166 (48.7%) and 175 
(51.3%) respectively.  The epilepsy treatment gap based on detectable and optimal AEDs blood 
levels was 74.9% (95% confidence interval (CI); 71.4-78.1).   
 
The most important factor affecting adherence was long duration of medication (Adjusted Odds 
Ratio (aOR) = 4.25, 95% CI 1.86–8.75) and (aOR = 6.50, 95% CI 1.58–9.63) in children and 
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adults respectively.  Other significant predictors were seizure frequency, injury during a seizure, 
number of AEDs prescribed and having a good relationship with the healthcare provider.   
 
Conclusion 
 
This study identified a subset of PWE at risk of low adherence and highlighted several reasons 
why they fail to adhere to AEDs.  This will greatly help in developing interventions to improve 
patient adherence and reduce preventable seizures.  There is also a need for healthcare providers 
to continually improve their relationship and communication with patients in addition to 
educating and counselling them. 
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6.1 Introduction  
 
Patient adherence to medication regimens is important in the management of epilepsy (Gomes 
Mda et al., 1998; Jones et al., 2006; Osterberg & Blaschke, 2005).  Adherence to a medication 
regimen is defined as the extent to which patients take medication as prescribed by their 
healthcare providers (Osterberg & Blaschke, 2005). Non-adherence to medication is a major 
problem in the treatment of epilepsy (Kemp et al., 2007).  Patients may exhibit different types of 
non-adherent behaviour.  Unintentional non-adherence may be due to forgetfulness, or inability 
to follow treatment instructions due to poor understanding or physical problems such as poor 
eyesight, whereas intentional non-adherence arises when the patient rejects either the doctor‘s 
diagnosis or the doctor‘s recommended treatment (Horne, 1997; Marinker et al., 1997).  
Research has shown that between 25% and 75% of People with Epilepsy (PWE) fail to follow 
prescribed drug regimens (Leppik, 1990; Buck et al., 1997).  This reduces the benefit that could 
be gained from the Anti-epileptic Drugs (AEDs) leading to uncontrolled epilepsy and reduced 
quality of life (Dunbar-Jacob & Mortimer-Stephens, 2001; Eraker et al., 1984; Leppik, 1990; 
Stanaway et al., 1985).  
 
Adherence to treatment regimens is a complex phenomenon, which can be best understood 
within the patient‘s physical, economic, psychological and social circumstances (Haynes et al., 
2002; DiMatteo, 2004).  There are many factors that contribute to non-adherence, which can be 
attributed to healthcare professionals, the health care system, the community and the patients 
(WHO, 2003). Researchers have examined numerous factors as causes and correlates of 
adherence with the aim of developing effective intervention strategies to improve adherence.  
Factors such as age (Hassan et al., 2006; Osterberg & Blaschke, 2005), sex (Bloom, 2001), low 
socioeconomic status (Osterberg & Blaschke, 2005), severity of disease (Osterberg & Blaschke, 
2005), number of pills per day (Hassan et al., 2006; Bloom, 2001), side effects of medication 
(Hassan et al., 2006; Osterberg & Blaschke, 2005), patients‘ understanding of the disease and 
importance of treatment (Osterberg & Blaschke, 2005; Hassan et al., 2006), co-morbid medical 
conditions (Osterberg & Blaschke, 2005), lack of social support, poor patient- healthcare 
provider relationship (Wang et al., 2002), cost and  forgetfulness (Almas et al., 2006), have all 
been shown to affect adherence in various populations.  
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Adherence can be measured either directly or indirectly.  Direct measures involve measurement 
of drug levels in blood, urine, saliva and hair (Paschal et al., 2008).  Indirect measures involve 
non-biological tools such as self-reported measures, pill counts, appointment attendance, 
medication refills or surrogate markers such as seizure frequency (Paschal et al., 2008).  Direct 
measures are more robust and allow comparative analysis since they provide quantitative data on 
the chemical presence of medication in a patient‘s body.  An evidence base is more difficult to 
document for indirect measures due to variations in methodology used, although these measures 
also yield quantitative data about patient adherence (Paschal et al., 2008).  No single 
measurement strategy has been deemed optimal. Combining direct and indirect methods of 
adherence assessment may represent the most accurate way of assessing the degree to which a 
patient adheres to pharmacological treatment (Paschal et al., 2008; WHO, 2003).  We measured 
adherence to AEDs among PWE using blood levels and compared this to self-reported 
adherence. In addition, we investigated the factors associated with adherence as measured by 
AEDs in Kilifi, Kenya.  
 
6.2 Methods  
6.2.1 Study area 
 
The study was conducted in the Kilifi Health Demographic Surveillance System (KHDSS).  
Details of the study area are described in chapter 1.   
 
6.2.2 Identification of participants  
 
People with Epilepsy were identified in a cross-sectional survey that was conducted to determine 
the prevalence and incidence of epilepsy in KHDSS (Ngugi et al., In preparation). This 
methodology is described in details in chapter 1.   
 
6.2.3 Data collection 
 
The questionnaires for the study were developed in English and translated into the local 
language, Kigiriama. They were grouped into six categories: socio-demographic characteristics 
(age, sex, religion, education, occupation and marital status); accessibility (distance from home 
to health facilities, Socio Economic Status (SES) and relationship with healthcare providers); 
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severity of epilepsy (duration of epilepsy, frequency and duration of seizures, injury during a 
seizure); details of prescribed medication regimen (number of prescribed AEDs, frequency of 
taking AEDS  per day, AEDs side effects and number of years they have taken AEDs); stigma 
and questions on epilepsy beliefs and attitudes.  Three field staff were trained for four days on 
how the tools were developed, how to approach homesteads, how to administer the 
questionnaires and check data. The questionnaires were administered to participants following 
written informed consent.  Where PWE was a child, a caregiver (mother, father or guardian) was 
interviewed.  The participants were interviewed between June and December 2008.  
 
Blood samples (2 mL) were collected by a clinician after obtaining informed consent from the 
participants.  The blood samples were collected into lithium-heparinized tubes, centrifuged (3000 
rpm, 10 minutes at 4oC).  The plasma was separated into a clean cryo-vial, labelled with the PWE‘s 
number, the date and time the sample was collected.  The samples were stored at –800 C until 
assayed for AEDs levels.  The study was reviewed and approved by the KEMRI/National Ethical 
Review Committee and the Swiss Tropical and Public Health Research Committee. 
 
6.2.3.1 Measuring self-reported adherence 
 
Data on self reported adherence were collected using questionnaires.  People with epilepsy were 
asked if they were currently taking any AEDs.  The actual tablets were presented on the surface 
of a board to aid recognition of different AEDs.  Those who reported taking AEDs were assessed 
using the Morisky Medication Adherence Scale (MMAS) (Morisky et al., 1986), a four item 
scale with high reliability and validity (Morisky et al., 1986), which was developed in America 
but has been adopted and used in other countries (Hashmi et al., 2007; Pratt et al., 2001; 
Krousel-Wood et al., 2005; Al-Qazaz et al., 2010; Stack et al., 2010; Vik et al., April 2005).  
This scale measures both intentional and unintentional adherence based on forgetfulness, 
carelessness, stopping medication when feeling better, and stopping medication when feeling 
worse. The scale is dichotomous and is scored zero points for each ―no‖ and one point for each 
―yes‖.  People with epilepsy were categorized as adherent if they had a total score of 0 on all the 
four items and non-adherent if they had a score ranging from 1-4. 
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6.2.3.2 Measuring blood level adherence  
 
Blood samples were assayed for the most commonly used AEDs in Kilifi District (phenobarbital, 
phenytoin and carbamazepine).  Plasma drug concentrations were measured using a fluorescence 
polarisation immunoassay analyser (TDx FLx Abbott Laboratories, Abbott Park, IL, USA).  The 
detectable range for the different drugs were: phenobarbital 1.1-9.9 μg/mL, phenytoin 1.0-9.9 
μg/mL and carbamazepine 0.5-3.9 μg/mL (Shakya et al., 2008).  The optimal ranges were 
defined as follows: phenobarbital 10-40 μg/mL, phenytoin 10-20 μg/mL and carbamazepine 4.0-
12 μg/mL (Gomes Mda et al., 1998).  An individual was defined as adherent if AEDs were 
detectable in their blood.   
 
6.2.3.3 Measuring agreement between self-reporting and blood level adherence 
 
We established concordance and discordance between self-reporting and AED blood levels.  A 
Kappa statistic (k) was then used to measure the level of agreement between self-reporting and 
each individual AED (phenobarbital, phenytoin and carbamazepine).  
 
6.2.3.4 Measuring the epilepsy treatment gap 
 
We estimated the proportion of people with Active Convulsive Epilepsy (ACE) whose seizures 
were not appropriately treated by subtracting those who were adherent based on AED blood 
levels from the total number of PWE, dividing by the total number of PWE, then multiplying by 
100%. 
 
6.2.3.5 Measuring stigma, epilepsy beliefs and attitudes  
 
Perceived stigma and epilepsy beliefs and attitudes were measured using Likert scales. The Kilifi 
Stigma Scale for Epilepsy had 15 questions and measured only one construct (perceived stigma).  
The Kilifi Epilepsy Beliefs and Attitude Scale had 34 questions which constituted five subscales 
(causes of epilepsy, biomedical treatment of epilepsy, cultural treatment of epilepsy, risk and 
safety concerns and negative stereotypes about epilepsy). The development, validation and 
scoring of these tools is explained in Chapters 3 and 4.  
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6.2.4 Statistical analysis  
 
Data were double entered and verified in MySQL.  Statistical analyses were undertaken using 
STATA version 11 (StataCorp, College Station, TX, USA). The data were screened for 
consistency, missing values and unexplained outliers.  The distribution pattern was examined for 
shape and skewing before selecting the appropriate test statistic.  The sensitivity and specificity 
of self-reporting was determined using AED blood levels as the gold standard. 
 
PWE were categorized by age into children (<18 years) and adults (≥18 years) and factors 
influencing adherence were investigated. First, a chi-square test was used to measure 
associations between socio-demographic characteristics and adherence. Second, a univariate 
regression analysis was performed to identify which of the predictor variables were significant to 
the outcome measure, i.e. adherence based on AED blood levels.  In the univariate analysis, any 
factor with a p-value > 0.20 was not considered an important covariate of adherence.  
 
All variables with a p-value ≤ 0.20 in the univariate analysis were included in a multivariate 
logistic regression model, using a forward stepwise strategy to identify their combined effect on 
adherence.  At each step, non-significant explanatory variables were removed and only variables 
with a p ≤ 0.1 were retained in the model.  Regression models were compared with the 
Likelihood Ratio Test (LRT).  Parameter estimates, Odds Ratio (OR), 95% Confidence Interval 
(CI) and p-values were recorded for each predictor.   
 
6.3 Results 
6.3.1 Study participants 
 
A total of 673 PWE were interviewed.  Of these, 499 (74.1%) reported seeking treatment but 
only 385 (77.2%) reported taking AEDs to control seizures (Fig 6.1, A).   Of the 385 taking 
AEDs, 191 (49.6%) were on monotherapy and 194 (50.3%) on polytherapy (Fig 6.1, A).  Of the 
385 PWE who reported taking AEDs, 341 (88.6%) gave blood samples.  Most PWE reported 
taking phenobarbital and this was evident from the large number of blood samples that had 
phenobarbital in the optimal range (Table 6.1).  Phenobarbital also has a longer half-life which 
increases its ability to be detected over a long duration after ingestion. The demographic 
characteristics of the participants (who gave blood) are reported in (Table 6.2). 
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Figure 6.1: Venn diagrams of self reported and blood level adherence 
 
 
*In diagram A, 385 PWE reported taking AEDs and in B only 169 had AEDs in their blood. 
 
 
 
 
Table 6.1: Self reported and blood levels of individual antiepileptic drugs 
 
Antiepileptic 
drugs 
Published 
Half life 
Dose range Number of 
patients 
reporting 
use 
Number with 
detectable 
drug level 
(%) 
Number 
with optimal 
drug level 
(%) 
Phenobarbital 2-7 days 30-300 mg/day 219 30 (13.7) 96 (43.8) 
 
Phenytoin 7-42 hours 100-600 mg/kg 81 37 (45.7) 12 (14.8) 
 
Carbamazepine 25-65 hours  400-1200 mg/day 85 13 (15.3) 45 (52.9) 
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Table 6.2: Demographic characteristics of participants who gave blood samples (n=341) 
 
 Children (n=175) Adults (n=166) 
Variable Adherent 
n=78 
Non- 
adherent 
n=97 
X
2
 P 
value 
Adherent 
n=91 
Non-
adherent 
n=75 
X
2
 P 
value 
Age years: 
Median  
[IQR] 
 
13 
17-8 
 
13 
15-8 
   
26 
32-22 
 
31 
55- 24 
  
Sex: n (%) 
Female  
Male 
 
39 (54.2) 
39 (37.8) 
 
33 (45.8) 
64 (62.2) 
0.55 0.457  
43 (51.2) 
48 (58.5) 
 
41 (48.8) 
34 (41.5) 
0.904 0.342 
Religion:  
n (%) 
Traditional 
Christian 
Islam 
 
 
29 (46.8) 
41 (46.6) 
8 (30.0) 
 
 
33 (53.2) 
47 (53.4) 
17 (68.0) 
1.87 0.393  
 
31 (50.0) 
50 (56.8) 
10 (62.5) 
 
 
31 (50.0) 
38 (43.2) 
6 (37.5) 
1.104 0.576 
Educational 
level n: (%) 
None  
Primary 
Secondary 
Tertiary 
 
 
36 (50.7) 
32 (37.2) 
10 (55.6) 
n/a 
 
 
35 (49.3) 
54 (62.8) 
8 (44.4) 
n/a 
5.65 0.130  
 
38 (52.0) 
44 (58.7) 
8 (72.7) 
1 (14.3) 
 
 
35 (48.0) 
31 (41.3) 
3 (27.3) 
6 (85.7) 
6.741 0.081 
SES: n (%) 
Least poor 
Less poor 
Poor 
Very poor 
Most poor 
 
20 (50.0) 
16 (41.0) 
18 (45.0) 
10 (34.5) 
14 (51.8) 
 
20 (50.0) 
23 (59.0) 
22 (55.0) 
19 (65.5) 
13 (48.2) 
2.45 0.653  
30 (62.5) 
19 (59.4) 
16 (53.3) 
12 (42.9) 
14 (50.0) 
 
18 (37.5) 
13 (40.6) 
14 (46.7) 
16 (57.1) 
14 (50.0) 
3.499 0.478 
Occupation:  
n (%) 
Farmer 
Trader 
Casual labourer 
Other 
 
 
n/a 
n/a 
n/a 
n/a 
 
 
n/a 
n/a 
n/a 
n/a 
n/a n/a  
 
47 (53.4) 
14 (46.7) 
14 (63.6) 
16 (61.5) 
 
 
41 (46.6) 
16 (53.3) 
8 (36.4) 
10 (38.5) 
2.040 0.564 
Marital status: 
n (%) 
Single 
Married 
Separated 
Divorced 
Widowed 
 
 
n/a 
n/a 
n/a 
n/a 
n/a 
 
 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a n/a  
 
38 (64.4) 
33 (44.0) 
3 (75.0) 
5 (62.5) 
12 (60.0) 
 
 
21 (35.6) 
42 (56.0) 
1 (25.0) 
3 (37.5) 
8 (40.0) 
6.801 0.147 
* Socio Economic Status was estimated using principal component analysis 
   n/a: Not applicable 
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6.3.2 Sensitivity and specificity of self-reporting 
 
Based on the self-reported Morisky scale, 179 (46.5%) PWE were classified as adherent and 206 
(53.5%) as non-adherent (Table 6.3).  Based on drug levels, 169 (49.6%) PWE had AEDs in 
their blood and were classified as adherent (Fig 6.1 B) whereas 172 (54.4%) were non-adherent.  
Of the 169, 41 (24.3% %) had drug concentrations in the detectable range and 128 (75.7 %) were 
in the optimal range.  The sensitivity and specificity of self-reported adherence, compared to the 
AEDs detected in the blood was 44.4% (95% CI 36.8-52.2) and 52.9% (95% CI 45.2-60.5%), 
respectively. The concordance and discordance between self-reporting and blood levels for the 
three AEDs was 166 (48.7%) and 175 (51.3%) respectively. There was no difference between 
those who were concordant and discordant across socio-demographic characteristics. The 
agreement between self-reporting and blood levels for individual AEDs was k=0.63 for 
phenobarbital, k=0.59 for phenytoin and k=0.62 carbamazepine.  The ETG based on AED blood 
levels was 74.9% (95% CI; 71.4-78.1).   
 
Table 6.3: Self-reported Morisky Medication Adherence Scale (n=385) 
 
Item No: n (%) 
 
Yes: n (%) 
Do you ever forget to take your medication? 
 
112 (29.1) 273 (70.9) 
Are you careless at times about taking your medication?  
 
114 (29.6) 271 (70.4) 
When you feel better, do you sometimes stop taking your 
medication? 
44 (11.4) 341 (88.6) 
Sometimes, if you feel worse when you take your medication, do 
you stop taking it? 
29 (7.5) 356 (92.5) 
Self Reported Medication Adherence  
 
179 (46.5) 206 (53.5) 
 
6.3.3 Factors influencing adherence to anti-epileptic drugs 
 
We studied 21 variables as potential predictors of adherence.  Of these, 13 had univariate p-
values > 0.20 and were excluded from the multivariate analysis (Table 6.4).  The remaining eight 
variables were retained in the multivariate logistic regression model building process to predict 
adherence (Table 6.4).  
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The most important factor affecting adherence among children and adults was long duration of 
treatment.  Children who had taken AEDs for more than five years were four times more likely 
to adhere to medication than those who had taken drugs for less than one year whereas adults 
who had taken drugs for a similar period were six times more likely to adhere to medication.  
Children and adults who experienced more than six seizures in three months were three times 
more likely to take their medication. Children and adults on polytherapy were twice as likely to 
take their medication than those on monotherapy.  Other significant predictors were injury during 
a seizure and having a good relationship with the healthcare provider (Table 6.5).  
 
Table 6.4: Factors included in univariate analysis to predict blood level adherence among 
people with epilepsy (n=341)  
 
 Children Adults 
Variable OR (95%CI) P value OR (95%CI) P value 
 
Sex 
Female 
Male 
 
1.0 
1.21 (0.73-2.01) 
 
 
0.457 
 
1.0 
1.35 (0.73-2.49) 
 
 
0.342 
Religion 
Traditional 
Christian 
Islam 
 
1.0 
0.99 (0.52-1.90 
0.53 (0.20-1.42) 
 
 
0.982 
0.210 
 
 
1.31 (0.69-2.53) 
1.67 (0.54-5.12) 
 
 
0.410 
0.375 
Education level 
None  
Primary 
Secondary 
Tertiary 
 
1.0 
0.58 (0.30-1.09) 
0.97 (0.33-2.88) 
n/a 
 
 
0.291 
0.959 
n/a 
 
1.0 
1.30 (0.68-2.50) 
2.46 (0.60-5.01) 
0.15 (0.02-1.34) 
 
 
0.419 
0.210 
0.090 
Marital status 
Single 
Married 
Separated 
Divorced 
Windowed 
 
n/a 
n/a 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
n/a 
n/a 
 
1.0 
0.70 (0.29-1.72) 
1.66 (0.16-6.95) 
0.92 (0.20-4.24) 
0.83 (0.29-2.35) 
 
 
0.438 
0.670 
0.916 
0.724 
Occupation 
Farmer 
Trader 
Casual 
Other 
 
n/a 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
n/a 
 
1.0 
0.76 (0.33-1.75) 
1.53 (0.58-4.00) 
1.40 (0.57-3.41) 
 
 
0.524 
0.390 
0.465 
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Table 6.4: Continued from previous page 
 
 Children Adults 
Variable OR (95%CI) P value OR (95%CI) P value 
 
SES n (%) 
Least poor 
Less poor 
Poor 
Very poor 
Most poor 
 
1.0 
1.08 (0.41-2.86) 
0.53 (0.20-1.41) 
0.82 (0.34-1.97) 
0.70 (0.29-1.69) 
 
 
0.882 
0.202 
0.654 
0.424 
 
1.0 
0.60 (0.23-1.54) 
0.45 (0.17-1.16) 
0.69 (0.27-1.73) 
0.88 (0.35-2.19) 
 
 
0.289 
0.299 
0.424 
0.779 
Distance to health 
facility (Kms) 
<10 
10-20 
20-30 
>30 
 
 
1.0 
0.58 (0.27-1.25) 
0.62 (0.29-1.32) 
1.30 (0.37-4.60) 
 
 
 
0.266 
0.214 
0.681 
 
 
1.0 
0.53 (0.28-1.01) 
0.68 (0.36-1.30) 
0.74 (0.22-2.41) 
 
 
 
0.361 
0.244 
0.611 
Duration of 
epilepsy (years) 
<1  
1-5  
6-10 
>10 
 
 
1.0 
0.38 (0.42-1.48) 
0.47 (0.51-2.45) 
0.51(0.64-4.54) 
 
 
 
0.234 
0.372 
0.310 
 
 
1.0 
0.16 (0.06-1.44) 
0.50 (0.91-1.71) 
0.81 (0.05-3.69) 
 
 
 
0.890 
0.777 
0.882 
Seizure frequency 
in three months 
None 
1-3 
4-6 
>6 
 
 
1.0 
2.58 (1.29-5.14) 
1.80 (1.61-4.74) 
3.61(1.31-3.21) 
 
 
 
0.007 
0.023 
0.030 
 
 
1.0 
3.06 (1.49-6.28) 
2.45 (1.98-6.10) 
1.6 (1.07-3.34) 
 
 
 
0.002 
0.040 
0.065 
Injury  
during seizure 
No 
Yes 
 
 
1.0 
1.21 (1.66-2.21) 
 
 
 
0.050 
 
 
1.0 
1.37 (1.64-2.95) 
 
 
 
0.041 
Duration of 
medication (years) 
<1 
1-3 
4-5 
>5 
 
 
1.0 
2.68 (1.09-6.56) 
1.88 (1.65-5.44) 
4.30 (1.76-7.05) 
 
 
 
0.031 
0.024 
0.001 
 
 
1.0 
2.60 (1.92-4.34) 
5.97 (1.52-3.42) 
5.02 (1.87-3.45) 
 
 
 
0.071 
0.010 
0.001 
No of AEDs 
Monotherapy 
Polytherapy 
 
1.0 
2.29 (1.05-4.67) 
 
 
0.010 
 
1.0 
2.49 (1.15-4.47) 
 
 
0.016 
Stigma scores 
*0-10 points 
±11-30 points 
 
1.0 
1.00 (0.53-1.90) 
 
 
0.990 
 
1.0 
1.1 4 (0.61-2.12) 
 
 
0.686 
* Those with stigma scores below 66
th
 percentile that were categorized as not stigmatized 
± Those with stigma scores above 66
th
 percentile that were categorized as stigmatized 
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Table 6.4: Continued from previous page 
 
 Children Adults 
Variable OR (95%CI) P value OR (95%CI) P value 
 
AEDs side effects 
No 
Yes 
 
1.0 
0.61 (0.38-0.97) 
 
 
0.057 
 
1.0 
0.43 (0.20-0.89) 
 
 
0.074 
Good relation 
with provider 
No 
Yes 
 
 
1.0 
2.01 (1.22-3.79) 
 
 
 
0.032 
 
 
1.0 
1.51 (1.18-2.57) 
 
 
 
0.025 
Availability of 
family support 
No  
Yes 
 
 
1.0 
0.59 (0.26-1.35) 
 
 
 
0.215 
 
 
1.0 
0.77 (0.38-1.57) 
 
 
 
0.479 
Beliefs about causes 
of epilepsy 
*0-6 points 
±7-10 points 
 
 
1.0 
1.91 (1.03-3.56) 
 
 
 
0.041 
 
 
1.0 
1.15 (1.60-2.18) 
 
 
 
0.062 
Beliefs about 
biomedical 
treatment  
*0-11 points 
±12-16 points 
 
 
 
1.0 
1.66 (0.48-5.74) 
 
 
 
 
0.421 
 
 
 
1.0 
2.09 (0.48-9.07) 
 
 
 
 
0.323 
Beliefs about 
cultural treatment 
*0-14 points 
±15-18 points 
 
 
1.0 
1.12 (0.59-2.12) 
 
 
 
0.711 
 
 
1.0 
0.67 (0.35-1.29) 
 
 
 
0.231 
Risk and safety 
concerns beliefs  
*0-5 points 
±6-8 points 
 
 
1.0 
1.87 (0.62-5.62) 
 
 
 
0.267 
 
 
1.0 
1.22 (0.24-6.24) 
 
 
 
0.809 
Negative stereotype 
beliefs  
*0-10 points 
±11-16 points 
 
 
1.0 
0.34 (0.18-0.66) 
 
 
 
0.101 
 
 
1.0 
0.31 (0.13-0.73) 
 
 
 
0.126 
*Scores below 66
th
 percentile that were categorized as negative beliefs 
± Scores above 66
th
 percentile that were categorized as positive beliefs 
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Table 6.5: Multivariate analysis of factors associated with blood level adherence among 
people with epilepsy(n=341) 
 
 Children Adults 
 
Variable OR (95%CI) P value OR (95%CI) P value 
 
Seizure 
frequency in 
three months 
None 
1-3 
4-6 
>6 
 
 
 
1.0 
1.82 (1.78-4.85) 
2.83 (1.49-5.65) 
3.67 (1.35-7.30) 
 
 
 
 
0.008 
0.006 
0.003 
 
 
 
1.0 
1.55 (1.56-5.99) 
2.66 (1.23-5.64) 
3.87 (2.79-6.42) 
 
 
 
 
0.036 
0.012 
0.001 
Injury  
during seizure 
No 
Yes 
 
 
1.0 
2.55 (1.35-5.74) 
 
 
 
0.010 
 
 
1.0 
2.49 (1.37-4.56) 
 
 
 
0.005 
Duration of 
medication(years) 
<1 
1-3 
4-5 
>5 
 
 
1.0 
2.89 (1.67-5.74) 
3.60 (1.03-6.46) 
4.25 (1.86-8.75) 
 
 
 
0.023 
0.041 
0.002 
 
 
1.0 
2.78 (1.52-6.77) 
5.43 (1.89-7.57) 
6.50 (1.58-9.63) 
 
 
 
0.031 
0.020 
0.004 
No of AEDs 
Monotherapy 
Polytherapy 
 
1.0 
2.51 (1.45-4.35) 
 
 
0.001 
 
1.0 
2.28 (1.43-3.63) 
 
 
0.020 
Good relation 
with provider 
No 
Yes 
 
 
1.0 
2.48 (1.07-5.77) 
 
 
 
0.042 
 
 
1.0 
1.91 (1.23-2.96) 
 
 
 
0.004 
 
6.4 Discussion 
 
Patient adherence to treatment regimens is a complex phenomenon dependent on a number of 
factors. Some investigators emphasize the central role that the health care provider plays in 
shaping adherence, while others stress the active role of the patient.  In this study we investigated 
factors that influence adherence among PWE in Kilifi from a patient perspective.   
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6.4.1 Sensitivity and specificity of self-reporting 
 
Patient self-report using reliable and varied questionnaires is an efficient and cost-effective 
method for assessing adherence (Morisky et al., 1986; Osterberg & Blaschke, 2005; Horne & 
Weinman, 1999).  Self-report is also viable and useful as it can identify the reasons behind non-
adherence, which could then help in addressing underlying issues (Turner & Hecht, 2001).  
Despite it being a good measure, some researchers have reported that patients tend to 
underestimate or overestimate their adherence (Stephenson et al., 1993; Thorbecke, 1988).  
However, when self-report is combined with direct methods, it has been shown to have better 
sensitivity and specificity (Gomes Mda et al., 1998; Ley, 1987).  We evaluated the sensitivity 
and specificity of self reporting by using blood levels of AEDs as the gold standard.  Sensitivity 
and specificity of self-reporting was low, indicating that self-reporting is not a reliable measure 
of adherence in PWE in this community. Other studies have also shown that adherence levels 
based on blood assays were not correlated with patient-reported adherence, indicating the 
relative unreliability of patient report as a measure of adherence (Hazzard et al., 1990; Garber et 
al., 2004).  The discordance between self-reporting and AED blood levels observed in this study 
could be explained by: (a) participants giving positive responses (saying they take AEDs) 
because they understand expectations of the researcher or (b) participants giving negative 
responses (saying they don‘t take AEDs) because they expect some benefits from the researcher, 
such as being supplied with AEDs. 
 
The Kappa statistic for the three AEDs ranged from 0.59-0.63.  Kappa of 0.40-0.75 is considered 
good whereas that above 0.75 is excellent (Landis & Koch, 1977).  Phenobarbital, which has a 
very long half life (two to seven days) had the highest level of agreement between self-reporting 
and blood level (Levy et al., 1995; Faught, 2001).  Phenytoin, which has the shortest half life (7-
42 hours) had the lowest agreement (Levy et al., 1995; Faught, 2001).  The level of agreement 
for Carbamazapine was very close to phenobarbital, although it has a half life ranging from 25-
65 hours (Levy et al., 1995; Faught, 2001).  
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6.4.2 Factors associated with adherence 
 
Most of the factors that influenced adherence were clinical (epilepsy-related) and only one factor 
was provider-specific. 
 
6.4.2.1 Clinical Characteristics 
 
We found a strong relationship between seizure frequency and adherence, which shows that 
PWE who perceive their epilepsy to be severe are more likely to take their medication with the 
hope of minimizing the seizures.  In contrast, a study by Mitchell and colleagues found that 
seizure frequency did not affect adherence to treatment in American children (Mitchell et al., 
2000).  Participants who reported injuries directly associated with epilepsy such as burns, broken 
bones, cuts and bruises were more likely to take medication because such injuries further 
complicate their life situation.  People with Epilepsy who had taken medication for a long 
duration were more adherent because they had experience of the effectiveness of AEDs in 
controlling seizures. We found that patients on polytherapy were more likely to adhere than 
those on monotherapy and other studies have had similar results (Buck et al., 1997; Stanaway et 
al., 1985), although they did not mention the specific AEDs that were used.  One reason for our 
finding could be that patients on multiple pills feel the severity of their condition and are more 
cautious with treatment, compared to those on monotherapy, who may take treatment less 
seriously.  Another reason may be that when patients have to take multiple medications, they are 
less likely to forget to take them, compared to having to take only one pill.  In Kilifi, very few 
PWE are on more than two AED which may also explain this finding (Figure 6.1). 
 
6.4.2.2 Provider Characteristics 
 
Studies suggest that patients tend to be more adherent when healthcare providers have open 
dialogue regarding epilepsy and its treatment and when patients are comfortable speaking with 
their provider (Buck et al., 1997; Francis et al., 1969; Feuerstein et al., 1989).  If the provider is 
viewed as concerned and prescribing medication as a reflection of that concern, then adherence 
may be higher than if the prescription is seen as an indication that the provider has no time for or 
interest in the patient.  In our study, a significant relationship was found between how well 
patients related with the provider and adherence: those who reported a good relationship were 
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more likely to adhere than those who felt the relationship was strained.  Similar findings have 
been reported by other studies (Freeman et al., 1971), but results from our study should be 
interpreted with caution because the quality of the provider-patient relation was simply measured 
as a (yes/no) response. Substantial research has also shown that patients base decisions about 
taking medication on many considerations besides their provider‘s advice (Arluke, 1980; 
Conrad, 1985; Trostle, 1988a; Trostle, 1988b).  Scambler and Hopkins emphasize that patients 
are usually not passive, but play an active role in managing their own condition, and at times this 
will be in conflict with the advice of their provider (Scambler & Hopkins, 1988).  
 
6.4.3 Factors not associated with adherence 
 
None of the socio-demographic characteristics, distance from home to health facilities, SES, 
stigma and beliefs and attitudes predicted adherence. Two of the clinical characteristics (duration 
of epilepsy and AEDs side-effects) also had no association with adherence. 
 
6.4.3.1 Socio-demographic characteristics 
 
Our study showed that sex was not associated with adherence and  other studies have reported 
similar findings (Buck et al., 1997; Horne & Weinman, 1999; Dowse & Futter, 1991). Religion 
affects the self and may improve recovery by instilling hope, purpose and meaning in life in 
addition to affecting adherence to treatment. Although the findings from our study did not 
demonstrate a significant relationship between religion and adherence, a study by Borras and 
colleagues showed that 31% of patients with schizophrenia underlined an incompatibility or 
contradiction between their religion and taking medication (Borras et al., 2007).  Educational 
level showed no association with adherence probably because of the low literacy level among the 
study participants. Other studies have also found educational level was not correlated with 
adherence (Ukwe et al., 2010; Dowse & Futter, 1991).  Marital status did not predict adherence, 
which could mean PWE or their caregivers did not get the social support expected from such an 
institution. 
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6.4.3.2 Distance and social economic status 
 
Distance did not influence adherence probably because PWE in both the adherent and non-
adherent groups travelled long distances to seek specialized care for epilepsy.  Both groups lived 
close to peripheral health facilities.  This suggests that distance is likely to influence treatment-
seeking as opposed to adherence because PWE had already obtained their AEDs.  
 
Previous studies indicate that non-adherence to AED therapy is fairly evenly spread throughout 
social classes (Buck et al., 1997; Cramer & Mattson, 1991).  However, no significant differences 
were found between SES and adherence.  Even though there was no difference in SES among the 
study participants, we suppose SES is likely to be a hindrance when accessing AEDs as opposed 
to deciding whether to take the medication or not.   
 
6.4.3.3 Stigma and epilepsy beliefs and attitudes   
 
Whereas some studies have reported a significant association between stigma and adherence 
(Buck et al., 1997), we found no significant relationship between perceived stigma and 
adherence.  This may be because over two thirds of PWE did not feel stigmatized based on their 
low scores on the stigma scale (Chapter 3).  A study that investigated adherence to antidepressant 
treatment also showed that patients‘ adherence was not predicted by perceived stigma (Sher et 
al., 2005).  Horne and colleagues revealed an association between specific beliefs about 
medication and drug adherence (Horne & Weinman, 1999).  Contrary to these findings, none of 
the five subscales on the Kilifi Epilepsy Beliefs and Attitudes Scale (KEBAS) were associated 
with adherence. If PWE had already made a decision to seek treatment from a health facility, it is 
likely that they had already overcome the myths and misconceptions associated with epilepsy. 
This is substantiated by the positive beliefs (high scores) on the KEBAS by the majority of the 
study participants (Chapter 4). 
 
6.4.3.4 Clinical characteristics 
 
The duration of epilepsy was not associated with adherence, suggesting that people with 
longstanding epilepsy were not more inclined to take their medication.  Regarding the side 
effects of AEDs, Scambler and Hopkins found that some patients took it upon themselves to alter 
their drug taking behaviour because of adverse side-effects (Scambler & Hopkins, 1988).   
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A study by Buck and colleagues also demonstrated that side-effects of AEDs such as tiredness, 
memory problems, sleepiness, depression and headaches affected adherence (Buck et al., 1997).  
Our findings were contrary as we did not find a significant association between AED side-effects 
and adherence.  However, these findings need to be interpreted with caution because side effects 
were measured as a single (yes/no) response as opposed to recording adverse events in a detailed 
way like was done by  Buck and colleagues (Buck et al., 1997). 
 
6.5 Limitations 
 
The strength of this study was the use of  a robust pharmacological measure of adherence but it 
may be influenced by factors other than adherence, including age (Yamatogi, 2004), sex (Eadie 
et al., 1977), altered pharmacokinetics (Gidal, 2001; Faught, 2001), time since the drug was 
ingested and genetic differences in drug metabolism (Yamatogi, 2004).  Furthermore, for 
patients taking more than one medication, there are drug interactions, with some drugs altering 
the blood level concentrations of other drugs (Gidal, 2001).  Although we assessed adherence at 
one point in time as opposed to monitoring it over a period of time, this approach helped to 
estimate the ETG at a point in time, which was one of the objectives of this study. 
 
6.6 Conclusion 
 
This study measured adherence based on blood levels of multiple AEDs but this many not be 
feasible in most rural settings due to the expense.  Other indirect measures such as pill counts, 
appointment attendance and medication refills are also not feasible in most rural settings as they 
are characterized by many methodological difficulties. The simplicity and feasibility of using 
self-reported adherence may see it continued use despite its low sensitivity and specificity. 
 
This study has identified a subset of PWE at risk of low adherence and highlighted several 
reasons why they fail to adhere to AEDs, most of which are clinical in nature.  Findings of this 
study will greatly help to develop interventions to improve patient adherence and reduce 
preventable seizures.  In rural Africa, such interventions should focus more on clinical aspects, 
such as how to prevent injuries among PWE as well as how AEDs work to reduce seizure 
frequency.  There is also a need for health providers to continually improve their relationship and 
communication with patients in addition to educating and counselling them. 
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Abstract 
 
Epilepsy is a common chronic neurological disorder, affecting over 69 million people 
worldwide, of whom 80% are estimated to live in Low- or Middle Income Countries (LMICs).  
Anti-epileptic Drugs (AEDs) are effective in controlling seizures in over 75% of People with 
Epilepsy (PWE), but most PWE in LMICs do not receive appropriate treatment.  This ‗‗Epilepsy 
Treatment Gap (ETG)‘‘ is influenced by factors such as limited knowledge, poverty, cultural 
beliefs, stigma, poor health delivery infrastructure, and shortage of trained health care workers.  
Several studies implementing interventions at the community level (for example, training 
programs for primary health care workers) have successfully improved the identification of PWE 
and reduced the ETG.  The sustainability of these interventions needs to be addressed, however, 
and efforts must be made to ensure a continuous supply of AEDs. 
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7.1 Introduction 
 
Epilepsy is one of the most common and widespread neurological disorders.  Recent estimates 
suggest that it accounts for 1% of the global burden of disease (WHO, 2005) and affects over 69 
million people (Ngugi et al., 2010).  In addition, because the relatives and friends of People with 
Epilepsy (PWE) also bear the burden of this condition, more than 500 million people are 
indirectly affected by epilepsy (Kale, 2002).  Thus, epilepsy imposes a large economic burden on 
global health care systems and is a major public health problem in Low and Middle-Income 
Countries (LMICs) (WHO, 2005). 
 
The World Health Organization (WHO) estimates that 80% of PWE live in LMICs.  The 
incidence and prevalence of epilepsy are thought to be higher in LMICs than in High-Income 
Countries (HIC)—the median prevalence in LMICs is 9.5/1,000 compared to 8/1,000 in Europe, 
although the prevalence varies widely among countries (WHO, 2005; Ngugi et al., 2010).  The 
incidence of epilepsy in LMICs is thought to be up to five times that in HICs, although there are 
fewer studies on which to base this estimate. Worldwide, mortality among PWE is two to three 
times higher than in the general population and it is thought to be higher in LMICs than in HICs 
although data are scarce (Diop et al., 2005).  The Epilepsy Treatment Gap (ETG), i.e., the 
difference between the number of people with active epilepsy and the number whose seizures are 
being appropriately treated, is high in many LMICs (WHO, 2005). Overall, 56% (range 7%–
98%) of PWE in LMICs remain untreated, with 73% remaining untreated in rural regions 
compared to 46% in urban settings (Mbuba et al., 2008). 
 
The International Classification of Disease (ICD) 10 diagnostic criteria for epilepsy are given in 
(Textbox 7.1) (WHO, 2007). The definition of epilepsy has recently been revised by the 
International League Against Epilepsy (ILAE) (Fisher et al., 2005), but the original classification 
of seizures (transient occurrences of signs and/or symptoms due to excessive or synchronous 
discharge of neuronal activity in the brain) as partial (focal), generalized, or unclassified remains 
useful (ILAE, 1981).  Epilepsy has many different etiologies, with head trauma, central nervous 
system infections, perinatal problems, and cerebrovascular accidents most commonly identified 
(WHO, 2005), although in most cases a cause is not found.  Focal epilepsies represent a greater 
proportion of epilepsies in LMICs than in HICs and risk factor analysis has identified many 
causes that are preventable. 
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Although seizures are its most overt manifestations, epilepsy is associated with significant 
psychological (Fisher et al., 2000) and psychiatric conditions (LaFrance et al., 2008), which have 
social consequences for everyday living (Baker, 2002). Psychiatric disorders occur in 25%–30% 
of PWE (LaFrance et al., 2008), with depression being the most common, followed by anxiety 
disorders, psychoses, and personality disorders (Devinsky, 2003; Gaitatzis et al., 2004).  
Psychiatric comorbidity appears to be particularly common in some LMICs (Nubukpo et al., 
2004). Stigma poses a major burden to PWE and their families, interfering with the opportunities 
that PWE have for employment and marriage (Baskind & Birbeck, 2005b). Finally, women with 
epilepsy are particularly vulnerable to sexual exploitation, physical abuse, and extreme poverty 
(Birbeck et al., 2007). 
 
7.2 Methods 
 
In this article, we focus on the management of epilepsy in LMICs.  We review the evidence from 
LMICs on the efficacy of treatments and delivery of interventions.  Because this evidence is 
often limited, we also refer to systematic reviews, meta-analyses, and key trials from HICs where 
appropriate. On the basis of this review, we propose a package of care—a combination of 
interventions aimed at improving the recognition and management of conditions to achieve 
optimal outcomes—for epilepsy. 
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Textbox 7.1: International Classification of Diseases 10 Criteria for Epilepsy  
‘‘G40.0 Localization-related (focal or partial) idiopathic epilepsy and epileptic syndromes  
with seizures of localized onset 
Benign childhood epilepsy with centrotemporal EEG spikes 
Childhood epilepsy with occipital EEG paroxysms 
G40.1 Localization-related (focal or partial) symptomatic epilepsy and epileptic syndromes 
with simple partial seizures 
Attacks without alteration of consciousness  
Simple partial seizures developing into secondarily generalized seizures 
G40.2 Localization-related (focal or partial) symptomatic epilepsy and epileptic syndromes 
with complex partial seizures 
Attacks with alteration of consciousness, often with automatisms 
Complex partial seizures developing into secondarily generalized seizures 
G40.3 Generalized idiopathic epilepsy and epileptic syndromes 
Benign: 
   Myoclonic epilepsy in infancy 
   Neonatal convulsions (familial) 
Childhood absence epilepsy 
Epilepsy with grand mal seizures on awakening 
Juvenile: 
   Absence epilepsy 
   Myoclonic epilepsy [impulsive petit mal] 
Nonspecific epileptic seizures: 
   Atonic 
   Clonic 
   Myoclonic 
   Tonic 
   Tonic-clonic 
G40.4 Other generalized epilepsy and epileptic syndromes 
Epilepsy with: 
   Myoclonic absences 
   Myoclonic-astatic seizures 
Infantile spasms 
Lennox-Gastaut syndrome 
Salaam attacks 
Symptomatic early myoclonic encephalopathy 
West‘s syndrome 
G40.5 Special epileptic syndromes 
Epilepsia partialis continua 
Epileptic seizures related to: alcohol, drugs, hormonal changes, sleep deprivation or stress 
G40.6 Grand mal seizures, unspecified (with or without petit mal) 
G40.7 Petit mal, unspecified, without grand mal seizures 
G40.8 Other epilepsy 
Epilepsies and epileptic syndromes undetermined as to whether they are focal or generalized 
G40.9 Epilepsy, unspecified’’ 
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7.3 Results 
 
7.3.1 The Evidence on the Treatment of Epilepsy 
 
The evidence for most aspects of the management of epilepsy is poor in both high- and low-
income settings (Table 7.1). 
 
7.3.1.1 Detection of Epilepsy 
 
Much epilepsy in the world is not identified, particularly in LMICs, and thus PWE may not 
benefit from treatment.  The diagnosis of epilepsy is based on clinical history alone, but since 
patients may become unconsciousness during seizures, an independent observer is often 
necessary.  In HICs misdiagnosis occurs in 5%–30% of cases (Chowdhury et al., 2008), and in 
LMICs this is likely to be higher. In HICs, clinical examination may identify the cause of 
epilepsy and help with prognosis (Dooley et al., 2003).  For example, electroencephalography 
(EEG) may detect epileptic discharges, which support the diagnosis, but is not necessary for 
confirmation.  Although this test lacks sensitivity and specificity (Chowdhury et al., 2008), it is 
useful for classification of seizures and epilepsy syndromes. Video electroencephalography 
(telemetry) is particularly useful for management of intractable epilepsy.  Various biochemical 
tests can help in differential diagnosis and can determine an underlying cause of epilepsy. 
Computerized Tomography (CT) scanning is useful for  demonstrating gross abnormalities, 
haemorrhages, and calcification and for detecting parasitic diseases, e.g., neurocysticercosis 
(Bernal & Altman, 2003). Magnetic Resonance Imaging (MRI) is more sensitive than 
tomography in identifying structural abnormalities (Wieshmann, 2003).  It is recommended that 
patients with refractory epilepsy undergo functional neuroimaging. Finally, single-photon 
emission computer tomography and positron emission tomography may help locate ictal foci, 
and are particularly useful in identifying candidates for surgery (Duncan, 2002).  Unfortunately, 
these investigations are rarely available in LMICs. 
 
7.3.1.2 Anti-epileptic Drug Therapy 
 
Because the cause of epilepsy is often undetermined, and in most cases the epileptogenic focus 
cannot be removed, Antiepileptic Drugs (AEDs) are used to control seizures. In HICs, AEDs 
may be considered if the person has had seizures within the past 2–5 years (active epilepsy), but 
in many LMICs AEDs are only often recommended in PWE with a seizure in the past year. 
Packages of care for epilepsy 
119 
 
AEDs are very effective in controlling seizures: 75% of those treated may become seizure free; 
20%–30% of PWE have spontaneous remission of seizures without treatment (Kwan & Sander, 
2004).  Phenobarbital is the least expensive and most widely used AED.  It controls a range of 
seizure types and is on the essential drug list of 95% countries surveyed by the WHO; phenytoin, 
carbamazepine, and valproate (also first-line AEDs) are on the essential drug list in 86%, 93%, 
and 87% of countries, respectively (WHO, 2005).  Many other AEDs have been introduced to 
HICs but are not widely available in LMICs.  Each of these AEDs has a profile of adverse 
events, which may influence their use. 
 
Few randomized trials have compared the efficacy and effectiveness of these first-line AEDs, 
and most of these trials were conducted in HICs.  In a recent review by the ILAE, evidence for 
the efficacy and effectiveness of AEDs as initial monotherapy was found only in adults with 
partial-onset seizures (carbamazepine, phenytoin, and valproate), children with partial-onset 
seizures (oxcarbazepine), and elderly adults with partial-onset seizures (gabapentin and 
lamotrigine) (Glauser et al., 2006). In Cochrane reviews, no significant differences were 
documented in efficacy between phenobarbital, carbamazepine, phenytoin, or valproate in 
patients with generalized or partial-onset seizures (Taylor et al., 2001; TudurSmith et al., 2001; 
TudurSmith et al., 2002; TudurSmith et al., 2003).  In LMICs, carbamazepine was not shown to 
be better than phenobarbital in Ecuadorian (Placencia et al., 1993) or Kenyan adults (Feksi et al., 
1991b).  In Indian children, there was no difference in efficacy between phenobarbital and 
phenytoin (Pal et al., 1998).  However, questions have been raised about the suitability of 
phenobarbital because of its adverse events (Scott et al., 2001), and the ILAE has argued that the 
status of this drug is based on economic factors, rather than on efficacy and suitability (ILAE, 
1985). 
 
7.3.1.3 Surgery  
 
Surgical removal of the epileptic focus is the only cure for epilepsy.  Palliative procedures can 
also be performed.  Surgery requires a thorough evaluation to identify the epileptic focus and the 
relationship of this focus to other functionally important areas of the brain (for example, the 
speech centre).  A recent meta-analysis identified factors associated with seizure remission 
following surgery (Table 7.1) (Tonini et al., 2004). Because surgery requires sophisticated 
Packages of care for epilepsy 
120 
 
facilities and specialized staff, it is usually only available in HICs.  Nevertheless, surgery is 
increasingly being performed in LMICs (Asadi-Pooya & Sperling, 2008). 
 
7.3.1.4 Vagus Nerve Stimulation 
 
This technique is proposed for the treatment of refractory epilepsy and for the treatment of PWE 
who are not candidates for surgical treatment. It is effective in treatment of epilepsy patients with 
partial seizures (Ben-Menachem, 2002), but is not widely available in LMICs. 
 
7.3.1.5 Lifestyle Changes 
 
Although seizures cannot be prevented by lifestyle changes alone, PWE can nevertheless make 
changes that improve their lives and give them a sense of control.  For example, although many 
PWE do not know the precipitants for their seizures, inadequate sleep, food allergies, alcohol, 
smoking, and flashing lights may trigger seizures in some patients and can be avoided.  
Similarly, exercise is important for many aspects of epilepsy (Arida et al., 2008) particularly to 
counteract the side effects of some AEDs.  However, exercise can trigger seizures in some 
patients.  Finally, dietary changes may prevent the adverse events of some AEDs— phenytoin 
interferes with vitamin D metabolism, for example. The ketogenic diet (high-fat, no-sugar, low 
protein diet) is indicated in specific epilepsy syndromes (Kossoff, 2008) but requires specialized 
nutritional support that is often not available in LMICs (Seo & Kim, 2008). Other diets are 
unproven. 
 
7.3.1.6 Psychosocial Therapy 
 
Psychological interventions such as psychotherapy, individual, group, or family counseling, 
progressive relaxation therapy, and cognitive behaviour therapy have all been used in epilepsy 
(Table 7.1).  However, the trials were small and were mainly conducted in HICs and a systematic 
review concluded that there was no reliable evidence to support the use of these treatments 
(Ramaratnam et al., 2008). 
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Table 7.1: The evidence in support of epilepsy treatment 
 
Epilepsy 
Management 
HICs LMICs 
Detection and 
diagnosis 
Screening questionnaires (Corey et al., 2009; 
Reutens et al., 1992); Use of medical records 
(Cockerell et al., 1996; Hauser et al., 1991); 
Neurological Examination (Dooley et al., 
2003); EEG (Chowdhury et al., 2008); MRI, 
CT scan (Bernal & Altman, 2003; Wieshmann, 
2003; Duncan, 2002). 
Screening questionnaires (Feksi et 
al., 1991b; Placencia et al., 1992; 
Preux, 2000); EEG (Sawhney et 
al., 1996); CT scan (Murthy et al., 
1998); MRI scan in those with 
abnormal EEG (Mohamed et al., 
2006). 
AEDs Systematic review of initial monotherapy in 
adults with partial-onset seizures 
(carbamazepine, phenytoin, and valproic acid), 
children with partial-onset seizures 
(oxcarbazepine), and elderly adults with partial-
onset seizures (gabapentin and lamotrigine) 
(Glauser et al., 2006). Cochrane reviews of 
efficacy and withdrawal rates associated with 
phenobarbital, carbamazepine, phenytoin, or 
sodium valproate use in patients with 
generalized or partial onset seizures (Taylor et 
al., 2001; TudurSmith et al., 2001; TudurSmith 
et al., 2002; TudurSmith et al., 2003). 
RCTs of carbamazepine and 
phenobarbital in Ecuadorian 
(Placencia et al., 1993) and  
Kenyan adults (Feksi et al., 1991b) 
and in Indian(Pal et al., 1998) and 
Bangladeshi children (Banu et al., 
2007). Observational studies of 
phenobarbital in China (Wang et 
al., 2006), and phenobarbital and 
phenytoin in India (Pal et al., 
1998; Mani et al., 2001). 
Surgery Meta-analysis to identify prognostic indicators 
of seizure remission after 
surgery (Tonini et al., 2004). 
Overview of more than 1,000 
operations  for epilepsy in India 
(Radhakrishnan, 2009). 
Ketogenic diet Systematic review of trials of the  ketogenic 
diet (Kossoff, 2008). RCT of the ketogenic diet 
in children with AED-resistant epilepsy (Neal et 
al., 2008). 
Ketogenic diet (Seo & Kim, 2008). 
Psychosocial and 
psychoeducational 
interventions 
RCT of a 2-day psychoeducational treatment 
program (Helgeson et al., 1990). RCT of a 6-
week structured psychoeducational group 
intervention for adolescents with epilepsy and 
their  parents (Snead et al., 2004).  RCT of a 
structured nurse-led intervention (Helde et al., 
2005). 
Nonrandomized intervention study 
that provided leaflets about drug 
information to Taiwanese adults 
with epilepsy (Liu et al., 2003). 
Cognitive 
behaviour therapy 
— RCT of acceptance and 
commitment therapy in South 
Africa (Lundgren et al., 2006). 
Relaxation therapy Two-phase experimental group                    
investigation of a contingent relaxation 
treatment program (Dahl et al., 1987). 
— 
EEG: Electroencephalography; CT: Computerized Tomography;                                            
MRI: Magnetic Resonance Imaging; RCT: Randomized Controlled Trial. 
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7.3.2 Delivery of Effective Interventions 
 
Delivery of efficacious interventions in LMICs can only be achieved if PWE are correctly 
identified.  Unfortunately, the symptoms of some types of epilepsy (for example, hallucinations) 
may not be recognized as part of an illness, particularly in LMICs where epilepsy is interpreted 
within traditional belief systems.  Furthermore, in LMICs, trained personnel for the detection and 
management of epilepsy and facilities for investigations of underlying causes are scarce (WHO, 
2005).  However, nurses, community health workers, and key informants such as teachers can 
improve the identification of PWE (Feksi et al., 1991b; Mielke et al., 1997), and these PWE can 
then benefit from various interventions (Table 7.2). 
 
7.3.2.1 Interventions to Ensure an Adequate Drug Supply 
 
One of the factors contributing to the ETG in LMICs is the lack of a continuous and affordable 
supply of AEDs (Scott et al., 2001; ILAE, 1985).  Phenobarbital is most widely used in LMICs.  
Other available AEDs such as phenytoin, carbamazepine, and valproate are three, 11, and 16 
times more expensive, respectively, than Phenobarbital (WHO, 2005); and are often not 
available and/or routinely prescribed in peripheral health facilities. Because only a 1–3-month 
supply of AEDs is dispensed at any one time, PWE have to attend clinics frequently and the cost 
of these visits may interrupt adherence. Furthermore, the systems for providing a continuous 
supply of AEDs, particularly to rural clinics, often fail, which discourages attendance.  Studies in 
Kenya and India have shown that programs that ensure a continuous supply of AEDs can 
improve adherence (Feksi et al., 1991b; Mani et al., 2001), thereby reducing the ETG. Drug 
banks set up by nongovernmental organizations (NGOs) in some LMICs to supply hospitals 
when there is a shortage within the government sector can help to ensure adequate drug supplies 
but are difficult to sustain. 
 
7.3.2.2 Interventions to Educate PWE and Caregivers about Epilepsy 
 
Education of PWE and caregivers about epilepsy is important for several reasons. First, PWE 
with limited knowledge of epilepsy are at increased risk of the complications of seizures, such as 
fractures, burns, and accidental death (Beghi, 2005; Josty et al., 2000).  Second, one of the major 
conflicts in LMICs is the community‘s beliefs of the cause of epilepsy, and thus its treatment.   
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In many societies, epilepsy is not thought to be caused by diseases of the brain, but is attributed 
to traditional beliefs such as spirits (Jilek-Aall, 1999).  Finally, in LMICs, PWE often have 
cognitive impairment and psychiatric comorbidity, which impairs their understanding of epilepsy 
and the need to take AEDs daily. Thus, the care of PWE often falls onto family members and 
friends.  Although psychoeducational interventions tested in randomized controlled trials in HICs 
significantly improved knowledge and coping with epilepsy and decreased seizure frequency in 
HICs (Table 1), there have been no similar trials in LMICs, and the educational interventions 
required are likely to be different in these settings.  There have been some programs that 
increased the knowledge of epilepsy in LMICs as part of a package of interventions but the 
components of these programs with the most significant effect on AED adherence, seizure 
outcome, and self-esteem among PWE are difficult to identify (Adamolekun et al., 1999; Gourie-
Devi et al., 2003; Olley, 2004). 
 
Patient support groups are found in many countries and play an important role in educating PWE 
and their caregivers, as well as in advocacy (http://www.ibe-epilepsy.org/links). In addition to 
education, PWE and their families may also benefit from targeted psychosocial interventions. 
For example, a study in a London outpatient clinic provided evidence that the provision of 
skilled counseling to patients with epilepsy in addition to ‗‗routine‘‘ therapeutic intervention is 
useful (Usiskin, 1993).  Counseling helps to deal with many of the problems associated with 
epilepsy that are not related to the medical or technical aspects of seizure control. Unfortunately, 
the resources needed for counseling PWE and their caregivers are often not available in LMICs 
and the provision of such services competes with other health needs. 
 
7.3.2.3 Community-Based Interventions to Improve Awareness  
 
Public education is generally advocated as the best method to reduce the stigma attached to 
conditions such as epilepsy, but interventions need to be based upon qualitative and quantitative 
assessments to identify the causes of stigma in each region (Baskind & Birbeck, 2005b).  
Information, education, communication, and social marketing are needed to enhance compassion 
and reduce blame (Weiss & Ramakrishna, 2006). Community programs to achieve these aims 
must be based on the local perceptions of epilepsy and needs and must consider social and 
cultural conditions in the region. To date, community programs have met with some success in 
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Kenya (Feksi et al., 1991b), Ecuador (Placencia et al., 1993), Malawi (Watts, 1989), Ethiopia 
(Berhanu et al., 2009) and India (Mani et al., 2001).  Community-based studies in Kenya and 
India that supplied free AEDs reported low rates of withdrawal and good adherence and response 
to therapy (Mani et al., 2001; Feksi et al., 1991b).  In Ethiopia, community awareness and a 
regular supply of phenobarbital increased the number of patients attending the clinic (Berhanu et 
al., 2009).  In Malawi, the model tested included publicity of accessible services, adequate 
supplies of AEDs, setting up of mobile clinics, and frequent follow up by health workers (Watts, 
1989).  Unfortunately, most of these programs do not appear to have been sustained since they 
relied on external funds.  Thus, epilepsy care needs to be integrated into primary health care 
delivery, perhaps with patients providing some of the cost of AEDs to enhance sustainability 
(Adamolekun et al., 1999). 
 
The Global Campaign Against Epilepsy, a partnership between the WHO, ILAE, and the 
International Bureau for Epilepsy was launched in 1997 to improve the acceptability, treatment, 
services, and prevention of epilepsy worldwide  (Reynolds, 2000).  Several demonstration 
projects are currently underway under the auspices of this Campaign that aim to reduce the ETG 
and the physical and social burden of epilepsy through community-level interventions. The most 
successful is the Chinese project, which started with a media-based education program to create 
awareness about epilepsy and to convey the message that epilepsy is treatable.  The program 
provided free  phenobarbital at local health centres and patients were followed up by primary 
health care physicians who had received basic training in the diagnosis and management of 
epilepsy (Wang, 2008).  Lectures and group discussions for PWE and their families were 
arranged and community leaders and teachers were given information about epilepsy.  This 
project improved adherence to AEDs and significantly decreased the ETG from 63% to 50% 
(Wang, 2008). 
Packages of care for epilepsy 
125 
 
7.3.2.4 Interventions to Train Health Care Providers 
 
There are few specialists, particularly neurologists, in LMICs (WHO, 2005) and health care 
providers are often ignorant about epilepsies, particularly about their causes, diagnosis, 
treatment, and psychosocial aspects.  Interventions to train health care workers should, therefore, 
equip them with the knowledge and skills needed to diagnose and manage epilepsy, to counsel 
PWE, and to make appropriate referrals.  The training should promote strategies to ensure 
adherence and follow-up care (Gourie-Devi et al., 2003).  Training facilities often cannot be 
established in LMICs because of the expense (WHO, 2005).  Thus, the training of health care 
providers in such countries requires the production and distribution of educational materials, 
including standard guidelines for diagnosis and care of PWE.  Our review indicates that 
educational interventions that targeted health care providers in Zimbabwe and Ethiopia greatly 
improved the diagnosis and management of epilepsy (Adamolekun et al., 1999; Berhanu et al., 
2009). 
 
7.3.2.5 Interventions to Involve Traditional Healers 
 
Despite important advances in the understanding and treatment of epilepsy, many communities 
in LMICs still believe that epilepsy is supernatural or sacred and is associated with possession, 
impurity, contagion, heredity, and madness.  In many parts of Africa and Asia, notions about 
epilepsy are rooted not in a medical model but in a spiritual model (Whyte, 1995).  Often these 
beliefs involve external factors and so PWE seek a contextually relevant cure from a traditional 
healer (TH) that removes the alien factor from the body rather than seeking preventative or 
biomedical treatment.  Traditional healers live within the community and know the communities‘ 
perceptions of ill health. Their concentration is much higher in many populations than medical 
staff  (Baskind & Birbeck, 2005a), and they provide explanations that members of the 
community believe.  They can also provide psychosomatic support, spend longer with their 
clients than medical staff, and will accept flexible payment systems (Kendall-Taylor et al., 
2008).  But as a group of health care providers, their training, expertise, and beliefs are very 
variable, and their activities rarely regulated.  Nevertheless, because they are frequently 
consulted in many LMICs, involving THs in the management of epilepsy might be a useful 
intervention. 
Packages of care for epilepsy 
126 
 
7.3.2.6 Interventions to Integrate Epilepsy Care into Existing Health Services 
 
Acceptance of epilepsy treatment may be markedly improved by integrating it into existing 
health care services.  Mental health services are particularly important in LMICs since there are 
more psychiatrists than neurologists and PWE often have considerable psychiatric comorbidity. 
Experience in both Kenya and Malawi has shown that although epilepsy care can be successfully 
provided in LMICs, it is much harder to sustain it when it is not integrated into such services 
(Feksi et al., 1991b; Watts, 1989).  Programs that address epilepsy alone are unlikely to be 
sustained, and there is a compelling argument that such programs should be incorporated into 
mental illness or chronic disease services.  The sustainability of these programs depends on 
community participation in planning, implementation, and evaluation as well as integration into 
primary health care (Scott et al., 2001).  A study conducted in Ethiopia illustrated how an 
existing health care infrastructure developed for treatment of infectious diseases could be 
adapted to deal with epilepsy (Berhanu et al., 2009).  An Indian study showed that management 
of epilepsy should be set within the context of rehabilitation and incorporated into wider 
programs aimed at the alleviation of poverty (Pal et al., 2000b).  In addition, a commitment 
needs to be made to deal with the many preventable causes of epilepsy in LMICs such as poor 
perinatal care, head trauma, and parasitic infections, by integrating epilepsy into wider public 
health programs (Scott et al., 2001). 
 
Epilepsy services could also be improved in the community through approaches such as 
‗‗extension services‘‘ (satellite clinic model) of apex institutions and collaboration with other 
organizations (Table 7.2).  Satellite clinics facilitate the provision of services to the neglected 
populations of rural areas by reducing the distances travelled by PWE to attend health facilities. 
Similarly, the creation of partnerships between governmental, private, and voluntary agencies 
has proved a useful, cost-effective, and sustainable way to improve the identification and 
management of PWE (Mani et al., 2001; Gourie-Devi et al., 2003).  More specifically, in two 
studies in India where workers in NGOs that were already involved in community-based health 
care received training in case ascertainment and in informing communities about epilepsy, the 
epilepsy service continued after the studies ended because it was integrated into existing health 
care provision (Mani et al., 2001; Pal et al., 2000b). 
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Table 7.2: Delivering epilepsy treatments 
 
Step How By Whom In What Settings 
Increasing demand for 
the package 
Advocacy campaign with the 
message: ‗‗Epilepsy can 
be controlled‘‘(WHO, 2005; 
Reynolds, 2000).  
Patients and support 
groups; Community 
health workers; Nurses 
and physicians; 
Traditional healers; 
Public health personnel 
(Feksi et al., 1991b; 
Mani et al., 2001; 
Adamolekun et al., 1999; 
Gourie-Devi et al., 2003; 
Adamolekun et al., 2000; 
Mani et al., 1994) 
 
Community 
meetings; Schools; 
Media, e.g., radio, 
newspapers; 
General practice; 
Homesteads 
Increasing access to 
the package 
Making AEDs available in 
health facilities(Feksi et al., 
1991b; Mani et al., 2001; 
Berhanu et al., 2009); 
Improving awareness about the 
access to AEDs in health 
facilities (Feksi et al., 1991b; 
Gourie-Devi et al., 2003; 
Berhanu et al., 2009); 
Organizing satellite clinics 
(Gourie-Devi et al., 2003; 
Watts, 1989); Collaborating 
with other stakeholders in the 
health sector (Mani & 
Subbakrishna, 2003; Pal et al., 
2002). 
Ministries of Health 
(WHO, 2005; Scott et al., 
2001); NGOs (Mani & 
Subbakrishna, 2003; Pal 
et al., 2002);  
Private and voluntary 
agencies 
Primary health 
centres; Private 
clinics; Hospitals 
Improving recognition 
of the disorder 
Community-based and 
practice-based screening to 
identify the patients and 
causes; Clinical history; 
Neurological examination;  
Examination of blood AED 
levels and parasitic infections 
(WHO, 2005). 
Health care workers 
(Feksi et al., 1991b; 
Mani et al., 2001; 
Gourie-Devi et al., 2003; 
Berhanu et al., 2009); 
Research assistants; 
Technicians 
(Adamolekun et al., 
1999). 
Community; Primary 
health centres; 
Maternal and child 
health clinics; District 
General Hospitals; 
Referral hospitals 
Initiation of evidence-
based treatments 
Supply of first-line 
AEDs(Feksi et al., 1991b; Pal 
et al., 1998; Mani et al., 2001; 
Wang et al., 2006); Training 
on  principles of AED use 
Health care workers with 
license to 
prescribe AEDs 
Primary health 
centres; Private 
clinics; Hospitals 
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Managing serious or 
complex cases 
Referral to other centres with 
specialist resources (Gourie-
Devi et al., 2003). 
Specialist health care 
workers 
Centres with medical 
staff with expertise in 
epilepsy 
Achieving optimal 
outcomes 
Increasing AED adherence to 
reduce seizures, e.g., 
adherence management until 
full control achieved 
for at least 2 years (Feksi et al., 
1991b; Adamolekun et al., 
1999). 
Health care workers 
(Adamolekun et al., 
1999). 
Primary health 
centres; Private 
clinics; Hospitals; 
Homesteads 
Addressing impacts on 
other health/social 
outcomes 
Improving quality of life by, 
for example, psychosocial 
counseling of the family and 
PWE (Usiskin, 1993; Olley et 
al., 2001); Reducing 
stigma (Baskind & Birbeck, 
2005b; Watts, 1989). 
Health care workers 
(Adamolekun et al., 
1999; Adamolekun et al., 
2000); Traditional 
Healers (Baskind & 
Birbeck, 2005a; Kendall-
Taylor et al., 2008); 
Psychiatrists (Gourie-
Devi et al., 
2003);Psychologists 
(Olley, 2004). 
Primary health 
centres; Private 
clinics; Hospitals; 
Homesteads; 
Counseling centres 
 
 
7.4 Discussion and Conclusion 
7.4.1 Packages of Care for Epilepsy in LMICs 
 
Epilepsy, one of the most common neurological conditions, is under-resourced and undertreated 
in LMICs.  A large number of people have significant morbidity and mortality because of the 
failure to identify cases, difficulties with infrastructure, and the unavailability of suitable AEDs. 
Education of the community and of health care workers will improve the identification of PWE 
and thus reduce the ETG, provided inexpensive and reliable supplies of AEDs are available. 
Governments in LMICs need to recognize the burden of epilepsy and need to develop packages 
of care to reduce the disability associated with this condition in an efficient, sustainable, and 
equitable manner.  We propose two packages of care based on the availability of resources 
(Table 7.3).  Ideally, the delivery of these packages should be integrated into existing primary 
health care with the help of NGOs and other nonmedical staff involved in community-based and 
mental health care. 
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Table 7.3: Packages of care for epilepsy 
 
Low Resourced Settings High Resourced Settings 
Epidemiological surveys; Key informants such 
as community health workers 
and teachers trained in identification 
Primary health care workers, doctors, and 
neurologists trained in identification 
and diagnosis 
Nurses and clinical officers trained in diagnosis Specialists in epilepsy 
Educational and psychoeducational 
interventions 
Educational and psychoeducational 
interventions 
Limited choice of inexpensive AEDs; 
Continuous supply of AEDs; Generic 
formulations 
Wide choice of AEDs 
Limited services for epilepsy surgery Services for epilepsy surgery; Ketogenic diet 
Health care workers trained in psychological 
support and counseling 
Health care workers trained in psychological 
support and counseling 
Advocacy by NGOs Advocacy by NGOs 
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Abstract 
 
Introduction 
 
Existing studies have identified demographic and resource-related barriers to treatment-seeking 
and have focused on treatment seekers in exploring and modeling decision-making.  While the 
treatment-seeking literature acknowledges the role of the characteristics of treatment providers, 
few studies have adopted an explicit focus on these determinants, nor have they approached the 
study of treatment-seeking with an in-depth ethnographic focus on the providers themselves.  
The following article analyzes the structural aspects of treatment provision as one influence on 
how families in Kilifi, Kenya seek care for children with epilepsy.  While not a comprehensive 
decision model, the study examines the ways in which treatment-seeking may be facilitated or 
deterred by the characteristics of available treatment options. 
 
Methods 
 
Ethnographic methods were applied, including interviews, participant observations and surveys, 
to examine factors that may affect the choice of families on the coast of Kenya between 
traditional healing and biomedical care for epilepsy. 
 
Results 
 
Traditional healers were found to have a profound influence in the treatment of epilepsy in Kilifi. 
Their treatments differ from those available at health facilities in the following key dimensions: 
explanations of causation, communication styles, social roles, referral practices, location and 
systems of payment. 
 
Conclusion 
 
The article identified key differences between biomedical and traditional treatments that may 
help to explain the existence of the biomedical treatment gap in Kilifi. This study suggests that 
comparing data on treatment providers reveals barriers to obtaining biomedical care, thereby 
offering an important tool in intervention design research. 
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8.1 Introduction 
 
The prevalence of epilepsy in Kilifi, Kenya, where the present study was conducted, is estimated 
to be 4.5% (Edwards et al., 2008) .  The high prevalence of epilepsy in RPCs may be related to 
more prevalent alcoholism and childhood trauma (Shorvon, 1990), as well as poor sanitation that 
includes parasitic contamination (Diop et al., 2003).  Other research suggests that the high 
prevalence of epilepsy in RPCs may reflect marriage practices in which individuals with epilepsy 
are the only suitable partners for others with the disorder, or may result from perinatal head 
trauma associated with the birthing practices of some cultures (Jilek-Aall & Jilek, 1993).  
Striking gaps in Kilifi between the prevalence of epilepsy and the number of individuals 
receiving effective biomedical treatment make these statistics even more dramatic (Carter, 2002). 
 
In this article, the public health issues of access to care are addressed with an intervention design 
from an anthropological perspective that focuses on treatment providers.  Previous studies have 
documented the Epilepsy Treatment Gap (ETG) and identified demographic and resource-related 
barriers to treatment-seeking (Mansour et al., 2000; Coleman et al., 2002; Weisner & Matzger, 
2002; Reilley et al., 2002).  Ethnographic studies have concentrated on the treatment decision-
makers, examining motives beyond material resource factors including cultural models, past 
experiences and assessment of results (Beckerleg, 1994; Sussman, 1981; Young & Garro, 1994; 
Fabrega, 1974; Finkler, 1994; Good & Delvecchio, 1981; Kleinman, 1980; Mathews & Hill, 
1990; Quinn, 1978; McGrath, 1999).  However, few studies have examined the social and 
procedural factors that shape and constrain choices, such as the roles of providers in the 
community, and structural differences between biomedical and alternative treatments (Good, 
1986).  Furthermore, explanations by decision-makers given for past treatment-seeking events 
may be attempts to establish meaning and continuity for choices already made and may not 
capture the actual decision making process (Boster, 1984; Bibeau, 1997)  
 
To address these shortcomings, this study focused explicitly on treatment providers as a source 
of data and the ways in which treatment-seeking may be facilitated or deterred by the availability 
of treatment options and characteristics of service providers, rather than by characteristics of the 
persons in need of treatment (a study by Finkler (Finkler, 1994) is a notable example of this 
approach).  
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Therefore the following analysis does not represent a comprehensive decision model about how 
families seek care for Children with Epilepsy (CWE).  Instead it documents factors related to 
treatment providers in these decision-making processes.  Furthermore, the comparison between 
provider characteristics represents an important tool in intervention research and serves as a 
means of identifying and assessing structural barriers to treatment-seeking and adherence. 
 
A comparative ethnographic approach was employed to explore the distinguishing characteristics 
of services for childhood epilepsy in Kilifi.  To our knowledge, this is the first study to contrast 
the characteristics of service providers as potential determinants of treatment choice for CWE.  A 
review of data from our sample of providers revealed important differences between the two 
options that inform future efforts to develop a more effective healthcare delivery system. 
 
8.2 Study area and religious beliefs 
 
Kilifi town, the administrative center of the Kilifi District, is approximately 64 km north of 
Mombasa, Kenya‘s second largest city, and 64 km south of the city of Malindi.  The majority of 
people who live in this coastal district reside in rural areas. Traditionally, Arab traders and the 
Islamic religion have had a strong presence on the coast.  However since the time of British 
colonization, Christianity has become more prominent.  The majority of the traditionally 
up-country tribes and some members of the coastal tribes practice various forms of Christianity 
(Parkin, 1991).  Forty-seven per cent of individuals in the study area identify as Christian, 13% 
Muslim, 24% Traditionalists, 12% ‗other‘ and 4% unknown (KEMRI, 2005).  Some tribes, such 
as the  Giriama, have managed to retain elements of their unique religious beliefs and practices 
that form the basis of traditional healing and local epilepsy beliefs (Parkin, 1991).  
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8.3 Treatment in Kilifi 
8.3.1 Traditional 
 
While Parkin has provided invaluable background on the Mijikenda culture (Parkin, 1991; 
Parkin, 1968; Parkin, 1970; Parkin, 1972; Parkin, 1989), treatment seeking in this area remains 
largely unstudied from an anthropological perspective. The most notable exception is the work of 
Susan Beckerleg in a Swahili settlement in Watamu located in Malindi District, to the north of 
Kilifi District (Beckerleg, 1994). While her findings are illuminative of health beliefs and 
healing related to fever, or homa, in this Swahili cultural pocket, treatment and treatment-seeking 
in Kilifi District vary dramatically from what is described in her study.  Differences include the 
underlying model used to explain illness and treatment, and the actual treatment techniques 
employed (Kendall-Taylor, 2009). For example, individuals in the Beckerleg study attributed 
illness to imbalances in hot and cold states, while for the Mijikenda, ill health is less frequently 
about these humoral balances and more often perceived as the physical manifestation of events 
occurring in the spiritual realm.  Thus, while many of the treatments Beckerleg describes are 
designed to improve balance, Mijikenda treatments focus on communicating with spirits and 
addressing the needs and desires of these spirits. These differences are likely due to the fact that 
Beckerleg studied a Swahili population, while the present study focused on traditional Mijikenda 
beliefs and practices. 
 
In the system of Mijikenda traditional healing, illnesses, as well as social problems more 
generally, are caused by a system of spirits. This system can be divided into four general 
categories. Healers deal with each of these categories by employing a different general treatment 
ideology. 
 
In cases where traditional treatment is sought, the healer must divine which type of spirit is 
causing a particular problem, determine the best way to deal with the spirit responsible,  
administer the treatment, and finally follow up to assess the necessity of on-going intervention. 
The perception of which spirit is causing a problem is key to determining which specific 
treatment will be used and, because certain healers are specialists in dealing with specific spirits, 
who the most qualified healer is to administer such treatment. 
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8.3.2 Biomedical  
 
Biomedical treatment in Kilifi is provided by a government hospital, government health centers, 
and private clinics. Kilifi District Hospital (KDH), the only hospital in Kilifi District, is located 
in Kilifi town.  Thirty-four government health centers and dispensaries are dispersed throughout 
the district, staffed by doctors, nurses, and health workers with various degrees of training in 
biomedicine, ranging from limited course work and experience, to medical degrees and extensive 
experience in practice. In addition, approximately 25 private clinics operate in the district, which 
vary widely in staff training and medical supplies. 
 
The KDH, in conjunction with Kenya Medical Research Institute (KEMRI), operates a special 
clinical program for CWE.  It provides free assessment and clinical services and Anti-epileptic 
Drugs (AEDs) at subsidized prices and is staffed by three clinicians with experience in the 
management of epilepsy.  Government health centers do not offer this level of service.  The latter 
facilities are only permitted to prescribe the AED phenobarbital, and consistently lack supplies of 
this medication.  The staff members at these health facilities and at private clinics frequently 
have little training in epilepsy diagnosis and management.  Research with families of CWE in 
Kilifi (Kendall-Taylor, 2009) revealed that neither government nor private clinics are seen as 
viable options for  epilepsy treatment, and that KDH is perceived as the only option for 
biomedical treatment of the disorder. 
 
8.4 Methods 
8.4.1 Sample and procedures 
 
Treatment provider data was collected from approximately 200 hours of person-centered 
interviews (Levy & Hollan, 1998) and observations over 9 months with a group of Traditional 
Healers (THs). Data consisted of both audio-taped interviews and field notes from informal 
participant observation sessions.  Researchers observed a total of 52 healing sessions with these 
healers. The TH sample was selected using a combination of convenience and snowball 
sampling.  Researchers located the families of CWE in four different sub-locations of Kilifi 
District. Families were asked to identify THs who were known to provide treatment for epilepsy.  
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Healers identified by members of multiple families were located and asked if they would be 
willing to participate in the study. One healer was selected from each sub-location. Each of these 
healers was then asked to identify a colleague who also treated epilepsy. This procedure resulted 
in a final sample of eight THs from approximately 35 to 60 years of age.  The sample of THs 
also represented a range of treatment specializations or specific ‗types of spirits‘ that the 
individual was known to be proficient in treating. 
 
To understand the types and delivery of treatment provided in KDH, area clinics, and drug 
dispensaries, interview and observation data was gathered between the years 2006 and 2008 from 
12 biomedical health workers, including doctors, neurological technicians, research staff, nurses 
and general health aids. This sample was also assembled using convenience and snowball 
sampling. Several medical professionals working in the epilepsy clinic at the District hospital 
were approached.  These individuals referred the researcher to other health workers involved in 
epilepsy treatment. Efforts were made to select a sample that represented the range of biomedical 
services and professional specialization and training in Kilifi. However, the sample was 
purposefully selected to over-represent health workers at the District hospital.  This choice was 
made after preliminary research revealed problems relating to the supply of drugs and training of 
staff at local clinics and dispensaries.  The research suggested that the District hospital was the 
primary, if not the only, practical place for families to seek biomedical care for their children. 
 
Following transcription and translation, NVivo qualitative analysis software (QSR; Melbourne, 
Vic, Australia; http://www.qsrinternational.com) was used to analyze both transcripts and field 
notes to generate themes and code materials.  To assure informant anonymity, each participant 
was given a pseudonym that was used in all research and publication materials; only two 
researchers had access to data during the project. 
 
8.4.2 Ethics 
 
All participants in the study were given an oral description of the study design, purpose, and 
consent procedures. Participants were also given a page of written description of these 
procedures and the local contact information of the lead researcher.  Each participant signed 
written consent to participate in the research. Human subjects approval was obtained from the 
KEMRI/National Ethical Review Committee and the University of California, Los Angeles. 
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8.5 Results 
8.5.1 Epilepsy in the spirit system of traditional healing 
 
Within the four-category framework of the Mijikenda system of traditional healing, there are 
three causes of epilepsy, or Kifafa as it is traditionally called. 
 
8.5.1.1 Natural spirits (mapepo ya pori) 
 
Natural spirits are believed to cause a variety of diseases and conditions, including dizziness, and 
loss of appetite.  Individuals may be infected by one of these spirits if they have passed the 
residence of a natural spirit, or if the spirit is attracted to the ‗sweetness‘ of the person‘s blood. 
Mzee Haro, one of the healers in the sample, explained: 
 
This woman here [healer points to the patient] she is having stomach problems because 
she now has Mapepo ya Bahari [spirit of the beach]. She said that she passed by a large 
cave at the beach the other day in the evening. This is when the spirit came to her. Now it 
will not leave. 
 
Nyagu is the natural spirit most commonly considered to cause seizures in the traditional system. 
Mzee Makanju, another healer, explained, „These are spirits that live in the environment, they 
come as signs of animals.  When a child sees the vision of a hawk in his mind Nyagu has come to 
him‟. Seizures occur when the spirit comes to a child and subside when the spirit leaves. Tremors 
and convulsions experienced during seizures are perceived as attempts to break free of the 
Nyagu. Nyagu is attracted by the smell or taste of certain children‘s blood.  The spirit‘s 
preference for specific types of blood is used to explain why the spirit comes to some children 
and not others, as well as variation in the persistence of childhood seizures. If the Nyagu 
continues to visit the child, the spirit matures and reaches full maturity when the child is between 
the ages of five and ten, at which point the condition transforms from Nyagu to Kifafa. 
 
Kifafa caused by Nyagu is thought to be heritable to some degree.  Once a member of a family 
has a Nyagu spirit, it may develop a proclivity to the person‘s blood and be drawn to other 
members due to familial similarities in blood.   
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Mama Mzingo, a healer, explained, „Nyagu can come from the mother to the child but then if it is 
not treated by a healer it can move to another child in the family‟. There is also the belief that 
Nyagu may be transmitted from mother to child while breast-feeding.  For this reason a mother 
with epilepsy is not to breast feed her children. 
 
There are two essential components of treating a natural spirit: removal and deflection. A healer 
must remove the spirit and assure that it does not return.  As natural spirits inhabit an individual 
they develop an affinity for the person‘s blood.  Treatment becomes more difficult and the 
prognosis less promising if the person has been living with the spirit for an extended period.  An 
immature Nyagu is weak, can be easily pulled from the child, and prevented from re-entering.  
As the spirit matures, treatment becomes more difficult. For this reason, in the traditional system, 
early treatment of this condition is paramount. 
 
The methods healers use to remove natural spirits fall into two general groups. First, a healer can 
drive the spirit out using herbal baths, root concoctions, or dung that the spirit is known to islike.  
Mzee Makanju explained, „It [a specific herbal mixture] drives the Nyagu out. It does not like 
the smell of my medicines‟. Another healer explained his treatment for immature Nyagu: 
 
You must look for the Mtasalafu, Mrori, and Mrashapungu.  You must bring these leaves 
and tear them up and mix them in a container [bucket] of water.  You may have to go far 
to find these, but for me they are not far.  The child must come and be washed in the 
water [with the leaves].  It is very important to wash the head of that child.  If you are 
able it is good to get elephant dung and burn this near the child to smoke him [the child]. 
The spirit does not like these two things and will go from the child…Also, if you are a 
Muslim and know how to read from the Koran you can read „The Resurrection‟ verse. 
The Nyagu does not like the verse and it is very powerful for treating Nyagu. Doing these 
two things will make the child unattractive to the Nyagu. 
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Healers also explained a process of waving a cloth or basket in front of the patient to ‗blow out‘ 
the spirit. Mzee Haro explained: 
 
First I go to select those herbs. I put them in a container and fill it with water. When it 
has been mixed very well, I grab the child and dip his head into the water. Then I put the 
child on the ground and wave a basket over him 7 times.  I do this thing in three different 
places where I know the Nyagu likes to stay [the doorway, the rubbish area, and under a 
tree].   This is an easy treatment and is not long. 
 
The second method of healing a natural spirit is to entice it out of the person through offerings. 
Objects offered included incense, herbs, rose water, honey, and animal blood.  Once drawn out, 
the healer calls on his own spirits to battle the natural spirit.  Involving other spirits in the cure is 
thought to be a stronger but more difficult procedure and is used to treat the more mature Nyagu. 
Mzee Kahindi described this procedure: 
 
You must get a red chicken and a black chicken [the healer later explained that red 
chickens are for attracting/appeasing spirits from the land and white chickens are for 
attracting/appeasing spirits that come from the beach/coast]. First I say the part of the 
Koran that makes the spirit weak because it is now strong…I kill the black chicken and 
put its blood on the ground. This attracts the Nyagu, which leaves the person to drink the 
blood.  Then I kill the red chicken and put its blood on the ground also. This pulls the 
Marahani spirit [a very powerful Muslim spirit that Hassan uses in his healing 
practice]… I then tell the Marahani to kill the Nyagu who is weak from the words of the 
Koran.  If the Marahani is able to defeat the Nyagu, the epilepsy will be cured.  It is 
difficult if the Nyagu is very strong… I must work hard to make the Marahani happy so 
that he helps me. 
 
Once removed, healers employed techniques to deflect future re-entry of the natural spirit. The 
two most common practices were to periodically repeat the bathing technique mentioned above 
and to construct an amulet.  The amulet is a pouch the individual wears on a string around their 
neck, arm, or leg, which contains materials the spirit dislikes. These materials included herbs, 
roots, or parts of particular animals.  
Treatment providers 
140 
 
Mzee Ruwa, another healer explained: 
 
I make this. [Healer holds up a small leather pouch attached to a string].  I give it to the 
child and he/she wears it around the neck…I put many things inside. Inside there is hair 
of the child, leaves, and the claws of a bird. The claws are to make the Nyagu know it will 
be defeated. It will not come to the child if they wear it. 
 
8.5.1.2 Majini 
 
Majini are malevolent spirits controlled by witches and are blamed for a host of problems 
ranging from insomnia to social and economic troubles. Witches are contracted by jealous parties 
to send Majini to specific individuals or families. Majini are sent in two ways.  A witch can draw 
a special picture in the sand.  Once the targeted individual walks over the drawing, the curse is 
cast.  A witch may also send Majini directly to a person by verbally casting a spell. Seizures 
caused by witchcraft are considered easier to treat than the Nyagu type because Majini are not as 
strong or persistent as Nyagu. 
 
Healers employed methods of reversal to treat these problems. The healer typically guides the 
patient back across the symbol believed to have caused the illness, and in this way reverses the 
curse.  This procedure is called mihambo.  Mama Mzingo, a female healer explained, „Passing 
over the drawing that I have said words to breaks the curse‟. Mzee Haro explained, „This is how 
witchcraft comes and also the way it goes. They [the witch] did this and to heal this it is 
necessary that I also do this. But my medicine is much stronger‟. Majini are also thought to have 
a fondness for blood or certain foods including coconuts and eggs.  For this reason some healers 
used animal blood in the drawing or placed broken coconuts or eggs beside the drawing.  Mama 
Mzingo said, „If it [Majini] is happy, it will leave more times than if it is mad.  You can‟t just 
kick it out. You have to give it something to make it happy‟. 
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The following is an excerpt from an interview with Mzee Ruwa describing the treatment used for 
epilepsy caused by Majini. 
 
Brought that boy to this sacred place here.  He sat right there where you are sitting now. 
I made him sit there while I made the drawing in the dirt.  Then I sent Katana to get me 
the leaves that I use for this problem.  I made the boy cross the drawing seven times and 
each time he crossed, I threw some of the herbs on him.  I was saying words to the spirits 
so that they would come and help me change these Majini so that this boy would not be 
bothered by them anymore. 
 
8.5.1.3 Ancestral spirits (mapepo ya kiasili)  
 
Ancestral spirits are the descendants of original Mijikenda ancestors.  The Mijikenda believe that 
their first TH was Mepoho, the mother of two sisters, Matsezi and Mbodze. These daughters were 
also powerful healers and had 12 children of their own who became renowned healers.  The 
spirits of these 12 children are the primary Mijikenda ancestral spirits, and can cause various 
problems from bad luck in farming to headaches and infertility.  Other secondary ancestral spirits 
may also cause these problems, and anyone who has died has the possibility of becoming a spirit 
of this type and affecting the world of the living. 
 
Ancestral spirits are believed to cause problems because of unfulfilled desires. Mzee 
Kangwangu, another healer, said, „Those spirits [ancestral spirits] are always wanting things. 
They want a chicken or goat or even a piece of cloth…They are like living people, they just want 
things to have them, because they are hungry‟. An ancestral spirit may also demand a sacrifice 
due to improper behavior. 
 
Healers employed an appeasement ideology to treat illnesses caused by ancestral spirits. The 
healer communicates with the spirit, or through a proxy spirit, to learn what items or actions are 
desired. As a temporary appeasement, the healer may offer the spirit an herbal or root 
concoction.  However, to cure the affliction, the desired items must be offered.  Commonly 
desired items included goats, chickens, or swatches of colored cloth. 
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Epilepsy may be transferred between family members if specific rituals are not performed 
following the death of a member with epilepsy.  When someone with Kifafa has died, a special 
set of rituals must replace normal funeral procedures.  The family is not to remain in the village 
for the normal mourning period, and they are not to perform the normal funeral anniversary 
ceremony.  The family is to bury the individual and must have a TH present to prepare a special 
herbal mixture that each family member must wash with.  The concoction is believed to repel the 
spirit of the deceased.  Several months after the burial, the family must again enlist the help of a 
healer to prepare a second herbal bath to ensure the spirit does not return.  If these rituals are not 
performed, the spirit of the dead relative may return and the next child born may have the 
condition.  As Mzee Kahindi said, „If the funeral is handled correctly there will be no infection‟. 
Mzee Kahindi elaborated on the treatment used for epilepsy inherited from a relative: 
 
[This type of epilepsy] can be treated.  The people who have celebrated the funeral and 
have done all of the normal things ask for forgiveness from the spirit of the person who is 
causing the illness in the child.  They must make offerings to this spirit.  It might be a 
goat or even a cow if they have one. They must tell the spirit that they are sorry for 
having made a mistake and they should try to make the spirit happy. This is why they 
must make a sacrifice. If the spirit is not made happy the child will continue having 
seizures.  This is an easy kind of epilepsy to treat because all you must do is make the 
spirit forgive you and then it will go. 
 
8.5.1.4 Islamic spirits (mapepo ya Kiislamu) 
 
Islamic spirits are not believed to cause epilepsy. They are the spirits of important Muslim 
teachers and religions figures and are believed to be more powerful than their Mijikenda 
counterparts.  This power is attributed to two factors. First, they gain strength from the spiritually 
powerful places they inhabit.  Second, they are associated with the Koran, which is a powerful 
spiritual symbol in the coastal region.  Because of the tremendous spiritual power required to 
manipulate one of these spirits, they are rarely sent.  Islamic spirits, like the Mijikenda variety, 
come to living individuals because of specific desires. 
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8.6 Distinguishing features of the biomedical and traditional treatment options 
 
Interviews with and observations of THs and biomedical personnel revealed several 
characteristics that distinguished these two treatment options (Table 8.1).  
 
8.6.1 Explanations of causation 
 
Biomedical explanations of causes, symptoms, and treatment were dramatically different from 
those employed in traditional healing. Traditional healers referred to spirits to explain the 
occurrence and intermittent presentation of seizures.  The spirit comes to an individual and 
causes a seizure, and the individual regains consciousness with the spirit‘s departure.  Symptoms 
are sporadic because of Nyagu‘s attraction to multiple children concurrently. Similar 
explanations were offered for symptoms of epilepsy caused by Majini.  Healers accounted for the 
tremors and shaking associated with seizures as the struggle between the affected individual and 
the spirit grabbing them.  The common looks of surprise or screams prior to seizure onset were 
rationalized as the individual‘s reactions to the spirit‘s sudden appearance.  The traditional 
system offered treatments that directly addressed the assumed causes of the patient‘s symptoms. 
Biomedical practitioners and treatments did not address the connection between causation, 
treatment, and seizure symptoms.  
 
8.6.2 Communication style 
 
Communication during treatment also differed substantially between the two treatments. One 
patient summed it up: 
 
When I am at this place [the traditional healer] I can sit and talk and explain things for 
many hours.  Sitting here is important for healing.  It is necessary to do this if you want 
to be cured…I walk here and then return [over the diagram the healer has drawn].  I turn 
this way and follow his instructions…when I go to Kilifi [hospital], the doctor does not 
talk to me.  He just asks me some few questions and then gives me a paper [prescription]. 
That is it! 
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The traditional process of diagnosis and treatment involved constant communication between 
healer and patient over a one- to four-hour period.  To establish a diagnosis, patients were asked 
numerous questions and encouraged to communicate with the spirit via healer-facilitated 
‗channeling‘.  Conversations during treatments covered subjects directly related to the illness as 
well as general community topics, and the patient was a physically active participant in the 
healing process. 
 
In contrast, appointments at clinics and hospitals were brief, and doctor/patient interaction 
limited.  Patients were not acquainted with their doctors and the average length of visit was less 
than 20 min.  Communication was frequently strained and patients were guarded in sharing 
personal information.  Biomedical patients were also passive rather than active participants in 
their care. Typically, they sat in a chair in an office, answered a few questions, sometimes 
without having the doctor even facing them, and were handed a prescription.  
 
Traditional healers also reported strained relationships with doctors and expressed animosity 
towards them. One of the healers explained, ‗…they [biomedical doctors] do not care about us 
here in the community.  They do not talk to healers or even know what we do, but they think we 
are all quacks!‟ The general community perceived this dynamic, and several patients reported 
social pressure not to seek care from biomedical facilities. 
 
8.6.3 Social roles of providers 
 
Most of the biomedical practitioners interviewed were wealthy and well educated by community 
standards.  Many of those who practiced at KDH were Kenyans from other areas of the country 
who trained at national universities.  Some expatriate doctors working at the KEMRI also saw 
patients at the hospital.  Doctors at KDH were generally not members of the communities they 
treated and were unaware of the daily activities and lives of their patients, nor did they hold 
much power in community social or political dynamics.  Unlike THs who lived in the same 
communities as their patients, biomedical health workers were largely unaware of other 
treatments received by their patients. 
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However, patients and THs were often members of the same community, shared acquaintances, 
and were aware of important events in each others‘ lives.  Such familiarity created an open 
dynamic in which patients freely asked questions and sought further information about the 
causes of illness and the specific detail of treatments.  Healers were well-respected community 
members, and their ability to communicate with spirits contributed to their elevated status.  One 
healer received up to 15 patients a day, and all had clear advisory roles in a wide range of social 
issues. 
 
8.6.4 Referral practices 
 
A further distinguishing feature was the manner in which THs referred patients for additional 
treatment.  When treatments failed to reduce or eliminate symptoms, healers claimed that the 
offending spirit was too powerful or that they were not proficient at handling the specific spirit 
responsible for the child‘s disorder. A community member described this referral system: 
 
[Traditional healers] say that they can treat you but when they fail they say „this spirit 
was too strong‟ and they send you to another healer and then to another.  You can go to 
many healers before you get cured because each healer has his own medicines. 
 
Seven of the eight healers in the sample described cases in which their treatments had failed to 
cure Kifafa (epilepsy).  In each case the child was treated a second time.  If this second attempt 
failed, the healer referred the patient to another healer believed to provide more powerful or 
specialized treatments, maintaining hope in an eventual cure within the traditional system. 
 
In contrast, no explanation was available for the families of children treated at KDH who 
continued to have seizures. Although these children may have had their AED regimens modified, 
there were no further biomedical treatment options. 
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8.6.5 Location of care 
 
The accessibility of care was another distinguishing characteristic. While THs were located 
within local communities, the only location for viable biomedical epilepsy treatment was in 
Kilifi Town. Kilifi District is large and many individuals live in rural areas a long way from 
Kilifi Town and KDH. Because of the lack of effective epilepsy treatment at rural health 
facilities, individuals had to choose between traveling long distances to KDH or walking minutes 
to a local TH. 
 
8.6.6 Systems of payment 
 
Finally, the two treatment modalities differed according to models of payment. The THs 
interviewed used a flexible payment system. Treatment was provided regardless of the 
individual‘s ability to pay and payment was not discussed until after treatment.  If the individual 
was unable to pay, they were expected to return and pay at a later date.  In 49 of the 52 
traditional treatment interactions observed, individuals paid less than 25% of the payment asked 
by the healer.  The balances were carried for several months, or even years, and healers and 
patients reported that in many cases such debts are never settled.  The traditional model of 
payment was also flexible in terms of the type of payment accepted.  Each healer in the sample 
accepted livestock, grain, palm wine, cloth, clothing, and labor in lieu of monetary payment. 
 
In comparison, individuals were required to pay 40 Ksh (approximately US$0.75) to receive 
AEDs at KDH.  While this treatment was less expensive than that provided by THs, there was no 
alternative form of payment, and deferrals or loans were not granted. 
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Table 8.1: Summary of the comparison of traditional healers’ and biomedical treatments 
 
Themes Provider 
Traditional healing Biomedicine 
Causation/treatment Offered by healer 
Consonant with local ideas 
Not explained by doctor 
Dissonant with local beliefs 
Communication High quality 
Extended and participatory 
interaction 
Limited 
Strained interaction 
Role in community Centrally involved in local 
communities 
Removed from local 
communities 
Referrals Rationalizes treatment failures 
Keeps patients within system 
Infrequent and limited to KDH 
Location 
 
Within local communities Single semi-urban location 
System of payment 
 
Flexible Rigid 
KDH, Kilifi District Hospital. 
 
 
8.7 Discussion 
 
Consistent with previous research in other areas of Africa (Birbeck, 1999; Chavunduka, 1978; 
Feierman, 1981; Gessler et al., 1995; McMillen, 2004; Millogo et al., 2004; Oppong, 1989), this 
study documented the importance of THs as an option for treatment of childhood epilepsy.  
However, investigators have rarely compared interview and observation data collected from THs 
with data from biomedical practitioners as a means of understanding the gap between treatment 
needs and healthcare utilization, and identifying potential barriers to treatment access and 
adherence. This research shows this comparative ethnographic method to be particularly useful 
in identifying targets and questions for further qualitative and quantitative research on decision-
making and intervention design. 
 
The extent to which a family‘s beliefs about epilepsy causation correspond to this traditional 
system of spirits is important to understanding why some families seek traditional treatments 
while others choose biomedicine; this is discussed in greater detail elsewhere (Kendall-Taylor, 
2009). The  comparative provider focus used in this study is effective due to the implicitness of 
cultural models and their role in decision making (Quinn & Holland, 1987) . 
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Individuals seeking treatment may be limited in explicitly identifying the factors that shape their 
treatment decisions, such as payment methods, explanations of causation, social roles of 
providers, and systems of referral.  Service providers have a unique perspective on treatment. 
Their opinions and structural aspects of the services they provide are critical to understanding the 
determinants of health decisions. 
 
Previous research on families of CWE has demonstrated that distance-to-facility was an 
important factor in treatment-seeking (Kendall-Taylor, 2009).  However, cases in which families 
were willing to travel significant distances for either treatment option suggests that other factors, 
such as consonance between a family‘s beliefs of causation and that employed in treatment, 
appear to be important considerations in modeling treatment decisions (Kendall-Taylor, 2009).  
In the present study the observed ability of THs to generate convincing explanations for the 
mysterious, intermittent, and dramatic symptom presentation and to offer logical justifications 
for treatment helped explain the popularity of traditional epilepsy treatments in Kilifi.  In 
contrast, there were no explanations for failed biomedical treatments for children treated at KDH 
who continued to have seizures.  The traditional system‘s method of explaining treatment 
failures and referring patients to other healers plays a role in keeping patients in the traditional 
system and away from the hospital. 
 
Biomedical practitioners would benefit from instruction in effective and appropriate 
communication styles.  Training in culturally accessible ways of framing epilepsy, symptoms, 
causation, and treatment in doctor–patient interaction is vital. This component would increase 
patient satisfaction with biomedical services and improve treatment adherence. 
 
Further, observations of traditional treatment encounters suggested the difference in type and 
flexibility of payment appears to be a significant factor in families deciding where to seek 
treatment for their child‘s epilepsy. 
 
Our results suggest several promising strategies for improving access to biomedical care in Kilifi 
District.  First, because THs are generally well accepted in local communities, and traditional 
treatments for epilepsy in Kilifi were found to be culturally meaningful, the expansion of 
biomedical care should involve the cooperation and involvement of traditional practitioners. This 
could be generalized to other settings where healers assume a major role in treatment. 
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However, before any TH inclusion program can be implemented, the quality of biomedical care 
must be addressed.  The low quality of epilepsy treatment at health centers throughout the 
District and the limited accessibility of KDH to those living in remote areas suggest the need to 
improve services at rural health facilities. Such improvements could be accomplished through a 
diagnostic and treatment training program instituted and supervised by KDH.  Increasing the 
supply of AEDs to these facilities, and implementing a more flexible payment plan should also 
be components of such interventions. 
 
8.8 Limitations 
 
The primary limitation of this study is the lack of data from individual decision-makers.  To 
address this, research was also conducted with the families of CWE (Kendall-Taylor, 2009). This 
research obtained information on the perceived relevance of provider characteristics to family 
members‘ treatment-seeking. The results corroborate the significance to treatment decisions of 
factors identified in the present study, such as payment methods, systems of referral, and 
explanations of causation. 
 
8.9 Implications of the study 
 
The findings of this study have implications for future research on treatment-seeking.  
Comparing treatment providers is a tool for an initial step in building more comprehensive 
models of treatment decision-making that include factors that facilitate or deter treatment-
seeking.  These findings are relevant to programs aimed at improving access to health care. 
 
The strategies discussed could be applied in intervention research designed to improve healthcare 
utilization for CWE.  Outcomes could be assessed by evaluating program effectiveness in 
decreasing the epilepsy ETG and improving the quality of life of children and their families. 
Treatment studies could also examine the specific intervention components most responsible for 
improved outcomes, which could be tested in a randomized cluster trial.  This would be the 
ultimate test of the benefits of ethnographic comparisons of service providers.  
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An intervention program informed by the present findings as well as additional research 
conducted with families of CWE is currently being designed in Kilifi. It is hoped that the 
effectiveness of this program will provide improved healthcare access and reduce the morbidity 
of childhood epilepsy in the developing world. 
 
8.10 Conclusion 
 
The article identified the following six key differences between biomedical and traditional 
treatments (explanations of causation, communication styles, social roles, referral practices, 
location and systems of payment) that may help to explain the existence of the biomedical ETG 
in Kilifi. This study suggests that comparing data on treatment providers reveals barriers to 
obtaining biomedical care, thereby offering an important tool in intervention design research. 
 
Acknowledgement 
 
The authors acknowledge support from the KEMRI/Welcome Trust, the National Science 
Foundation and the Institute of International Education.  The authors also acknowledge Thomas 
Weisner for his guidance on research design, data analysis, and his comments on drafts of the 
paper.  Finally, the authors acknowledge Carolina Izquierdo for her comments on drafts and her 
guidance on the theoretical underpinnings of the research.  Charles Newton is funded by the 
Wellcome Trust, United Kingdom. 
 
 151 
 
Chapter 9 
 
 
 
The reasons for the epilepsy treatment gap in Kilifi, Kenya: using formative research to 
develop interventions to improve adherence to anti-epileptic drugs 
 
 
 
J A Carter1*, S Molyneux2, CK Mbuba2, J Jenkins1, CRJC Newton2,3,4,5, SD Hartley6  
 
 
 
1 Centre for International Health and Development, Institute of Child Health, London, United 
Kingdom (UK)  
2 KEMRI/Wellcome Trust Research Programme, Centre for Geographic Medicine Research 
(Coast), Kilifi, Kenya  
3 Neurosciences Unit, Institute of Child Health, University College London, London, UK  
4 London School of Hygiene and Tropical Medicine, London, UK 
5 Department of Pyschiatry, University of Oxford, Oxford, UK  
6 Faculty of Health, University of East Anglia, Norwich, UK 
 
*Corresponding author 
 
Email: j.carter@ich.ucl.ac.uk 
 
 
 
 
This article has been prepared for submission to Social Science and Medicine  
 
Using formative research to develop interventions 
152 
 
Abstract 
 
Introduction 
 
Approximately 75% of People with Epilepsy (PWE) in Kilifi, Kenya, do not receive appropriate 
treatment, a phenomenon referred to as the Epilepsy Treatment Gap (ETG).  We conducted a 
qualitative study to investigate the reasons for this gap and identified possible interventions. 
 
Methods 
 
The study employed a qualitative approach using a combination of methods for data collection.  
Focus Group Discussions (FGDs) were carried out with PWE and their caregivers.  Individual 
in-depth interviews were conducted with PWE, caregivers of PWE, traditional healers, 
community health workers, community leaders, nurses and doctors.  Trained field staff fluent in 
the local language, conducted the interviews.  The data were transcribed, translated and entered 
into NVivo qualitative analysis software. Two independent researchers analyzed the data 
thematically and validation was done through triangulation.  Drawing on the information 
gathered above, a series of workshops were conducted to negotiate realistic and sustainable 
interventions with stakeholders.  
 
Results 
 
Nine FGDs and 17 in-depth interviews were conducted.  Four factors contributing to the ETG in 
Kilifi, were identified: 1) Lack of knowledge about causes, treatment and prognosis of epilepsy; 
2) Inaccessibility to anti-epileptic drugs associated with financial constraints, distance to health 
facilities and unavailability of drugs; 3) Misconceptions about epilepsy derived from 
superstitions about its origin; 4) Dissatisfaction with the communication skills of health 
providers.  These data indicated several possible avenues for interventions: 1) Education and 
support for PWE and their caregivers; 2) Communication skills training for health providers; 3) 
Need for the Ministry of Health to improve drug provision.  
 
Conclusion 
 
The ETG was associated with a combination of factors that could be addressed through the 
development of appropriate interventions. 
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9.1 Introduction 
 
Over 69 million people worldwide have epilepsy, of whom 62 million live in Resource Poor 
Countries (RPCs) (Ngugi et al., 2010).  More than 500 million people are indirectly affected by 
epilepsy as parents, relatives and friends (Kale, 2002).  The World Bank has prioritised epilepsy 
as a highly cost-effective condition to treat (World Bank, 1993), since relatively inexpensive 
Antiepileptic Drugs (AEDs ) are very effective in controlling seizures: 75% of those treated will 
become seizure free (Coleman et al., 2002). Despite this, over 90% of People with Epilepsy 
(PWE) in RPCs do not receive appropriate treatment for their condition (Birbeck, 2000; Nicoletti 
et al., 1999; Scott et al., 2001), a phenomenon that has been called the ‗Epilepsy Treatment Gap 
(ETG).  The International League Against Epilepsy (ILAE) has defined the ETG as the 
difference between the number of people with active epilepsy and the number whose seizures are 
being appropriately treated (Meinardi et al., 2001). 
 
In response to the diverse factors involved in the effective treatment of PWE in RPCs, several 
researchers have tried to instigate affordable community-based interventions. Previous 
interventions at community level have met with some success in Nakuru, Kenya (Feksi et al., 
1991b), Ecuador (Placencia et al., 1993), Malawi (Watts, 1989) and India (Mani et al., 1998; Pal 
et al., 2000b).  Recent directives from the World Health Organization (WHO) state that health 
care delivery will increasingly have to move away from acute illness episodes and concentrate 
more on treatment adherence, client self-management and quality of life issues (Epping-Jordan, 
2002).  
 
The characteristic of most successful interventions is integration within community health care 
delivery and community involvement in the planning and implementation processes.  
Community-based interventions have been used with some success in several conditions.  In 
Nigeria, community-designed and administered treatment programmes have been successful in 
the control of onchocerciasis (Akogun et al., 2001).  In Bangladesh, Community Health Workers 
(CHWs) have successfully identified Tuberculosis (TB) and increased adherence to treatment in 
their own villages (Chowdhury et al., 1997) and in Malawi, a TB assistant with good standing in 
the local community received training and raised the cure rate from 29% to over 85%.  In Kenya, 
an intervention to prevent Neonatal Tetanus (NNT) allowed the identification of the cultural 
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significance of birthing rituals and negotiated culturally acceptable alternatives, involved 
community leaders in defining and promoting the changes in rituals and used traditional birth 
attendants to maintain the changed behaviour.  After introduction of the intervention, death rates 
from NNT dropped to 0.75 per 1000 births compared to 82 per 1000 in control areas (Meegan et 
al., 2001).  However, effective behaviour change is notoriously difficult to initiate, sustain and 
measure.  Curtis and colleagues reviewed the literature between 1987 and 2001 and found only 
three articles with good evidence of health interventions impacting on behaviour or health in 
RPCs, although they don‘t define what they mean by ‗good evidence‘ (Curtis et al., 2001).   
 
Most commentators highlight the need for good anthropological or community-based data on 
practices and perceptions for behavioural interventions to succeed (Green & Kreuter, 1991).  In 
Kilifi, there is some evidence that bio-medical treatment regimens for Children with Epilepsy 
(CWE), are in conflict with local perceptions (El Sharkawy et al., 2006).  Parents may have a 
‗health‘ versus ‗sickness‘ model that influences their perceptions of treatment.  Occasional 
seizures may be placed in the ‗health‘ sphere, making the recommendation of regular and 
continued medication illogical for what is perceived to be a generally healthy child.  If regular 
seizures persist beyond a certain age, the child may be placed in the ‗sickness‘ sphere, suggesting 
that the child is incurable and treatment attempts are futile.  El Sharkawy and colleagues also 
found that belief in ‗external‘ causes (such as witchcraft, contact with certain animals/birds) of 
epilepsy was commonly held and that treatment choices  favoured external treatments such as 
wearing charms or pouring liquid on the child‘s body (El Sharkawy et al., 2006).  These findings 
are similar to those of Hausmann-Muela and colleagues, who investigated what they termed 
‗medical syncretism‘ in Tanzania (Hausmann-Muela et al., 2002).  They found that in the case of 
malaria, biomedical knowledge is blended with indigenous concepts (Hausmann-Muela et al., 
2002).  These examples fall under Helman‘s description of ‗externalising‘ belief systems, which 
concentrate on aetiologies arising outside of the sick child‘s body (Helman, 1994) .  If the cause 
of an illness is believed to be found in the natural, social or supernatural worlds, biomedicine 
may be sought for symptomatic relief only,  but cure and explanations about causality are sought 
from Traditional Healers (THs) (Helman, 1994).  
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Identifying the cultural context, values, beliefs and community norms of target groups through 
qualitative research is the key to the design and implementation of successful interventions 
(Stephenson & Imrie, 1998).  Akogun and colleagues comment that their experience of working 
with a Nigerian community to implement a behavioural intervention suggests that within certain 
parameters, the structure of interventions may be less important than the process through which 
they are introduced, in terms of acceptability and sustainability (Akogun et al., 2001).  Building 
upon the work of El Sharkawy and colleagues (El Sharkawy et al., 2006), we aimed to carry out 
a qualitative investigation to develop alternative intervention strategies based on the expressed 
needs and perceptions of the stakeholders.  While El Sharkawy and colleagues focused on the 
effect of attitudes and practices on service utilization for epilepsy (El Sharkawy et al., 2006), we 
specifically conducted this descriptive research as part of preliminary work to develop an 
intervention to address the ETG in Kilifi.  Our research questions were: 
1. What are the stakeholders‘ (CWE, their families and service providers) attitudes and 
beliefs relating to CWE and how do they affect the utilization of the traditional and 
biomedical services offered to this population group? 
2. What are the specific needs of PWE and their families? 
3. Using techniques such as participatory workshops, can a consensus be reached with key 
community members on an intervention that will reduce the ETG and improve the quality 
of life of PWE in Kilifi? 
 
9.2 Methods 
 
Qualitative data gathering techniques were used because they are valuable tools for collecting 
meaning-centred, contextually-based data applicable to the design of culturally relevant 
intervention strategies.  
 
9.2.1 Study setting  
 
This study was undertaken in Kilifi District, on the coast of Kenya which has the highest rates of 
poverty, the lowest rates of literacy and the largest sex differentials in education in the country.  
Community-based research is focused on the Kilifi Health Demographic Surveillance System 
(KHDSS) which is described in Chapter 1.  
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9.2.2 Sample 
 
Families from different educational backgrounds and with different experiences of AEDs 
treatment were purposively selected using the baseline information recorded on the KHDSS.  
The criteria for selection are outlined in (Table 9.1).  Once appropriate participants were 
identified, convenience sampling was used, influenced by willingness to participate, 
geographical distribution and time constraints.  
 
Table 9.1: Criteria for sample selection for focus group discussions 
 
Key 
informant 
group 
Selection factors Method of identification 
Children with 
epilepsy (14-
18yrs) 
 Have/have never received 
available treatment 
 Have received and rejected 
available treatment 
 Attending school/not attending 
school 
 Identified from KHDSS 
Adults with 
epilepsy 
 Have/have never received 
available treatment 
 Have received and rejected 
available treatment 
 Less educated*/more educated* 
 Identified from KHDSS 
Parents of 
children with 
epilepsy  
 Child has/has never received 
available treatment 
 Child has received and rejected 
available treatment 
 Less educated*/more educated* 
 Identified via the child‘s record 
on the KHDSS 
Other family 
members of 
children living 
with epilepsy 
 Grandmothers of children with 
mild and severe epilepsy 
 Siblings (aged 14-18 years) of 
children with mild and severe 
epilepsy 
 Identified via the child‘s record 
on the KHDSS 
* Less educated residents indicated 8 years or less of schooling. 
* More educated residents indicated more than 8 years of schooling. 
Severe epilepsy was defined as more than one seizure per week; mild epilepsy was defined as 
less than one per month. 
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Service providers (CHWs, in the case of the FGDs) were identified from lists of active 
community health worker groups held by the local Ministry of Health. Initial pools of 
participants for individual interviews and participatory workshops were elicited from FGD 
participants, using a snowballing technique.  Final selection and participation was again based on 
convenience and voluntary informed consent.  The composition of key informant groups is 
described in (Table 9.2). 
 
Table 9.2: Data collection methods and key informant groups 
 
 
Key informant 
group 
Data collection method 
Focus group discussions 
(no of participants in 
parentheses) 
Individual interviews Participatory workshops 
(no of participants in 
parentheses) 
Adults with 
epilepsy 
1 (3) 1 1 people with epilepsy 
(11) 
Children with 
epilepsy 
1 (6) 1 1 people with epilepsy (1) 
Family members 
of children with 
epilepsy 
1 mothers (5) 
1 fathers (3) 
2 siblings (4, 3) 
1 grandmothers (3) 
2 mothers 
1 father 
1 grandmother 
1 parents and 
grandparents (14) 
1 people with epilepsy (2 
grandparents, 2 parents, 1 
sibling*) 
Biomedical 
service providers 
2 community health 
workers (CHWs) (8, 10) 
2 dispensary nurses 
2 clinical officers (private 
clinic) 
1 psychiatrist 
(government hospital) 
1 paediatrician 
(government hospital) 
1 traditional healers and 
CHWs (7 CHWs) 
1 biomedical service 
providers and CHWs (6 
CHWs, 1 nurse**) 
Traditional 
service providers 
 3 traditional healers  1 traditional healers and 
CHWs (3) 
Community 
intervention 
organisations 
 1 chairlady of ‗Maendeleo 
ya wanawake‘ (women‘s 
organization) 
1 member of staff at 
APDK (organization for 
the rehabilitation of 
people with disabilities) 
 
Units of analysis 
(number of 
people)*** 
9 (45) 17 (17) 4 (48) 
* Although this participatory workshop was intended for people with epilepsy (PWE), 5 family members also 
accompanied some of the PWE and participated in the workshop 
* We invited other biomedical service providers to this workshop but all except one nurse said they were too busy to 
attend 
*** Total units of analysis = 30; total number of people involved =110 
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9.2.3 Procedure 
 
The study included a combination of strategies for data collection – FGDs, individual interviews 
and participatory workshops – to enhance the validity of the results and provide material for 
triangulation.  Finally, the intervention was piloted.  The progress of the study is illustrated in 
(Figure 9.1). 
 
First, FGDs were held with CWE, parents of CWE, and with other family members of CWE.  
Efforts were made to ensure that groups of CWE and of parents covered the spectrum of severity 
of disease, educational levels and exposure to AED treatment. Such purposive convenience 
sampling is appropriate for research designs such as this, which aim to explore the range - rather 
than a representative cross-section - of views and perspectives.  Excluded from discussions were 
adults or CWE who considered themselves or were considered by family members to be too ill to 
participate. 
 
Focus group discussions elicited data relating to the four research questions: 
 experiences and beliefs about epilepsy in the household and in the community 
(particularly schools, marriage and the workplace);  
 how the above relates to the quality of life, parental satisfaction and depression; 
 the range of treatments available for children and the pros and cons of different types and 
sources of treatment, including experiences of and views about AEDs;  
 perspectives of the principal needs of CWE, of the barriers to meeting these needs, and – 
where appropriate - of locally applicable interventions to improve access to AEDs. 
 
Individual in-depth interviews were organised to explore issues arising in more detail, including 
PWE, their families and service providers.  The aim was to identify providers working in a wide 
range of settings who have substantial experience of managing epilepsy.  It was hoped that 
discussions with THs would bring opportunities to present locally held ideas about causation and 
preventive treatment (Coleman et al., 2002), so particular attention was given to this group and 
the possible necessity for increasing the sample size to access further data.  Epilepsy may offer a 
particularly good basis for co-operation between biomedical and traditional medicine, 
particularly when neither may satisfy the needs of the patients alone (Meinardi et al., 2001). 
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Individual interviews with these participants focused on: 
 experiences of and views about the range of treatments available for children;   
 the extent and nature of the ETG in Kilifi, and the range of factors contributing to these 
gaps (including regulatory and supply factors, and information, education and 
communication issues at provider, patient and caretaker levels); 
 relevant and sustainable interventions to reduce the ETG, and – if appropriate – the inputs 
that would be required to improve access to AEDs. 
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Figure 9.1: Progress of the study and how the findings informed intervention development 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
Focus group discussions with PWE, family members and community health workers 
Participants were asked to identify further 
individuals who might provide particularly 
valuable information, for example other 
community members, service providers and 
THs. These individuals were approached and 
asked if they would participate in an in-depth 
interview 
Individual in-depth interviews with PWE, family members and service providers 
Participatory workshops with PWE, family members and service providers 
Initial analysis of the data from the FGDs and 
interviews was undertaken at this point in order 
that preliminary intervention plans could be 
presented at the participatory workshops 
Using information from the workshops, the 
intervention plans were modified according to the 
views and perceptions of the participants 
Pilot study 
The intervention was then piloted among all 
stakeholders: CHWs, PWE and their family, THs, 
community members and biomedical providers 
 
Data from the pilot study informed the final 
intervention plans 
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9.2.4 Participatory workshops 
  
Drawing on the information gathered above, a series of workshops was arranged.  The 
workshops aimed to negotiate a realistic and sustainable intervention with key stakeholders to 
improve the ETG in Kilifi District.  Key stakeholders included PWE, their families and service 
providers from the District.  
 
We anticipated that users and providers would have differences of opinion at the outset, and that 
the intervention would require processes of negotiation.  To ensure that all viewpoints were 
heard and incorporated, separate one-day workshops were held with representatives from the 
following groups:  CWE and their siblings; parents and grandparents; and service providers (four 
workshops over four days).  During the workshops, initial intervention plans (developed from the 
FGD and interview data) were presented to the participants to elicit group consensus or 
normative reaction.  Participants were also asked to give specific input about the practicalities of 
the intervention: length, administered by whom, location, incentives and outcome measures. 
 
Based on the suggestions from the workshops, an education intervention was developed for all 
stakeholders.  It was divided into four parts: The first one for CHWs, second for THs, third for 
community members and fourth for biomedical providers.  The intervention components for the 
first three groups were similar and covered the following: 
 What is epilepsy? 
 Types of seizures 
 Causes of epilepsy 
 Effects of epilepsy on child development 
 Treatment of epilepsy: What drugs can and cannot do? 
 Side effects of drugs 
 Drug safety 
 What to do and not to do during a seizure 
 When to take PWE to hospital 
 Prevention of epilepsy 
 What PWE can and cannot do 
 Advise to  families on how to live with PWE 
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The intervention for biomedical providers had the following components:   
 Epidemiology of epilepsy 
 Definition of epilepsy, seizures and other terminologies  
 Causes of epilepsy 
 Common precipitating factors of epilepsy 
 International classification of epileptic seizures 
 Diagnosis of epilepsy 
 Differential diagnosis of epilepsy 
 Conditions co-existing with epilepsy 
 Management of epilepsy 
 
9.2.5 Pilot study 
 
The educational element of the proposed intervention was piloted among all stakeholders: 
CHWs, PWE and their families, THs, community members and biomedical providers.  Nineteen 
CHWs first attended a three-day training workshop led by three trained facilitators then initiated 
a visiting and educational programme for PWE and their families.  Three further workshops were 
conducted: a four-hour workshop attended by 27 THs; second, a six-hour awareness session for 
community members and finally, a three-day residential programme for biomedical service 
providers.  The sessions included lectures, group discussions, brainstorming, role plays, pictures 
and narratives.  Evaluation was performed through informal feedback and administration of pre-
post questionnaire to the biomedical providers.  
 
9.2.6 Analysis 
 
Focus group discussions and interviews were conducted in the languages of the participants, 
namely, Kigiriama, Kiswahili and English.  They were recorded, translated and transcribed.  The 
data were entered onto an NVivo qualitative analysis software (QSR; Melbourne, Vic, Australia; 
http://www.qsrinternational.com/) to enable easy storage, organisation and retrieval. Data were 
analysed using framework analysis, as described by Ritchie and Spencer (Ritchie & Spencer, 
1994). Themes were independently generated from the data by two researchers and once 
thematic consensus was reached, all the data was coded.  This process served to maximise the 
rigour and validity of the analysis.  
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 Emerging patterns and relationships were used to generate an initial intervention plan that was 
grounded in the qualitative data.  Two stages of modification then took place.  The plan was 
presented at the participatory workshops, at which modifications were made until a consensus 
was reached among the participants.  Second, the research team made final modifications to the 
educational element of the intervention following the pilot study. 
 
9.3 Results and Discussion 
 
9.3.1 Themes 
 
In using these results to inform the intervention, the findings were focused on two categories: (1) 
reasons for the ETG and how the intervention could address these issues; (2) intervention content 
and format.  In looking at the reasons for the ETG, five main themes emerged from the data: 
differing causal explanations for the causes, treatment and prognosis of epilepsy; the issue of 
cure; diminished access to and utilisation of biomedical health services; poor doctor-patient 
relationships and communication and access issues for PWE and their families. 
 
9.3.1.1. Differing explanations for the causes, treatment and prognosis of epilepsy: Impact on 
treatment choice  
 
Among PWE and their families, knowledge about the biomedical causes, treatment and 
prognosis of epilepsy was minimal.  There were multiple causal explanations for the condition.  
Discussions on the root causes of symptoms suggested that they can be attributed to the natural 
order (brain insults following diseases such as malaria, accident, perinatal injury, inheritance, 
caught from contagious urine, drugs):  
“[Epilepsy] is inherited. Some people fear even marrying from a family where people 
have fits…They think if you marry from such a family, it is easy to have a child who has 
it.” (FGD CHWs) 
“[It was caused by] falling down from the back of the mother.  She fell when she was still 
very young…the cloth loosened and she fell and the back of the head depressed. It all 
started from then. She fitted up to now.” (Interview grandmother) 
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“When not fitting the person is very fine and like if someone is not asthmatic and you 
give anti-asthma drugs, they get it so it‟s the same to the epileptic person, if you give 
epileptic drugs he will get epilepsy.” (Interview diviner) 
 
Others ascribed epilepsy to interpersonal issues (bewitchment/genies due to jealousy or 
arguments; home/marital issues): 
“It is said that it is witchcraft. She was bewitched, that is according to our customs. That 
is when you will go to a mganga [traditional healer] because you want to untrap them.” 
(FGD grandmothers) 
“They say it‟s [caused by] jealousy from the surrounding people because you have 
children.” (Interview father) 
 
However, there were shifting causal explanations, often depending on the perceived type of 
epilepsy: one grandmother commented “if it‟s normal or from God, one can be healed, but if it‟s 
due to somebody‟s wish [i.e. a curse], you will treat in vain” (FGD grandmothers).   
 
Beliefs inevitably impacted on the type of treatment sought.  One man with epilepsy commented 
that the cause of his condition was ―things that go wrong in the home‖.  He explained: “[A 
family member] can go to the extent of having sex with a cousin. When they are discovered, it‟s 
when a sheep can be slaughtered if not, that‟s what can bring illnesses” (Interview Adult with 
epilepsy).  El-Sharkawy and colleagues discussed the differentiation of perceived causes of 
epilepsy into internal and external phenomena in this community (El Sharkawy et al., 2006).  
They found that belief in ‗external causes‘ (i.e. requiring an agent independent of the child, such 
as trauma or witchcraft) was reflected in treatment choices, usually that of traditional medicine 
(El Sharkawy et al., 2006).  Our findings were similar and reinforce the importance of THs to the 
treatment of epilepsy in this community, emphasizing the need to recognize this factor in the 
design of the intervention: 
 “With me, I think they didn‟t see the illness, that‟s why they discharged her.  Maybe she 
was bewitched and the machines [at the hospital] can‟t detect witchcraft.” (FGD CHWs) 
“We also tell people if they have gone to the hospital and found the condition is not the 
type to be treated there, they should come back to us.” (Interview Traditional Healer) 
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Apart from traditional beliefs, the local churches and mosques also played a role in some 
people‘s treatment-seeking behaviours (usually, taking the person to be prayed for).  More 
commonly, though, people said they had no idea what caused the condition.  Several comments 
suggested that the transient nature of seizures and less recognizable types of epilepsy added to 
the confusion about causality: 
“I don‟t know [what it is] because it‟s something that comes just for some time then it 
goes.” (Interview CWE) 
“According to her symptoms, I have not believed it is epilepsy because there are signs 
that come first and then she fits…initially you will see that she has changes and becomes 
pale, and then she reports about leg pains; then at night she jerks and says „my legs are 
pulled away‟…So I think in my mind, does an epileptic person have such symptoms? 
No!” (Interview mother) 
 
9.3.1.2 The issue of cure 
 
Adherence to drugs is known to be problematic when regimens are drawn out or where there is 
rapid decline of symptoms before the completion of the course of drugs (Manderson, 1998).  
Malaria is the most common cause of febrile illness in children living in Kilifi and thus informs 
much of the understanding of biomedical treatment (i.e. a biomedical condition requires drug 
treatment and cure will follow within days or weeks).  The concept of prolonged drug regimens 
to control, rather than to cure, a condition is difficult to understand: 
“If they take the drugs, they stay for a long time without fitting but they will eventually fit 
but what we want is that they get cured completely.” (FGD grandmothers) 
“When they take drugs, instead of getting better then it comes back again, what we want 
is that they take the drugs – no matter for how long – but when they finish them, the 
illness is gone.” (Interview father) 
“There should be drugs which people are sure if they take, they get cured completely.” 
(FGD CHWs) 
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Several people expressed confusion and frustration about where they should go for treatment.  
Many expressed comments such as ―searching in vain‖ and ―going here and there‖, for example: 
“You will find that sometimes you are moving here and there looking for the treatment 
which can heal your child but in vain. It is not in every place that you go that you can get 
healed.” (FGD mothers) 
 
9.3.1.3 Diminished access to and utilization of biomedical health services 
 
Distance to health facilities as a barrier to biomedical health services was a recurrent theme from 
both service providers and users: 
“I want to say that taking a child to [the hospital], it takes a long time.  If you could 
bring the drugs here, people would save time and bus fare.” (FGD CHWs) 
“You have to make sure that you get bus fare before the drugs are finished but if you pass 
two weeks without drugs because you don‟t have the fare, then he fits so seriously.” 
(FGD grandmothers) 
“The hospital is far away and we don‟t have transport.  We have to find a vehicle to get 
there.” (Interview dispensary nurse) 
 
Even for those who had reached the hospital, service wasn‘t always assured and participants 
complained that they could spend a whole day without seeing a health professional: 
 “The bad thing about the hospital service is the delay…You are sent here and there until 
whenever you reach where you are supposed to, you have really taken a long time and 
you lose hope because of the many trips you make.” (FGD CHWs) 
“Sometimes one spends the whole day [at the hospital] without being served.” (FGD 
CHWs) 
 
Focus group participants noted that the other major constraint to utilising services was financial 
restrictions.  The recurrent cost of treatment, the effects of diverting limited financial resources 
from the family‘s needs to the funding of treatment and the fact that in the Kenyan medical 
system, an inability to pay means doing without the necessary drugs were all prominent themes, 
for example: 
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“The child could start fitting again or even worse until you run back to the mganga 
[traditional healer].  He treats him again and the money owed becomes bigger and you 
have to make sure you have paid fully if you want your child to get better.” (FGD 
mothers) 
 “This child is sick, so the money that I would use on another project which could support 
the family I use it for him. I deteriorate because of the one with epilepsy.” (FGD 
mothers)‖ 
 “The hospital is good but sometimes you go there, you are examined and drugs are 
prescribed but you need money for those drugs.  So if you don‟t have the money, then you 
just remain with the illness.” (FGD CHWs) 
 
These findings highlighted the fact that a successful intervention will have to include factors 
other than education and information.   
 
9.3.1.4 Poor doctor-patient relationships and communication 
 
With one or two exceptions, participants generally felt that the doctors they consulted showed 
little interest or sensitivity and lacked communication skills: 
“Sometimes, just as you have started explaining the problem, the doctor has already 
finished prescribing the drugs.  So you take drugs that you are not confident with at all.” 
(FGD CHWs) 
“When the drugs had finished, I didn‟t understand the doctor, whether I was to go back 
when the drugs were over.  When I went the other day, he asked me why I hadn‟t gone for 
more drugs so I told him that I didn‟t understand him on the first day.‖ (Interview 
mother) 
“I brought my child and was taking him down from my back as the doctor was asking 
what was wrong.  He said he didn‟t need to see the child and just prescribed drugs.  I 
took the prescription and tore it in two pieces then went to see another doctor and my 
child was admitted to hospital.” (Participatory workshop, parents/grandparents) 
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Lack of understanding of what the doctor was prescribing or the course of treatment he/she was 
suggesting was a prominent theme.  This also extended to knowledge of hospital treatment: 
―When I go with him to the hospital, they take him inside so I don‟t know what they do to 
him.” (FGD mothers) 
 
The lack of understanding was often linked to lack of time with the doctor, a feeling that 
consultations were rushed.  A comment from a doctor during an interview suggested that they 
also feel these pressures: “Usually there are so many people in the clinic, we don‟t have time for 
them all.  We are under-resourced.” (Interview Dr L) 
 
9.3.1.5 Access issues for PWE and their families 
 
Many participants described the challenges in the lives of PWE and their families, emphasising 
the fact that epilepsy brings a range of access issues: physical, financial, social and cultural.  
Several families described how epilepsy had affected their children‘s development: 
“It‟s [child‟s name]  who is still having that problem, though it‟s four years since she 
fitted but her brain still is not normal” (FGD mothers) 
“She has changed…the brain…the words show you that there is something wrong with 
her because you will see the words have changed.” (Interview mother) 
“With my granddaughter you have to feed her.  Even toileting has to be assisted.” (FGD 
grandmothers) 
 
Perceived and actual risks also meant that some CWE missed out on schooling: 
“My high hopes are that she gets healed so that she can go to school. For I tried taking 
her to school but the teachers were concerned about how it would be if she falls.” 
(Interview father) 
“Some children even want to go to school but they can‟t because of how they are.  They 
just stay at home.” (FGD CHWs) 
“Some parents think that because the child has epilepsy, he is not going to learn, maybe 
will get the seizures when at school.” (Interview Dr I) 
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Physical injuries sustained during seizures were also reported: 
“When you are cooking you may fall into the fire and lose consciousness.  You may get 
burns.” (FGD CWE) 
“My granddaughter is missing two of her teeth because she fell in a bad place.‖ (FGD 
grandmothers) 
 
Expressions of hopelessness and despair were common and often accompanied feelings that all 
potential options had been exhausted or with difficulties in obtaining treatment: 
“I am feeling so bad, I don‟t know how [the epilepsy] will stop.” (Interview CWE) 
“I went everywhere until I had despaired. I would be given things or advised to do things 
but on administering, it would worsen.  He could stay awake the whole night or take even 
a whole week fitting.” (FGD mothers) 
“I try my best to take the child to the hospital for although I have a husband, he is not 
around, he doesn‟t come home. I am alone.” (FGD mothers) 
“You take him to a Mganga not at will but out of desperation.” (FGD mothers) 
 
Several family members of PWE described the desperate measures people may feel driven to: 
“Some people are tired of taking care of that child for the illness has stayed for a long 
time, so they just leave the child with burns or even still on the fire.‖ (FGD grandmothers) 
“You can be very scared, especially when you don‟t know anything about it.  You can run 
away because whatever you are trying doesn‟t work.” (Interview father) 
 
These findings emphasised the need for support to be part of any intervention to address the ETG 
and the wider issues of quality of life of PWE and their families. 
 
9.3.2 Recommended strategies, content and format for intervention 
 
These data indicated several possible avenues for intervention: first, a lack of understanding 
about epilepsy and its treatment suggested the necessity of information and education; second, 
dissatisfaction with the interpersonal skills of service providers suggested communication skills 
training for those providing epilepsy care; third, problems with accessibility of drugs suggested 
the need to work with the Ministry of Health to improve drug provision in the community; 
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fourth, the prominent role of traditional healers highlights the need to increase cooperation and 
dialogue with these service providers and finally, the levels of stress expressed by many 
participants highlighted the importance of support for PWE and their families. 
 
9.3.2.1 Education and information 
 
The need for information was a prominent theme during the discussions: 
“People should be educated, especially at a time like this. In case such things happen, 
they shouldn‟t use herbal baths or urinate on the child.  They should take him to the 
hospital.” (FGD CHWs) 
“Another way I‟m thinking is just advice.  To know that this is caused by this or that or 
what their symptoms will be.  Let‟s say it is a woman: she can avoid being near a fire or 
any other dangerous place.  This is a good way of giving services.” (FGD Adult with 
epilepsy) 
 
Service providers also expressed a desire for information: 
“Even us, we want to know about fits.  Even me, sometimes I feel there are things I have 
forgotten about the illness…Though we treat it, still I don‟t know much about it…So if 
they come to teach us more about the illness, we will get some experience.” (Interview 
dispensary nurse) 
“To speak the truth, I don‟t know the cause of fits in children: it is caused by fever 
entering the head but for epilepsy, I don‟t know what causes it.” (FGD CHWs) 
 
In the participatory workshops, service providers again emphasized that CHWs, doctors, nurses 
and public health technicians should also be included in any educational interventions, although 
THs and CHWs suggested that relatives of PWE should be given first priority for education. 
 
Various suggestions for who should provide information and education were given during the 
participatory workshops.  CHWs were keen to be involved, one commenting “we are the ones 
who stay in the community so it would be better if we were involved more” (Participatory 
workshop: CHWs/THs).  Other participants suggested staff from KEMRI and parents and family 
members of PWE, supported by advisors from KEMRI, the rationale being that family members 
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are the ones with direct experience of the issue (Participatory workshop: parents/grandparents). 
The participatory workshops also dealt with issues such as where an educational intervention 
should be held and how long it should last.  On the former issue, participants in three workshops 
(parents/grandparents; THs/CHWs; service providers/CHWs) felt that a central place that could 
easily be reached, such as a church or school, would be the most appropriate location.  This 
would reduce the cost issue (i.e. transport costs) and allow more people to attend because the 
disorder is everywhere.  Other suggestions included a location near health facilities so that 
participants could make use of them at the same time (Participatory workshop, THs/CHWs) or in 
people‘s homes (Participatory workshop: PWE). 
 
Regarding the time any educational intervention should take, a longer-term educational 
programme with regular home visits was favoured as it was felt to be new information, which 
needed time to be digested (Participatory workshop: PWE).  In addition, participants commented 
that breadwinners cannot afford a chunk of time away from the household (Participatory 
workshop: parents/grandparents; THs/CHWs).  Practicalities such as the provision of meals or 
compensation for time (a packet of corn flour was mentioned) were also raised (Participatory 
workshop: service providers/CHWs; THs/CHWs; parents/grandparents). 
 
9.3.2.2 Communication skills training 
 
Participants in all of the participatory workshops felt that people weren‘t given a clear 
explanation about AEDs and they generally didn‘t know what was happening in treatment.  
There was general agreement that the service provider‘s interpersonal skills made a difference to 
the patient‘s wellbeing and to other patients‘ use of the service, as exemplified by these 
comments: 
“Sometimes it depends on the person providing the service.  Some are human and treat 
people so well, just the reception can give you hope.  But there are those who are so 
inhuman, they mistreat people.” (FGD CHWs) 
“It‟s the reception that people don‟t know but if you treat them well, you will see other 
people coming.  If you treat somebody well, that is a lamp already to bring more people.” 
(Interview APDK) 
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9.3.2.3 Increasing accessibility to AEDs 
 
Accessibility was related to both finances and distance to the health facilities: 
“I want to say that taking a child to Kilifi, it takes a long time.  So if they could bring the 
drugs here, we would have saved time and fare.” (FGD CHWs) 
“The hospital is far and we don‟t have transport.  We have to board vehicles so as to 
reach there.” (Interview dispensary nurse) 
“This hospital is good but sometimes you go there, get examined and prescribed for 
drugs and you need money for those drugs.  So if you don‟t have money, then you just 
remain with the illness.” (FGD CHWs) 
 
Several of the service providers stressed that any new venture should be incorporated into the 
existing health system to ensure sustainability: 
“If it‟s within the medical wards or the medical out-patients, even if the study runs out, it 
will have been established within an already running system so it will remain there, it 
will not die.  But if you‟ve got an external thing, it will stop with the study.‖ (Interview Dr 
I) 
 
9.3.2.4 Providing support for PWE and their families 
 
The 19 CHWs who were trained were expected to initiate a visiting and educational programme 
for 13 PWE and their families. Therefore an evaluation was done one month after the training to 
gauge the kind of information that CHWs were passing to PWE and their families.  Most CHWs 
emphasized on the importance of taking AEDs but less information was provided on potentially 
harmful self-management practices such as pouring water on PWE during seizures. Overall, 
CHWs did a good job in reaching and supporting PWE and their families.  Some made as many 
as four visits but the median number of visits was two.  On average CHWs spent 17 minutes with 
PWE.  They also played a role in referring PWE to the nearest health facility.  Only nine CHWs 
were active and they provided support to only 7 PWE.  The others cited long distance between 
CHW and PWE as a hindering factor.   
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The 15 biomedical providers who attended the training were drawn from the health facilities in 
the KHDSS. They were trained on communication skills as well as diagnosis and management of 
epilepsy so that they would provide efficient services to PWE. Their level of knowledge on 
diagnosis and management of epilepsy was evaluated using a pre-post questionnaire (Appendix 
IV). The training led to an in increase in epilepsy knowledge from a median of 18 to 19 as shown 
below (Figure 9.2). 
 
Figure 9.2: Epilepsy knowledge scores of health providers: pre and post delivery of 
education intervention  
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It is envisaged that the awareness created among TH and community members led to better 
support for PWE and their families though it was difficult to evaluate this arm of the 
intervention. 
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9.4 Conclusion 
 
Manderson emphasizes that although research into community perceptions of illness, including 
local taxonomies, is useful in the design of interventions, a more in-depth understanding of 
illness and its social and cultural dimensions is more useful in highlighting barriers to behaviour 
change and how interventions can be both effective and sustainable (Manderson, 1998).  The 
process we used here was an attempt to understand these complexities.  Panter-Brick and 
colleagues say that it is now widely accepted that to be effective, interventions should build upon 
local existing practices, identify and target the most receptive community members, bolster local 
skills and priorities, recognize constraints (time, financial, cognitive and social) on human 
agency and feature mobilization of the community (Panter-Brick et al., 2006).  We believe that 
the process we used to develop this intervention has resulted in a programme that is more likely 
to be effective and sustainable. 
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10.1 Introduction 
 
This thesis investigates the factors associated with the Epilepsy Treatment Gap (ETG).  It also 
presents an example of how results from exploratory studies can be used to inform the 
development of interventions aimed at reducing the ETG.  This last chapter starts with a brief 
background about epilepsy, a review of the methodological approaches, followed by a discussion 
of the main research findings with reference to the original objectives described in Chapter 1.  
Finally this Chapter puts forward some recommendations and needs for future research. 
 
10.2 Background  
10.2.1 Epilepsy 
 
Epilepsy is one of the most common neurological disorders, accounting for 1% of the global 
burden of disease, determined by the number of productive life years lost as a result of disability 
or premature death (WHO, 2005; Leonardi & Ustun, 2002; Murray & Lopez, 1994).  The 
condition is associated with psychosocial problems, reduced life expectancy, social isolation and 
increased risk of unexpected death (Jilek-Aall & Rwiza, 1992; Jilek-Aall et al., 1997; Matuja, 
1990b; Nilsson et al., 1999). People with Epilepsy (PWE) are vulnerable due to the 
unpredictable and uncontrollable nature of seizures (DiIorio et al., 2003), which in many cultures 
are associated with witchcraft or sorcery (Baskind & Birbeck, 2005a; El Sharkawy et al., 2006).  
Epilepsy consists of more than seizures because it imposes enormous physical, psychological, 
social and economic burdens on individuals, families and countries (Baker, 2002; Jilek-Aall et 
al., 1997; Hong et al., 2009; Forsgren et al., 2005).  
 
10.2.2 Epilepsy in resource poor countries 
 
Epilepsy is more common in Resource Poor Countries (RPCs) because of poor perinatal care 
with greater risk of brain injury, increased traumatic head injury, endemic parasitic and 
infectious diseases (Shorvon, 2009; Pal et al., 2000a; Carter et al., 2004; Matuja, 1990a).  The 
majority of epilepsy-related deaths and disability in childhood and adolescents also occur in 
RPCs (WHO, 2006), mainly because of the scarcity of resources to identify and manage epilepsy 
in RPCs (World Bank, 1993; Bangdiwala et al.).  Results obtained from a survey conducted by 
the International League Against Epilepsy (ILAE)/International Bureau for Epilepsy 
(IBE)/World Health Organization (WHO) in 160 countries showed that available resources for 
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epilepsy care in the world are insufficient when set against the large number of people needing 
such care (Dua et al., 2006).  In addition, large inequalities exist across regions and income 
groups of countries, with RPCs having extremely meagre resources (Dua et al., 2006).  Such is 
the case in the rural setting of Kilifi, where diagnostic services and epilepsy specialists are 
lacking.  Poverty, unemployment and illiteracy influence the lives of PWE, by making them 
vulnerable to serious economic, social and emotional suffering (GOK, 2000), which affects how 
they seek and adhere to treatment.  
 
The Global Campaign Against Epilepsy, a partnership between the ILAE/IBE/ WHO was 
launched in 1997 to improve the acceptability, treatment, services and prevention of epilepsy 
worldwide (Reynolds, 2000; Diop et al., 2003; De Boer, 2002).  In 2002, the Global Campaign 
entered its second phase and several demonstration projects were set up in various countries, to 
reduce the ETG and the physical, economic and social burden of epilepsy through community-
level interventions (Sander, 2002).  By 2004, activities and events in 85 countries were held and 
projects in China, Zimbabwe, Senegal and Brazil have been successfully completed (Wang, 
2008; Ndoye et al., 2005; Li et al., 2007).  The Global Campaign has also produced useful 
reports which are a good reference for countries committed to reducing the ETG (WHO, 2005; 
WHO, 2004; ILAE/IBE/WHO, 2003).  
 
10.2.3 Treatment seeking for epilepsy in Kilifi  
 
The findings of this study revealed that PWE in Kilifi utilize both biomedical and traditional 
medicine.  Beliefs about the causes of epilepsy impacted on the type of treatment sought.  Belief 
in ‗external causes‘ such as witchcraft, curses and evil spirits lead to consulting Traditional 
Healers (THs) whereas biomedical treatment was sought when epilepsy resulted from natural 
causes such as perinatal injury, accidents and malaria.  In reality, PWE and their families often 
use both traditional medicine and biomedicine since these modalities deal with different aspects.  
Traditional medicine provides information about the causes of the epilepsy, offers the hope of a 
cure and the THs provide significant psychosocial support.  In contrast, biomedicine provides 
AEDs to control the seizures but the explanations given by the biomedical practitioners (nurses 
and clinicians) are often not intelligible to the clients.  These practitioners are also not able to 
spend much time with the clients as the THs due to clinical commitments. 
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10.3 Methodological issues 
 
Research reported in this thesis demonstrates how complementary methodologies can lead to 
understanding of the ETG.  The qualitative part enabled us to understand cultural reasons for 
treatment seeking behaviour for epilepsy while the quantitative part allowed us to estimate the 
ETG using a robust pharmacological measure.  One limitation of these methods is the reliance on 
self-reported answers that are subject to recall and reporting bias.  Attempts were made to 
minimize this potential source of bias by piloting the questionnaires using experienced field staff 
who had a good rapport with the community members.  The field team was also well trained and 
conversant with the local language (Kigiriama).  As a member of the research team, the author of 
this thesis participated in developing the tools, training the field team, field supervision, checking 
quality of data, analysis and interpretation of the results.   
 
10.3.1 Choice of study site 
 
The Kilifi Health Demographic Surveillance System (KHDSS) provided an excellent 
epidemiological framework for the studies in this thesis.  The constant demographic surveillance 
facilitated the identification of PWE who were the main study participants (Chapters 1).  
However, studies conducted in the KHDSS may not be necessarily generalisable to the rest of the 
country.  The Kilifi Health Demographic Surveillance KHDSS has been the focus of continued 
research since 2001 which means this population is more exposed to health information 
compared to the rest of the county.   
 
10.4 Overview of findings 
 
This research identified factors that are responsible for the ETG in Kilifi and ways that the gap 
can be reduced.  Each of the chapters elaborated a complimentary aspect to address this issue.  
The systematic review in chapter 2 examined ETG in RPCs. Findings indicated a wide 
variability in ETG estimates with a prevalence of 46.8/100 in urban settings and 73.3/100 for 
rural regions.  The ETG was mainly attributed to inadequate skilled manpower, cost of treatment, 
cultural beliefs, and unavailability of Antiepileptic Drugs (AEDs).  These factors were addressed 
using intervention strategies such as education and supply of AEDs.  These preliminary findings 
informed the design of the studies that were conducted in Kilifi.  
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Chapters 3 and 4 examined how to construct culturally varied tools that were used to collect data 
from study participants.  The Kilifi Stigma Scale for Epilepsy (KSSE) was unidimensional, 
indicating that it measured only one construct (perceived stigma).  In addition, it had high 
internal consistency (Cronbach‘s α= 0.91) and excellent test-retest reliability (r=0.92).  The Kilifi 
Epilepsy Beliefs and Attitude Scale (KEBAS) had five subscales (causes of epilepsy, biomedical 
treatment of epilepsy, cultural treatment of epilepsy, risk and safety concerns and negative 
stereotypes about epilepsy).  The subscales demonstrated adequate internal consistency ranging 
from α=0.56 to α=0.76 and acceptable test-retest reliability ranging from r=0.64 to r=0.81. 
 
The studies in Chapters 5 and 6 investigated factors associated with treatment seeking and 
adherence.  People who were identified to have active convulsive epilepsy were asked about 
their treatment seeking behaviour.  Whereas 499 (74%) of those identified sought treatment, only 
385 (77%) reported taking AEDs though there was a large discrepancy between self reporting 
and AEDs blood levels. The findings also showed a high ETG in Kilifi and factors that constrain 
PWE from seeking and adhering to treatment.  Some of these factors included religion, distance 
from home to health facilities, paying for AEDs, injury during a seizure, beliefs about causes of 
epilepsy, beliefs about biomedical treatment of epilepsy, seizure frequency, duration of 
medication, number of AEDs prescribed and good relationship with the healthcare provider. 
 
Chapter 7 reviewed literature that highlights the delivery of packages of care for epilepsy in low- 
and middle income countries (LMICs).  Some of the treatments available for epilepsy in LMICs 
include AEDs therapy, surgery and psychosocial therapy.  Among the interventions feasible in 
these countries are: ensuring an adequate drug supply, educating PWE and caregivers about 
epilepsy, community-based interventions to improve awareness, training health care providers, 
involving THs and integrating epilepsy care into existing health services, particularly mental 
health.  These findings provided useful background information that informed development of 
suitable interventions in Kilifi. 
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Chapter 8 used an ethnographic approach to compare characteristics of epilepsy treatment 
providers in KHDSS. The study identified six key differences between biomedical and 
traditional treatments (explanations of causation, communication styles, social roles, referral 
practices, location and systems of payment). Traditional healers play a major role in the 
treatment of epilepsy which can be explained by the supernatural and cultural beliefs associated 
with epilepsy in Kilifi. 
 
The study reported in chapter 9 outlines reasons for the ETG in Kilifi from a qualitative 
perspective and how the findings were used to inform development of interventions.  Five main 
themes emerged from the data as reasons for the ETG: differing causal explanations for the 
causes, treatment and prognosis of epilepsy; the issue of curing epilepsy; diminished access to 
and utilisation of biomedical health services; poor doctor-patient relationships and 
communication and access issues for PWE and their families. These findings indicated several 
possible avenues for intervention such as education of PWE and their caregivers, communication 
skills training for health providers, improving drug supply in health facilities; increasing 
cooperation and dialogue with THs and supporting PWE and their families. 
 
10.5 Recommendations for action 
 
Specific recommendations which arise from the findings of this study concern the community, 
health care providers, policy makers and researchers. 
 
10.5.1 Community 
 
The community constitutes the external environment in which PWE live and the level of support 
derived from it can influence treatment seeking and adherence to medication.  Therefore, efforts 
should be put to improve community knowledge about epilepsy. Some of the concepts that 
awareness programmes should focus on include: 
1. Explaining that epilepsy is a chronic condition despite unpredictability of seizures;  
2. Explaining the causes and prognosis of epilepsy; 
3. How to prevent epilepsy through measures such as sleeping under bed nets and attending 
antenatal care for pregnant women; 
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4. Informing people about AEDs and importance of adherence. The most important 
information is to explain why seizures may persist despite taking medication and what to 
do if someone has a seizure; 
5. Emergency treatment of seizures and how to support PWE and their families; 
6. Encouraging people to be self reliant by initiating income generating activities so that 
they can comfortably meet their health care costs. 
 
10.5.2 Medical providers 
 
The use of primary health care providers to identify cases of epilepsy and initiate simple 
treatment protocols has been advocated as a solution to the inadequate and uneven distribution of 
medical manpower available for the management of epilepsy in RPCs. World Health 
Organization has advocated the use of primary health care personnel to identify cases of 
epilepsy, apply simple treatment protocols and monitor therapy within a framework of an 
integrated primary health care program for epilepsy (WHO, 1990; WHO, 1985).  A report from 
Kenya confirmed the feasibility of this approach for the monitoring of drug therapy in epilepsy 
patients using primary care workers (Feksi et al., 1991a).  This emphasizes the need to give these 
health providers appropriate training and facilities for providing epilepsy care.   
 
The study in Chapter 6 showed that health providers have a role to play in improving adherence 
hence they should explain to patients the chronic nature of their condition and the need to take 
AEDs over a long period of time.  There is also a need for healthcare providers to continually 
improve their relationship and communication with patients in addition to educating and 
counseling them.  Findings from studies in Chapters 5, 8 and 9 show that PWE consult THs 
hence the need for medical providers to be aware of traditional beliefs and practices that foster 
the use of traditional medicine among PWE.  This could provide a good basis for non 
competitive relationship between biomedical practitioners and THs, particularly when neither 
may satisfactorily meet all the needs of PWE.   
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10.5.3 Traditional Healers 
 
The WHO defines THs as a group of persons recognized by the community in which they live as 
being competent to provide health by using vegetable, animal and mineral substances.  The 
treatment methods used by these groups of people are based on the social, cultural and religious 
backgrounds as well as on the knowledge, attitudes and beliefs that are prevalent in the 
community regarding physical, mental and social well being and the causation of disease and 
disability (WHO, 1976).  In Africa, it is estimated that THs provide up to 80% of all health care 
services in poor rural families (Hoff, 1997). 
 
In the Alma Ata Declaration of 1978, and in the context of Health for All resolution, THs started 
to be considered as an important potential for primary health care coverage.  In 1978, WHO 
launched a big, cross-cultural programme of promoting the integration of THs into the formal 
health care sector (WHO, 1978).  After a first boom of the ambitious collaboration projects, a 
shift towards more focused contributions of healers to specific health issues has taken place, for 
example in the management of AIDS and STDs (Green, 1999a; Green, 1999b).  
 
In the case of epilepsy, THs play a major role in treatment as described in Chapter 8.  This is 
reinforced by studies conducted in other settings which have documented the role of THs in 
treatment of epilepsy (Millogo et al., 2004; Moshi et al., 2005; Baskind & Birbeck, 2005a; 
Balogou et al., 2000; Gessler et al., 1995).  This supports the potential benefits of integrating 
THs in health workers‘ trainings.  In such trainings they can learn about first aid during seizures 
and the importance of referring PWE to health facilities as well as some effective interventions 
that are consistent with their ability and style of knowledge.  However, mutual agreement 
between THs and biomedical providers need to be established to avoid misunderstanding 
especially pertaining ownership of indigenous traditional knowledge. 
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10.5.4 Policy makers 
 
Findings suggest that epilepsy is an important public health problem that needs commitment of 
resources by governments of RPCs if ETG is to be reduced.  Policy makers need to take 
deliberate action to address hindering factors that prevent PWE from accessing appropriate care.  
They also need to make commitment to deal with the many preventable causes of epilepsy in 
RPCs such as poor perinatal care, head trauma, parasitic infections, alcohol and drug abuse.  If 
action is taken against these preventable causes, this will indirectly lead to reduction of the ETG.  
In Kenya, some of the measures that can be implemented at policy level include: 
1. The division of non-communicable diseases, of the Ministry of Health (MoH) together 
with other stakeholders should develop an epilepsy strategic policy and come up with 
national guidelines for the management of epilepsy in the country. Furthermore, a 
National Epilepsy Forum (NEF) comprising of representatives from organisations has 
been constituted to bring together stakeholders involved in epilepsy work. The main 
objective of the forum is to improve care and access to services to PWE. Out of this 
forum, a eight member National Epilepsy Co-coordinating Committee was formed to 
coordinate epilepsy activities in the country. 
2. Incorporating epilepsy in the National Health Agenda and integrating epilepsy 
interventions in the existing primary health care system.  It would also be worth including 
epilepsy on the list of diseases for surveillance that are reported on a monthly basis at 
various health care facilities. Already a proforma has been developed by NEF to collect 
data from health facilities.  This will provide information that is vital for planning for 
epilepsy services.  
3. Uninterrupted supply of essential AEDs, especially in the peripheral health facilities. 
AEDS stock-outs are a recurrent problem in health facilities because the Kenya Medical 
Supplies Agency uses the ‗push‘ system whereby each health facility receives a pre-
determined quantity of drugs.  The ‗push‘ system does not respond to health facility 
needs and this leads to either stock outs or wastages.  There is need for the government to 
adopt the ‗pull‘ system that allows health facilities to request for the drugs that they need 
which minimizes wastage. 
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4. Creating Information, Education and Communication (IEC) materials to raise awareness 
about epilepsy among the general public.  There is also need to sensitize the public about 
the global day of epilepsy awareness (purple day) that is marked on 26th March every 
year. 
5. The government can lobby pharmaceutical companies to reduce prices of AEDs. It 
should also ensure pharmaco-vigilance so that AEDs that are sold are effective and 
efficacious. 
6. The government needs to invest in health systems strengthening so that health 
interventions including those related to epilepsy can be delivered effectively.  Essential 
medical supplies and equipment such as Electroencephalography and Computerized 
Tomography should be availed to district level hospitals.  In terms of manpower, there is 
need to employ enough personnel to deliver health services. This will curb staff shortages 
and lead to improved care for PWE.  
7. The government needs to pay increased attention to the problem of economic constraints 
for people‘s health care expenditure.  Implementation of universal health insurance 
system would be a possible way of helping PWE to cope with treatment cost.  This can be 
achieved by ensuring both people in the formal and inform sector contribute to the 
National Health Insurance Scheme. 
 
10.5.5 Researchers 
 
One of the key roles of a researcher is to disseminate research findings.  In addition to presenting 
the findings in international conferences and scientific journals researches should: 
1.  Strive to simplify the findings and present to policy makers.  Follow up should also be 
done to be sure that action is taken on the recommendations made. The researchers in this 
study have began sharing findings with the department of non-communicable disease, 
MoH. 
2. Share findings with other stakeholders involved in epilepsy work.  In Kenya we have 
began sharing our findings with the following  members of NEF: MoH, Kenya Society of 
Epilepsy, Kenya Association for Welfare of People with Epilepsy, Youth on the Move, 
Joint Epilepsy Foundation and Pharmaceuticals companies.  
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3. Provide feedback to the community using research summaries written in lay language.  
Feedback can also be given through community meetings or to individual participants. 
This has been done through implementation of Kilifi Epilepsy Education Program 
(KEEP), an intervention that was designed to create awareness about epilepsy in KHDSS. 
4. The findings from studies in chapters 8 and 9 show the value of THs in providing 
epilepsy care and points to the need of sharing information and research findings with 
them. All the THs identified in KHDSS participated in the KEEP intervention that 
provided information about epilepsy. 
5. The systematic review in Chapter 2 shows the need to improve research on the 
epidemiology of epilepsy in RPCs so that PWE can be correctly identified.  Research 
tools for such studies need to be standardized and validated.   
 
10.6 Implication for future research 
 
The studies in this thesis have clearly looked at ETG from various perspectives.  Attempts have 
also been made to incorporate the findings from the studies in developing tools and 
interventions. However, there remain a number of research issues that need to be addressed: 
1. Information from study participants indicates that there is still need to increase awareness 
about various aspects of epilepsy.  In Chapter 9 we attempted to develop an education 
intervention with the help of study participants.  Such an intervention would call for 
development of IEC messages that are culturally appropriate.  With our example as a 
background, and the fact that there are no educational materials on epilepsy that are 
culture specific, it would be useful to study, compare and find the best advocacy 
strategies for delivering epilepsy messages.  Such research should also aim to evaluate if 
such strategies have an impact at reducing the ETG.  
2. Several outcome measures are used in epilepsy care, such as seizure control, quality of 
life, knowledge of illness, attitudes of people, stigma and discrimination levels.  There is 
need for prevalence studies to estimate ETG so that it can also be used as an outcome 
measure in health care. 
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3. This thesis mainly focused on personal attributes that hinder treatment seeking. Future 
research can look at healthcare delivery system characteristics such as policies, resources, 
organization and financial arrangements influencing the accessibility, availability and 
acceptability of epilepsy care services. 
4. The cost-effectiveness of possible interventions needs to be modeled and calculated. This 
would allow the Public Health personnel to implement interventions that are sustainable.    
5. We determined adherence by taking AEDs blood levels at one point in time.  Future 
studies can monitor it over a duration of time to find out if there is variation in drug levels 
in individual patients. 
 
10.7 Conclusion 
 
After studying various aspects of the ETG from risk factors to intervention strategies we 
conclude that: 
1. ETG is a public health problem that can be effectively addressed if stakeholders work 
together.  
2. Using mixed methodologies to understand the  ETG provides evidence based approaches 
of addressing the gap 
3. There is need for advocacy strategies to increase awareness about epilepsy and to ensure 
sustained supply and distribution of AEDs at peripheral health facilities  
4. Traditional healers may perform some useful roles in management of epilepsy such as 
providing psychosocial support that is deficient in the health care facilities hence a need 
to initiate sustainable collaboration with them 
5. Measures that prevent epilepsy can indirectly lead to reduction of the ETG 
6. There is need for encompassing research to inform epilepsy policy and practice  
Bibliography 
187 
 
Bibliography 
 
Abbas AA & Walker GJ. (1986) Determinants of the utilization of maternal and child health 
services in Jordan. Int J Epidemiol 15(3): 404-7. 
 
Abubakar A, Fons JR, De Vijver V, Mithwani S, Obiero E, Lewa N, Kenga S, Katana K & 
Holding P. (2007) Assessing Developmental Outcomes in Childeren from Kilifi, Kenya, 
Following Prophylaxis for seizures in Cerebral Malaria. J Health Psychology 12: 417. 
 
Abubakar A, Holding P, Van Baar A, Newton CRJC & VanDe Vijver FJR. (2008) Monitoring 
psychometric development in a resource-limited setting: an evaluation of the Kilifi 
Developmental Inventory. Annnals of Tropical Paediatrics 28: 217-26. 
 
Adamolekun B, Mielke J, Ball D & Mundanda T. (2000) An evaluation of the management of 
epilepsy by primary health care nurses in Chitungwiza, Zimbabwe. Epilepsy Res 39(3): 
177-81. 
 
Adamolekun B, Mielke JK & Ball DE. (1999) An evaluation of the impact of health worker and 
patient education on the care and compliance of patients with epilepsy in Zimbabwe. 
Epilepsia 40(4): 507-11. 
 
Aday LA. (1996) Designing and conductiong health surveys. San Francisco: Jossy-Bass. 
 
Akogun OB, Audu Z, Weiss MG, Adelakun AO, Akoh JI, Akogun MK & Remme H. (2001) 
Community-directed treatment of onchocerciasis with ivermectin in Takum, Nigeria. 
Trop Med Int Health 6(3): 232-43. 
 
Al-Qazaz H, Hassali MA, Shafie AA, Sulaiman SA, Sundram S & Morisky DE. (2010) The 
eight-item Morisky Medication Adherence Scale MMAS: translation and validation of 
the Malaysian version. Diabetes Res Clin Pract 90(2): 216-21. 
 
Albert RM. (1983) Exploring patient beliefs. Archives of internal medicine 143: 1773-5. 
 
Allison D. (2000) Multiple Imputation for Missing Data: A Cautionary Tale. Sociological 
Methods and Research 28: 301-9. 
 
Almas A, Hameed A, Ahmed B & Islam M. (2006) Compliance to antihypertensive therapy. J 
Coll Physicians Surg Pak 16(1): 23-6. 
 
Andermann LF. (1995) Epilepsy in developing countries. Transcult Psychiatr Res Rev 32: 351-
84. 
 
Andermann LF. (2000) Epilepsy in our world: an ethnographic view. Epilepsy Behav 1: 169-75. 
 
Andersen R. (1968) Behavioral Model of Families' Use of Health Services, Research Series no. 
25. Chicago: Center for Health Administration Studies, University of Chicago. 
Bibliography 
188 
 
Andersen R. (1995) Revisiting the Behavioral Model and Access to Medical Care: Does it 
matter? Journal of Health and Social Behavior 36: 1-10. 
 
Andersen R, Rice TH & Kominski GF. (2001) Changing the US health care system: key issues in 
health services, policy and management (2nd ed). San Francisco:Jossey-Bass. 
 
Annegers JF, Hauser WA, Beghi E, Nicolosi A & Kurland LT. (1988) The risk of unprovoked 
seizures after encephalitis and meningitis. Neurology 38(9): 1407-10. 
 
Annegers JF, Hauser WA, Coan SP & Rocca WA. (1998) A population-based study of seizures 
after traumatic brain injuries. N Engl J Med 338(1): 20-4. 
 
Annis S. (1981) Physical access and utilization of health services in rural Guatemala. Soc Sci 
Med D 15(4): 515-23. 
 
Antonak R. (1990) Psychometric Analysis and Validation of the Scale of Attitudes Toward 
Persons with Epilepsy. J Epilepsy  3: 11-6. 
 
Antonak R & Livneh H. (1988) The measurement of attitudes towards people with disability: 
methods, psychometrics and scales. Springfield, IL: Charles C Thomas. 
 
Arida RM, Cavalheiro EA, da Silva AC & Scorza FA. (2008) Physical activity and epilepsy: 
proven and predicted benefits. Sports Med 38(7): 607-15. 
 
Arluke A. (1980) Judging drugs: patients' conceptions of therapeutic efficacy in the treatment of 
arthritis. Hum Organ 39(1): 84-8. 
 
Asadi-Pooya AA & Sperling MR. (2008) Strategies for surgical treatment of epilepsies in 
developing countries. Epilepsia 49(3): 381-5. 
 
Asawavichienjinda T, Sitthi-Amorn C & Tanyanont W. (2003) Compliance with treatment of 
adult epileptics in a rural district of Thailand. J Med Assoc Thai 86(1): 46-51. 
 
Asindi AA, Antia-Obong OE, Ibia EO & Udo JJ. (1995) Neonatal seizures in Nigerian infants. 
Afr J Med Med Sci 24(3): 243-8. 
 
Atadzhanov M, Chomba E, Haworth A, Mbewe E & Birbeck GL. (2006) Knowledge, attitudes, 
behaviors, and practices regarding epilepsy among Zambian clerics. Epilepsy Behav 9(1): 
83-8. 
 
Atadzhanov M, Haworth A, Chomba EN, Mbewe EK & Birbeck GL. (2010) Epilepsy-associated 
stigma in Zambia: What factors predict greater felt stigma in a highly stigmatized 
population? Epilepsy Behav. 
 
Bibliography 
189 
 
Austin J, MacLeod J, Dunn DW, Shen J & Perkins SM. (2004) Measuring stigma in children 
with epilepsy and their parents: instrument development and testing. Epilepsy Behav 5: 
472-82. 
 
Austin JK & Huberty TJ. (1993) Development of the Child Attitude Toward Illness Scale. J 
Pediatr Psychol 18(4): 467-80. 
 
Austin JK, Shafer PO & Deering JB. (2002) Epilepsy familiarity, knowledge, and perceptions of 
stigma: report from a survey of adolescents in the general population. Epilepsy Behav 
3(4): 368-75. 
 
Aziz H, Akhtar SW & Hasan KZ. (1997a) Epilepsy in Pakistan: stigma and psychosocial 
problems. A population-based epidemiologic study. Epilepsia 38(10): 1069-73. 
 
Aziz H, Guvener A, Akhtar SW & Hasan KZ. (1997b) Comparative epidemiology of epilepsy in 
Pakistan and Turkey: population-based studies using identical protocols. Epilepsia 38(6): 
716-22. 
 
Baker GA. (2002) The psychosocial burden of epilepsy. Epilepsia 43 Suppl 6: 26-30. 
 
Baker GA, Brooks J, Buck D & Jacoby A. (1999) The stigma of epilepsy: a European 
perspective. . Epilepsia 41: 98-104. 
 
Baker GA, Jacoby A, Gorry J, Doughty J & Ellina V. (2005) Quality of life of people with 
epilepsy in Iran, the Gulf, and Near East. Epilepsia 46(1): 132-40. 
 
Balogou AA, Dodzro K. C & Grunitzky E. K. (2000) [Traditional tattoos with neurological 
diseases in Togo]. Bulletin de la Societe de pathologie exotique (1990) 93(5): 361-4. 
 
Bandura A. (1988) Organizational Application of Social Cognitive Theory. Australian Journal of 
Management 13 (2): 275-302. 
 
Banerjee T & Banerjee G. (1995) Determinants of help-seeking behaviour in cases of epilepsy 
attending a teaching hospital in India: an indigenous explanatory model. The 
International journal of social psychiatry 41(3): 217-30. 
 
Bangdiwala SI, Sharon F, Osegbeaghe O & Stephen T. Workforce Resources for Health in 
Developing Countries. Public Health Reviews, 32(1): 296-318. 
 
Banu SH, Jahan M, Koli UK, Ferdousi S, Khan NZ & Neville B. (2007) Side effects of 
phenobarbital and carbamazepine in childhood epilepsy: randomised controlled trial. 
BMJ 334(7605): 1207. 
 
Baskind R & Birbeck G. (2005a) Epilepsy care in Zambia: a study of traditional healers. 
Epilepsia 46(7): 1121-6. 
Bibliography 
190 
 
Baskind R & Birbeck GL. (2005b) Epilepsy-associated stigma in sub-Saharan Africa: the social 
landscape of a disease. Epilepsy Behav 7(1): 68-73. 
 
Bassili A, Omar T, Zaki A, Abdel-Fattah M & Tognoni G. (2002) Pattern of diagnostic and 
therapeutic care of childhood epilepsy in Alexandria, Egypt. Int J Qual Health Care 
14(4): 277-84. 
 
Baulac S, Gourfinkel-An I, Nabbout R, Huberfeld G, Serratosa J, Leguern E & Baulac M. (2004) 
Fever, genes, and epilepsy. Lancet neurology 3(7): 421-30. 
 
Beckerleg S. (1994) Medical pluralism and Islam in Swahili communities in Kenya. Medical 
Anthropology Quarterly 8: 299-313. 
 
Beghi E. (2005) Injuries in patients with epilepsy. Lancet neurology 4(2): 71-2. 
 
Ben-Menachem E. (2002) Vagus-nerve stimulation for the treatment of epilepsy. Lancet 
neurology 1(8): 477-82. 
 
Berhanu S, Alemu S, Asmera J & Prevett M. (2002) Primary care treatment of epilepsy in rural 
Ethiopia. Ethiop. J.Health Dev 16(3): 235-40. 
 
Berhanu S, Alemu S, Prevett M & Parry EH. (2009) Primary care treatment of epilepsy in rural 
Ethiopia: causes of default from follow-up. Seizure 18(2): 100-3. 
 
Bernal B & Altman NR. (2003) Evidence-based medicine: neuroimaging of seizures. 
Neuroimaging Clin N Am 13(2): 211-24. 
 
Bharucha NE. (2003) Epidemiology of epilepsy in India. Epilepsia 44 Suppl 1: 9-11. 
 
Bibeau G. (1997) At work in the fields of public health: the abuse of rationality. Med Anthropol 
Q 11(2): 246-51. 
 
Birbeck G, Chomba E, Atadzhanov M, Mbewe E & Haworth A. (2007) The social and economic 
impact of epilepsy in Zambia: a cross-sectional study. Lancet neurology 6(1): 39-44. 
 
Birbeck GL. (1999) Traditional African medicines complicate the management of febrile 
seizures. Eur Neurol 42(3): 184. 
 
Birbeck GL. (2000) Seizures in rural Zambia. Epilepsia 41(3): 277-81. 
 
Birbeck GL, Chomba E, Atadzhanov M, Mbewe E & Haworth A. (2008) Women's experiences 
living with epilepsy in Zambia. Am J Trop Med Hyg 79(2): 168-72. 
 
Bloom BS. (2001) Daily regimen and compliance with treatment. BMJ 323(7314): 647. 
 
Bibliography 
191 
 
Borras L, Mohr S, Brandt PY, Gillieron C, Eytan A & Huguelet P. (2007) Religious beliefs in 
schizophrenia: their relevance for adherence to treatment. Schizophr Bull 33(5): 1238-46. 
 
Boster J. (1984) Inferring decision making from preferences and behaviour: an analysis of 
Aquaruna Jivaro Manioc selection. Human Ecology 12: 343-58. 
 
Buck D, Jacoby A, Baker GA & Chadwick DW. (1997) Factors influencing compliance with 
antiepileptic drug regimes. Seizure 6(2): 87-93. 
 
Burn J, Dennis M, Bamford J, Sandercock P, Wade D & Warlow C. (1997) Epileptic seizures 
after a first stroke: the Oxfordshire Community Stroke Project. BMJ 315(7122): 1582-7. 
 
Camilo O & Goldstein LB. (2004) Seizures and epilepsy after ischemic stroke. Stroke 35(7): 
1769-75. 
 
Carpio A, Escobar A & Hauser WA. (1998) Cysticercosis and epilepsy: a critical review. 
Epilepsia 39(10): 1025-40. 
 
Carr-Hill R, Roce N & Roland M. (1996) Socio-economic determinants of rates of consultations 
in general practice based on fourth national morbidity survey of general practices. British 
Medical Journal 312: 1008-12. 
 
Carter JA. (2002) Epilepsy and developmental impairments following severe malaria in Kenyan 
Children: a study of their prevalence, relationships, clues to pathogenesis and service 
requirements.  PHD thesis. London: University of London.  
 
Carter JA, Neville BG, White S, Ross AJ, Otieno G, Mturi N, Musumba C & Newton CR. 
(2004) Increased prevalence of epilepsy associated with severe falciparum malaria in 
children. Epilepsia 45(8): 978-81. 
 
Chavunduka GL. (1978) Traditional healers and the Shona patient. Gwelo:Mambo. 
 
Choi-Kwon S, Park KA, Lee HJ, Park MS, Lee CH, Cheon SE, Youn MH, Lee SK & Chung 
CK. (2004) Familiarity with, knowledge of, and attitudes toward epilepsy in residents of 
Seoul, South Korea. Acta Neurol Scand 110(1): 39-45. 
 
Chowdhury AM, Chowdhury S, Islam MN, Islam A & Vaughan JP. (1997) Control of 
tuberculosis by community health workers in Bangladesh. Lancet 350(9072): 169-72. 
 
Chowdhury FA, Nashef L & Elwes RD. (2008) Misdiagnosis in epilepsy: a review and 
recognition of diagnostic uncertainty. Eur J Neurol 15(10): 1034-42. 
 
Chuma J & Molyneux C. (2009) "Estimating inequalities in ownership of insecticide treated 
nets: does the choice of socio-economic status measure matter? Health Policy and 
Planning. 24: 83-93. 
Bibliography 
192 
 
Cicchetti D. (1994) Guidelines, Criteria, and Rules of Thumb for Evaluating Normed and 
Standardized Assessment Instruments in Psychology. Psychological Assessment 6: 284-
90. 
 
Clark AJ, Espie CA & Paul A. (2001) Adults with learning disabilities and epilepsy: knowledge 
about epilepsy before and after an educational package. Seizure 10(7): 492-9. 
 
Cleland JG & Van Ginneken JK. (1988) Maternal education and child survival in developing 
countries: the search for pathways of influence. Social science & medicine (1982) 27(12): 
1357-68. 
 
Cockerell OC, Goodridge DM, Brodie D, Sander JW & Shorvon SD. (1996) Neurological 
disease in a defined population: the results of a pilot study in two general practices. 
Neuroepidemiology 15(2): 73-82. 
 
Coleman R, Loppy L & Walraven G. (2002) The treatment gap and primary health care for 
people with epilepsy in rural Gambia. Bull World Health Organ 80(5): 378-83. 
 
Collings JA. (1990) Epilepsy and well-being. Social Science and medicine 31: 165-70. 
 
Conrad P. (1985) The meaning of medications: another look at compliance. Social science & 
medicine (1982) 20(29-37). 
 
Corey LA, Kjeldsen MJ, Solaas MH, Nakken KO, Friis ML & Pellock JM. (2009) The accuracy 
of self-reported history of seizures in Danish, Norwegian and U.S. twins. Epilepsy Res 
84(1): 1-5. 
 
Cortinovis I, Vella V & Ndiku J. (1993) Construction of a socio-economic index to facilitate 
analysis of health data in developing countries. Social science & medicine (1982) 36(8): 
1087-97. 
 
Costelllo A & Osborne JW. (2003) Exploring best practices in factor analysis: four mistakes 
applied researchers make.  Paper presented at the annual meting of the American 
Educational Research Association; chicago, IL. 
 
Cramer J & Mattson RH. (1991) Monitoring compliance with antiepileptic drug therapy.  In: 
Patient Compliance in Medical Practice and Clinical Trials (Eds J.A. Cramer and B. 
Spilker).  New York, Raven Press Ltd.: 123-37. 
 
Cramer JA, Westbrook LE, Devinsky O, Perrine K, Glassman MB & Camfield C. (1999) 
Development of the Quality of Life in Epilepsy Inventory for Adolescents: the QOLIE-
AD-48. Epilepsia 40(8): 1114-21. 
 
Crombie I. (1996) A pocket guide to critical appraisal: A handbook for health care professionals. 
BMJ publishing group. 
Bibliography 
193 
 
Cronbach L. (1951) Coefficient alpha and the internal structure of test. Psychometrika 16: 297-
334. 
 
Curtis V, Kanki B, Cousens S, Diallo I, Kpozehouen A, Sangare M & Nikiema M. (2001) 
Evidence of behaviour change following a hygiene promotion programme in Burkina 
Faso. Bull World Health Organ 79(6): 518-27. 
 
Dahl J, Melin L & Lund L. (1987) Effects of a contingent relaxation treatment program on adults 
with refractory epileptic seizures. Epilepsia 28(2): 125-32. 
 
Das G. (1987) Selective discrimination against female children in rural Punjab, India. Population 
and Development Review 13: 77-100. 
 
Das K, Banerjee M, Mondal GP, Devi LG, Singh OP & Mukherjee BB. (2007) Evaluation of 
socio-economic factors causing discontinuation of epilepsy treatment resulting in seizure 
recurrence: A study in an urban epilepsy clinic in India. Seizure. 
 
De Boer HM. (2002) "Out of the shadows": a global campaign against epilepsy. Epilepsia 43 
Suppl 6: 7-8. 
 
De Vellis R. (1991) Scale development: theory and applications California: SAGE Publications. 
 
Dekker PA. (1994) A Manual for Medical and Clinical Officers in Kenya, 2nd edition.  Kenya 
Association for Welfare of Epilepsy.  
 
Dent W, Helbok R, Matuja WB, Scheunemann S & Schmutzhard E. (2005) Prevalence of active 
epilepsy in a rural area in South Tanzania: a door-to-door survey. Epilepsia 46(12): 1963-
9. 
 
Desai P, Padma MV, Jain S & Maheshwari MC. (1998) Knowledge, attitudes and practice of 
epilepsy: experience at a comprehensive rural health services project. Seizure 7(2): 133-8. 
 
DeVellis R. (1991) Scale development: theory and applications California: SAGE Publications; 
1991. 
 
Devinsky O. (2003) Psychiatric comorbidity in patients with epilepsy: implications for diagnosis 
and treatment. Epilepsy Behav 4 Suppl 4: S2-10. 
 
DiIorio C, Osborne Shafer P, Letz R, Henry T, Schomer DL & Yeager K. (2003) The association 
of stigma with self-management and perceptions of health care among adults with 
epilepsy. Epilepsy Behav 4(3): 259-67. 
 
Dilorio CA, Kobau R, Holden EW, Berkowitz JM, Kamin SL, Antonak RF, Austin JK, Baker 
GA, Bauman LJ, Gilliam F, Thurman DJ & Price PH. (2004) Developing a measure to 
assess attitudes toward epilepsy in the US population. Epilepsy Behav 5(6): 965-75. 
Bibliography 
194 
 
DiMatteo MR. (2004) Variations in patients' adherence to medical recommendations: a 
quantitative review of 50 years of research. Med Care 42(3): 200-9. 
 
Diop AG, de Boer HM, Mandlhate C, Prilipko L & Meinardi H. (2003) The global campaign 
against epilepsy in Africa. Acta Trop 87(1): 149-59. 
 
Diop AG, Hesdorffer DC, Logroscino G & Hauser WA. (2005) Epilepsy and mortality in Africa: 
a review of the literature. Epilepsia 46 Suppl 11: 33-5. 
 
Dooley JM, Gordon KE, Wood EP, Camfield CS & Camfield PR. (2003) The utility of the 
physical examination and investigations in the pediatricneurology consultation. Pediatric 
neurology 28(2): 96-9. 
 
Dowse R & Futter WT. (1991) Outpatient compliance with theophylline and phenytoin therapy. 
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 80(11-12): 
550-3. 
 
Dreifuss FE. (1997) Critical review of health care for epilepsy.  In: Engel J Jr, Pedley T, eds.  
Epilepsy: a comprehensive  textbook. Philadelphia, PA, Lippincott-Raven, . 2903-6. 
 
Dua T, de Boer HM, Prilipko LL & Saxena S. (2006) Epilepsy Care in the World: results of an 
ILAE/IBE/WHO Global Campaign Against Epilepsy survey. Epilepsia 47(7): 1225-31. 
 
Dunbar-Jacob J & Mortimer-Stephens MK. (2001) Treatment adherence in chronic disease. J 
clin Epidemiol 54(December (Suppl.1)): S57-60. 
 
Duncan JS. (2002) Neuroimaging methods to evaluate the etiology and consequences of 
epilepsy. Epilepsy Res 50(1-2): 131-40. 
 
Eadie MJ, Lander CM, Hooper WD & Tyrer JH. (1977) Factors influencing plasma 
phenobarbitone levels in epileptic patients. British journal of clinical pharmacology 4(5): 
541-7. 
 
Edwards T, Scott AG, Munyoki G, Odera VM, Chengo E, Bauni E, Kwasa T, Sander LW, 
Neville BG & Newton CR. (2008) Active convulsive epilepsy in a rural district of Kenya: 
a study of prevalence and possible risk factors. Lancet neurology 7(1): 50-6. 
 
El Sharkawy G, Newton C & Hartley S. (2006) Attitudes and practices of families and health 
care personnel toward children with epilepsy in Kilifi, Kenya. Epilepsy Behav 8(1): 201-
12. 
 
Elechi CA. (1991) Default and non-compliance among adult epileptics in Zaria, Nigeria. The 
need to restructure continued care. Tropical and geographical medicine 43(1-2): 242-5. 
 
Engel J, Jr. (2006) ILAE classification of epilepsy syndromes. Epilepsy Res 70 Suppl 1: S5-10. 
Bibliography 
195 
 
Epping-Jordan J. (2002) Building blocks for Action: Global Report.Geneva: WHO, Report no. 
WHO/MNC/CCH/02.01. J.Innovative Care for Chronic Conditions. 
 
Eraker S, Kirscht JP & Becker MH. (1984) Understanding and improving patient compliance. . 
Ann intern Med 100(February (2)): 258-68. 
 
Fabrega H. (1974) Disease and social behaviour. Cambridge: MIT Press. 
 
Faught E. (2001) Phamacokenitics considerations in prescribing antiepiletic drugs. Epilepsia 
42(suppl 4): 19-23. 
 
Feierman EK. (1981) Alternative medical services in rural Tanzania: a physician's view. Soc Sci 
Med B 15(3): 399-404. 
 
Feksi AT, Kaamugisha J, Gatiti S, Sander JW & Shorvon SD. (1991a) A comprehensive 
community epilepsy programme: the Nakuru project. Epilepsy Res 8(3): 252-9. 
 
Feksi AT, Kaamugisha J, Sander JW, Gatiti S & Shorvon SD. (1991b) Comprehensive primary 
health care antiepileptic drug treatment programme in rural and semi-urban Kenya. 
ICBERG (International Community-based Epilepsy Research Group). Lancet 337(8738): 
406-9. 
 
Fernandes PT, Noronha AL, Sander JW & Li LM. (2008) Stigma scale of epilepsy: the 
perception of epilepsy stigma in different cities in Brazil. Arq Neuropsiquiatr 66(3A): 
471-6. 
 
Fernandes PT, Salgado PC, Barbosa FD, Souza EA & Li LM. (2004) Stigma Scale of Epilepsy: 
Conceptual Issues. J Epilepsy clin Neurophysio 10(4): 213-8. 
 
Fernandes PT, Salgado PC, Noronha AL, Sander JW & Li LM. (2007) Stigma Scale of Epilepsy: 
validation process. Arq Neuropsiquiatr 65 Suppl 1: 35-42. 
 
Feuerstein M, Lieb-Juckstock V, Schnaus H, Springmann E, Weber B & Wunderlich M. (1989) 
Compliance-a joint effort of the patient and his doctor. Epilepsy research supp 1, 51-56. 
 
Filmer D & Pritchett LH. (2001) Estimating wealth effects without expenditure data--or tears: an 
application to educational enrollments in states of India. Demography 38(1): 115-32. 
 
Finkler K. (1994) Sacred healing and biomedicine compared. Medical Anthropology Quarterly 
8: 178-97. 
 
Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P & Engel J, Jr. (2005) 
Epileptic seizures and epilepsy: definitions proposed by the International League Against 
Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46(4): 470-2. 
 
Bibliography 
196 
 
Fisher RS, Vickrey B.G & Gibson P. (2000) The impact of epilepsy from the patient's pespective 
I. Descriptions and subjective perceptions. Epilepsy Res 41: 39-51. 
 
Forsgren I, Beghi E & Ekman M. (2005) Cost of epilepsy in Europe. Eur J Neurol 12 Suppl 1: 
54-8. 
 
Francis V, Korsch BM & Morris MJ. (1969) Gaps in doctor-patient communication. Patients' 
response to medical advice. N Engl J Med 280(10): 535-40. 
 
Freeman B, Negrete V, Davis M & Kossch B. (1971) Gaps in doctor-patient 
communication:doctor-patient interaction analysis. Paediatric Research 5: 298-311. 
 
Gaitatzis A, Trimble MR & Sander JW. (2004) The psychiatric comorbidity of epilepsy. Acta 
Neurologica Scandinavica 110: 207-20. 
 
Gajjar M, Geva E, Humphries T, Peterson-Badali M & Otsubo H. (2000) A New Scale to Assess 
Culture-Specific Beliefs and Attitudes about Epilepsy. Epilepsy Behav 1(4): 235-55. 
 
Gambhir SK, Kumar V, Singhi PD & Goel RC. (1995) Public awareness, understanding & 
attitudes toward epilepsy. The Indian journal of medical research 102: 34-8. 
 
Ganatra B & Hirve S. (1994) Male bias in health care utilization for under-fives in a rural 
community in western India. Bull World Health Organ 72(1): 101-4. 
 
Garber MC, Nau DP, Erickson SR, Aikens JE & Lawrence JB. (2004) The concordance of self-
report with other measures of medication adherence: a summary of the literature. Med 
Care 42(7): 649-52. 
 
George J, Mackinnon A, Kong DC & Stewart K. (2006) Development and validation of the 
Beliefs and Behaviour Questionnaire (BBQ). Patient Educ Couns 64(1-3): 50-60. 
 
Gerow JR. (1993) Social Psychology. In: Josh R Gerow, editor.  Essentials psychology: concepts 
and applications. New York: Harper Collins College. 458-87. 
 
Gessler MC, Msuya DE, Nkunya MH, Schar A, Heinrich M & Tanner M. (1995) Traditional 
healers in Tanzania: sociocultural profile and three short portraits. J Ethnopharmacol 
48(3): 145-60. 
 
Gidal BE. (2001) Pharmacokinetics of the new antiepileptic drugs. The American journal of 
managed care 7(7 Suppl): S215-20. 
 
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, 
Mattson R, Perucca E & Tomson T. (2006) ILAE treatment guidelines: evidence-based 
analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for 
epileptic seizures and syndromes. Epilepsia 47(7): 1094-120. 
 
Bibliography 
197 
 
GOK. (1997) Government of Kenya, Ministry of Health: Health Policy Framework. 
 
GOK. (2000) Kilifi District Development Plan. 
 
Gomes Mda M, Maia Filho Hde S & Noe RA. (1998) Anti-epileptic drug intake adherence. The 
value of the blood drug level measurement and the clinical approach. Arq Neuropsiquiatr 
56( December (4)): 708-13. 
 
Good B. (1986) Explanatory models and care-seeking: a critical account. In: S Mchugh, TM 
Vallis (Eds).  Illness behaviour: a multidisciplinary model. New York, NY: Plenum. 
 
Good B & Delvecchio M. (1981) The meaning of symptoms: A cultural hermeneutic model of 
clinical practice.  In: L Esienberg, A Kleinman(Eds.  The relevance of social science for 
medicine. Hingham,MA: Kluwer Boston. 
 
Goodman SN. (1989) Meta-analyses and evidence. Control Clin Trials 10: 188 - 204. 
 
Gordon E & Devinsky O. (2001) Alcohol and marijuana: effects on epilepsy and use by patients 
with epilepsy. Epilepsia 42(10): 1266-72. 
 
Gourie-Devi M, Satishchandra P & Gururaj G. (2003) Epilepsy control program in India: a 
district model. Epilepsia 44 Suppl 1: 58-62. 
 
Green EC. (1999a) The Involvement of African Traditional Healers in the prevention of AIDS 
and STDs " in Hahn, R.A., Anthropology in Public Health: Bridging Differences in 
Culture and Society.  Oxford Univ. Press.: 63-83. 
 
Green EC. (1999b) Involving healers. AIDS Action (46): 3. 
 
Green L & Kreuter M. (1991) Health Promotion Planning: an Educational and Environmental 
Approach. Mountain VIew, CA: Mayfield. 
 
Greenhalgh T. (2001) How to Read a Paper. The Basics of Evidence-based Medicine. 2nd 
edition. London. BMJ. 
 
Greenland S. (1994) Quality scores are useless and potentially misleading. Am J Epidemiology 
140: 300-2. 
 
Habib OS & Vaughan JP. (1986) The determinants of health services utilization in southern Iraq: 
a household interview survey. Int J Epidemiol 15(3): 395-403. 
 
Hashmi SK, Afridi MB, Abbas K, Sajwani RA, Saleheen D, Frossard PM, Ishaq M, Ambreen A 
& Ahmad U. (2007) Factors associated with adherence to anti-hypertensive treatment in 
Pakistan. PLoS One 2(3): e280. 
 
Bibliography 
198 
 
Hassan NB, Hasanah CI, Foong K, Naing L, Awang R, Ismail SB, Ishak A, Yaacob LH, Harmy 
MY, Daud AH, Shaharom MH, Conroy R & Rahman AR. (2006) Identification of 
psychosocial factors of noncompliance in hypertensive patients. J Hum Hypertens 20(1): 
23-9. 
 
Hauser W, A,, Annergers JF & Kurkland LT. (1991) Prevalence of epilepsy in Rochester , 
Minnesotta. Epilepsia 32: 429-45. 
 
Hausmann-Muela S, Ribera JM & Nyamongo I. (2003) Health-seeking behaviour and the health 
system response. DCPP working paper No.14. 
 
Hausmann-Muela S, Ribera JM, Mushi AK & Tanner M. (2002) Medical syncretism with 
reference to malaria in a Tanzanian community. Social science & medicine (1982) 55(3): 
403-13. 
 
Haynes RB, McDonald HP & Garg  AX. (2002) Helping patients follow prescribed treatment: 
clinical applications. JAMA 288(22): 2880-3. 
 
Hazzard A, Hutchinson SJ & Krawiecki N. (1990) Factors related to adherence to medication 
regimens in pediatric seizure patients. J Pediatr Psychol 15(4): 543-55. 
 
Helde G, Bovim G, Brathen G & Brodtkorb E. (2005) A structured, nurse-led intervention 
program improves quality of life in patients with epilepsy: a randomized, controlled trial. 
Epilepsy Behav 7(3): 451-7. 
 
Helde G, Brodtkorb E, Brathen G & Bovim G. (2003) An easily performed group education 
programme for patients with uncontrolled epilepsy--a pilot study. Seizure 12(7): 497-501. 
 
Helgeson DC, Mittan R, Tan SY & Chayasirisobhon S. (1990) Sepulveda Epilepsy Education: 
the efficacy of a psychoeducational treatment program in treating medical and 
psychosocial aspects of epilepsy. Epilepsia 31(1): 75-82. 
 
Helman CG. (1994) Culture, Health and Illness.  An introduction for Health Professionals. 3rd 
edition. Oxford: Butterworth-Heinemann. 
 
Higgins JA. (2003) Measuring inconsistency in meta-analyses. BMJ. 327:: 557 - 60. 
 
Higgins JP & Thompson SG. (2002) Quantifying heterogeneity in a meta-analysis. Statist. Med 
21: 1539 - 58. 
 
Hillbom M, Pieninkeroinen I & Leone M. (2003) Seizures in alcohol-dependent patients: 
epidemiology, pathophysiology and management. CNS Drugs 17(14): 1013-30. 
 
Hoff W. (1997) Traditional health practitioners as primary health care workers. Trop Doct 27 
Suppl 1: 52-5. 
 
Bibliography 
199 
 
Holding PA, Taylor HG, Kazungu SD, Mkala T, Gona J, Mwamuye B, Mbonani L & Stevenson 
J. (2004) Assessing cognitive outcomes in a rural African population: development of a 
neuropsychological battery in Kilifi District, Kenya. J Int Neuropsychol Soc 10(2): 246-
60. 
 
Hong Z, Qu B, Wu XT, Yang TH, Zhang Q & Zhou D. (2009) Economic burden of epilepsy in a 
developing country: a retrospective cost analysis in China. Epilepsia 50(10): 2192-8. 
 
Horne R. (1997) Representations of medications and treatment: advances in theory and 
measurement.  In: Petrie KJ, Weinman J, eds.  Perceptions of health and illness: current 
research and application. London : Harwood 155-87. 
 
Horne R & Weinman J. (1999) Patients' beliefs about prescribed medicines and their role in 
adherence to treatment in chronic physical illness. Journal of psychosomatic research   
47(6): 555-67. 
 
ILAE. (1981) Proposal for revised clinical and electroencephalographic classification of epileptic 
seizures. From the Commission on Classification and Terminology of the International 
League Against Epilepsy. Epilepsia 22(4): 489-501. 
 
ILAE. (1985) Availability and distribution of antiepileptic drugs in developing countries. III and 
IV Commissions on Antiepileptic Drugs of the International League Against Epilepsy. 
Epilepsia 26(2): 117-21. 
 
ILAE. (1993) Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology 
and Prognosis, International League Against Epilepsy. Epilepsia 34(4): 592-6. 
 
ILAE. (2009) Commission Report. Revised terminology and concepts for organization of the 
epilepsies: Report of the Commission on Classification and Terminology. 
 
ILAE/IBE/WHO. (2003) Global Campaign Against Epilepsy "Out of the Shadows." 
 
Inoue Y, Fujiwara T, Matsuda K, Kubota H, Tanaka M, Yagi K, Yamamori K & Takahashi Y. 
(1997) Ring chromosome 20 and nonconvulsive status epilepticus. A new epileptic 
syndrome. Brain 120 ( Pt 6): 939-53. 
 
Jacoby A. (1992) Epilepsy and the quality of everyday life.  Findings from a study of people 
with well-controlled epilepsy. Social Science and medicine 34: 657-66. 
 
Jacoby A. (1994) Felt versus enacted stigma: a concept revisited. Evidence from a study of 
people with epilepsy in remission. Social science & medicine (1982) 38(2): 269-74. 
 
Jacoby A, Baker G, Smith D, Michael D & Chadwick D. (1993) Measuring the impact of 
epilepsy:the develoment of a novel scale. Epilepsy research 16: 83-8. 
 
Bibliography 
200 
 
Jacoby A, Snape D & Baker GA. (2005) Epilepsy and social identity: the stigma of a chronic 
neurological disorder. Lancet neurology 4(3): 171-8. 
 
Jallon P. (1997) Epilepsy in developing countries. Epilepsia 38(10): 1143-51. 
 
Jarvie S, Espie CA & Brodie MJ. (1993) The development of a questionnaire to assess 
knowledge of epilepsy: 1. General knowledge of epilepsy. Seizure 2: 179-85. 
 
Jilek-Aall. (1999) Morbus sacer in Africa: Some Religious Aspects of Epilepsy in Traditional 
Cultures. Epilepsia 40(3): 382-6. 
 
Jilek-Aall L, Jilek M, Kaaya J, Mkombachepa L & Hillary K. (1997) Psychosocial study of 
epilepsy in Africa. Social science & medicine (1982) 45(5): 783-95. 
 
Jilek-Aall L & Jilek WG. (1993) The influence of culture on epilepsy in East Africa. Curare 
16(3): 141-4. 
 
Jilek-Aall L & Rwiza HT. (1992) Prognosis of epilepsy in a rural African community: a 30-year 
follow-up of 164 patients in an outpatient clinic in rural Tanzania. Epilepsia 33(4): 645-
50. 
 
Jones RM, Butler JA, Thomas VA, Peveler RC & Prevett M. (2006) Adherence to treatment in 
patients with epilepsy: associations with seizure control and illness beliefs. Seizure 15(7): 
504-8. 
 
Josty IC, Narayanan V & Dickson WA. (2000) Burns in patients with epilepsy: changes in 
epidemiology and implications for burn treatment and prevention. Epilepsia 41(4): 453-6. 
 
Juni P, Witschi A, Bloch R & Egger M. (1999) The hazards of scoring the quality of clinical trial 
for meta-analysis. JAMA 282: 1054-60. 
 
Kale R. (2002) Global Campaign Against Epilepsy:the treatment gap. Epilepsia 43 Suppl 6: 31-
3. 
 
Kemp S, Feely M, Hay A, Wild H & Cooper C. (2007) Psychological factors and use of 
antiepileptic drugs:  Pilot work using an objective measure of adherence. Psychilogy, 
Health & Medicine 12(1): 107-13. 
 
KEMRI. (2005) Kenya Medical Research Institute (KEMRI). Centre for Geographic Medicine 
(Coast), Kilifi, Kenya. Census Division. Religious identification. 
 
Kendall-Taylor N. (2009) Treatment seeking for a chronic disorder: How families in Coastal 
Kenya make epilepsy treatment decisions. Human Organization 68(2): 141-3. 
 
Kendall-Taylor N, Kathomi C, Rimba K & Newton CR. (2008) Traditional healers and epilepsy 
treatment on the Kenyan coast. Epilepsia 49(9): 1638-9. 
Bibliography 
201 
 
 
Kendall-Taylor NH, Kathomi C, Rimba K & Newton CR. (2009) Comparing characteristics of 
epilepsy treatment providers on the Kenyan coast: implications for treatment-seeking and 
intervention. Rural Remote Health 9(4): 1253. 
 
Khan A, Huerter V, Sheikh SM & Thiele EA. (2004) Treatments and perceptions of epilepsy in 
Kashmir and the United States: a cross-cultural analysis. Epilepsy Behav 5(4): 580-6. 
 
Khan KS, Riet G, Glanville J, Sowden AJ & Kleijnen J. (2001) Undertaking Systematic Reviews 
of Research on effectiveness: CRD Guidelines for Those Carrying out or Commissioning 
Reviews, 2nd Edition, York Publishing Services, York. 
 
Kim YJ, Snyder B.O & Lai-Bitker AY. (1996) Culturally responsive psychiatric case 
management with Southeast Asians.  In: Manoleas P, editor.  The cross-cultural practice 
of clinical case management in mental health.  New York: Haworth Press. 145-68. 
 
Kleinman A. (1980) Patients and healers in the context of culture: an explanation of the 
borderland between anthropology, medicine, and psychiatry.  Berkeley, CA: University 
of California Press. 
  
Kloos H. (1990) Utilization of selected hospitals, health centres and health stations in central, 
southern and western Ethiopia. Social science & medicine (1982) 31(2): 101-14. 
 
Kobau R, Diiorio CA, Anderson LA & Price PH. (2006) Further validation and reliability testing 
of the Attitudes and Beliefs about Living with Epilepsy (ABLE) components of the CDC 
Epilepsy Program Instrument on Stigma. Epilepsy Behav 8(3): 552-9. 
 
Kossoff EH. (2008) International consensus statement on clinical implementation of the 
ketogenic diet: agreement, flexibility, and controversy. Epilepsia 49 Suppl 8: 11-3. 
 
Krishnamoorthy ES, Satishchandra P & Sander JW. (2003) Research in epilepsy: development 
priorities for developing nations. Epilepsia 44 Suppl 1: 5-8. 
 
Krousel-Wood M, Hyre A, Muntner P & Morisky D. (2005) Methods to improve medication 
adherence in patients with hypertension: current status and future directions. Curr Opin 
Cardiol 20(4): 296-300. 
 
Kwan P & Brodie MJ. (2002) Refractory epilepsy: a progressive, intractable but preventable 
condition? Seizure 11(2): 77-84. 
 
Kwan P & Sander JW. (2004) The natural history of epilepsy: an epidemiological view. J. 
Neurol. Neurosurg. Psychiatry 75: 1376-81. 
 
LaFrance WC, Jr., Kanner AM & Hermann B. (2008) Psychiatric comorbidities in epilepsy. Int 
Rev Neurobiol 83: 347-83. 
 
Bibliography 
202 
 
Landis JR & Koch GG. (1977) The measurement of observer agreement for categorical data. 
Biometrics 33: 159-74. 
 
Lee SA, Yoo HJ & Lee BI. (2005) Factors contributing to the stigma of epilepsy. Seizure 14(3): 
157-63. 
Leonardi M & Ustun TB. (2002) The global burden of epilepsy. Epilepsia 43 Suppl 6: 21-5. 
 
Leppik I. (1990) How to get patients with epilepsy to take their mediation. The problems of 
noncompliance. . Postgrad Med 88(July (1)): 253-6. 
 
Leppik IE. (1988) Compliance during treatment of epilepsy. Epilepsia 29 Suppl 2: S79-84. 
 
Levy R & Hollan D. (1998) Person-centered interviewing and observation in Anthropology. In: 
HR Bernard (Ed). Handbook of methods in cultural anthropology.  Walnut Creek, MD: 
Alta Mira Press. 
 
Levy RH, Mattson RH & Meldrum BS. (1995) Antiepileptic Drugs. 4th Edition. Raven Press, 
New York. 
 
Lewis S & Clarke M. (2001) Forest plots: trying to see wood and trees. BMJ 322: 1479 - 80. 
 
Ley P. (1987) Improving patients' understanding, recall, satisfaction and compliance.  In: Health 
Psychology-Processes and Applications(Ed A.K. Broome).  London, Chapman & Hall. 
74-102. 
 
Li LM, Fernandes PT, Noronha AL, Marques LH, Borges MA, Cendes F, Guerreiro CA, Zanetta 
DM, de Boer HM, Espindola J, Miranda CT, Prilipko L & Sander JW. (2007) 
Demonstration Project on Epilepsy in Brazil: situation assessment. Arq Neuropsiquiatr 
65 Suppl 1: 5-13. 
 
Liu L, Yiu CH, Yen DJ, Chou MH & Lin MF. (2003) Medication education for patients with 
epilepsy in Taiwan. Seizure 12(7): 473-7. 
 
Lowe-Pearce C & Camfield CS. (2005) Elementary school epilepsy survey (ESES): a new 
measure of elementary school students' knowledge and attitudes about epilepsy. Epilepsy 
Behav 7(4): 687-96. 
 
Lundgren T, Dahl J, Melin L & Kies B. (2006) Evaluation of acceptance and commitment 
therapy for drug refractory epilepsy: a randomized controlled trial in South Africa--a pilot 
study. Epilepsia 47(12): 2173-9. 
 
Mac TL, Le VT, Vu AN, Preux PM & Ratsimbazafy V. (2006) AEDs availability and 
professional practices in delivery outlets in a city center in southern Vietnam. Epilepsia 
47(2): 330-4. 
 
Bibliography 
203 
 
Mac TL, Tran DS, Quet F, Odermatt P, Preux PM & Tan CT. (2007) Epidemiology, aetiology, 
and clinical management of epilepsy in Asia: a systematic review. Lancet neurology 6(6): 
533-43. 
 
Manderson L. (1998) Applying medical anthropology in the control of infectious disease. Trop 
Med Int Health 3(12): 1020-7. 
 
Mani KS, Rangan G, Srinivas HV, Kalyanasundaram S, Narendran S & Reddy AK. (1998) The 
Yelandur study: a community-based approach to epilepsy in rural South India--
epidemiological aspects. Seizure 7(4): 281-8. 
 
Mani KS, Rangan G, Srinivas HV, Srindharan VS & Subbakrishna DK. (2001) Epilepsy control 
with phenobarbital or phenytoin in rural south India: the Yelandur study. Lancet 
357(9265): 1316-20. 
 
Mani KS, Sidharta P & Pickering C. (1994) Educational aspects in the education of health 
workers, patients, and the public. Viewpoints from south India, Indonesia and Kenya. 
Tropical and geographical medicine 46(3 Suppl): S34-6. 
 
Mani KS & Subbakrishna DK. (2003) Perspectives from a developing nation with special 
reference to rural areas. Epilepsia 44 Suppl 1: 55-7. 
 
Mansour ME, Lanphear BP & DeWitt TG. (2000) Barriers to asthma care in urban children: 
parent perspectives. Pediatrics 106(3): 512-9. 
 
Marinker M, Blenkinsopp A, Bond C, Briten N, Feely M & C G. (1997) From compliance to 
concordance:achieving shared goals in medicine taking London: Royal Pharmaceutical 
Society of Great Britain. 
 
Martiniuk AL, Speechley KN, Secco M & Karen Campbell M. (2007) Development and 
psychometric properties of the Thinking about Epilepsy questionnaire assessing 
children's knowledge and attitudes about epilepsy. Epilepsy Behav 10(4): 595-603. 
 
Mathews H & Hill CE. (1990) Applying cognitive decision theory to the study of regional 
patterns of illness treatment choice. American Anthropologist 92: 155-69. 
 
Matuja WB. (1990a) Epilepsy following non-missile head injury among African people in Dar es 
Salaam: a retrospective clinical analysis study. Afr J Med Med Sci 19(2): 89-92. 
 
Matuja WB. (1990b) Psychological disturbance in African Tanzanian epileptics. Tropical and 
geographical medicine 42(4): 359-64. 
 
May TW & Pfafflin M. (2002) The efficacy of an educational treatment program for patients 
with epilepsy (MOSES): results of a controlled, randomized study. Modular Service 
Package Epilepsy. Epilepsia 43(5): 539-49. 
 
Bibliography 
204 
 
Mbuba CK, Ngugi AK, Newton CR & Carter JA. (2008) The epilepsy treatment gap in 
developing countries: a systematic review of the magnitude, causes, and intervention 
strategies. Epilepsia 49(9): 1491-503. 
 
McGrath BB. (1999) Swimming from island to island: healing practice in Tonga. Med Anthropol 
Q 13(4): 483-505. 
 
McKenzie D. (2003) Measuring Inequality with asset Indicators. In: Working paper No. 042. 
Cambridge MA: Bureau for Research and Economic Analysis of Development, Center 
for International Development, Harvard University. 
 
Mclin WM & de Boer HM. (1995) Public perceptions about epilepsy. Epilepsia 36: 957-9. 
 
McMillen H. (2004) The adapting healer: pioneering through shifting epidemiological and 
sociocultural landscapes. Social science & medicine (1982) 59(5): 889-902. 
 
Medina MT, Duron RM, Martinez L, Osorio JR, Estrada AL, Zuniga C, Cartagena D, Collins JS 
& Holden KR. (2005) Prevalence, incidence, and etiology of epilepsies in rural 
Honduras: the Salama Study. Epilepsia 46(1): 124-31. 
 
Meegan ME, Conroy RM, Lengeny SO, Renhault K & Nyangole J. (2001) Effect on neonatal 
tetanus mortality after a culturally-based health promotion programme. Lancet 
358(9282): 640-1. 
 
Meinardi H, Scott RA, Reis R & Sander JW. (2001) The treatment gap in epilepsy: the current 
situation and ways forward. Epilepsia 42(1): 136-49. 
 
Mendizabal JE & Salguero LF. (1996) Prevalence of epilepsy in a rural community of 
Guatemala. Epilepsia 37(4): 373-6. 
 
Meyer AC, Dua T, Ma J, Saxena S & Birbeck G. (2010) Global disparities in the epilepsy 
treatment gap: a systematic review. Bull World Health Organ 88(4): 260-6. 
 
Mielke J, Adamolekun B, Ball D & Mundanda T. (1997) Knowledge and attitudes of teachers 
towards epilepsy in Zimbabwe. Acta Neurol Scand 96(3): 133-7. 
 
Miller NE & Dollard J. (1941) Social Learning and Imitation. New Haven: Yale University 
Press. 
 
Millogo A, Ratsimbazafy V, Nubukpo P, Barro S, Zongo I & Preux PM. (2004) Epilepsy and 
traditional medicine in Bobo-Dioulasso (Burkina Faso). Acta Neurol Scand 109(4): 250-
4. 
 
Mitchell WG, Scheier LM & Baker SA. (2000) Adherence to treatment in children with epilepsy: 
who follows "doctor's orders"? Epilepsia 41(12): 1616-25. 
 
Bibliography 
205 
 
Mohamed Y, Alias NN, Shuaib IL, Tharakan J, Abdullah J, Munawir AH & Naing NN. (2006) 
Referral of epileptic patients in North East Coast of West Malaysia an area with poor 
MRI coverage: an analysis. Southeast Asian J Trop Med Public Health 37(6): 1199-208. 
 
Montgomery MR, Gragnolati M, Burke KA & Paredes E. (2000) Measuring living standards 
with proxy variables. Demography 37(2): 155-74. 
 
Morisky DE, Green LW & Levine DM. (1986) Concurrent and predictive validity of a self-
reported measure of medication adherence. Med Care 24 (January (1)): 67-74. 
 
Morrel MJ. (2002) Stigma and epilepsy. Epilepsy Behav 3: 21-5. 
 
Moshi M, Kagashe G & Mbwambo. (2005) Plants used to treat epilepsy by tanzanian traditional 
healers. J of Ethnopharmacology 97: 327-36. 
 
Muller I, Smith T, Melor S, Rare L & Genton B. (1998) The effects of distance from home on 
attendance at a small rural health centre in Papua New Guinea. International Journal of 
Epidemiology 27: 878-84. 
 
Munyoki G, Edwards T, White S, Kwasa T, Chengo E, Kokwaro G, Odera VM, Sander JW, 
Neville BG & Newton CR. (2010) Clinical and neurophysiologic features of active 
convulsive epilepsy in rural Kenya: A population-based study. Epilepsia. 
 
Murray CJL & Lopez AD. (1994) Global comparative assessment inthe health sector: disease 
burden, expenditures, and intervention packages (collected articles from the Bulletin of 
the World Health Organization). Geneva, World Health Organization. 
 
Murthy JM, Yangala R & Srinivas M. (1998) The syndromic classification of the International 
League Against Epilepsy: a hospital-based study from South India. Epilepsia 39(1): 48-
54. 
 
Ndoye NF, Sow AD, Diop AG, Sessouma B, Sene-Diouf F, Boissy L, Wone I, Toure K, Ndiaye 
M, Ndiaye P, de Boer H, Engel J, Mandlhate C, Meinardi H, Prilipko L & Sander JW. 
(2005) Prevalence of epilepsy its treatment gap and knowledge, attitude and practice of 
its population in sub-urban Senegal an ILAE/IBE/WHO study. Seizure 14(2): 106-11. 
 
Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, Whitney A & Cross 
JH. (2008) The ketogenic diet for the treatment of childhood epilepsy: a randomised 
controlled trial. Lancet neurology 7(6): 500-6. 
 
Neumark Y, Palti H, Donchin M & Ellencweig AY. (1992) Utilization of pediatric health 
services in Jerusalem. J Community Health 17(5): 271-82. 
 
Ngubane H. (1981) Aspects of clinical practice and traditional organization of indigenous healers 
in South Africa. Social science & medicine 15(3): 361-5. 
 
Bibliography 
206 
 
Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW & Newton CR. (2010) Estimation of the 
burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 51(5): 883-
90. 
 
Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW & Newton CR. (In preparation) Prevalence 
and incidence of epilepsy in Kilifi, Kenya. 
 
Ngugi AK, Symon MK, Christian B, Immo K, Josemir WS & Charles RN. (In press) Incidence 
of Epilepsy: A systematic review and meta-analysis. 
 
Nicoletti A, Reggio A, Bartoloni A, Failla G, Sofia V, Bartalesi F, Roselli M, Gamboa H, 
Salazar E, Osinaga R, Paradisi F, Tempera G, Dumas M & Hall AJ. (1999) Prevalence of 
epilepsy in rural Bolivia: a door-to-door survey. Neurology 53(9): 2064-9. 
 
Nilsson L, Farahmand BY, Persson PG, Thiblin I & Tomson T. (1999) Risk factors for sudden 
unexpected death in epilepsy: a case-control study. Lancet 353(9156): 888-93. 
 
Noor AM, Zuvorac D, Hay SI, Ochola SA & Snow RW. (2003) Defining equity in physical to 
clinical services using geographic information systems as part of malaria planning and 
monitoring in Kenya. Trop Med Int Health 8: 917-26. 
 
Noronha AL, Borges MA, Marques LH, Zanetta DM, Fernandes PT, de Boer H, Espindola J, 
Miranda CT, Prilipko L, Bell GS, Sander JW & Li LM. (2007) Prevalence and pattern of 
epilepsy treatment in different socioeconomic classes in Brazil. Epilepsia 48(5): 880-5. 
 
Noronha AL, Marques LH, Borges MA, Cendes F, Guerreiro CA & Min LL. (2004) Assessment 
of the epilepsy treatment gap in two cities of south-east of Brazil. Arq Neuropsiquiatr 
62(3B): 761-3. 
 
Nubukpo P, Preux PM, Houinato D, Radji A, Grunitzky EK, Avode G & Clement JP. (2004) 
Psychosocial issues in people with epilepsy in Togo and Benin (West Africa) I. Anxiety 
and depression measured using Goldberg's scale. Epilepsy Behav 5(5): 722-7. 
 
Nunnally J & Bernstein IH. (1994) Psychometric theory.  New York:Mc-Graw-Hill. 
 
Nyamae PK & Biritwum RB. (1997) Epilepsy: knowledge, attitude and practice in literate urban 
population, Accra, Ghana. West Afr J Med 16: 139-45. 
 
Olley BO. (2004) Psychosocial and seizure factors related to depression and neurotic-disorders 
among patients with chronic epilepsy in Nigeria. Afr J Med Med Sci 33(1): 39-44. 
 
Olley BO, Osinowo HO & Brieger WR. (2001) Psycho-educational therapy among Nigerian 
adult patients with epilepsy: a controlled outcome study. Patient Educ Couns 42(1): 25-
33. 
 
Oppong AC. (1989) Healers in transition. Social science & medicine (1982) 28(6): 605-12. 
Bibliography 
207 
 
 
Osterberg L & Blaschke T. (2005) Drug therapy: Adherence to Medication N Engl J Med 353: 
487-97. 
 
Pal D, Carpio A & Sander JWAS. (2000a) Neurocysticercosis and epilepsy in developing 
countries. J Neurol Neurosurg Psychiatry 68: 137-43. 
 
Pal DK, Das T, Chaudhury G, Johnson AL & Neville BG. (1998) Randomised controlled trial to 
assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 
351(9095): 19-23. 
 
Pal DK, Das T & Sengupta S. (2000b) Case-control and qualitative study of attrition in a 
community epilepsy programme in rural India. Seizure 9(2): 119-23. 
 
Pal DK, Das T, Sengupta S & Chaudhury G. (2002) Help-seeking patterns for children with 
epilepsy in rural India: implications for service delivery. Epilepsia 43(8): 904-11. 
 
Panter-Brick C, Clarke SE, Lomas H, Pinder M & Lindsay SW. (2006) Culturally compelling 
strategies for behaviour change: a social ecology model and case study in malaria 
prevention. Social science & medicine (1982) 62(11): 2810-25. 
 
Parkin DJ. (1968) Medicines and men of influence. Man 3(3): 424-39. 
 
Parkin DJ. (1970) Politics of ritual syncretism: Islam among the Non-Muslim Giriama of Kenya. 
J of the International African Institute 40(3): 217-33. 
 
Parkin DJ. (1972) Palms, wine, and witnesses: public spirit and private gain in an African 
farming community. San Francisco, CA: Chandler. 
 
Parkin DJ. (1989) Swahili Mijikenda: facing both ways in Kenya. . J of the International African 
Institute 59(2): 161-75. 
 
Parkin DJ. (1991) Sacred void: spatial images of work and rituals among the Giriama of Kenya. 
Cambridge: Cambridge University Press. 
 
Paschal AM, Hawley SR, St Romain T & Ablah E. (2008) Measures of adherence to epilepsy 
treatment: review of present practices and recommendations for future directions. 
Epilepsia 49(7): 1115-22. 
 
Paul A, Michael FG, David JM & David WR. Geographic Information Systems and Science. 2nd 
edition.  John Wiley and Sons Ltd. 
 
Perez-Cuevas R, Guiscafre H, Romero G, Rodriguez L & Gutierrez G. (1996) Mothers' health-
seeking behaviour in acute diarrhoea in Tlaxcala, Mexico. J Diarrhoeal Dis Res 14(4): 
260-8. 
 
Bibliography 
208 
 
Phillips KA, Morrison KR, Andersen R & Aday LA. (1998) Understanding the context of 
healthcare utilization: assessing environmental and provider-related variables in the 
behavioral model of utilization. Health services research 33(3 Pt 1): 571-96. 
 
Pillai RK, Williams SV, Glick HA, Polsky D, Berlin JA & Lowe RA. (2003) Factors affecting 
decisions to seek treatment for sick children in Kerala, India. Social science & medicine 
(1982) 57(5): 783-90. 
 
Placencia M, Farmer PJ, Jumbo L, Sander JW & Shorvon SD. (1995) Levels of stigmatization of 
patients with previously untreated epilepsy in northern Ecuador. Neuroepidemiology 
14(3): 147-54. 
 
Placencia M, Sander JW, Roman M, Madera A, Crespo F, Cascante S & Shorvon SD. (1994) 
The characteristics of epilepsy in a largely untreated population in rural Ecuador. J 
Neurol Neurosurg Psychiatry 57(3): 320-5. 
 
Placencia M, Sander JW, Shorvon SD, Ellison RH & Cascante SM. (1992) Validation of a 
screening questionnaire for the detection of epileptic seizures in epidemiological studies. 
Brain 115 ( Pt 3): 783-94. 
 
Placencia M, Sander JW, Shorvon SD, Roman M, Alarcon F, Bimos C & Cascante S. (1993) 
Antiepileptic drug treatment in a community health care setting in northern Ecuador: a 
prospective 12-month assessment. Epilepsy Res 14(3): 237-44. 
 
Pratt RJ, Robinson N, Loveday HP, Pellowe CM, Franks PJ, Hankins M & Loveday C. (2001) 
Adherence to antiretroviral therapy: appropriate use of self-reporting in clinical practice. 
HIV Clin Trials 2(2): 146-59. 
 
Preux PM. (2000) [Questionnaire in a study of epilepsy in tropical countries]. Bulletin de la 
Societe de pathologie exotique (1990) 93(4): 276-8. 
 
Preux PM & Druet-Cabanac M. (2005) Epidemiology and aetiology of epilepsy in sub-Saharan 
Africa. Lancet neurology 4(1): 21-31. 
 
Preux PM, Tiemagni F, Fodzo L, Kandem P, Ngouafong P, Ndonko F, Macharia W, Dongmo L 
& Dumas M. (2000) Antiepileptic therapies in the Mifi Province in Cameroon. Epilepsia 
41(4): 432-9. 
 
Quinn N. (1978) Do mfantse fish sellers estimate probabilities in their heads. American 
Ethnologist 5: 206-26. 
 
Quinn N & Holland D. (1987) Culture and cognition. In: Holland D, Quinn N (Eds). Cultural 
models in language and thought.  Cambridge University Press. 
 
Radhakrishnan K. (2009) Epilepsy surgery in India. Neurol India 57(1): 4-6. 
 
Bibliography 
209 
 
Radhakrishnan K, Pandian JD, Santhoshkumar T, Thomas SV, Deetha TD, Sarma PS, 
Jayachandran D & Mohamed E. (2000) Prevalence, knowledge, attitude, and practice of 
epilepsy in Kerala, South India. Epilepsia 41(8): 1027-35. 
 
Rafael F, Houinato D, Nubukpo P, Dubreuil CM, Tran DS, Odermatt P, Clement JP, Weiss MG 
& PM P. (2010) Sociolcultural and psychological features of perceived stigma reported 
by people with epilepsy in Benin. Epilepsia: 1-8. 
 
Rajbhandari KC. (2004) Epilepsy in Nepal. Can J Neurol Sci 31(2): 257-60. 
 
Ramaratnam S, Baker GA & Goldstein LH. (2008) Psychological treatments for epilepsy. 
Cochrane database of systematic reviews (Online) (3): CD002029. 
 
Ray BK, Bhattacharya S, Kundu TN, Saha SP & Das SK. (2002) Epidemiology of epilepsy--
Indian perspective. J Indian Med Assoc 100(5): 322-6. 
 
Reilley B, Abeyasinghe R & Pakianathar MV. (2002) Barriers to prompt and effective treatment 
of malaria in northern Sri Lanka. Trop Med Int Health 7(9): 744-9. 
 
Reis R. (1994) Anthropological aspects. Tropical and geographical medicine 46(3 Suppl): S37-
9. 
 
Reis R & Meinardi H. (2002) ILAE/WHO "Out of the Shadows Campaign" Stigma: does the 
flag identify the cargo? Epilepsy Behav 3(6S2): 33-7. 
 
Reutens DC, Howell RA, Gebert KE & Berkovic SF. (1992) Validation of a questionnaire for 
clinical seizure diagnosis. Epilepsia 33(6): 1065-71. 
 
Reynolds EH. (2000) The ILAE/IBE/WHO Global Campaign against Epilepsy: Bringing 
Epilepsy "Out of the Shadows". Epilepsy Behav 1(4): S3-S8. 
 
Reynolds EH. (2001) ILAE/IBE/WHO Global Campaign "out of the shadows": global and 
regional developments. Epilepsia 42(8): 1094-100. 
 
Reynolds EH. (2002a) The ILAE/IBE/WHO epilepsy global campaign history. International 
League Against Epilepsy. International Bureau for Epilepsy. Epilepsia 43 Suppl 6: 9-11. 
 
Reynolds EH. (2002b) Introduction: epilepsy in the world. Epilepsia 43 Suppl 6: 1-3. 
 
Ritchie J & Spencer E. (1994) Qualitative data analysis for applied policy research. In, Bryman, 
A and Burgess RG (eds.). Analyzing Qualitative Data. London: Routledge. 
 
Rosenstock IM. (1966) Why people use health services. Milbank Mem Fund Q 44(3): Suppl:94-
127. 
 
Bibliography 
210 
 
Rosenstock IM. (1974) Historical Origins of the Health Belief Model. Health Education 
Monographs Vol. 2 No. 4. 
 
Rubin DB. (1976) Inference and Missing Data. Biometrika 63 (3): 581-92. 
 
Rwiza HT, Matuja WB, Kilonzo GP, Haule J, Mbena P, Mwang'ombola R & Jilek-Aall L. 
(1993) Knowledge, attitude, and practice toward epilepsy among rural Tanzanian 
residents. Epilepsia 34(6): 1017-23. 
 
Ryan R, Kempner K & Emlen AC. (1980) The stigma of epilepsy as a self concept. Epilepsia 21: 
433-44. 
 
Sander J, W. Prevention of epilepsy. In: Shorvon SD et al, eds.  The management of epilepsy in 
developing countries: an  ICBERG manual.  London, Royal Society of Medicine, 1991.  
International Congress and Symposium Series, No. 175:19-21. 
 
Sander JW. (2002) Global Campaign Against Epilepsy. Overview of the demonstration projects. 
Epilepsia 43 Suppl 6: 34-6. 
 
Sander JWAS & Sharvon S. (1996) Epidemiology of the epilepsies. J of Neurology, 
Neurosurgery and Psychiatry 61: 433-43. 
 
Sawhney IM, Lekhra OP, Shashi JS, Prabhakar S & Chopra JS. (1996) Evaluation of epilepsy 
management in a developing country: a prospective study of 407 patients. Acta Neurol 
Scand 94(1): 19-23. 
 
Scambler G & Hopkins A. (1986) Becoming epileptic: coming to terms with stigma. Social 
Health Illn 8: 26-43. 
 
Scambler G & Hopkins A. (1988) Accomodating epilepsy in families.  In:Living with Chronic 
Illness:The experience of patients and their families (Eds R. Anderson and M. Bury).  
London, Allen & Unwin. 156-76. 
 
Schellenberg JA, Victora CG, Mushi A, de Savigny D, Schellenberg D, Mshinda H & Bryce J. 
(2003) Inequities among the very poor: health care for children in rural southern 
Tanzania. Lancet 361(9357): 561-6. 
 
Scott RA, Lhatoo SD & Sander JW. (2001) The treatment of epilepsy in developing countries: 
where do we go from here? Bull World Health Organ 79(4): 344-51. 
 
Seema V & Lilani K. (2006) Constructing socio-economic status indices:how to use principal 
components analysis. Health Policy and Planning 21(6): 459-68. 
 
Senanayake N & Abeykoon P. (1984) Epilepsy in Sri Lanka: public awareness and attitudes. J 
Trop Med Hyg 87(2): 61-6. 
 
Bibliography 
211 
 
Seo JH & Kim HD. (2008) Cultural challenges in using the ketogenic diet in Asian countries. 
Epilepsia 49 Suppl 8: 50-2. 
 
Shakya G, Malla S, Shakya KN & Shrestha R. (2008) Therapeutic drug monitoring of 
antiepileptic drugs. JNMA J Nepal Med Assoc 47(171): 94-7. 
 
Shannon G, Bashshur RL & Metzner CA. (1969) The concept of distance as a factor in 
accessiblity and utilization of health care. Med Care Review 26: 143-61. 
 
Sher I, McGinn L, Sirey JA & Meyers B. (2005) Effects of caregivers' perceived stigma and 
causal beliefs on patients' adherence to antidepressant treatment. Psychiatr Serv 56(5): 
564-9. 
 
Shorvon S. (2009) Epilepsy. Oxford University Press Inc., New York. 
 
Shorvon SD. (1990) Epidemiology, classification, natural history, and genetics of epilepsy. 
Lancet 336(8707): 93-6. 
 
Shorvon SD & Farmer PJ. (1988) Epilepsy in developing countries: a review of epidemiological, 
sociocultural, and treatment aspects. Epilepsia 29 Suppl 1: S36-54. 
 
Singh R, Gardner RJ, Crossland KM, Scheffer IE & Berkovic SF. (2002) Chromosomal 
abnormalities and epilepsy: a review for clinicians and gene hunters. Epilepsia 43(2): 
127-40. 
 
Snead K, Ackerson J, Bailey K, Schmitt MM, Madan-Swain A & Martin RC. (2004) Taking 
charge of epilepsy: the development of a structured psychoeducational group intervention 
for adolescents with epilepsy and their parents. Epilepsy Behav 5(4): 547-56. 
 
Somoza MJ, Forlenza RH, Brussino M & Liliana L. (2005) Epidemiological survey of epilepsy 
in the primary school population in Buenos Aires. Neuroepidemiology 25: 62-8. 
 
Sreeramareddy CT, Shankar RP, Sreekumaran BV, Subba SH, Joshi HS & Ramachandran U. 
(2006) Care seeking behaviour for childhood illness--a questionnaire survey in western 
Nepal. BMC Int Health Hum Rights 6: 7. 
 
Sridharan R. (2002) Epidemiology of epilepsy. Current science 82(6): 664-70. 
 
Stack RJ, Bundy CE, Elliot RA, New JP, Gibson M & Noyce PR. (2010) Intentional and 
unintentional non-adherence in community dwelling people with type 2 diabetes: the 
effect of varying numbers of medicines. Br J Diabetes Vasc 10: 148-52. 
 
Stanaway L, Lambie DG & Johnson RH. (1985) Non-compliance with anticonvulsant therapy as 
a cause of seizures. N Z Med J 98(March (774)): 150-2. 
 
Bibliography 
212 
 
Stephenson BJ, Rowe BH, Haynes RB, Macharia WM & Leon G. (1993) The rational clinical 
examination. Is this patient taking the treatment as prescribed? JAMA 269(21): 2779-81. 
 
Stephenson J & Imrie J. (1998) Why do we need randomised controlled trials to assess 
behavioural interventions? BMJ 316: 611-13. 
 
Stock R. (1983) Distance and the utilization of health facilities in rural Nigeria. Social science & 
medicine (1982) 17(9): 563-70. 
 
Streatfield K, Singarimbun M & Diamond I. (1990) Maternal education and child immunization. 
Demography 27(3): 447-55. 
 
Sue S. (1998) In search of cultural competence in psychotherapy and counseling. The American 
psychologist 53(4): 440-8. 
 
Sussman LK. (1981) Unity in diversity in a polyethnic society: the maintenance of medical 
pluralism on Mauritius. Soc Sci Med B 15(3): 247-60. 
 
Taylor S, Tudur SC, Williamson PR & Marson AG. (2001) Phenobarbitone versus phenytoin 
monotheraphy for partial onset seizures and Generalized onset tonoc-clonic seizures. 
Cochrane database of systematic reviews (Online): CD002217. 
 
Teasell R, Bayona N, Lippert C, Villamere J & Hellings C. (2007) Post-traumatic seizure 
disorder following acquired brain injury. Brain Inj 21(2): 201-14. 
 
Thind A & Andersen R. (2003) Respiratory illness in the Dominican Republic: what are the 
predictors for health services utilization of young children? Social Science and medicine 
56: 1173-82. 
 
Thind A & Cruz AM. (2003) Determinants of children's health services utilization in the 
Philippines. J Trop Pediatr 49(5): 269-73. 
 
Thorbecke R. (1988) Measurement of compliance through patient interviews. Epilepsy research 
1: 79-83. 
 
Tonini C, Beghi E, Berg AT, Bogliun G, Giordano L, Newton RW, Tetto A, Vitelli E, Vitezic D 
& Wiebe S. (2004) Predictors of epilepsy surgery outcome: a meta-analysis. Epilepsy Res 
62(1): 75-87. 
 
Trostle J. (1988a) Doctors' orders and patients' self-interest: two views of medication usage? 
Epilepsy research 1: 57-69. 
 
Trostle JA. (1988b) Medical compliance as an ideology. Social science & medicine (1982) 
27(12): 1299-308. 
 
Bibliography 
213 
 
TudurSmith C, Marson AG, Clough HE & Williamson PR. (2002) Carbamazepine versus 
phenytoin monotherapy for epilepsy. Cochrane database of systematic reviews (Online) 
CD001911. 
 
TudurSmith C, Marson AG & Williamson PR. (2001) Phenytoin versus valproate monotherapy 
for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane database 
of systematic reviews (Online) CD002217. 
 
TudurSmith C, Marson AG & Williamson PR. (2003) Carbamazepine versus phenobarbitone 
monotherapy for epilepsy. Cochrane database of systematic reviews (Online) CD001904. 
 
Turner BJ & Hecht FM. (2001) Improving on a coin toss to predict patient adherence to 
medications. Ann intern Med 134(10): 1004-6. 
 
Ukwe C, Ekechukwu OI, Udeogaranya OP & Iwuamadi UI. (2010) Self reported adherence to 
HAART in South-Eastern Nigeria is related to patient's use of pill box. J of Social 
Aspects of HIV/AIDS 7: 10-5. 
 
Usiskin SC. (1993) The role of counselling in an out-patient epilepsy clinic: a three year study. 
Seizure 2(2): 111-4. 
 
Van R. (1972) Epilepsy in Varanasi (India). Epilepsia 13: 113-8. 
 
Vik C, Maxwell CJ, Hogan DB, Patten SB, Johnson JA & Slack LR. (April 2005) Assessing 
medication adherence among older persons in community settings. J clin pharmacol 12 
(1): e152-e64. 
 
Walker A. (1972) Current status of in some developing countries. Epilepsia 13: 99-106. 
 
Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H & Avorn J. (2002) Noncompliance with 
antihypertensive medications: the impact of depressive symptoms and psychosocial 
factors. J Gen Intern Med 17(7): 504-11. 
 
Wang W, et al. (2008) Global Campaign against epilepsy: assessment of a demonstration project 
in rural China. Bulletin of World Health Organization 86: 964-9. 
 
Wang WZ, Wu JZ, Ma GY, Dai XY, Yang B, Wang TP, Yuan CL, Hong Z, Bell GS, Prilipko L, 
de Boer HM & Sander JW. (2006) Efficacy assessment of phenobarbital in epilepsy: a 
large community-based intervention trial in rural China. Lancet neurology 5(1): 46-52. 
 
Wang WZ, Wu JZ, Wang DS, Dai XY, Yang B, Wang TP, Yuan CL, Scott RA, Prilipko LL, de 
Boer HM & Sander JW. (2003) The prevalence and treatment gap in epilepsy in China: 
an ILAE/IBE/WHO study. Neurology 60(9): 1544-5. 
 
Watts AE. (1989) A model for managing epilepsy in a rural community in Africa. Bmj 
298(6676): 805-7. 
Bibliography 
214 
 
 
Weinstein ND & Sandman PM. (2002) The precaution adoption process model. In K. Glanz, B. 
K. Rimer & F. M. Lewis (Eds.), Health behavior and health education: Theory, research, 
and practice (3rd ed., pp. 121-143). San Francisco: Jossey-Bass. 
 
Weisner C & Matzger H. (2002) A prospective study of the factors influencing entry to alcohol 
and drug treatment. J Behav Health Serv Res 29(2): 126-37. 
 
Weiss MG & Ramakrishna J. (2006) Stigma interventions and research for international health. 
Lancet 367(9509): 536-8. 
 
Westbrook LE, Bauman LJ & Shinnar S. (1992) Applying stigma theory to epilepsy: a test of a 
conceptual model. J Pediatr Psychol 17: 633–49. 
 
WHO. (1976) African Traditional Medicine, AFRO Technical Report Series(1). Brazzaville: 
WHO Regional office for Africa. 
 
WHO. (1978) Declaration of the Alma-Ata. Report of the International Conference on Primary 
Health Care. Alma-Ata USSR. 6–12 September. Geneva, WHO. 
 
WHO. (1985) Community control of epilepsy: report of an informal consultation for the 
development of a strategy and protocol.  World Health Organization, Geneva. 
 
WHO. (1990) Initiative of support to people with epilepsy. Geneva: WHO. 
 
WHO. (1997) Epilepsy: social consequences and economic aspects. Fact Sheet 166. WHO Press 
Office. 
 
WHO. (2000) The global campaign against epilepsy-out of the shadows. Geneva: WHO  
 
WHO. (2003) Adherence to long-term therapies: evidence for action. 
 
WHO. (2004) Epilepsy in the WHO African Region. Bridging the Gap. WHO Press. 
 
WHO. (2005) Epilepsy Atlas: Epilepsy Care in the World. WHO Press. 
 
WHO. (2006) Neurological Disorders. Public Health Challenges. WHO Press. 
 
WHO. (2007) Diseases of the nervous system.  International classification of diseases and related  
health problems.  Geneva: WHO. pp G00-G99. 
 
Whyte SR. (1995) Constructing epilepsy: images and context in East Africa. In: Ingstad B, 
Whyte SR, editors. Disability and culture.  Berkely and Los Angeles (CA): University of 
California Press.: 226-45. 
 
Bibliography 
215 
 
Wieshmann UC. (2003) Clinical application of neuroimaging in epilepsy. J Neurol Neurosurg 
Psychiatry 74(4): 466-70. 
 
Wohlrab GC, Rinnert S, Bettendorf U, Fischbach H, Heinen G, Klein P, Kluger G, Jacob K, 
Rahn D, Winter R & Pfafflin M. (2007) famoses: A modular educational program for 
children with epilepsy and their parents. Epilepsy Behav 10(1): 44-8. 
 
Wolinsky FD. (1978) Assessing the effects of predisposing, enabling, and illness-morbidity 
characteristics on health service utilization. J Health Soc Behav 19(4): 384-96. 
 
World Bank. (1993) Investing in health: World development indicators; New York :Oxford 
University Press. 
Yamatogi Y. (2004) Principles of antiepileptic drug treatment of epilepsy. Psychiatry and 
clinical neurosciences 58(3): S3-6. 
 
Young J & Garro L. (1994) Medical Choice in a Mexican Village,  New Brunswick, NJ:Rutgers 
University Press. 
 
Young JC. (1981) Medical Choice in a Mexican Village. New Brunswick, NJ: Rutgers 
University Press. 
 
 
 
 
Appendices 
216 
 
APPENDIX I 
 
STRUCTURED QUESTIONNAIRES 
 
PART 1: PERSONAL DETAILS 
 
Today’s date: ---------------------------------- [   ][   ]/[   ][   ]/[   ][   ][   ][   ]  (TDATE)                     
 
Name: ---------------------------------------------------------------------------------- (NAME) 
 
PID No: ------------------------------------------------------ [   ][   ][   ][   ][   ][   ][   ](PID) 
 
EZHHID: ---------------------------------------------------- [   ][   ][   ][   ][   ][   ](RESID) 
 
DOB: ------------------------------------------------- [   ][   ]/[   ][   ]/[   ][   ][   ][   ] (DOB) 
 
Age: -------------------------------------------------------------------------- [   ][   ][   ] (AGE) 
 
Sex: -------------------------------------------------------------------      [   ] (SEX) 
 
Respondent’s name: ------------------------------------------------------------------- (RNAME) 
 
Relationship to index: ---------------------------------------------------------- [    ]  (RELAT) 
 
1. Mother   
2. Father   
3. Guardian       
4. Self 
 
Informed consent obtained:                        Y/N [     ] (ICO) 
 
Questionnaires completed: 
 
 
Questionnaire Date of 
interview 
Start time End time Total time Inter 
initials 
1. SOCIAL DEMO /        / [   ][   ]:[   ][   ]           [ ][   ]:[   ][   ]           [ ][   ]:[   ][   ]            
2. SES /        /     
3. ACCESSIBILITY /        /     
4. ADHERENCE /        /     
5. STIGMA /        /     
6. EBAS /       /     
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PART 2: SOCIO DEMOGRAPHIC INFORMATION 
 
Question Response Code 
1. Religion (RELIG) 
 
1. Catholic    
2. Protestant    
3. Islam  
4. Traditional    
5. None    
6. Other (specify) 
[      ] 
2. Education level (EDULEV) 1. None 
2. Nursery 
3. Primary finished 
4. Primary Not finished 
5. Secondary finished 
6. Secondary Not finished 
7. College 
8. University 
9. Other (specify) 
[      ] 
3. Occupation (OCCUP) 
 
1. Farmer 
2. Trader/Business 
3. Casual labourer 
4. Fisher man 
5. Professional 
6. Student 
7. Other (specify) 
[      ] 
4. Marital status (MARST) 1. Never married     
2. Married    
3. Separated     
4. Divorced    
5. Widowed 
[      ] 
5. Number of siblings in the family (SIBL) 
 
 
Number [      ] 
6. Position of sibling with epilepsy in the   
    family (PSIBL) 
1. First born  
2. Middle 
3. Last born  
[      ] 
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PART 3: ASSETS AND OTHER INDICATORS OF SOCIAL ECONOMIC STATUS 
 
Question (Type of asset) 
 
Response  
1=Yes   0=No 
How many? 
Goats [      ] [      ] 
Cows  [      ] [      ] 
Chickens/Ducks [      ] [      ] 
Other livestock (specify) [      ] [      ] 
 
Radio [      ] 
Television sets [      ] 
Video machine [      ] 
Fridges/freezers [      ] 
Cookers (electricity/gas) [      ] 
Telephone/mobile phones [      ] 
 
Bicycle (adult) [      ] 
Motor bike  [      ] 
Car or truck [      ] 
 
Land/ Plot [      ] 
 
Question Response Code 
1. What are the walls of the main dwelling (house)  
     predominantly made of? (WALL) 
1. Stone 
2. Brick/Blocks 
3. Mud 
4. Wood  
5. Cement  
6. Iron sheets  
7. Tin 
8. Grass/Straw 
9. Other (specify) 
   
[      ] 
 
2. What is the roof of the main dwelling   
     Predominantly made of? (ROOF) 
1. Iron sheets 
2. Tiles 
3. Concrete 
4. Makuti 
5. Grass 
6. Tin 
7. Other (specify) 
 
[      ]    
3. What is the floor of the main dwelling  
     predominantly made of? (FLOOR) 
1. Cement  
2. Tiles 
3. Wood 
4. Mud/Earth 
5. Other  
 
[      ] 
 
4. Does your household own the land on which the  
    structure (house) sits (OWNLAND) 
 
 
 
1. Owns 
2. Pays rent 
3. No rent with consent from 
owner 
4. No rent, squatting 
 
[      ] 
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Question Response Code 
5. What is the main source of water for  
members of your household? (SWATER) 
1. Piped into house 
2. Piped into 
plot/compound 
3. Public tap 
4. Open well in compound 
5. Open public well 
6. Covered well in 
compound 
7. Covered public well 
8. River/Stream 
9. Lake/pond 
10. Dam 
11. Other (specify) 
 
[      ] 
6. How frequently is water available from this  
source? (FWATER) 
1. Always available 
2. Several hours per day 
3. Once or twice a week 
4. Infrequently  
 
[      ] 
7. What kind of toilet facility does your household  
have? (TOILET) 
1. Flush toilet 
2. Traditional pit latrine 
3. Ventilated Pit latrine 
(VIP) 
4. Free range (bush) 
5. Other (specify) 
 
[      ] 
 
8. What is the household‘s main source of cooking 
fuel? (FUEL) 
1. Firewood  
2. Kerosene  
3. Electricity 
4. Gas 
5. Charcoal 
6. Dung  
7. Other (specify) 
[      ] 
[      ] 
[      ] 
 
9. What is the household‘s main source of lighting?  
(LIGHT) 
1. Pressure lamp 
2. Kerosene lamp 
3. Tin lamp 
4. Electricity 
5. Firewood  
6. Solar 
7. Candles 
8. Other (specify) 
 
[      ] 
[      ] 
[      ] 
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PART 4: ACCESSIBILITY OF HEALTH SERVICES 
 
Question Response Code 
1.  Have you ever sought epilepsy treatment from a  
     health facility? (STREAT) No go to Sec 4 
1. Yes 
0. No 
[      ]   
 
2.  From which health facility do you seek epilepsy 
     Treatment? (HFACIL)    
    
1.  Bomani dispensary 
2.  Chasimba dispensary 
3.  Junju dispensary 
4.  Jaribuni dispensary 
5.  Kilifi district hospital 
6.  Kizingo dispensary 
7.  Matsangoni dispensary 
8.  Mtepeni dispensary 
9.  Mtwapa dispensary 
10. Ngerenya dispensary 
11. Pingilikani  dispensary 
12. Takaungu dispensary 
13. Vipingo health center 
14. KEMRI neuro clinic 
15. Other (specify) 
[      ]   
 
[      ]  
  
[      ]   
 
     
 
3.  Can the health facility be reached on foot?   
     (FOOT) No go to 5 
1. Yes 
0. No 
[      ]   
 
4.  How long does it take on foot? ( LFOOT) 
 
Minutes [      ] 
5.  Do you use a vehicle to reach the health facility? 
     (VEH) 
1. Yes 
0. No 
[      ] 
6. How long does it take by foot and vehicle?  
(LVEH) 
Minutes  [      ] 
 
7.  Does the amount of distance you have to cover  
     discourage you from seeking treatment? (DISTD) 
1. Always  
2. Sometimes  
3. Not at all 
[      ]   
 
8.  What is the total amount of fare used per person  
      to reach the health facility? (TFARE) 
Ksh [      ] 
 
9.  Does use of fare discourage you from seeking  
     treatment? (FARED) 
1. Always  
2. Sometimes  
3. Not at all 
[      ]   
 
10.  How long do you wait before you are attended to 
by a health provider? (LWPROV) 
Minutes [      ]   
 
11. How long do you spend with the health provider? 
(LSPROV) 
Minutes [      ]   
 
12. Do you feel the health provider gives you clear 
explanation about your medication? (CEXPLA) 
1. Always  
2. Sometimes  
3. Not at all 
[      ]   
 
13. What is the total amount of time you spend 
seeking treatment? (TTIME) 
Hours 
 
 
[      ]   
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Question Response Code 
14. Do you feel this is a long time? (FTIMEL) 1. Always  
2. Sometimes  
3. Not at all 
[      ]   
 
15. Does the total amount of time you spend 
discourage you from seeking treatment? 
(TTIMED) 
1. Always  
2. Sometimes  
3. Not at all 
[      ]   
 
16. Are epilepsy drugs always available in the health 
facility? (AEDS) 
1. Always  
2. Sometimes  
3. Not at all 
[      ]   
 
17. Does absence of epilepsy drugs discourage you 
from seeking treatment? (AEDSD) 
1. Always  
2. Sometimes  
3. Not at all 
[      ]   
 
18. Do you pay for epilepsy drugs? (PAY)               
No go to 20 
1. Yes 
0. No 
[      ]   
 
19. Does the cost of drugs discourage you from 
seeking treatment? (COSTD) 
1. Always  
2. Sometimes  
3. Not at all 
[      ]   
 
20. Overall are the epilepsy services at the health 
facility: (EPISER) 
1. Satisfactory    
2. Indifferent     
3. Unsatisfactory 
[      ]   
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PART 5: SEIZURE FREQUENCY, SEVERITY AND ADHERENCE 
 
Question Response Code 
1. How many years have u had seizures (YRSSEIZ) 
 
Years [      ] 
2. How often have you had seizures in the past 3 
    months? (OFTSEIZ) 
1. None 
2. 1-3  
3. 4-6 
4. >6 
[      ] 
3. How long do the seizures last? (LSEIZ) 1. Less than 5 minutes 
2. 5-10 minutes 
3. 11-20 minutes 
4. 21-30 minutes 
5. More than 30 minutes 
6. Don‘t  know 
[      ] 
4. Have you ever been seriously injured during a  
    seizure? (INJURE) No go to 6 
1. Yes 
0. No 
[      ] 
5.  If yes, specify the type of injury (TYINJURE) 
 
1. Burns 
2. Broken bones 
3. Cuts 
4. Bruises 
5. Other (specify) 
[      ] 
[      ] 
[      ] 
      
    
Thinking of the drugs used to control seizures, please answer the following questions: 
6.   Have you ever taken medication to control  
      seizures? (MED) No go to section 5 
1. Yes 
0. No 
[      ] 
7.  For how many years have you been taking  
     medication to control seizures? (YRSMED) 
1.<1 
2. 1-3 
3. 4-5 
4. >5 
[      ] 
 
8. How many types of seizure medication has the 
doctor prescribed for you? (TYMED) 
1. One 
2. Two 
3. Three 
4. Four 
[      ] 
 
9. How many times per day do you take your 
seizure medication? (TDAY) 
1. Once 
2. Twice 
3. Thrice 
4. Four times 
[      ] 
 
10. How many tablets do you take each day to 
control seizures? (NOTABS) 
1. 1-2 
2. 3-4 
3. 4-6 
4. >6 
[      ] 
 
11. How often do you take your seizure medication? 
(OFTMED) 
1. Regularly 
2. When seizures occur 
[      ] 
12. Have you ever skipped taking your seizure 
medication? (SKIPMED) No go to 14 
1.Yes 
0. No 
[      ] 
 
13.  Did you have a seizure when you skipped your 
seizure medication? (SKIPSEIZ) 
1.Yes 
0. No 
 
[      ] 
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Question Response Code 
14. Do you think skipping medication makes a 
      difference? (SKIPDIFF) 
1.Yes 
0. No 
[      ] 
 
15. Do you think your seizures are controlled?  
(SEIZCONT) 
1. Controlled   
2. Uncontrolled 
[      ] 
16. How long do you take to go for more seizure     
      drugs after the previous ones are over? (LAEDS) 
1. Before they are over 
2. The day they are over 
3. Up to one week after they   
    are over 
4. Up to one month after they  
     are  over 
[      ] 
Morisky Self Reported Medication Adherence Scale 
Question Response Code 
17 (a). Do you ever forget to take your medications? 
            (FORMED) 
1.Yes 
0. No 
[      ] 
17 (b). Are you careless at times about taking your  
             medication? (CARMED) 
1.Yes 
0. No 
[      ] 
17 (c). When you feel better, do you sometimes stop   
            taking your medication? (SBETTMED) 
1.Yes 
0. No 
[      ] 
17 (d). Sometimes, if you feel worse when you take  
            your medication, do you stop taking your   
            medication? (SWORMED) 
1.Yes 
0. No 
[      ] 
17 (e). Total Self Reported Medication Adherence  
           Score (a+b+c+d) (TSCORE) 
Total Score [      ] 
There are various factors that influence how people take medications prescribed to them by 
the doctor.  Thinking of your seizure medication, please answer the following questions: 
Question Response Code 
18. What encourages/reminds you to take your  
       epilepsy medications regularly (ENCMED) 
  
(a) Understanding instructions by the doctor (UNDINST) 
 
1.Yes 
0. No 
[      ] 
(b) Understanding need for long term treatment  
      (UNDNLTRE) 
 
― 
[      ] 
(c) Understanding the need of medication (UNDNMED) 
 
 
― 
[      ] 
(d) Understanding the effectiveness of medication 
      (UNDEFMED) 
 ― 
 
[      ] 
(e) Availability of family support system (FAMSUPP) 
 
― [      ] 
(f) Making medication a habit (MEDHAB) 
 
― [      ] 
(g) Accessibility /Availability of medication (ACCMED) 
 
― [      ] 
(h) Good patient-doctor relationship (GPDRELA) 
 
― [      ] 
(i) Keeping medication in sight (SIGHMED) 
 
― [      ] 
(j) Others (specify): 
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Question Response:  Code 
19. What might discourage you from taking your   
       seizure medication regularly (DISMED) 
  
(a) Misunderstanding instructions by the doctor 
     (MISINST) 
1.Yes 
0. No 
[      ] 
(b) Misunderstanding need for long-term treatment 
      (MISNLTRE) 
― [      ] 
(c) Lack of understanding of need of medication 
     (MISNMED) 
― [      ] 
(d) Lack of understanding of effectiveness of  
      Medication (MISEFMED) 
― [      ] 
(e) Continuity of seizures despite treatment 
     (CONSEIZ) 
― [      ] 
(f) Infrequent seizures (INFRSEIZ) 
 
― [      ] 
(g) Drug side effects (AEDSEFF) 
 
― [      ] 
(h) Lack of family support system (LFAMSUPP) 
 
― [      ] 
(i) Lack of access to medication (LACCMED) 
 
― [      ] 
(j) Fear of getting addicted to medication 
    (ADDMED) 
― [      ] 
(k) Cost of medication (COSTMED) 
 
― [      ] 
(l) Forgetting (FORGET) 
 
― [      ] 
(m) Dissatisfaction with treatment (DISSTRE) 
 
― [      ] 
(n) Traveling (TRAVEL) 
 
― [      ] 
(o) Others (specify): 
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PART 6: KILIFI STIGMA SCALE FOR EPILEPSY 
 
Question Response  Code 
Different diseases impact on people’s lives in one way or another.  Because of epilepsy: 
1. Do you feel different from other people? 
    (FDIFF)     
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
 
2. Do you feel lonely? (FLONE) 0. Not at all  
1. Sometimes  
2. Always 
[      ] 
 
3. Do you feel embarrassed? (FEMBAR) 0. Not at all  
1. Sometimes  
2. Always 
[      ] 
 
4. Do you feel disappointed in yourself? (FDISAPP) 0. Not at all  
1. Sometimes  
2. Always 
[      ] 
 
5. Do you feel you cannot have a rewarding life? 
    (FRLIFE) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
 
6. Do you feel you cannot contribute anything in  
    society (FCONSOC)  
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
 
7. Do you feel you cannot join others in public  
    places? (FPUBLIC) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
 
8. Do you feel other people are uncomfortable with  
    you? (FPUNCOMT) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
9. Do you feel other people would not want to go to  
    occasions with you? (FPOCCAS) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
 
10. Do you feel other people treat you like an  
      inferior person? (FPINFER) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
 
11. Do you feel other people would prefer to avoid 
      you? (FPAVOID) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
12. Do you feel other people would avoid to  
      exchange greetings with you? (FPGREET) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
13. Do you feel you do not relate well with family  
members? (FRELFAM) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
14. Do you feel you are not accepted by your peers? 
(FACCPEER) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
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15. Do you feel you are mistreated by other people? 
(FPMIST) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
16. Do you feel other people discriminate against  
you? (FPDISCR) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
 
17. Do you feel other people do not take you 
seriously? 
(FPLSERI) 
0. Not at all  
1. Sometimes  
2. Always 
[     ] 
 
18. Do you feel other people treat you like an 
outcast? (FPOTCAST) 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
Sometimes people fall victim of circumstances and find themselves in a helpless situation.  
Thinking about yourself: 
19. Have you ever been abused or beaten by  
anybody? (ABUSE) 
 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
20. Have u ever been sexually harassed? (SEXHR) 
 
0. Not at all  
1. Sometimes  
2. Always 
[      ] 
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PART 7: KILIFI EPILEPSY BELIEFS AND ATTITUDES SCALE (KEBAS) 
INTRODUCTION 
Please listen to the following story describing a person with a particular type of epilepsy and 
keep it in your mind while responding to the rest of the Epilepsy Belief Scale. 
This story is about Bahati.  Bahati has epilepsy, and has one seizure per week. 1-2 days before 
the seizure, his behaviour changes.  He/she may become naughty, sometimes may isolate 
him/herself or may look sleepy and wants to sleep. His/her eyes may become red and may also 
complain of headache.  Just before the fit, he/she may feel her/his heart has skipped a beat and 
feels mixed up (a feeling you may have when you suddenly see a scaring and unexpected thing- 
e.g. a dead body).  He/she then falls down and looses consciousness, starts jerking in all 4 limbs 
with eyes either rolling upwards, deviating to the sides or wide open, bites the tongue and foams 
for about 3 minutes then he/she urinates and the jerking movements stop. He/she remains 
unconscious for a couple of minutes then wakes up drowsy and goes to sleep. 
 
This is about your belief. Only you know what you believe, so if you tell us how you feel, all your answers 
will be correct. 
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PART 7: KILIFI EPILEPSY BELIEFS AND ATTITUDE SCALE 
  Totally 
Believe 
Believe 
a little 
Not 
at all 
Don’t 
know 
Score 
Causes       
1. I believe that epilepsy can be inherited/be caused by 
family ancestors (INHERIT)    
                                     
 2 1 0 .  
2. I believe that a person like Bahati can have epilepsy 
because he has been bewitched (BEWITCH) 
 
 
R 
0 1 2 .  
3. I believe that when the sun heats the brain of a person 
like Bahati, it may cause epilepsy  (SUN) 
 
 
R 
0 1 2 .  
4. I believe that when a person like Bahati has a head 
injury/falls on the head can cause epilepsy (HINJURY) 
 
 2 1 0 .  
5. I believe that an injury at birth can result in a person like 
Bahati having epilepsy (for example prolonged labour) 
(BINJURY) 
 2 1 0 .  
6. I believe that when a person takes anti-convulsant 
medication when not epileptic can result to having the 
disease (AEDS)                            
 
R 
0 1 2 .  
7. I believe that a serious disease (like malaria) affecting 
the brain of a person like Bahati can cause epilepsy 
(MALARIA) 
 2 1 0 .  
8. I believe that when a mother uses FPs before conception 
can make a child like Bahati have epilepsy when born 
(FPs)                                          
 
R 
0 1 2 .  
9. I believe that when one comes into contact with urine of 
a fitting person like Bahati can be infected with epilepsy 
(URINE)                                   
 
R 
0 1 2 .  
10. I believe that after a child like Bahati was born and his 
faeces did not clear then it may result to epilepsy 
(FAECES)                                                           
 
R 
0 1 2 .  
11. I believe that a person like Bahati can have epilepsy 
because part of his brain is damaged (BRAIN) 
 
 2 1 0 .  
Treatment       
12. I believe it is possible to treat a person like Bahati 
(TREAT) 
 
 2 1 0 .  
13. I believe that if a person like Bahati is burned, he will 
never get healed from epilepsy (BURN)   
                
 
R 
0 1 2 .  
14. I believe that nyuni/nyago is treatable but vitsala isn‘t  
(TNYUNI)                    
                                           
 
R 
0 1 2 .  
15. I believe that a person like Bahati has to take drugs 
continuously for them to work (DRUGS) 
 
 2 1 0 .  
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  Totally 
Believe 
Believe 
a little 
Not 
at all 
Don’t 
know 
Score 
16. I believe that vitsala is better treated by a mganga than a 
doctor (MVITSALA)             
                                         
 
R 
 
0 
 
1 
 
2 
.  
 
17. I believe there are drugs available that can treat epilepsy 
(ADRUGS) 
 
 2 1 0 .  
18. I believe that pouring water to a person like Bahati when 
fitting helps treat epilepsy (WATER)   
        
 
R 
0 1 2 .  
19. I believe that the best person to treat nyuni /nyago is a 
medical doctor (DNYUNI) 
 
 2 1 0 .  
20. I believe smearing rob/paraffin on the body of a person 
like Bahati when fitting helps treat epilepsy 
(PARAFFIN)                                                            
 
R 
0 1 2 .  
21. I believe that epilepsy in a person like Bahati can be 
treated through fumigation (FUMIG) 
                      
 
R 
 
0 
 
1 
 
2 
 
. 
 
22. I believe that some types of fits are not suitable for 
hospital treatment (HFITS) 
                                            
 
R 
 
0 
 
1 
 
2 
 
 
 
23. I believe that during a fit, it is good to put a stick 
between the person‘s teeth to prevent biting one self  
(STICK)                                                                  
 
R 
0 1 2 .  
24. I believe that during a fit, it is good to straighten the 
joints of a person like Bahati (JOINTS) 
                   
 
R 
0 1 2 .  
25. I believe that during a fit, it is good to put a person like 
Bahati in a safe place (SAFE) 
 
 2 1 0 .  
26. I believe that drugs (from hospital) can control seizures 
(CDRUGS) 
 
 2 1 0 .  
27. I believe that nyuni/ nyago is better treated by a mganga 
than a medical doctor (MNYUNI)       
                   
 
R 
0 1 2 .  
28. I believe a person like Bahati should only take drugs 
when he is having a fit (FITAEDS)        
                    
 
R 
0 1 2 .  
29. I believe that if a person like Bahati misses drugs he/she 
may fit again (MISSAEDS) 
 
 2 1 0 .  
30. I believe that the best person to treat vitsala is a medical 
doctor (DVITSALA) 
 
 2 1 0 .  
31. I believe that drugs for epilepsy can cause side effects 
such as drowsiness or hyperactivity to a person like 
Bahati (SEFFECTS) 
 2 1 0 .  
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  Totally 
Believe 
Believe 
a little 
Not 
at all 
Don’t 
know 
Score 
Prevention       
32. I believe that preventing serious diseases like malaria 
will reduce the number of people with epilepsy 
(PDISEASE) 
 2 1 0 .  
33. I believe that proper medical care during pregnancy and 
delivery will reduce the number of people with epilepsy 
(PREG) 
 2 1 0 .  
Living with epilepsy       
34. There is a belief that people like Bahati cannot marry, 
what do you think? (MARRY)          
                     
 
R 
0 1 2 .  
35. I believe that people like Bahati cannot climb trees or 
work high up (TREES)      
                             
 
 
2 1 0 .  
36. I believe that children like Bahati cannot go to school              
(SCHOOL)                 
                                  
 
R 
0 1 2 .  
37. I believe that people like Bahati cannot have a job                 
       (JOB)           
                                          
 
R 
0 1 2 .  
38. I believe that people like Bahati cannot do risky jobs 
(like driving/running machinery) (DRIVE)   
                     
 2 1 0 .  
39. I believe that people like Bahati can lead a normal life 
like other people (NLIFE) 
 
 2 1 0 .  
40. I believe that people like Bahati should avoid being near 
fires (FIRE) 
 
 2 1 0 .  
41. I believe that people like Bahati should avoid being near 
waters (like sea, lake or river water) (SEA) 
 
 2 1 0 .  
42. There is a belief that people like Bahati should be kept 
in isolation, what do you think? (ISOLATE) 
            
 
R 
2 1 0 .  
43. There is a belief that people like Bahati should be 
rejected, what do you think? (REJECT)    
                                              
 
R 
2 1 0 .  
44. I believe that parents feel resentful towards their 
children like Bahati because he/she has epilepsy 
(RECENT) 
 2 1 0 .  
45. There is a belief that people like Bahati are burdens to 
their parents, what do you think? (BURDEN)   
                                    
 
R 
0 1 2 .  
The effect of epilepsy on development       
46. I believe that continued seizures can damage the brain of 
a person like Bahati (DAMAGE) 
 
 2 1 0   
Appendices 
231 
 
  Totally 
Believe 
Believe 
a little 
Not 
at all 
Don’t 
know 
Score 
47. I believe that epilepsy can affect the development and 
behaviour of a person like Bahati (DEVELOP) 
 
 2 1 0 .  
48. I believe that a child like Bahati often performs poorly 
in school (PSCH)                              
                   
 
R 
0 1 2 .  
49. I believe that people like Bahati are dull (DULL)    
 
R 0 1 2 .  
50. I believe that people like Bahati are mad (MAD) 
 
R 0 1 2 .  
R: Reverse coded 
 
 
51. Are you aware of any traditional healer who treats epilepsy? (TH)  Y/N   [      ]   
      No go to 55 
 
52. If yes, what is the name of the traditional healer (NAMETH) 
 
53. Where does the traditional healer live? (THLIVE) 
  
54. Have you ever sought treatment from this traditional healer? (SEEKTH) Y/N   [      ] 
 
55. Do you have any comments on these questionnaires? (COMMENT) 
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APPENDIX II 
 
FIRST QUALITATIVE STUDY CHECKLIST 
 
Themes and questions for initial interviews with traditional healers:  
 
Interview 1: Initial background, general causation and treatment beliefs 
 
Name: 
 
1. How long you have been working at this job? 
 
2. What types of illness/problems do you treat (list)? 
 
3. What are the most common illnesses/problems that you treat (list): 
 
4. How many patients do you have in a normal week? 
 
5. You have told me that you treat ________, _________ and __________.   
 
6. What do you think is the cause of each of these illnesses (go through these illnesses one 
at a time and tell me what you think causes them)? 
 
7. Explain to me how you treat each of these illnesses (go through each of the illnesses that 
you have mentioned and tell me how you treat them)? 
 
8. Why do you think that the treatments you have just discussed are good ways of treating 
the specific illnesses that you have mentioned? 
 
9. We know that traditional healing is a very important part of life in the community. Why 
do you think that it is so important? 
 
10. Do you like being a traditional healer?  Why is this is such a good job? 
 
11. Tell us about how you became a healer.   
 
12. Explain to us the process of learning to be a healer. 
 
13. If you had a teacher where did this teacher learn to be a healer and where did their powers 
come from?    
 
14. Do you ever come together with other healers to share ideas/ concerns?  What are these 
meetings like?  What do you talk about and do you think these types of meetings are 
useful or not? 
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Interview 2: Tools of trade and payment 
 
1. Tell us about the specific things/objects that you use to treat illnesses and help people 
with their problems. 
 
2. Where do you get these things from and what gives them their power? 
 
3. How do you know how much medicine to give? 
 
Payment: 
 
4. Tell us about what sort of payment you receive. 
 
5. How do you decide on the payment that you ask for? 
 
6. What happens if the person is healed?  What are you given? 
 
7. What happens if the person is not healed?  What is given to the healer and what happens 
next? 
 
8. Have you ever had cases where individuals were not able or willing to pay?  What did 
you do in these cases? 
 
9. Tell me more specifically how you know what to do when someone comes to you with an 
illness. 
 
10. Tell me about the ancestral spirits. Do they have names and if so tell me a little about 
each one? 
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Interview 3: Specific spirits and views about epilepsy 
 
1. Tell me specifically how you know what to do when someone comes to you with an 
illness. 
 
2. Tell me about the ancestral spirits. Do they have names and if so tell me a little about 
each one? 
 
3. You have told us some of the conditions that you treat and how you help people.  We are 
interested specifically in the condition of epilepsy. 
 
4. Have you had any experience treating epilepsy? 
 
5. Tell us about some of the cases of this condition which you have treated. 
 
6. What do you think causes this condition? 
 
7. Describe how you treat this condition. 
 
8. Where do you get the medicine to treat epilepsy? 
 
9. Why do you think these types of treatments help the condition? 
 
10. Tell us about how you know when there has been some improvement in the child after 
treatment or that the child has been healed.  If you can think of specific cases where this 
has occurred these would be good examples to talk about. 
 
11. What do you do when the child you a treating does not get better? 
 
12. How do you know if/when you have been defeated by this particular illness (how do you 
know when you have failed)? 
 
13. We know that traditional healing can be very powerful in treating this condition.  Why do 
you think it is powerful and why is it good for people with this condition to come and 
seek treatment from a traditional healer such as yourself? 
 
14. What happens when someone with epilepsy dies (are there different rituals, what happens 
to his spirit)? 
 
15. Do you think epilepsy can be inherited? 
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Interview 4: Traditional healers 
 
1. What makes one happy and what makes one think that they and their family are living a 
good life. 
 
2. Imagine a family that you know in the community that you think is very happy with their 
lives.  Tell me about this family. 
 
3. Why do you think they are very happy? 
 
4. Think about a family that you know in the community that you think is very unhappy 
with their lives.  Tell me about this family. 
 
5. Why do you think they are very unhappy with their lives? 
 
6. Many people go to hospital or clinic to receive treatment for illnesses and problems.  
What are you opinions of hospital treatment and of the individuals who work there: 
 
7. What conditions do you think hospitals are good at treating and why? 
 
8. What conditions do you think hospitals are not good at treating and why? 
 
9. Do you think that people who work at hospitals realize the power and importance of 
traditional healing? 
 
10. If you could tell them some things about your job that might change what they think 
about traditional healing what would you tell them? 
 
11. For people who have epilepsy, do you think it is good for them to go to hospital?  Why? 
 
12. Do you think that it is possible for traditional healers such as yourself to work with 
hospital doctors to improve the health of the community?  How would you propose this 
to occur? 
 
13. How do you think that the lives of families who have children with epilepsy are different 
from the lives of families who have children without this disorder? 
 
14. Do you think that these families are as happy as other families? 
 
15. Do you think that they are able to achieve the same goals as normal families? 
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Interview 5: Traditional healers (Follow up questions)  
 
1. I have been trying to understand the system of traditional healers.  I understand that there 
are different types of healers.  Can you tell me about the different types of traditional 
healers that are in Kilifi? 
2. I am also interested in how people make decisions on where to seek treatment.  Tell me 
about what you think influences the decisions that people make when they choose where 
to seek treatment.   
3. What makes one person go to a traditional healer and another to a hospital for the same 
disease?   
4. Also what makes the same person go to a traditional healer for one illness but to hospital 
for another? 
5. Why do you think many people come to see you for treatment? 
6. If you can imagine a time back when there were no hospitals on the Coast (or very few at 
least), what are the differences between that time and now? 
7. I would also like to know more about what you are saying when you chant during the 
healing. 
8. You have described the treatments that you do for epilepsy. I am interested in knowing if 
you are aware of any other treatments that traditional healers perform to treat epilepsy? 
9. Another one of the ideas that I have after talking to many healers is that individuals might 
be influenced in making decision based on the two different systems of payment; the one 
in biomedicine and the one in traditional healing.  Do you think that there is a difference 
in the way that people pay for treatment at these two different places? 
10. Would you say that you know most people that you treat (meaning, do you know their 
names and do you recognize them). 
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APPENDIX III 
 
SECOND QUALITATIVE STUDY CHECKLIST  
 
Appendix IIIa 
 
Parents/Grandmothers of children from antiepileptic drug study 
 
We would like to conduct this interview because you have been to hospital and been told that 
your child has epilepsy. What do you think about this? 
This condition, does it have different names? 
So, you‘ve mentioned....What are the typical signs that someone has this (i.e. each one 
mentioned above) problem? 
What is the most important indicator of this problem (e.g. Behaviour problems, 
convulsions etc)? 
What happens when your child has a fit? 
What does the child look like? Does he/she get hurt? Does he/she know what‘s    
 happening? 
How do other people react? Is your child helped? By whom? How? 
What do you do when this happens to your child? 
 So far you have mentioned.....Anything else you would do? 
 Where would you go for help? 
 Who decides what to do? 
So far you have mentioned.....is there anyone else who provides services for children with your 
child‘s condition? 
Let‘s take each one (i.e. Service or action) in turn. 
What‘s good about this service/action? 
For everything that‘s good, there is also a bad thing. Can you tell me what are the bad things 
about this service/action? 
What might be improved/changed? 
Who uses each type of service? 
 (e.g. Rich people vs. poor people? Urban vs. rural? Christians vs. non-Christians) 
Going back to your child‘s condition, why do you think it happens? 
What do other people think is the reason? 
 What do neighbours, doctors, wagangas etc think? 
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What can anyone do to prevent this from happening? 
 Traditional ways? Church ways? Hospital ways? 
Was there a time when your child took tablets every day? 
What were your experiences of doing this? 
 What were the benefits? 
 What were the problems? (e.g. getting tablets, getting to the clinic, finances, side effects,     
             husband didn‘t approve, busy in shamba, child refused) 
 What did you think of the idea of giving tablets every day? 
 How did you or your child feel about the drugs‘ taste, size, colour, effectiveness? 
Where did you get the tablets from? What were the staff like? What were the instructions 
like?  How did you feel about this? 
Have you got any questions about what we‘ve talked about? 
How do you feel your child‘s condition impacts upon your life in general? 
What are your hopes for your child‘s future? 
What are your hopes for your other children? 
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Appendix IIIb 
 
Mothers/Grandmothers/Fathers of children with epilepsy 
 
We would like to conduct this interview because you have been to hospital and been told that 
your child has epilepsy. What do you think about this? 
This condition, does it have different names? 
So you‘ve mentioned.....What are the typical signs that someone has this problem? 
What is the most important indicator of this problem (e.g. behaviour problems, convulsions etc)? 
What happens when someone has a fit? 
 What does the child look like? Does he/she get hurt? Does he/she know what‘s    
             happening? 
 How do other people react? Are children helped? By whom? How? 
What do you do when this happens to your child? 
 So far you‘ve mentioned....Anything else you would do? 
 Where would you go for help? 
 Who decides what to do? 
So you have mentioned....who else provides help/services for children with this problem? 
Let‘s take each one (i.e. Service or action) in turn. 
What‘s good about this service/action? 
For everything that‘s good, there is also a bad thing. Can you tell me what are the bad things 
about this service/action? 
What might be improved/changed? 
Who uses each type of service? 
 Rich people vs. poor people? Urban vs. rural? Christians vs. non-Christians. 
Going back to your child‘s conditions, why do you think it happens? 
What do other people think is the reason? 
 What do neighbours, doctors, wagangas etc think? 
What can anyone do to prevent this from happening? 
 Traditional ways? Church ways? Hospital ways? 
Was there a time when your child took tablets every day? 
What were your experiences of doing this? 
 What were the benefits? 
What were the problems? (e.g. getting tablets, getting to the clinic, finances, side effects, 
doesn‘t believe in it, husband didn‘t approve, busy in shamba, child refused). 
What did you think of the idea of giving tablets every day? 
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How did you or your child feel about the drugs‘ taste, size, colour, effectiveness? 
Where did you get the tablets from? What were the staff like? What were the instructions 
like? How did you feel about this? 
Have you any question about this? 
How do you feel your child‘s condition impacts upon your life in general? 
What are your hopes for your child‘s future? 
What are your hopes for your other children? 
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Appendix IIIc 
 
Children with epilepsy 
 
Can you tell me about a typical day? 
 What are the good things that happen in a typical day (or week)? 
 What are the bad things that happen in a typical day (or week)? 
 Further probes if child mentions fits: 
 What do you call that? 
 (if not mentioned ask – have you ever had a fit?) 
 When this happens, what do you do? 
 What if at school, church etc? 
 What do you feel like afterwards? 
 What do other people do when it happens? 
 What do you think you can do to make it go away? 
So far you have mentioned....is there anyone else who provides services for children with your 
condition? 
Let‘s take each one (i.e. Service or action) in turn. 
What‘s good about this service/action? 
For everything that‘s good, there is also a bad thing. Can you tell me what are the bad things 
about this service/action? 
What might be improved/changed? 
Who uses each type of services? 
(e.g. Rich people vs. poor people? Urban vs. rural? Christians vs. non-Christians) 
Why do you think this happens to you? 
Why do other people think this happens to you? 
What can anyone do to prevent this from happening? 
 Traditional ways? Church ways? Hospital ways? 
Have you ever heard of drugs to prevent fits? If so, have you ever taken them? 
 What were your experiences of doing this? 
 What were the benefits? 
What were the problems? (e.g. getting tablets, getting to the clinic, finances, side 
effects, doesn‘t believe in it, busy in shamba, child refused) 
What did you think of the idea of taking tablets every day? 
How did you feel about the drugs‘ taste, size, colour, effectiveness? 
Where did you get the tablets from? What were the staff like? What were the 
instructions like? How did you feel about this? 
What would you like to happen when you grow up? 
What effect do you think your condition has on your life now/in the future? 
 Does it prevent you from doing things? If so, what? 
Does it affect your interaction with family/friends/other people? 
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Appendix IIId 
 
Traditional healers/CHWs/dispensaries/private clinics/doctors  
 
What illness do you treat? 
 Do you treat fits? 
 How many fits do you treat per month, for example? 
 Are your patients usually children or adults? 
What types of fits do you treat? 
 In what ways do they differ (e.g. Cause, symptoms/signs, severity, age group, treatment)? 
Are there some types of fits that are particularly feared/disliked in this community? For 
what reasons? 
Are there any types of fits that you are unable to treat? 
 What types of fits? 
 What happens to people with these problems? Are they referred? To whom? 
Why do you think children have this problem? 
Why do other people think children have this problem? 
What can anyone do to prevent this from happening? 
 Traditional ways? Church ways? Hospital ways? 
You‘ve mentioned.........as providing services for children with fits. Are there any other places 
where children with fits can be assisted? 
 What types of fits can be treated there? 
 What is good about that service? 
 What is bad about that service? 
What could be improved/changed about that service? 
How do parents decide where to take their child? 
How do parents know the type of fits their children are suffering from? 
Is there anything else you would like to share with us relating to children with epilepsy? 
Would you be interested in collaborating with our group to try to improve the care that children 
with epilepsy receive? If so, what form could that collaboration take? 
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Appendix IIIe 
 
Adults with epilepsy 
 
Can you tell me about a typical day/week? 
 What are the good things that happen in a typical day/week? 
 What are the bad things that happen in a typical day/week? 
 Further probes if person mentions fits: 
 What do you call that? 
 (if not mentioned, ask – have you ever had a fit?) 
 Does it have other/different names? 
What happens when someone has a fit? 
 When it happens to you, what do you do? 
 What if at work, church, cooking, looking after children etc? 
 Who decides what to do? 
 How do other people react? 
 What do you feel like afterwards? 
So far you‘ve mentioned that you would do....when this happens to you. Is there anything else 
you would do? 
Let‘s take each one (i.e. Service or action) in turn. 
What‘s good about this service/action? 
For everything that‘s good, there is also a bad thing. Can you tell me what are the bad things 
about this service/action? 
What might be improved/changed? 
Who uses each type of service? 
 (e.g. Rich people vs. poor people? Urban vs. rural? Christians vs. non-Christians) 
Why do you think the condition happens to you? 
What do other people think is the reason? 
 What do neighbours, doctors, wagangas, your spouse etc think? 
What do you think you can do to make it stop? 
 What do other people think they can do to make it stop? 
What can anyone do to prevent this from happening? 
 Traditional ways? Church ways? Hospital ways? 
 Have you ever heard of drugs to prevent fits? If so, have you ever taken them? 
What would you like to happen in your future? 
 What effect does the condition have on your life now/in the future? 
 Does it ever prevent you from doing things? If so, what? 
 Does it affect your interaction with family/friends/other people? 
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APPENDIX IV 
 
A pre-post questionnaire for medical providers training on diagnosis and management of 
epilepsy 
 
Answer True [T] or False [F] 
 
1. Epilepsy                   T    F 
A] Recurrent unprovoked seizure episodes         [   ] [   ]     
B] Can only be diagnosed in adults          [   ] [   ] 
C] Can present as partial or generalized seizures        [   ] [   ] 
D] Children less than 6yrs can‘t get epilepsy         [   ] [   ]  
E] Phenorbarbital is the drug of choice of all seizure                   [   ] [   ] 
 
2. Classification of seizure type      
A] Does not help in management of epilepsy                    [   ] [   ]  
B] Should not be taken seriously because phenorbarbital   
    will cure the disease                       [   ] [   ]  
C] Can only be done by epileptologist                     [   ] [   ] 
D] Is the mainstay of making the right diagnosis of epilepsy       [   ] [   ] 
E] All above statements are true           [   ] [   ] 
 
 3. Partial seizures 
A] Manifestation depends on the site of the lesion        [   ] [   ] 
B] Consciousness is completely lost          [   ] [   ] 
C] Consciousness may be retained or impaired        [   ] [   ]   
D] It‘s a seizure type of children          [   ] [   ] 
E] May spread to become generalized seizures        [   ] [   ] 
 
4. In seizures 
A] Patients can control themselves if it happens  
      when they are conscious          [   ] [   ] 
B] Psychogenic seizures may mimic generalized 
    tonic clonic seizures                [   ] [   ] 
C] In malingering patients are faking the symptoms        [   ] [   ] 
D] Tonic clonic seizure is the commonest presentation  
     of all seizure types           [   ] [   ] 
E] Partial seizures can never be status        [   ] [   ] 
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5. Musa is 10 years old.  One Monday morning he complained of slight headache and was 
given panadol before he went to school. Mr. Ndegwa his class teacher noticed something 
unusual about Musa.  His eyes were red and he looked quite dull.  After lunch break, Musa 
suddenly fell down in class and was unconscious.  He remained stiff for a few seconds then 
started jerking movements in all 4 limps and biting his tongue and frothing.  This continued 
for about 3 minutes then he slept after that episode. 
 
A] From the above history it is impossible to make  
     a diagnosis of epilepsy                  [   ] [   ] 
B] From the above history it is possible that  
      Musa had an epileptic seizure                 [   ] [   ] 
C] Musa could be having a serious medical condition               [   ] [   ] 
D] Musa will benefit from phenobarbital                 [   ] [   ] 
E] The above history is enough to make a diagnosis of epilepsy        [   ] [   ] 
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